CA2239301A1 - Composition for treating pain - Google Patents
Composition for treating pain Download PDFInfo
- Publication number
- CA2239301A1 CA2239301A1 CA002239301A CA2239301A CA2239301A1 CA 2239301 A1 CA2239301 A1 CA 2239301A1 CA 002239301 A CA002239301 A CA 002239301A CA 2239301 A CA2239301 A CA 2239301A CA 2239301 A1 CA2239301 A1 CA 2239301A1
- Authority
- CA
- Canada
- Prior art keywords
- azabicyclo
- thiadiazole
- oxy
- octyl
- endo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
The present invention provides a composition and method for treating pain using Selected Muscarinic Compounds and one or more compounds selected from the group consisting of Nonsteroidal Anti-inflammatory drugs, acetaminophen, opioids, and alpha-adrenergic compounds.
Description
W O 97/2081g PCTrUS96/19229 COMPOS~TION FOR TREATING PAIN
The present invention relates to a method for using a combination of compounds for treating pain.
This invention relates to a therapeutic combination of compounds to provide analgesic activity.
More active analgesic combinations effects are in constant demand because they offer the attractive possibility of relieving pain with reduced dosages, there~y ~;min; shing the expected side e~fects and toxicity that would otherwise result ~rom higher dosages. It would ~e particularly desirable to acquire a synergistic combination effect. Such a composition is the subject of the present invention.
The composition of this invention provides a surprising synergistically effective treatment for pain using compounds which are independently known in the art. The synergistic effect of the present composition provides a means for treating pain using a lower dosage of each compound in the composition, thus providing a treatment with a more desirable side effect profile.
The present invention provides a composition useful for the treatment of pain, comprising a First Compound selected from the group consisting of:
Formula I
~ (C~2) r W~ ~R
~ :~ ~N
o Formula I' W O 97/20819 pcTrus96/l9229 G--(CH2)r W N~
\/~
R \N
wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, NHR6, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4~ C3_10-cycloalkyl, C4_12-(cycloalkylalkyl), -z-C3_10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl) wherein R4 is Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1_ 4-alkyl, Cl_~-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1_4-alkyl, C1_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -oR5y~ -SR5Y, oR5-z-y~ -SR5ZY, -o-R5-Z-R4 or -S-R5-Z-R4 wherein Z is oxygen or sulphur, R5 is Cl_l5-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, and Y i5 a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
W O 97/20819 PCT~US96/19229 \ ~ S ~ R3' h~t-l het-2 het-3 het-4 ~,1 R~RN3~ ~ R2 het-5 het-6 het-7 or G can optionally be substituted C3-Cg cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, Cl_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl_ls-alkyl, C2_s-alkenyl, C2_s-alkynyl, Cl_l0-alkoxy, Cl_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, Cl_5-alkyl, C2_5-alkenyl or C2_5-alkynyl;
R6' is hydrogen, Cl_6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
~ is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; and "
Formula Il W O 97/20819 PCTrUS96/19229 G'~(CH2)r~~W R' N \ ~her~
S (Il' ) wherein W' is oxygen or sulfur;
R' is hydrogen, amino, halogen, NHR6 , ~R6 R7 , R4 , -oR4 -SR4 , -SoR4 , -So2R4 , C3_10-cycloalkyl, C4_12-(cycloalkylalkyl), -Z'-C3_l0-cycloalkyl and -Z~-C~_12-(cycloalkylalkyl) wherein R4' iS Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3 , -CN, Y ', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-al3~oxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R~ is -oR5 Y~, -SR5 Y~, oR5 -Z~-Y', -SR5 Z'Y', -o-R5 -Z-R4 or -S-R5 -Z~-R4 wherein Z' is oxygen or sulphur, R5 is Cl_ l5-alkyl, C2_1s-alkenyl~ C2_1s-alkynyl~ and Y~ is a 5 or 6 membered heterocyclic group; and G' is selected from one of the following azacyclic or azabicyclic ring systems:
W O 97/20819 PCT~US96/19229 < ~ RZ ~
het-l t~l het-2 het-3 het-4 R2 ~l ~ R~ ~ R2 he~-5 het-6 he~-7 or G~ can optionally be substituted C3-Cg cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6'R7';
R6 and R7 independently are hydrogen, Cl_6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl-ls-alkYl, C2-s-alkenyl, C2_s-alkynyl, Cl_lo-alkoxy, Cl-s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NHz, carboxy, or phenyl;
R3 is hydrogen, Cl_s-alkyl, C2_s-alkenyl or C2_s-alkynyl;
R6 ' i.s hydrogen, Cl_ls-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof and one or more Synergistic Analgesics in a weight ratio of First Compound to Synergistic Analgesic of from about 1 to about 1000.
W O 97~0819 PCT~US96/19229 The present invention provides a method for treating pain comprising administering to a patient in need thereof, using an anagesic composition comprising a First Compound selected from the group consisting of:
Formula I
Cl--(CHz) r ~ ~R
\0/
Formula I' G--(CH~ N~
\/ ~
R ~N~ I ' wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, N~R6, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4, C3-10-cycloalkyl, C4_12-(cycloalkylalkyl), -Z-C3_10-cycloalkyl and -Z-C4-12-(cycloalkylalkyl) wherein R4 is C1_15-alkyl, C2-1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1_ 4-alkyl, C1_~alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each o~ which is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONX2 or -CSNH2; or R is -oR5y~ -SR5Y, oR5-z-y~ -SR5ZY, -o-R5-z-R4 or -S-R5-Z-R4 wherein Z is oxygen or sulphur, R5 is C1_1s-alkyl, C2-1s-alkenyl, C2_1s-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
W O 97/20819 PCTnJS96/19229 R3 ~ ~ R
het~ het-2 het-3het-4 R'~R3~ ~ R2~
het-5 het-6 het-7 or G can optionally be substituted C3-C8 cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, Cl_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl_ls-alkyl, C2-s-alkenyl, c2_s-alkynyl, Cl_lo-alkoxy, C~-s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, Cl_s-alkyl, C2_s-alkenyl or C2_s-alkynyl;
R6' is hydrogen, Cl_6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; and Formula Il W O 97/20819 PCT~US96/19229 G'~(CH2)r~~W R' N ~her~
S/ (Il' ) wherein W~ is oxygen or sul~uri R~ is hydrogen, amino, halogen, NHR6 , NR6 R7 , R4 , -oR4 , -SR4 , -SoR4 , -So2R4 , C3 lo-cycloalkyl~ C4_l2-(cycloalkylalkyl), -Z'-C3-10 -cycloalkyl and -Z'-C4_12-(cycloalkylalkyl) wherein R4' is Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R~ is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R~ is -oR5 Y~, -SR5 Y~, oR5 -z~-Y~, -SR5 Z~Y~, -o-R5 -Z-R4 or -S-R5'-Z'-R4 wherein z~ is oxygen or sulphur, R5 is Cl_ 15-alkyl, C2_15-alkenyl~ C2_1s-alkynyl~ and Y~ is a 5 or 6 membered heterocyclic group; and G~ is selected from one of the following azacyclic or azabicyclic ring systems:
W O 97/20819 PCT~US96/19229 _g _ R' -het- het-2 ~ t-3 ~ _ t-4 het-5 het-6 het-7 or G' can optionally be substituted c3-C8 cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6'R7';
R6' and R7' independently are hydrogen, Cl_6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl-ls-alkyl~ c2-s-alkenyl, C2-s-alkynyl, Cl_lo-alkoxy, Cl_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, Cl_s-alkyl, C2_s-alkenyl or C2_s-alkynyl;
R6'' is hydrogen, Cl_ls-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof;
one or more Synergistic Analgesics in a weight ratio of First Compound to Synergistic Analgesic of from about 1 to about 1000.
W O 97/20819 PCTrUS96/19229 It is to be understood that the invention extends to ~he use of each of the stereoisomeric forms of the compounds of the present invention as well as the pure diastereomeric, pure enantiomeric, and racemic forms of the named compounds.
As used herein, the terms "Synergistic Analgesic"
and "Synergistic Analgesics~ refer to the group consisting of Nonsteroidal anti-inflammatory drugs (NSAIDS), acetaminophen, alpha-adrenergic compounds, and opioids.
As used herein, the term ~'Selected Muscarinic Compound" and "Selected Muscarinic Compounds~ refers to a compound selected from the group consisting of Formula I
G - (CH2)r~ ~ / R
N \ ~ N
(~ , Formula I~
G-(CH2)r W N
\/~
R N
wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, NHR6, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4~ C3_l0-cycloalkyl, C4_l2-(cycloalkylalkyl), -Z-C3_l0-cycloalkyl and -z-C4_l2-(cycloalkylalkyl) wherein R4 is Cl_ls-alk~l, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s~, -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cl_ 4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or ~ , W O 97/20819 PCT~US9G/19229 R is phenyl or benzyloxycarbonyl, each o~ which is optionally substituted with halogen, -CM, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -oR5~l -SR5Y, oR5-Z-Y, -SR5ZY, -o-R5-Z-R4 or -S-R5-Z-R4 wherein z is oxygen or sulphur, R5 is Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected ~rom one of the following azacyclic or azabicyclic ring systems:
~ ~ R3 ~ '3 het-l het-2 het-3 het-4 R
het-5 het-6 het-7 or G can optionally be su3~stituted C3-C~ cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, Cl_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl-ls-alkYl, C2-s-alkenyl, C2_s-alkynyl, Cl-lo-alkoxy, Cl_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R~ is hydrogen, Cl_5-alkyl, c2 s-alkenyl or C2-s-alkynyl;
R6' is hydrogen, Cl_6-alkyl;
n is 0, 1 or 2;
-W O 97~0819 PCTrUS96¢19229 m is 0, 1 or 2;
p is 0, 1 or 2;
~ is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; and Formula I1 G'-(CH2)r~~W' R' N \ / N
wherein W~ is oxygen or sulfur;
R' iS hydrogen, amino, halogen, NHR6 , NR6 R7 , R4 , -oR4 -SR4 , -SoR4 , -So2R4 , C3-10-CYCl0alkYl~ C4-l2-(cycloalkylalkyl), -Z'-C3-1o-cycloalkyl and -Z'-C4_12-(cycloalkylalkyl) wherein R4' iS Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y~, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' iS phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1_4-alkyl, C1_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' iS -oR5 Y', -SR5 Y', oR5 -Z'-Y', -SR5 Z'Y', -o-R5 -Z-R~
or -S-R5'-Z'-R4' wherein z' is oxygen or sulphur, R5 iS Cl_ l5-alkyl~ c2-ls-alkenyl~ c2-ls-alkynyl~ and Y' is a 5 or 6 membered heterocyclic group; and G' is selected ~rom one of the following azacyclic or azabicyclic ring systems:
R2 \ N ~ ~ R3 ~ R;
h~t-l Rl het-2 het-3 het-4 het-5 het-6 het-7 or G' can optionally be substituted C3-Cg cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6'R7';
R6 and R7' independently are hydrogen, Cl_6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl_ls-alkyl, C2-5-alkenyl, C2_s-alkynyl, Cl_lo-alkoxy, Cl_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 iS hydrogen, Cl_s-alkyl, C2_s-alkenyl or C2_s-alkynyl;
R6'' is hydrogen, Cl_ls-alkyl 15n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
g is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; or a pharmaceutically acceptable salt or solvate thereo~.
The term "alkyl" refers to the number of carbon atoms indicated; however, when no number is speci~ied, the W O 97/20819 PCT~US96/19229 term refers to C1_6 alkyl. The alkyl may be linear or branched unless specified.
As used herein with reference to the G and/or G' substituent, the -(CH2) r ~ -W ' - thiadiazole, -(CH2)r-W-oxadiazole, or -(CH2)r-W-pyrazine moiety can be attached at any carbon atom o~ the azacyclic or azabicyclic ring.
Further, Rl and R2 of the G and/or G~ substituent may be present at any position, including the point of attachment of the -(CH2)r~-W'-thiadiazole, -(CH2)r-W-oxadiazole, or -(CH2)r-W-pyrazine moiety.
As used herein with reference to the G and/or G' substituent, the phrase "R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring~ and ~R~' and R7' together with the nitrogen atom optionally ~orm a 4- to 6-member ring" means that R6 and R7 or R6' and R7' are each independently hydrogen, Cl-C6 alkyl wherein the R6 and R7 or R6 and R7 groups may optionally join to form a 4- to 6-member ring including the nitrogen. For example, optionally joined groups include, but are not limited to:
\N~ N ~ N
, and As used herein with reference to the G
substituent, the numbering shall be as follows:
~3 het-5 W O 97/20819 PCTnUS96/19229 As used herein the term a shall refer to a position on the G substituent which is one position away from the N atom of the G substituent. For example, in the following illustration (lE), both positions 2 and 6 are considered ~. The term ~ shall refer to the position on the G substituent which is opposite the N atom. For example, in the illustration (lE), position 4 is considered ~. Likewise, ~ shall refer to the 3 and 5 position in the illustration.
~ (a) (~) 4 ~ ~
~ N 1 (~) 1 E
As used herein the phrase "interacting with a muscarinic cholinergic receptor'~ shall include compounds which block muscarinic cholinergic receptors or modulate such receptors. Likewise, the term "interacting with a nicotinic cholinergic receptor~ shall include compounds which block or modulate the receptor. The phrase shall include the effect observed when compounds act as agonists, partial agonists and/or antagonists at a cholinergic receptor.
As used herein, the term h+ refers to an alkoxide metal, wherein the term "alkoxide metal~ means a metal suitable for alkoxide formation. Such alkoxide metals include, but are not limited to, Li+, K+, Na+, Cs+, and Ca++. Especially preferred alkoxide metals include Li+, K+, and Na+.
AS used herein, the term "halogen~ means Cl, sr, F, and I. Especially preferred halogens include Cl, Br, n and I.
As used herein the phrase "one or more selected fromll shall more pre~erredly refer to from 1-3 W O 97/20819 PCT~US96/19229 substituents. The term shall further preferredly refer to from 1-2 substituents.
The terms ~Cl-Cn alkyl~ wherein n~can be from 2 through 15, as used herein, represent a branched or linear alkyl group having from one to the specified number of carbon atoms. Typical Cl-C6 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.
The terms "C2-Cn alkenyl" wherein n~ can be from 3 through 10, as used herein, represents an olefinically unsaturated branched or linear group having from 2 to the specified number of carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, l-propenyl, 2-propenyl (-CH2-CH=CH2), 1,3-butadienyl, (-CH=CHC~=CH2), l-butenyl (-CH=CHCH2CH3), hexenyl, pentenyl, and the like.
The term 'IC2-C~ alkynyl" refers to an unsaturated branched or linear group having from 2 to 5 carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, l-propynyl, 2-propynyl, l-butynyl, 2-butynyl, l-pentynyl, and the like.
The terms "halogen(Cl-C6)alkyl" and "halogen(C2-C6)alkenyl" refer to alkyl or alkenyl substituents having one or more independently selected halogen atoms attached at one or more available carbon atoms. These terms include, but are not limited to, chloromethyl, l-bromoethyl, 2-bromoethyl, l,l,l-trifluoroethyl, 1,1,2-trifluoroethyl, 1,2,2-trifluoroethyl, 2,2,2-trifluoroethyl, trifluoromethyl, trifluoroethylenyl, 3-bromopropyl, 3-bromo-1-propenyl, 2-bromopropyl, 2-bromo-1-propenyl, 3-chlorobutyl, 3-chloro-2-butenyl, 2,3-dichlorobutyl, l-chloroethylenyl, 2-chloroethylenyl, 5-fluoro-3-pentenyl, 3-chloro-2-bromo-5-hexenyl, 3-chloro-2-bromobutyl, trichloromethyl, 1,1-dichloroethyl, 1,2-dichloroethyl, 2,2-dichloroethyl, 1,4-dichlorobutyl, 3-bromopentyl, 1,3-dichlorobutyl, 1,1-dichloropropyl, and the like.
CA 0223930l l998-06-02 W O 97/20819 PCTrUS96/19229 The term "C2-C1o alkanoyl~ represents a group of the formula C(O)~C1-Cg) alkyl. Typical C2-C1o alkanoyl groups include acetyl, propanoyl, butanoyl, and the like.
The term "(C1-C6 alkyl) amino~ refers to a monoalkylamino group. Examples of such groups are methylamino, ethylamino, iso-propylamino, n-propylamino, (n-propyl)amino, (iso-propyl)amino, n-propylamino, t-butylamino, and the like.
The term '~C3-Cn cycloalkyl" wherein n=4-8, represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term "substituted(Cs-Cn~) cycloalkyl" refers to a cycloalkyl group as described supra wherein the cycloalkyl group may be substituted with from one to four substituents independently selected from the group consisting of hydrogen, C1-C6 alkyl, NO2, halogen, halogen(C1-C6)alkyl, halogen(C2-C6)alkenyl~ C2-C6 alkenyl, C02R2~, (C1-C6 alkyl) amino, -SR20, and oR20; wherein R20 is selected from the group consisting of Cl-15-alkYl, C2_1s-alkenyl~ C2_1s-alkynyl.
The term "C3-Cg cycloalkyl-(C1-C3)alkyl" represents an alkyl group substituted at a terminal carbon with a C3-C8 cycloalkyl group. Typical cycloalkylalkyl groups include cyclohexylethyl, cyclohexylmethyl, 3-cyclopentylpropyl, and the like.
The term "Cs-Cg cycloalkenylll represents an olefinically unsaturated ring having five to eight carbon atoms. Such groups include, but are not limited to, cyclohexyl-1,3-dienyl, cyclohexenyl, cyclopentenyl, cycloheptenyl, cyclooctenyl, cyclohexyl-1,4-dienyl, cycloheptyl-1,4-dienyl, cyclooctyl-1,3,5-trienyl and the like.
The term "substituted (Cs-Cg) cycloalkenyl~ refers to a cycloalkenyl group as described supra. wherein the cycloalkenyl group may be substituted with from one to four substituents independently selected from the group consisting of hydrogen, C1-C6 alkyl, NO2, halogen, halogen(C1-C6)alkyl, halogen(C2-C6)alkenyl, C2-C6 alkenyl, COR20, C2-C1o alkanoyl, C7-C16 arylalkyl, CO2R20, (C1-C6 alkyl) amino, -SR20, and -oR2o; wherein R20 is selected from the group consisting of C1_1s-alkyl, C2-1s-alkenyl, and C2_1~-alkynyl.
The term "Cs-Cg cycloalkenyl-~C1-C3)alkyl~' represents a C1-C3 alkyl group substituted at a terminal carbon with a Cs-Cg cycloalkenyl group.
AS used herein, the phrase ll5 or 6 membered heterocyclic group" means a group containing from one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with C1-6-alkyl, -CF3, phenyl, benzyl or thienyl, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fused with a phenyl group. The phrase ~5 or 6 membered heterocyclic group"
includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. thiophenes, pyrroles, furans);
5-membered heterocycles having two heteroatoms in 1,2 or l,3 positions (e.g. oxazoles, pyrazoles, imidazoles, thiazoles, purines); 5-membered heterocycles having three heteroatoms (e.g. triazoles, thiadiazoles); 5-membered heterocycles having 3-heteroatoms; 6-membered heterocycles with one heteroatom (e.g. pyridine, quinoline, isoquinoline, phenanthrine, 5,6-cycloheptenopyridine); 6-membered heterocycles with two heteroatoms (e.g.
pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines)i 6-membered heterocycles with three heteroatoms (e.g. 1,3,5-triazine); and 6-member heterocycles with four heteroatoms. Particularly preferred are thiophenes, pyridines, and furans.
As used herein the term "carboxy" refers to a substituent having the common me~ni ng understood by the skilled artisan, wherein the point of attachment may be through the carbon or oxygen atom of the group.
As used herein the term "aryl" means an organic radical derived from an aromatic hydrocarbon by the removal W O 97/2Q8~9 PCTfUS96/19229 of one atom; e.g., phenyl or naphthyl. Most preferably, aryl refers to C6-Clo aryl, wherein the aryl ring system, including any alkyl substitutions, comprises from 6 to 10 ~ carbon atoms; e.g., phenyl, 3,3-dimethylphenyl, naphthyl, and the like. The aryl radical may be substituted by one - or two Cl-C6 straight or branched alkyl. The term ~aryl(Cl-C3)alkyl~ refers to any aryl group which is attached to the parent moiety via the alkyl group.
As used herein the term ~phosphorous(III3 compound" has the art accepted me~ning of the term. For example, the term includes, but is in no way limited to, triphenylphosphine, tri(p-toluyl) phosphine, tributyl phosphine, tri(p-dimethylaminiophenyl) phosphine, triethyl phosphine, and trimethyl phosphine. The artisan can choose other appropriate phosphorous (III) compounds using methods and literature references which are commonly available to the chemist artisan.
As used herein the term l'diester of azodicarboxylate~ has the art accepted meaning of the term.
The present invention relates to a method for using a combination of compounds for treating pain.
This invention relates to a therapeutic combination of compounds to provide analgesic activity.
More active analgesic combinations effects are in constant demand because they offer the attractive possibility of relieving pain with reduced dosages, there~y ~;min; shing the expected side e~fects and toxicity that would otherwise result ~rom higher dosages. It would ~e particularly desirable to acquire a synergistic combination effect. Such a composition is the subject of the present invention.
The composition of this invention provides a surprising synergistically effective treatment for pain using compounds which are independently known in the art. The synergistic effect of the present composition provides a means for treating pain using a lower dosage of each compound in the composition, thus providing a treatment with a more desirable side effect profile.
The present invention provides a composition useful for the treatment of pain, comprising a First Compound selected from the group consisting of:
Formula I
~ (C~2) r W~ ~R
~ :~ ~N
o Formula I' W O 97/20819 pcTrus96/l9229 G--(CH2)r W N~
\/~
R \N
wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, NHR6, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4~ C3_10-cycloalkyl, C4_12-(cycloalkylalkyl), -z-C3_10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl) wherein R4 is Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1_ 4-alkyl, Cl_~-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1_4-alkyl, C1_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -oR5y~ -SR5Y, oR5-z-y~ -SR5ZY, -o-R5-Z-R4 or -S-R5-Z-R4 wherein Z is oxygen or sulphur, R5 is Cl_l5-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, and Y i5 a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
W O 97/20819 PCT~US96/19229 \ ~ S ~ R3' h~t-l het-2 het-3 het-4 ~,1 R~RN3~ ~ R2 het-5 het-6 het-7 or G can optionally be substituted C3-Cg cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, Cl_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl_ls-alkyl, C2_s-alkenyl, C2_s-alkynyl, Cl_l0-alkoxy, Cl_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, Cl_5-alkyl, C2_5-alkenyl or C2_5-alkynyl;
R6' is hydrogen, Cl_6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
~ is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; and "
Formula Il W O 97/20819 PCTrUS96/19229 G'~(CH2)r~~W R' N \ ~her~
S (Il' ) wherein W' is oxygen or sulfur;
R' is hydrogen, amino, halogen, NHR6 , ~R6 R7 , R4 , -oR4 -SR4 , -SoR4 , -So2R4 , C3_10-cycloalkyl, C4_12-(cycloalkylalkyl), -Z'-C3_l0-cycloalkyl and -Z~-C~_12-(cycloalkylalkyl) wherein R4' iS Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3 , -CN, Y ', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-al3~oxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R~ is -oR5 Y~, -SR5 Y~, oR5 -Z~-Y', -SR5 Z'Y', -o-R5 -Z-R4 or -S-R5 -Z~-R4 wherein Z' is oxygen or sulphur, R5 is Cl_ l5-alkyl, C2_1s-alkenyl~ C2_1s-alkynyl~ and Y~ is a 5 or 6 membered heterocyclic group; and G' is selected from one of the following azacyclic or azabicyclic ring systems:
W O 97/20819 PCT~US96/19229 < ~ RZ ~
het-l t~l het-2 het-3 het-4 R2 ~l ~ R~ ~ R2 he~-5 het-6 he~-7 or G~ can optionally be substituted C3-Cg cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6'R7';
R6 and R7 independently are hydrogen, Cl_6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl-ls-alkYl, C2-s-alkenyl, C2_s-alkynyl, Cl_lo-alkoxy, Cl-s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NHz, carboxy, or phenyl;
R3 is hydrogen, Cl_s-alkyl, C2_s-alkenyl or C2_s-alkynyl;
R6 ' i.s hydrogen, Cl_ls-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof and one or more Synergistic Analgesics in a weight ratio of First Compound to Synergistic Analgesic of from about 1 to about 1000.
W O 97~0819 PCT~US96/19229 The present invention provides a method for treating pain comprising administering to a patient in need thereof, using an anagesic composition comprising a First Compound selected from the group consisting of:
Formula I
Cl--(CHz) r ~ ~R
\0/
Formula I' G--(CH~ N~
\/ ~
R ~N~ I ' wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, N~R6, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4, C3-10-cycloalkyl, C4_12-(cycloalkylalkyl), -Z-C3_10-cycloalkyl and -Z-C4-12-(cycloalkylalkyl) wherein R4 is C1_15-alkyl, C2-1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1_ 4-alkyl, C1_~alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each o~ which is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONX2 or -CSNH2; or R is -oR5y~ -SR5Y, oR5-z-y~ -SR5ZY, -o-R5-z-R4 or -S-R5-Z-R4 wherein Z is oxygen or sulphur, R5 is C1_1s-alkyl, C2-1s-alkenyl, C2_1s-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
W O 97/20819 PCTnJS96/19229 R3 ~ ~ R
het~ het-2 het-3het-4 R'~R3~ ~ R2~
het-5 het-6 het-7 or G can optionally be substituted C3-C8 cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, Cl_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl_ls-alkyl, C2-s-alkenyl, c2_s-alkynyl, Cl_lo-alkoxy, C~-s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, Cl_s-alkyl, C2_s-alkenyl or C2_s-alkynyl;
R6' is hydrogen, Cl_6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; and Formula Il W O 97/20819 PCT~US96/19229 G'~(CH2)r~~W R' N ~her~
S/ (Il' ) wherein W~ is oxygen or sul~uri R~ is hydrogen, amino, halogen, NHR6 , NR6 R7 , R4 , -oR4 , -SR4 , -SoR4 , -So2R4 , C3 lo-cycloalkyl~ C4_l2-(cycloalkylalkyl), -Z'-C3-10 -cycloalkyl and -Z'-C4_12-(cycloalkylalkyl) wherein R4' is Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R~ is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R~ is -oR5 Y~, -SR5 Y~, oR5 -z~-Y~, -SR5 Z~Y~, -o-R5 -Z-R4 or -S-R5'-Z'-R4 wherein z~ is oxygen or sulphur, R5 is Cl_ 15-alkyl, C2_15-alkenyl~ C2_1s-alkynyl~ and Y~ is a 5 or 6 membered heterocyclic group; and G~ is selected from one of the following azacyclic or azabicyclic ring systems:
W O 97/20819 PCT~US96/19229 _g _ R' -het- het-2 ~ t-3 ~ _ t-4 het-5 het-6 het-7 or G' can optionally be substituted c3-C8 cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6'R7';
R6' and R7' independently are hydrogen, Cl_6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl-ls-alkyl~ c2-s-alkenyl, C2-s-alkynyl, Cl_lo-alkoxy, Cl_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, Cl_s-alkyl, C2_s-alkenyl or C2_s-alkynyl;
R6'' is hydrogen, Cl_ls-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof;
one or more Synergistic Analgesics in a weight ratio of First Compound to Synergistic Analgesic of from about 1 to about 1000.
W O 97/20819 PCTrUS96/19229 It is to be understood that the invention extends to ~he use of each of the stereoisomeric forms of the compounds of the present invention as well as the pure diastereomeric, pure enantiomeric, and racemic forms of the named compounds.
As used herein, the terms "Synergistic Analgesic"
and "Synergistic Analgesics~ refer to the group consisting of Nonsteroidal anti-inflammatory drugs (NSAIDS), acetaminophen, alpha-adrenergic compounds, and opioids.
As used herein, the term ~'Selected Muscarinic Compound" and "Selected Muscarinic Compounds~ refers to a compound selected from the group consisting of Formula I
G - (CH2)r~ ~ / R
N \ ~ N
(~ , Formula I~
G-(CH2)r W N
\/~
R N
wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, NHR6, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4~ C3_l0-cycloalkyl, C4_l2-(cycloalkylalkyl), -Z-C3_l0-cycloalkyl and -z-C4_l2-(cycloalkylalkyl) wherein R4 is Cl_ls-alk~l, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s~, -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cl_ 4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or ~ , W O 97/20819 PCT~US9G/19229 R is phenyl or benzyloxycarbonyl, each o~ which is optionally substituted with halogen, -CM, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -oR5~l -SR5Y, oR5-Z-Y, -SR5ZY, -o-R5-Z-R4 or -S-R5-Z-R4 wherein z is oxygen or sulphur, R5 is Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected ~rom one of the following azacyclic or azabicyclic ring systems:
~ ~ R3 ~ '3 het-l het-2 het-3 het-4 R
het-5 het-6 het-7 or G can optionally be su3~stituted C3-C~ cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, Cl_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl-ls-alkYl, C2-s-alkenyl, C2_s-alkynyl, Cl-lo-alkoxy, Cl_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R~ is hydrogen, Cl_5-alkyl, c2 s-alkenyl or C2-s-alkynyl;
R6' is hydrogen, Cl_6-alkyl;
n is 0, 1 or 2;
-W O 97~0819 PCTrUS96¢19229 m is 0, 1 or 2;
p is 0, 1 or 2;
~ is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; and Formula I1 G'-(CH2)r~~W' R' N \ / N
wherein W~ is oxygen or sulfur;
R' iS hydrogen, amino, halogen, NHR6 , NR6 R7 , R4 , -oR4 -SR4 , -SoR4 , -So2R4 , C3-10-CYCl0alkYl~ C4-l2-(cycloalkylalkyl), -Z'-C3-1o-cycloalkyl and -Z'-C4_12-(cycloalkylalkyl) wherein R4' iS Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y~, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' iS phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1_4-alkyl, C1_4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' iS -oR5 Y', -SR5 Y', oR5 -Z'-Y', -SR5 Z'Y', -o-R5 -Z-R~
or -S-R5'-Z'-R4' wherein z' is oxygen or sulphur, R5 iS Cl_ l5-alkyl~ c2-ls-alkenyl~ c2-ls-alkynyl~ and Y' is a 5 or 6 membered heterocyclic group; and G' is selected ~rom one of the following azacyclic or azabicyclic ring systems:
R2 \ N ~ ~ R3 ~ R;
h~t-l Rl het-2 het-3 het-4 het-5 het-6 het-7 or G' can optionally be substituted C3-Cg cycloalkyl or optionally substituted Cl_6-alkyl wherein the substitution is -NR6'R7';
R6 and R7' independently are hydrogen, Cl_6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
Rl and R2 independently are hydrogen, Cl_ls-alkyl, C2-5-alkenyl, C2_s-alkynyl, Cl_lo-alkoxy, Cl_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 iS hydrogen, Cl_s-alkyl, C2_s-alkenyl or C2_s-alkynyl;
R6'' is hydrogen, Cl_ls-alkyl 15n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
g is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond; or a pharmaceutically acceptable salt or solvate thereo~.
The term "alkyl" refers to the number of carbon atoms indicated; however, when no number is speci~ied, the W O 97/20819 PCT~US96/19229 term refers to C1_6 alkyl. The alkyl may be linear or branched unless specified.
As used herein with reference to the G and/or G' substituent, the -(CH2) r ~ -W ' - thiadiazole, -(CH2)r-W-oxadiazole, or -(CH2)r-W-pyrazine moiety can be attached at any carbon atom o~ the azacyclic or azabicyclic ring.
Further, Rl and R2 of the G and/or G~ substituent may be present at any position, including the point of attachment of the -(CH2)r~-W'-thiadiazole, -(CH2)r-W-oxadiazole, or -(CH2)r-W-pyrazine moiety.
As used herein with reference to the G and/or G' substituent, the phrase "R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring~ and ~R~' and R7' together with the nitrogen atom optionally ~orm a 4- to 6-member ring" means that R6 and R7 or R6' and R7' are each independently hydrogen, Cl-C6 alkyl wherein the R6 and R7 or R6 and R7 groups may optionally join to form a 4- to 6-member ring including the nitrogen. For example, optionally joined groups include, but are not limited to:
\N~ N ~ N
, and As used herein with reference to the G
substituent, the numbering shall be as follows:
~3 het-5 W O 97/20819 PCTnUS96/19229 As used herein the term a shall refer to a position on the G substituent which is one position away from the N atom of the G substituent. For example, in the following illustration (lE), both positions 2 and 6 are considered ~. The term ~ shall refer to the position on the G substituent which is opposite the N atom. For example, in the illustration (lE), position 4 is considered ~. Likewise, ~ shall refer to the 3 and 5 position in the illustration.
~ (a) (~) 4 ~ ~
~ N 1 (~) 1 E
As used herein the phrase "interacting with a muscarinic cholinergic receptor'~ shall include compounds which block muscarinic cholinergic receptors or modulate such receptors. Likewise, the term "interacting with a nicotinic cholinergic receptor~ shall include compounds which block or modulate the receptor. The phrase shall include the effect observed when compounds act as agonists, partial agonists and/or antagonists at a cholinergic receptor.
As used herein, the term h+ refers to an alkoxide metal, wherein the term "alkoxide metal~ means a metal suitable for alkoxide formation. Such alkoxide metals include, but are not limited to, Li+, K+, Na+, Cs+, and Ca++. Especially preferred alkoxide metals include Li+, K+, and Na+.
AS used herein, the term "halogen~ means Cl, sr, F, and I. Especially preferred halogens include Cl, Br, n and I.
As used herein the phrase "one or more selected fromll shall more pre~erredly refer to from 1-3 W O 97/20819 PCT~US96/19229 substituents. The term shall further preferredly refer to from 1-2 substituents.
The terms ~Cl-Cn alkyl~ wherein n~can be from 2 through 15, as used herein, represent a branched or linear alkyl group having from one to the specified number of carbon atoms. Typical Cl-C6 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.
The terms "C2-Cn alkenyl" wherein n~ can be from 3 through 10, as used herein, represents an olefinically unsaturated branched or linear group having from 2 to the specified number of carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, l-propenyl, 2-propenyl (-CH2-CH=CH2), 1,3-butadienyl, (-CH=CHC~=CH2), l-butenyl (-CH=CHCH2CH3), hexenyl, pentenyl, and the like.
The term 'IC2-C~ alkynyl" refers to an unsaturated branched or linear group having from 2 to 5 carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, l-propynyl, 2-propynyl, l-butynyl, 2-butynyl, l-pentynyl, and the like.
The terms "halogen(Cl-C6)alkyl" and "halogen(C2-C6)alkenyl" refer to alkyl or alkenyl substituents having one or more independently selected halogen atoms attached at one or more available carbon atoms. These terms include, but are not limited to, chloromethyl, l-bromoethyl, 2-bromoethyl, l,l,l-trifluoroethyl, 1,1,2-trifluoroethyl, 1,2,2-trifluoroethyl, 2,2,2-trifluoroethyl, trifluoromethyl, trifluoroethylenyl, 3-bromopropyl, 3-bromo-1-propenyl, 2-bromopropyl, 2-bromo-1-propenyl, 3-chlorobutyl, 3-chloro-2-butenyl, 2,3-dichlorobutyl, l-chloroethylenyl, 2-chloroethylenyl, 5-fluoro-3-pentenyl, 3-chloro-2-bromo-5-hexenyl, 3-chloro-2-bromobutyl, trichloromethyl, 1,1-dichloroethyl, 1,2-dichloroethyl, 2,2-dichloroethyl, 1,4-dichlorobutyl, 3-bromopentyl, 1,3-dichlorobutyl, 1,1-dichloropropyl, and the like.
CA 0223930l l998-06-02 W O 97/20819 PCTrUS96/19229 The term "C2-C1o alkanoyl~ represents a group of the formula C(O)~C1-Cg) alkyl. Typical C2-C1o alkanoyl groups include acetyl, propanoyl, butanoyl, and the like.
The term "(C1-C6 alkyl) amino~ refers to a monoalkylamino group. Examples of such groups are methylamino, ethylamino, iso-propylamino, n-propylamino, (n-propyl)amino, (iso-propyl)amino, n-propylamino, t-butylamino, and the like.
The term '~C3-Cn cycloalkyl" wherein n=4-8, represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term "substituted(Cs-Cn~) cycloalkyl" refers to a cycloalkyl group as described supra wherein the cycloalkyl group may be substituted with from one to four substituents independently selected from the group consisting of hydrogen, C1-C6 alkyl, NO2, halogen, halogen(C1-C6)alkyl, halogen(C2-C6)alkenyl~ C2-C6 alkenyl, C02R2~, (C1-C6 alkyl) amino, -SR20, and oR20; wherein R20 is selected from the group consisting of Cl-15-alkYl, C2_1s-alkenyl~ C2_1s-alkynyl.
The term "C3-Cg cycloalkyl-(C1-C3)alkyl" represents an alkyl group substituted at a terminal carbon with a C3-C8 cycloalkyl group. Typical cycloalkylalkyl groups include cyclohexylethyl, cyclohexylmethyl, 3-cyclopentylpropyl, and the like.
The term "Cs-Cg cycloalkenylll represents an olefinically unsaturated ring having five to eight carbon atoms. Such groups include, but are not limited to, cyclohexyl-1,3-dienyl, cyclohexenyl, cyclopentenyl, cycloheptenyl, cyclooctenyl, cyclohexyl-1,4-dienyl, cycloheptyl-1,4-dienyl, cyclooctyl-1,3,5-trienyl and the like.
The term "substituted (Cs-Cg) cycloalkenyl~ refers to a cycloalkenyl group as described supra. wherein the cycloalkenyl group may be substituted with from one to four substituents independently selected from the group consisting of hydrogen, C1-C6 alkyl, NO2, halogen, halogen(C1-C6)alkyl, halogen(C2-C6)alkenyl, C2-C6 alkenyl, COR20, C2-C1o alkanoyl, C7-C16 arylalkyl, CO2R20, (C1-C6 alkyl) amino, -SR20, and -oR2o; wherein R20 is selected from the group consisting of C1_1s-alkyl, C2-1s-alkenyl, and C2_1~-alkynyl.
The term "Cs-Cg cycloalkenyl-~C1-C3)alkyl~' represents a C1-C3 alkyl group substituted at a terminal carbon with a Cs-Cg cycloalkenyl group.
AS used herein, the phrase ll5 or 6 membered heterocyclic group" means a group containing from one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with C1-6-alkyl, -CF3, phenyl, benzyl or thienyl, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fused with a phenyl group. The phrase ~5 or 6 membered heterocyclic group"
includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. thiophenes, pyrroles, furans);
5-membered heterocycles having two heteroatoms in 1,2 or l,3 positions (e.g. oxazoles, pyrazoles, imidazoles, thiazoles, purines); 5-membered heterocycles having three heteroatoms (e.g. triazoles, thiadiazoles); 5-membered heterocycles having 3-heteroatoms; 6-membered heterocycles with one heteroatom (e.g. pyridine, quinoline, isoquinoline, phenanthrine, 5,6-cycloheptenopyridine); 6-membered heterocycles with two heteroatoms (e.g.
pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines)i 6-membered heterocycles with three heteroatoms (e.g. 1,3,5-triazine); and 6-member heterocycles with four heteroatoms. Particularly preferred are thiophenes, pyridines, and furans.
As used herein the term "carboxy" refers to a substituent having the common me~ni ng understood by the skilled artisan, wherein the point of attachment may be through the carbon or oxygen atom of the group.
As used herein the term "aryl" means an organic radical derived from an aromatic hydrocarbon by the removal W O 97/2Q8~9 PCTfUS96/19229 of one atom; e.g., phenyl or naphthyl. Most preferably, aryl refers to C6-Clo aryl, wherein the aryl ring system, including any alkyl substitutions, comprises from 6 to 10 ~ carbon atoms; e.g., phenyl, 3,3-dimethylphenyl, naphthyl, and the like. The aryl radical may be substituted by one - or two Cl-C6 straight or branched alkyl. The term ~aryl(Cl-C3)alkyl~ refers to any aryl group which is attached to the parent moiety via the alkyl group.
As used herein the term ~phosphorous(III3 compound" has the art accepted me~ning of the term. For example, the term includes, but is in no way limited to, triphenylphosphine, tri(p-toluyl) phosphine, tributyl phosphine, tri(p-dimethylaminiophenyl) phosphine, triethyl phosphine, and trimethyl phosphine. The artisan can choose other appropriate phosphorous (III) compounds using methods and literature references which are commonly available to the chemist artisan.
As used herein the term l'diester of azodicarboxylate~ has the art accepted meaning of the term.
2~ For example, the term includes, but is in no way limited to diethylazodicarboxylate, dimethylazodicarboxylate, diisopropylazodicarboxylate, and di-tertbutylazodicarboxylate. The skilled chemist can determine other appropriate diesters of azodicarboxylate using methods and literature readily available to the chemist artisan.
Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical ~cience, 66, 2 (1977) which are known to the skilled artisan. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
W O 97/20819 PCT~US96/19229 The compounds of Formula I~ can be prepared using the chemical processes illustrated in Scheme I. The starting materials for the illustrated process are commercially available or may be prepared using methods known to the skilled artisan S~h~m~ T
1. HSR/Et2NH N N Oxidize N N
2. S2Hal2 ~ l ~
Hal l SR Hal 2 SO2R
l.HOR/Et3N
2~s2Hal2 \ G-(CH2)r-W-h+
G-(CH2)~-W-h+\
~ (CH2) r-w-h+ ~/ w~Hal Hal 3 OR ~ S
G-(CH2) r l~h+2s/MeI Y~ N\\ /N
2.0xidize \\ //~ l.Et3N
NCCN
G-(CH2)r-W 5 (ols)R4 2~s2Hal2 N ~ G-(CH2)r-OH
\ ~ --(CH2)r--W-h~
As used in Scheme I, R, h+, and G are as de~ined supra. As used in Scheme I, the term ~Hal~ refers to Cl, Br, and R9S02. Preferred oxidizing agents for the process of Scheme I include oxone and sodium periodate. Oxone is an especially preferred oxidizing agent for the process of Scheme I. Compounds of Formula 3, as illustrated in Scheme I wherein the OR group is replaced by an R4 group, can be prepared using methods well known in the art. See for example, U.S. Patent Number 5,~43,345.
W O 97/20819 PCTnU~96/19229 -21~
Further, compounds of Formula I may be prepared using the process illustrated in the following Scheme II
Scheme II
~ K2CO3 ~ ~
G(CH2)r-W P G(CHa)r~W SR4 (especially desired oxidize h+QR if P is Cl; W is o;
~ r is O) G(CH2)r~W QR24 G(CH2)r~W R25 As used in Scheme II, Q may be N, o or S; R24 is selected from the group consisting of hydrogen, R4, R5, R6, and R7; R25 is selected from the group consisting of SoR4 and So2R4; all other meanings are as defined supra .
Additional compounds of Formula I may be prepared using the process illustrated by Scheme III.
W ~nh~m~ III
G ~H2)r \ /
S amine ~ G- (CH2)r ~ / jS
Hal N 6 reduction G~(CH2)r \ ~
~ N
As used in Scheme III, Hal, W, r, and G are as defined supra . As used in Scheme III, R22 and R23 are independently selected from the group consisting of hydrogen, R6 and R7.
Certain intermediates of the present invention may be prepared using the process illustrated in Scheme IV.
~ w o g7nO819 PCTnUS96~192~9 .scheme IV
~ ~ ~ R~ OR~ si)(Rl3~l~ls si~
Cl R NRl5Rl6 R
1. HCl 2. Nitrosate Cu(Br,I) ~< /~
Br, I 11 As used in Scheme IV, R8, Si, R10~R11~ Rl2, R13, R14, R15', R15 and R16 are as defined supra. For example, R8N[(R10R11Rl2Si)(R13R14Rl5~Si) may be, but is not limited to lithium bis(tri-2-propylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, lithium bis(tri-2-propylsilyl)amide, sodium bis(ethyldimethylsilyl)amide, potassium bis(1-propylethylmethylsilyl~amide, lithium bis(tri-phenylsilyl)amide, sodium bis(tri-phenylmethylsilyl)amide, potassium bis(2-butyl-2-propylmethylsilyl)amide, lithium (tri-2-propylsilyl)(2-butyldiethylsilyl)amide, sodium (trimethylsilyl)(triphenylsilyl)amide, potassium (dimethyl phenylsilyl)(ethyldimethylsilyl)amide, and the like. Most preferably, R15 and R16 are each hydrogen when the process of Scheme III is used for preparing a compound of 11 from a compound of 10. The intermediate 10 may be nitrosated using standard nitrosating procedures. A preferred W O 97/20819 PCTrUS96/19229 nitrosating agent is isoamyl nitrite; however, other known nitrosating agents are appropriate. As used in Scheme III, the term "Cu(sr,I)" refers to copper (I) bromide, copper (II) bromide, or copper (I) iodide. The artisan will recognize that the copper (I) bromide, copper (II) bromide, or copper ( I) iodide reagent shall determine the substitution on the product of the process illustrated in Scheme III.
Certain compounds of this invention may more preferably be prepared by a process using a hydroxyalkylamine (G-OH) wherein G has the meaning defined supra. in the presence of a phosphorus(III) compound and a diester of azodicarboxylate to give the l,2,5-thiadiazoyloxyalkylamine as illustrated by Scheme V.
Scheme v ~ N + G---OH p~l~)3 ~ N
R' ll R' ~N
Co2R3' The G groups are as defined supra. The R'is selected from the group consisting of hydrogen, halogen, NR6R7, R4, -oR4, -SR4, -soR4, -S02R~, C3-1o-cycloalkyl, C4-12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl);
R4 is selected from the group consisting of Cl_ls-alkyl, C2-15-alkenYl, C2-ls-alkynyl~ each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, or -CF3; or R~ is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more independently W O 97/20819 PCT~US96/19229 selected from the group consisting of halogen, -CN, C1-4-alkyl, C1_4-alkoxy, -OCF3, and -CF3; or R' selected from the group consisting of -oR5Y, -SR5Y, oR5 Z-Y, -SR5ZY, -o-R5-Z-R4 and -S-R5-Z-R4;
Z is oxygen or sulphur;
R5 iS selected from the group consisting of C1_1s-alk~
C2_1s-alkenyl, and C2_1s-alkynyl;
Y is a 5 or 6 membered heterocyclic group:
R1~ is selected from the group consisting of phenyl, C1_1s-alkyl, C2_s-alkenyl, C2_s-alkynyl and (NR2')3;
R2 and R3 are independently selected from the group consisting of hydrogen, C1_1s-alkyl, C2_s-alkenyl, C2_s-alkynyl, and C1_s-alkyl substituted with one or more selected from the group consisting of halogen and phenyl;
W is oxygen or sulphur;
R6, and R7 independently are C1_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 are independently selected from hydrogen, C1-1s-alkyl, C2_s-alkenyl, C2_s-alkynyl, C1_10-alkoxy, and C1_s-alkyl substituted with one or more independently selected from the group consisting of -COR6 , halogen, and phenyl;
R6 is hydrogen or C1-C3 alkyl;
R3 is selected from the group consisting of C1_s-alk~l, C2-s-alkenyl and C2_s-alkynyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or ~;
....... is a single or double bond.
Preferred R1' groups include phenyl, C1_1s-alkyl, and (NR2 ~3. The process of Scheme IV is particularly advantageous because the process provides a method for inverting the stereochemistry at the carbon bearing the hydroxyl group in G.
W O 97/20819 PCT~US96/19229 Another new process illustrated by Scheme VI, involves the sequential reaction of 3,4-dihydroxy-1,2,5-thiadiazole with G-OH wherein G is defined as defined supra.
in the presence o~ a phosphorous(III) compounds and a diester of azodicarboxylate to give an unisolated hydrox~-1, 2,5-thiadiazole ether I'' followed by reaction of I'' with R~OH
where R4 is defined as supra. with phosphorous(III) compounds and a diester of azodicarboxylate to give the diethers of 3,4-dihydroxy-1,2,5-thiadiazole which are useful as muscarinic agonists and antagonists. (See, Org. Prep. &
Procedures 1969, 1, 255-258) The substituents illustrated in Scheme VI are as defined supra.
Scheme VI
G- OH
~_ CO2R2 ~ ~ N
OH N _ OH
~ P(Rl )3 CO2R3 R40H ,N
R4 ~ OH P(R~)3 ~ N
11 oR41 II N
Co2R3 Alternatively, the order of addition of the alcohols may be reversed as shown above to yive unisolated hydroxy-1,2,5-thiadiazole ether II which is subsequently converted to the same final muscarinic active compound.
W O 97/20819 PCT~US96/19229 The process illustrated by Scheme VII encompases the reaction of a phenol or hydroxyheteroaryl compound with compound III in the presence of a phosphorus(III) compound and a diester of azodicarboxylate to give compound IV.
S~heme VII
Aryl - OH
or Heteroa~yl- OH
P(Rl~)3 G ~ CE2 ) r w~ G ~ CH2 ~ r~w~
R6l ~ IV OAryl III Co2R3 (OHeteroaryl) In compound III, G(CH2)rW is as defined supra. and R6 is selected from the group consisting of R7, -oR7, -SR7, -SoR7, -So2R7~ C3_10-cycloalkyl, C4_12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl);
R7 is Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, -CN, Cl_4-alkyl, cl_4-alkoxy~
-OCF3, and -CF3;
provided that at least one alkyl atom of R6' is substituted with a hydroxyl group or R6'is a substituent selected from the group consisting of -oR8Y, -SR8Y, oR8-z-y~ -SR8ZY, -o-R
Z-R7 and -S-R8-Z-R7 wherein each -oR8Y, -SR8Y, oR8-Z-Y, -SR8ZY, -o-R8-z-R7 and -S-R8-Z-R7 is substituted with a alkylhydroxyl;
Y is a 5 or 6 membered heterocyclic group;
z is oxygen or sulphur;
R8 iS Cl_l5-alkyl, C2_1s-alkenyl, C2_1s-alkynyl;
W O 97/20819 PCT~US96/19229 aryl and heteroaryl is optionally substituted with one or more independently selected from the group consisting of halogen, -C~, Cl_4-alkyl, Cl_4-alkoxy, Cl_4-alkylthio, Cl-4-alkylsulfone, Cl_4-al~ylsulfoxide, -OCF3, NO2, N(R7)2, and -CF3; heteroaryl group is a 5 or 6 membered heterocycle containing one to four N, O, or S atomS or a combination thereof.
Another process of this inVention, illustrated by Scheme VIII, is the synthesis of 3-hydroxy-4-alkylthio-1,2,5-thiadiazoles by treating 3-halo-4-alkylthio-1,2,5-thiadiazoles with aqueous alkaline metal hydroxides in the preSence or absence o~ a dipolar aprotic solvent. In this scheme, Hal has the meanings defined supra. and M is an alkali metal, W iS O or S.
Scheme VI~I
~-'' \ MOH ~ ~ ~
Hal ~ HaO ( opt ) ~N
WRR ~Rr RR is hydrogen, R4, C3_l0-cycloalkyl~ C4-12-(cycloalkylalkyl), R4-Z-C3_1o-cycloalkyl and R4-Z-C4_12-(cycloalkylalkyl);
R4 is selected from the group consisting of Cl_ls-alkyl, C2_1s-alkenyl, and C2-1s-alkynyl, each of which iS
optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted With one or more selected from the group consisting of halogen, Cl_4-alkyl, Cl_4-alkoxy, and -CF3; or RR is phenyl or benzyloxycarbonyl, each of which is optionally substituted With one or more selected from the W O 97/20819 PCT~US96/19229 group consisting of halogen, Cl_4-alkyl, Cl_4-alkoxy, and -CF3; or RR is R~-oR5Y R4-SR5Y, R4-oR5-z-y, R4-SR5ZY, R4_o_R5_z_R4 or R4-S-R5-Z-;
z is oxygen or sulphur;
R5 is selected from the group consisting of C1_1s-alkyl, C2_1s-alkenyl, and C2_1s-alkynyl;
Y is a 5 or 6 membered heterocyclic group; and R6, and R7 independently are hydrogen, C1_6-alkyl, or R6 and R7 together with the nitrogen atom optionally form a 4-to 6-member ring;
R1 and R2 independently are hydrogen, C1-1s-alkYl, C2-s-alkenyl, C2_s-alkynyl, C1_10-alkoxy, C1_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R6 is hydrogen or C1-C3 alkyl;
W is O or S;
Hal is selected from Cl, Br, F, I, and if W is O then Hal may be SO2R4 ;
R4' is Cl-C3 alkyl or phenyl.
The compounds (11) are useful intermediates for the preparation of 1, 2, 5-thiadiazole compounds. The artisan will recognize that the intermediates 11 are useful for preparing 1,2,5-thiadiazole compounds as illustrated by the processes of Schemes I, II, and III.
When the G substituent contains a secondary nitrogen protected by a protecting group, the protecting group may be removed using standard methods known to the skilled artisan. An especially preferred protecting group is carbamate. One particularly useful reference concerning protecting groups is Greene, Protectina Grou~s in Ora~nic Svnthesis, (John Wiley & Sons, New York, 1981).
Compounds of this invention may be prepared by the process illustrated in Scheme II
W O 97/20819 PCT~US96/19229 Scl~
N G(CH?)rWh ~ N
~ he artisan will recognize that the starting materials for the process of Scheme II are commercially available or can be prepared using methods familiar to the skilled artisan.
Compounds of Formula I wherein R iS an R4 group, can be prepared using methods well known in the art. See for example, U.S. Patent Number 5,043,345.
Further, compounds of Formula I may be prepared using the process illustrated in the following Scheme III
Scheme m N~O~N 1. Na2S OI NaSH and ~O~
~ 2. RX N N
G(CH2~W P (especially desired G(cH2),-W 8R~
if PisCl;WisO;
r is 0) o~idize h+QR
N~ ~N
Q(CH2b~W QR2~ G(CH ~,-W R~
As used in Scheme III, Q may be N, o or S; R24 is selected from the group consisting of hydrogen, R~, R5, R6, and R7; R25is selected from the group consisting of SoR4 and So2R4; all other meanings are as defined supra.
Additional compounds o~ Formula I may be prepared using the process illustrated by Scheme IV.
W O 97/20819 PCT~US96/19229 SchemerV
G~CH~ ~ N~ amineG~CH~r ~/0 N NR22R2~
..
reduction ~W~N
N
As used in Scheme IV, Hal, W, r, and G are as defined supra . As used in Scheme IV, R22 and R23 are independently selected from the group consisting of hydrogen, R6 and R7.
Compounds of Formula I' can be prepared by a) reacting a compound of formula II
G~CH~fW ~ N ~
Cl \ N II
wherein G, W and r have the me;~ning de~ined above with h+QR
wherein h+ is an alkoxide metal; Q is O or S and R has the me~ning defined above, or b) reacting a compound of formula III or IV
P R III;
~ N~R
I
p ~ N IV;
wherein P is R9SO2 or halogen; R9 is Cl_g straight or branched chain alkyl or aryl; and R has the meaning defined above;
with G-(CH2)r-W-~h+ wherein h+, G, W and r have the meanings defined above.
The compounds of Formula I' can be prepared as described supra. and by using the chemical processes illustrated in Scheme I. The starting materials for the illustrated process are commercially available or may be prepared using methods known to the skilled artisan.
Scbeme I
Hal~
G(CH2~,Wh~ H~ J G(CH~),W ;~¢ ~
\~;~¢I'q R R40- b+
R4S' h+
G(CH~),W ~L
CA 0223930l l998-06-02 W O 97/20819 PCTnUS96/19229 As used in Scheme I, R, h+, and G are as defined supra. As used in Scheme I, the term ~Hal~ refers to Cl, sr, I, and R9so2.
When the G substituent contains a secondary nitrogen protected by a protecting group, the protecting group may be removed using standard methods known to the skilled artisan. An especially preferred protecting group is carbamate. One particularly useful reference concerning protecting groups is Greene, Protectina Grou~s in Oraanic Svnthes;s. (John Wiley & So~s, New York, lg81).
Certain compounds of this invention may more preferredly be prepared using the process of Scheme V.
Scheme v SH ~ ~ ~ O
Cl KOC(CH333 ~
Potassium t-butoxide or another appropriate alkali metal base was added at about 0~ C. to an alkylthiol in THF and stirred.
The haloopyra~ine was added and the reaction stirred at about room temperature. A sample of about 1 N acid was added and the aqueous solution washed. The pH was adjusted to about 12Ø The product was extracted, dried and evaporated. The salt was optionally formed using standard methods.
Certain of the compounds of this invention can more preferredly be prepared using the process illustrated by Scheme VI.
.
W O 97/20819 PCT~US96/19229 ~cheIne VI
~OH THF ~ ~ Na2S ~ O
KOC(CH~)3 ~ ~ "~~
Cl N~ ~ )= N DMF \~ = N
!1 (CH2)20CH3 Cl N' The alcohol was added to a mixture of potassium t-butoxide in THF at about room temperature. The reaction was cooled to about 5~ C. The 2,3-dichloropyrazine in THF was S added to the mixture. The reaction mixture was stirred at about room temperature for about 2 hrs, condensed, diluted with water and ethyl acetate. The organic solution was dried and condensed. The chloropyrazine derivative and sodium sulfide ~Na2S 9H2O), were heated in DMF at about 50~ C. for about 3.5 hr, cooled to about 0~ C. Then 2-Bromoethylmethyl-ether was added. The reaction was stirred at about room temperature overnight and diluted with ethyl acetate and about 5 N acid. The aqueous layer was washed and the pH
adjusted to about 12Ø The product was extracted, dried, condensed and purified by HPLC. The salt form of the product was optionally formed using standard methods.
The term '~analgesic dose", as used herein, represents an amount of compound necessary to prevent or treat a human susceptible to or suffering from pain following administration to such human. The active compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment o~ adult hllm~n~, the range o~ about 0.05 to about 100 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, W O 97~0819 PCT~US96/19229 weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
While the present compounds are preferably administered orally to hllm~n~ susceptible to or suffering from anxiety, the compounds may also be ~min;stered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes. such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
The term "NSAIDS", as used herein, represents a nonsteroidal anti-inflammatory drug which can be identified as such by the skilled artisan. For example, the Merck M~n~ , 16th Edition, Merck Research Laboratories (1990) pp 1308 - 1309 provide well known examples of NSAIDS. The term is intended to include, but is not limited to salicylates such as aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac. Especially preferred NSAIDS include aspirin, ibuprofen, and naproxen.
Alternative preferred NSAIDS are indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
Particularly preferred NSAIDS include aspirin and ibuprofen.
The salicylates may include acetylsalicylic acid, sodium acetylsalicylic acid, calcium acetylsalicylic acid, salicylic acid, and sodium salicylate. An especially preferred NSAID
is ibuprofen.
The term "acetaminophen", as used herein, shall have the art accepted me~n;ng and refers to N-(4-Hydroxyphenyl)acetamide and 4~-hydroxyacetanilide. The compound is claimed in U.S. Patent No. 2,998,450 and is known to the skilled artisan.
W O 97/20819 PCT~US96/19229 The term ~central alpha-adrenergic active compounds", as used herein, represents a compound having central alpha-adrenergic receptor activity. The most pre~erred central alpha-adrenergic active compound is clonidine or a pharmaceutically acceptable salt thereof having the chemical name: 2-(2,6-dichlorophenylamino)-2-imidazoline.
Clonidine is known to be useful for treating hypertension. see Physicians~ Desk Re~erence, 45th Ed.
(1991) p. 673.
The term "opioid", as used herein, represents opioid analgesics and antagonists including natural opioid analgesics, synthetic opioid analgesics, opioid antagonists and opioid agonist-antagonists. Preferred an opioid compounds are selected from the group consisting of morphine, codeine, meperidine, meth~one, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton~s cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabllph;ne, and buprenorphine. More preferred opioid compounds are selected ~rom the group consisting of codeine, nabuphine, naloxone, and naltrexone.
Preferred an opioid compounds are morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, bromptonls cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
Especially preferred opioid compounds are selected from the group con~isting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
Particularly preferred opioid compound~ are selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine. The especially particularly preferred opioid compounds are selected from morphine and codeine.
W O 97/20819 PCT~US96/19229 As used herein, the phrase "one or more" most preferredly refers to one; however, two, three, or more may be used.
We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with non-steroidal antiinflammatory agents (NSAIDS). More specifically, the invention provides a method of treating pain in hllm~n~ using a specified known compounds (collectively referred to herein as "selected muscarinic compoundsll) in combination with a NSAIDS to provide a synergistic ef~ect. The Selected Muscarinic Compounds are believed to be active based on activity at muscarinic cholinergic receptors; however, the present invention is in no way limited by the mechanism o~
action.
We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with acetaminophen.
More specifically, the invention provides a method of treating pain in hllm~n~ using a specified Selected Muscarinic Compounds in combination with acet~minophen to provide a synergistic effect.
Further, we have discovered that a group of compounds having muscarinic cholinergic activity can be particularly useful for treating pain when used in combination with central alpha-adrenergic active compounds.
More specifically, the invention provides a method of treating pain in humans using Selected Muscarinic Compounds in combination with a central alpha-adrenergic active compound to provide a synergistic effect.
Oral combinations of aspirin with codeine or other narcotic analgesics are known to provide additive analgesic effects in man. The Pharmacological Basis of Therapeutics, 5th edition, Macmillan Publishing Co., 1975, pp 325-358.
The present invention further envisions that one or more Selected Muscarlnic Compounds may be used at one time in the composition of this invention to provide the desired analgesic effect.
In the composition of this invention a Selected Muscarinic Compound and NSAIDS compound are combined in a weight ratio of Compound to NSAIDS of from about 1 to about 1000 .
A preferred composition is a weight ratio of Compound to NSAIDS of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A
further preferred ratio may be from about 1 to about 10. A
final preferred ratio may be from about 1 to about 3.
There are many NSAIDS known in the literature and to the skilled artisan.
In the composition of this invention a Selected Muscarinic Compound and acetaminophen are combined in a weight ratio of Selected Muscarinic Compound to acetaminophen of from about 1 to about 1000.
A preferred composition is a weight ratio of Selected Muscarinic Compound to acet~m;nophen of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The Selected Muscarinic Compounds are effective over a wide dosage range; however, it is de~irable to administer a dosage that is as low as possible. The amount of NSAIDS present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage. The amount of acetaminophen present in the composition is adjusted as described above in ratio to the Selected Muscarinic compound dosage.
In the composition of this invention a Selected Muscarinic Compound selected and one or more opioid compounds are combined in a weight ratio of Selected Muscarinic Compound to opioid compound of from about 1 to about 1000.
WO 97/20819 PCT~US96/19229 A preferred composition is a weight ratio of Selected Muscarinic Compound to opioid compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be ~rom about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The amount of opioid compound present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage.
However, for each composition claimed herein, it will be understood that the amount of the Selected Muscarinic Compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of ~elected Muscarinic Compound to be administered, the age, weight, and response of the individual patient, the severity of the patient~s symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. While the present compounds are preferably administered orally to hllmAn~ susceptible to or suffering from pain, the compounds may also be administered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes. Such formulations may be designed to provide delayed or controlled release using formulation techni~ues which are known in the art.
Transdermal formulations cont~;ning the composition claimed herein most preferably deliver the active substances in an effective amount for from about three days to about seven days. However, for chronic pain such as arthritis or cancer pain, a transdermal delivery of from about three days to up to about two weeks is desirable. Alternatively, it may be preferred to deliver the claimed compositions transdermally in an e~fective amount for from about one day to about three days.
AS used herein the ~erm ~treating~ includes prophylaxis o~ a physical and/or mental condition or amelioration or ~llmln~tion of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
The Selected Muscarinic Compounds employed in the invention are not believed to act via the GABA/benzodiazepine, 5HT1A, or Dl receptor systems in hl~m~ns.
Rather, the activity of the present Selected Muscarinic Compounds as analgesic agents is believed to be based upon modulation of muscarinic cholinergic receptors. However, the mechanism by which the present compounds function is not necessarily the mechanism stated supra., and the present invention is not limited by any mode of operation.
Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts lis~ed in ~ournal of Pharmaceutic~l Science, 66, 2 (1977) which are known to the skilled artisan. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
The dosage administered will, of course, vary depending on known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of the symptoms, kind of W O 97/20819 PCT~US96/19229 concurrent treatment, fre~uency of treatment, and the effect desired. Usually, the daily dosage can be such that the active ingredient is ~mlnistered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight Selected Muscarinic Compound and from about 0.6 to about 200 mg/kg of NSAIDS.
Compositions suitable for internal administration contain from about one half (0.5) milligrams to about 600 milligrams of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of from about 0.5%
to about 95% by weight based on the total weight of the composition.
For compositions containing acet~m;nophen, usually, the daily dosage can be such that the active ingredient is ~m; n; stered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Selected Muscarinic Compound and from about 0.6 to about 200 mg/kg of acetaminophen.
Typical compositions include a compound of Selected Muscarinic Compound and one or more NSAIDSs, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, W O 97/20819 PCT~US96/19229 alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
Typical compositions include a Selected Muscarinic Compound and acetaminophen, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used, as described above.
A preferred composition is a weight ratio of Selected Muscarinic Compound to central alpha-adrenergic active compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The Selected Muscarinic Compounds are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible. The amount of central alpha-adrenergic active compound present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage.
Usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Selected W O 97/20819 PCT~US96/19229 -43- .
Muscarinic ompound and from about 0.6 to about 200 mg/kg of central alpha-adrenergic active compound.
Typical compositions include a Selected Muscarinic Compound and one or more central alpha-adrenergic active compounds, associated with apharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the ~orm of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation o~ pharmaceutical compositions may be used.
The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsi~iers, salt for in~luencing osmotic pressure, bu~ers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
For parenteral application, particularly suitable are injectable solutions or suspensions, 2~ preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, andtor potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
Generally, the compositions of this invention are dispensed in unit form comprising from about 0.1 to about 300 mg in a pharmaceutically acceptable carrier per unit dosage.
The compositions of this invention may be suitable for administration to an ~nim~l, Such animals include both domestic ~nim~l S, for example livestock, W O 97/20819 PCT~US96/19229 laboratory animals, and household pets, and non-domestic ~nim~ls such as wildlife. More preferredly, the animal is a vertebrate. Most pre~erredly, a composition of this invention shall be ~min;stered to a m~mm~l, It iS
especially preferred that the animal is a domestic m~mmAl or a human. The most preferred mammal is a human. For such domestic ~nim~l purposes, a composition of this invention may be administered as a feed additive.
The following models and assays are useful for illustrating the effectiveness of the compositions claimed herein.
Nocice~tive ~ain model:
Acetic acid-induced writhing: A standard procedure for detecting and comparing the analgesic activity of different classes of analgesic drugs for which there is a good correlation with human analgesic activity is the prevention of acetic acid-induced writhing in mice. Mice, are subcutaneously ~m; n; stered various doses of the claimed composition and are injected injected intraperitoneally with acetic acid (0.5% solution, 10 ml/kg) 5 min prior to a designated observation period. For scoring purposes a ~writhe~ is indicated by whole body stretching or contraction of the abdomen during the observation period beginning 5 min after receiving the acetic acid. Inhibition of writhing behavior is demonstrative of analgesic activity.
See, Haubrich, D.R., Ward, S.J., Baizman, E., Bell, M.R., Bradford, J., Ferrari, R., Miller, M., Perrone, M., Pierson, A.K., Saelens, J.K. and Luttinger, D.:
Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
Neuro~thic Da~ n model:
Sciatic ner~e li~ation model: Rats are anesthetized and a nerve ligation procedure performed. The common sciatic nerve is exposed and 4 ligatures tied loosely around it with W O 97/20819 PCTnJS96/l9Z29 about 1 mm spacing. One day to 10 weeks after surgery, the nociceptive testing is performed. Responses to noxious heat are determined by placing the rats in a chamber with a clear glass floor and aiming at the plantar surface of the affected foot a radiant heat source from beneath the floor. Increased latency to withdraw the hindpaw is demonstrative of analgesic activity. Responses to normally innocuous mechanical stimuli is determined by placing the rats in a chamber with a screen floor and stimulating the plantar surface of the hind paw with graduated von Frey hairs which are c~l;hrated by ~he grams of force required to bend them. ~ats with sciatic nerve ligation respond to lower grams of mechanical stimulation b~r reflexive withdrawal of the foot than unoperated rats. This response to stimuli which are normally innocuous is termed allodynia. Increases in the grams o~
mechanical force required to produce foot withdrawal is demonstrative of antiallodynic activity.
See, Bennett, G.J. and Xie, Y.-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107.
See also, Lee, Y.-W., Chaplan, S.R. and Yaksh, T.L.:
Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neuroci Lett 186 (1995) 111-114.
Formalin paw test: Rats are anesthetized and when there is a loss of spontaneous movement the rats are injected subcutaneously in the dorsal surface of the hindpaw with 50 ul of 5% formalin solution using a 30 gauge needle. Rats are then individually placed in an open Plexiglas chamber for observation, and within a maximum interval of 1 to 2 min, the ~nlm~l displays recovery from anesthesia with spontaneous activity and normal motor function. Pain behavior is ~uantified by periodically counting the incidents of spontaneous flinching/shaking of the injected paw. The flinches are counted for l-min periods at 1- to 2-, 5- to 6-and 5min intervals during the interval from 10 to 60 min.
CA 0223930l l998-06-02 W O 97/20819 PCTrUS96/19229 Inhibition of the pain behavior is demonstrative of an analgesic activity.
See, Malm~erg, A.B. and Yaksh, T.L.: Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. The Journal of Pharmacology and Experimental Therapeutics 263 (1992) 136-146.
InflA~m~torY ~ain model:
srewer~ yeast-induced hyperalgesia (Randall-Selitto ~est): TO assess nociceptive threshold in rats, ascending pressure is applied gradually to the paw with a motor driven weight of a Ugo sasile Analgesy Meter. Rats respond to the pressure by either pulling free of the device, struggling or vocalizing. Hyperalgesia is induced by a hind paw subplantar injection of 0.1 ml of 1% suspension of brewerls yeast in 0.9~ saline. The composition of this invention is a~m;n;~tered at varying times ( 0 - 4 hr) after injection of brewerls yeast and pressure threshold ~or the inflamed paw again determined at varying times. Increases in the pressure which produces a behavioral response is demonstrative of analgesic activity.
See, Haubrich, D.R., Ward, S.J., Baizman, E., Bell, M.R., Bradford, J., Ferrari, R., Miller, M., Perrone, M., Pierson, A.K., Saelens, J.K. and Luttinger, D.:
Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
Utilitv Test Metho~
The unexpectedly enhanced analgesic activity of the composition of the invention is evidenced by tests intially conducted on mice. Male mice are fasted for 16-22 hours and weighed. Mice weighing from about 18-22 grams at the time of testing are used for the following studies.
All mice are dosed se~uentially by the oral route with suspensions of a composition of this invention. Doses are coded using a code unknown to the observer.
W O 97/20819 PCT~JS96/19229 A stock suspension of the test composition is prepared by mixing the active ingredients with about 40 mL
o~ an aqueous vehicle containing about 2% Tween 80 (R), a pharmacological dispersant and containing 100% polysorbate 80, and 1% by weight Methocel (R) MC powder, and containing 100% methylcellulose, in distilled water. The mixture may be sonicated for about 10 to about 15 seconds using an ultrasound sytem. All dosing suspensions are prepared by dilution of the stock suspension with Methocel/Tween 80.
All suspensions are used within two hours of preparation.
Mouse Writhina Test An accepted standard for detecting and comparing the analgesic activity of different classes of analgesic compounds for which there is a good correlation with human analgesic activity is the prevention of phenyl-p-benzoquinone induced writhing in mice. [H. slumberg et al.
Proc. Soc. Exp. biol. Med., 118, 763-766 (1965)].
Mice, treated with various doses of Selected Muscarinic Compound, composition or vehicle are injected intraperitoneally with a standard challenge dose of phenyl-p-benzoquinone 5 minutes prior to a designated observation period. The pheyl-p-benzoquinone is prepared as about 0.1 mg/ml solution in about 5% by volume of ethanol in water.
The writhing dose is 1.25 mg/kg injected at a volume of about 0.25ml/lOg. For scoring purposes a ~writhe~ is indicated by whole body stretching or contracting of the abdomen during an observation period beginning about five minutes after the phenyl-p-benzoquinone dose.
All ED50 values and their 95% confidence limits are determined using accepted numerical methods. For example, see W.F. Thompson, Bacteriolo~ical Rev., 11, 115-145 (1947). The interaction of the dosages on phenyl-p-benzoquinone induced writhing in mice is demonstrated by the Loewe isobologram (S. Loewe, Pharm. Rev. 9, 237-242 (1957).
W O 97120819 PCT~US96/19229 The solid line connecting the ED50 dosages of Selected Muscarinic Compound (alone) and Synergis~ic Analgesic as claimed herein (alone) represents the ~ED50 addition line" which indicates the expected location of the ED50's for Selected Muscarinic Compound and classical analagesic combinations if simple additivity were to describe their combined effects. The 95% confidence range for the ED50 addition line is shown by the area between the broken lines above and below the ED50 addition line.
According to Loewe's isobolic theory, if the analgesic effects are simply additive to one another, then the expected location of the ED50's of the Selected Muscarinic Compound and Synergistic Analgesic component of each fixed dosage ratio would be contained within or overlap the region of the ED5~ addition line. Combination ED50'S located significantly below the ED50 addition line would represent unexpectedly enhanced analgesic activity and combination ED50'S located above the line would represent unexpected ~;m;n; shed analgesic effect.
One method to establish the significance of such unexpected enhanced or ~;m;n;shed activity is to calculate the best fitting polynomial regression line to the observed ED50'S using standard mathematical techniques.
Such experiments demonstrate that compositions comprised of a Selected Muscarinic Compound and one or more Synergistic Analgesics provides a statistically significant synergistic analgesic effect.
Preferred compounds of Formula I' are selected from the group consisting of:
(+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-pyrazine, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(2,2,3,3,4,4,4-3 5 heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-pyrazine, 3-methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-pentylthio-4-(1-W O 97/20819 PCT~US96/19229 azabicyclo[2.2.2]ocytl-3-oxy)-pyrazine, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-pyrazine, 3-butylthio-4-(3-azetidinyloxy)-pyrazine, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-pyrazine, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-butylthio-4-[3-+-endo-(1-azabicyclo~2.2.13heptyloxy)]-pyrazine, 3-hexyloxy-4-[6-i--endo-(2-azabicyclo[2.2.2]ocyloxy)]-pyrazine, 3-~4,4,4-trifluorobuty]thio)-4-[2-+-exo-(7-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-(2-phenoxyethylthio)-4-[3-i--endo-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(5-hexenyloxy)-4-[7-+-endo-(2-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, and 3-cyclobutylmethyl-4-[2-~--endo-(8-azabicyclo[3.2.1]octyloxy)]-pyrazine.
Some examples of compounds of Formula I' for use in the present analgesic composition include, but are not limited to: 2-[exo-(~/-)-3-[1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-butylthio-2-(1-azabicyclo[2.2.2]ocytl-3-oxy)]pyrazine, 3-butyloxy-2-[3-+-endo-(l-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-butynyloxy)-2-[6-~-endo-(1-azabicyclo[3.2.1]octyloxy)pyrazine, 3-hexylthio-2-[6-+-exo-(2-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(3-phenylpropyny]thio)-2-[2-+-exo-(7-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-methylthioethoxy)-2-[3-i--exo-(1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-propargyl-2-[4-(1-azabicyclo[2.2.1]heptyloxy)]pyrazine, and 3-cyclopropylmethylthio-2-[2-+-exo-(8-azabicyclo[3.2.1]octyloxy)]pyrazine.
For analgesic use, Compounds of Formula I may be preferred. Alternatively, compounds of Formula I' may be preferred. Alternatively, Compounds of Formula Il may be preferred.
W097~0819 PCTAJS96/19229 Some prefered characteristics of compounds of Formula I' for use in the present analgesic composition are:
A) W is S;
B) r is 1 or 2;
C) G is selected from het-l and het-5;
D) G is unsaturated;
E) G is het-4;
F) G is an azabicycle having 7 ring carbon atoms and a nitrogen atom;
G) G is het-6;
H) r is 0;
I) R iS selected from halogen, -oR5Y, -SR5Y, oR5ZY -SR5ZY -oR5ZR4, -SR5ZR4, -oR4, and -SR4;
J) W is O;
K) m is l;
L) n is l;
M) p is 2;
N) G is het-3 O) G is het-2 P) a compound of Formula I' Q) a compound of Formula I' wherein W is oxygen or sulphur;
R is selected from the group consisting of hydrogen, amino, halogen, NHR6, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4, C3_10~
cycloalkyl, C4_12-(cycloalkylalkyl), -Z-C3_10-cycloalkyl and -Z-C4_12- (cycloalkylalkyl); R4 iS selected from the group consisting of Cl_ls-alkyl, C2-ls-alkenyl~ and C2-15-alkynyl, each of which is optionally su~stituted with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, -CN, Cl-4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of W O 97/20819 PCTAUS96/lg229 halogen, -CN, C1_4-alkyl, c1_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; or R is selected i~rom the group consisting o~ -oR5Y, -SR5Y, oR5-Z-Y, -SR5ZY, -o-R5-Z-R4 and -S-R5-Z-R4;
Z is oxygen or sulphur;
R5 is selected from the group consisting of C1_1s-alkyl, C2_1s-alkenyl, and C2_1s-alkynyl;
Y is a 5 or 6 membered heterocyclic group; and G is selected from one o~ the ~ollowing azacyclic or azabicyclic ring systems:
~ ~ R~
h~t-1 het-2 het-3 het-4 R ~ ~ R ~ ~2 het-5 het-6 het-7 or G can optionally be substituted C3-Cg cycloalkyl wherein the substitution is -NR6R7;
R6 and R7 independently are se:Lected ~rom the group consisting of hydrogen and C1_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;~ 20 R1 and R2 independently are selected from the group consisting of hydrogen, C1_1s-alkyl, C2_s-alkenyl, C2_s-al~ynyl, C1_1o-alkoxy, and C1_s-alkyl substituted with a subsituent independently selected ~rom the group consisting of -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, and phenyl;
W O 97/20819 PCT~US96119229 R3 is selected from the group consisting of hydrogen, Cl-s-alkyl, C2_s-alkenyl and C2_s-alkynyl;
R6' is selected from the group consisting of hydrogen and C1_6-alkyl;
n is Q, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
~ is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond;
provided that when w is o and G is a saturated azabicyclic group having from 7 to 11 ring carbon atoms and a nitrogen atom wherein the nitrogen atom is separated from the W atom by 2 to 3 ring carbon atoms;
or a pharmaceutically acceptable salt or solvate thereof;
R) The G substituent is selected from the group consisting of .
N R3--N~-- ~N
, , and S) The G substituent is W O 97/20819 PCTrUS96/19229 T) R is selected from the group consisting of -SR4 , SoR4', -S02R4', substituted benzyloxycarbonyl wherein the su~stitue~ts are one or more independently selected from the group consisting of -CN, -OCF3, -CF3, -CoNH2 and -CSNH2;
or C3_10-cycloalkyl, C4_12-~cycloalkylalkyl), -Z-C3_10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl).
U) R is selected from the group consisting of R4, C3_10-cycloalkyl, C4_12-(cycloalkylalkyl), -Z-C3-1o-cycloalkyl and -Z-C4_12-(cycloalkylalkyl); and R4 is selected from the group consisting o~ substituted Cs_1s-alkyl, optionally substituted C2_1s-alkenyl, and optionally substituted C2_1s-alkynyl, wherein such substituent is one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more substituents ~elected from the group consisting of halogen, -CN, C1_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2.
v~ G is selected from the group consisting of het-4, het-7, het-6 wherein n=2; het-3 wherein one of n and m is 0 or 2; and het-3 wherein the I or I' group is attached at tlle bridgehead of het-3.
Especially preferred compounds of this invention have the characteristics of A-F,P; A-F,Q; characteristics of A, G, H, M, F; characteristics of G-O,Q; or the characteristics of G-J,M,P; or G-J,M,Q. The characteristics of R and S may be particularly preferred.
Further, especially preferred R groups include phenyl, benzyloxycarbonyl, -oR5Y, -SR5Y, oR5-Z-Y, -SR5ZY, -o-R4-z-R5 or -S-R4-Z-R5, -SoR4~ c3 10-cycloalkyl, C4_l2-(cycloalkylalkyl), -Z-C3_10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl) wherein Z is oxygen or sulphur, R5 is C1_ l5-alkyl, C2_15-alkenyl~ C2_1s-alkynyl, Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, R4 is Cl_ls-alkyl, C2_ 15-al]~enY1, and C2_1s-alkynyl.
W O 97/20819 PCTrUS96/19229 Pre~erred compounds o~ Formula I1l are any one or more selected from the group consisting of:
(i)-3-Methoxy-4-(1-azabicyclo~2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Ethox~-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Propyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Butyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Pentyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Hexyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(4-Methylpentyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Chloro-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Propylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Butylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (S)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, W O 97/20819 PCT~US96/19229 (i)-3-Hexylthio-4-(1-azabicyclo[2.2.2]octyl-3-oAYy)-1,2,5-thiadiazole, (i)-3-(3,3-Dimethylbutylthio)-4-(1-azabicyclo~2.2.2]octyl-3-oxy) ~lr 2,5-thiadiazole, A
~i)-3-(2-(2-Thienylthio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (+)-3-(2,2,3,3,3-Penta~luoropropylthio)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-(2-Thienyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-sutylthio-4-((l-azabicyclo[2.2.2]octan-3-yl)methoAyy) 1,2,5-thiadiazole, (i)-Exo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (+)-Endo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (i)-Endo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole, (i)-Exo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Butyloxy-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-Butyloxy-4-(1-methyl-3-pyrrolidinyloxy)-1,2,5-thiadiazole, (+)-3-Butylthio-4-(1-methyl-3-piperidyloxy)-1,2,5-thiadiazole, wo 97nO819 PCTrUS96/19229 3-Butylthio-4-(1-methyl-4-piperidyloxy)-1,2,5-thiadiazole, (S)-3-sutyloxy-4-(1-methyl-2-pyrrolidinylmethoxy)-1,2,5-thiadiazole, (S)-3-sutyloxy-4-(2-pyrrolidinylmethoxy)-1,2,5-thiadiazole, 3-sutyloxy-4-(2-(dimethylamino)ethoxy)-1,2,5-thiadiazole, 3-Butylthio-4-(2-(diethylamino)ethoxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(2-(trimethylamino)ethoxy)-1,2,5-thiadiazole iodide, (R)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(4-Methylpentylthio)-4-(1-azabicyclo[2.2.2]octyl-3-2~ oxy)-1,2,5-thiadiazole, (~)-3-(3-Phenylpropylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(4-Cyanobenzylthio)-4-(1-azabicyclo~2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(4-Fluorobenzylthio)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5- thiadiazole, (~)-3-(2-Phenylethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (+)-3-(2-Phenyloxyethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, W O 97~0819 PCT~US96/19229 Endo-3-~utyloxy-4-(N-methyl-8-azabicyclo[3.2.1]octyl-3-oxy)-1,2,5-thiadiazole, (i)-Exo-3-butyloxy-4-~6-(N-methyl-8-azabicyclo[3.2.1]octan-3-onoxy))-1,2,5-thiadiazole, (i)-Exo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (+)-Endo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (i)-Endo-3-(4-cyanobenzylthio)-4-(1-azabicyclo~3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(3-azetidinyloxy)-1,2,S-thiadiazole, 3-Butylthio-4-(3-azetidinyloxy)-1,2,5-thiadiazole, (i)-Tran~-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole, (i)-3-Butylthio-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (i)-3-(2-(2-(5-(2-Thienyl)thienyl)thio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(2-(5-(2-Thienyl)thienyl)thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(3-N-(2-Thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5-thiadiazole, (i)3-Butylthio-4-(exo-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole, =
W O 97/20819 PCT~US96119229 (~)3-(2,2,3,3,4,4,4-heptafluorobutyloxy)-4-r-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole, (+)3-(1-butylthio)-4-[endo-6-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-thiadiazole, (i)3-(3-phenylpropylthio)-4-[endo-6-(1-azabicyclo-[3.2.1]octyloxy)]-1,2,5-thiadiazole (i)3-[3-(4-fluorophenyl)propylthio]-4-[-3-(1-azabicyclo-[2.2.2]octyloxy)]-1,2,5-thiadiazole (~)3-{3-[4-(trifluoromethyl)phenyl]propylthio}-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (i)3-(1-sutylamino)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (i)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-Butylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-Propylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-(4,4,4-Trifluorobutyloxy)-4-~1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-(2-Butynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[2.2.23octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Phenylpropynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Butenyloxy)-4-(1-azabicyclor2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-Methoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-sutynoxy)-4-(1-azabicycloE2.2.2~octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-(Methylthio)ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Chloropropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole -(i)-3-(4-Fluorobutyloxy)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5-thiadiazole ~ 3-(2-[4-Chlorophenoxy]ethoxy)-4-(1-azabicyclo~2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-[2-methoxy-5-pyridyl]propyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(trans-3-Chloro-2-propenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-[4-Fluorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy~-1,2,5-thiadiazole (i)-3-(4-Pentenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Fluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-(Cyclobutylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3,3,3,2,2-Pentafluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-[Phenylthio]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-[1-napthyloxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-[4-sromophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-Hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-Butylthio-4-hydroxy-1,2,5-thiadiazole w o 97nO819 PCT~US96/19229 (+)Exo-3-sutylthio-4~ azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[3-{1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2~octyl-3-oxy3-1,2,5-thiadiazole (i)-exo-3-sutyloxy-4-(7-azabicyclo ~2 . 2 .1] heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-sutyloxy-4-(3-piperidinyloxy)-1,2,5-thiadiazole 3-sutyloxy-4-( cis-lR-2 -aminocyclopentanoxy)-1,2,5-thiadiazole (i)-endo-3-Hexyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1, 2, 5-thiadiazole (5S,6S) -endo-3 -Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole f~R, 6R) -endo-3 -Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-trans-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1, 2, 5-thiadiazole (+)-cis-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole (+)-trans-3-Butylthio-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole 3-Butylthio-4-(2-dimethylaminoethoxy)-1,2,5-thiadiazole (+)-trans-3-Butylthio-4-(N-tert-butylcarboxy-4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole W O 97/20819 PCT~US96/19229 trans-3-Butylthio-4- (4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole (i) -endo-3-Butyloxy-4- (1-azabicyclo[3. 2.1]octyl-6-oxy)-1,2,5-thiadiazole ~+)-3 -(4-Phenylbutylthio)-4-( 1-azabicyclo[ 2.2. 2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3- (3-Phenyl-2-propenylthio) -4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-[4-Fluorophenyl]propan-3-onethio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-(3-[N-Phenothiazinyl]propylthio)-4-~1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (:~:) -3-(3-[4-Fluorophenyl]-3-[4-fluorophenoxy]propylthio)-4-(l-azabicyclo[2.2. 2~ octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Phenyl-3-[4-trifluoromethylphe~oxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(4,4,4-Trifluorobutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[3-Pyridyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-endo-3- (2-Phenoxyethylthio)-4-(1-azabicyclo [3. 2.1]octyl-6-oxy)-1,2,5-thiadiazole (i) -exo-3 -Propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole W O 97/208~9 PCTAUS96/19229 (+)-exo-3- Propylsulfonyl-4-~2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (+)-exo-3- (4,4,4-Trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(4,4, 4-Trifluorobutyloxy) -4- (2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (+) -exo-3- (Hexyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(4,4, 4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (+)-exo-3- (2-[Fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (+)-exo-3- (2-[Fluorophenoxy]ethylthio)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-Propylthio-4- (1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i) -endo-3 -Propylsulfonyl-4-(1-azabicyclo [3. 2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4, 4-Tri~luorobutoxy)-4-(1-azabicyclo[ 3. 2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3- (2-Butynyloxy)-4-(1-azabicyclo [3.2.1] octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-(trans-2 -Butenyloxy)-4-(1-3 5 azabicyclo[3.2.1]octyl-5-oxy)-1,2,5-thiadiazole (i)-endo-3-(2-Methylthioethoxy)-4-(1-azabicyclo~3.2.1]octyl-6-oxy)-1,2,5-thiadiazole ~i)-endo-3-(2-(4-Methyl-1,3-thiazol-5-yl)ethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(4-Methylthiobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole ~i)-endo-3-(2-Thienylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(2-Cyclohexenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(3-Pentynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(3-Hexynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Chloropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) -endo-3- [2-(2-Napthalyl)ethoxy]-4~
azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-t4-Chloro-~-cyclopropyl-benzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(4-Methyl-3-pentenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+) -endo-3 - (Cyclopropylmethoxy)-4-(1-azabicyclo [3 . 2 .1] octyl-6-oxy)-1,2,5-thladiazole (+)-endo-3-(2-Methoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole -(+) -endo-3- (3-Butenyloxy)-4-~1-azabicyclo [3 .2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole ~ endo-3-(3-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+) -endo-3- (4,4,4, 3, 3, 2,2-Heptafluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-[2-(3-Trifluoromethylphenyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-[2-(2-Thienyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+) - endo-3 - ( 3, 3, 3, 2,2,Pentafluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(4-n-sutylbenzyloxy)-4-(1-~ azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole ( i ) - end o- 3-[3-(4-Methoxyphenyl)propoxy]-4-(1-azabicyclo [3 . 2.1]octyl-6-oxy)-1,2,5-thiadiazole W O 97/20819 PCT~US96/19229 (i) -endo-3- (4-Fluorobenzyloxy)-4-(1-azabicyclo [3 . 2.1]octyl-6-oxy)-1,2,5-thiadiazole (i) -endo-3- (2, 4-Di~luorobenzyloxy)-4~
azabicyclo [3 . 2 .1] octyl-6-oxy)-1, 2, 5-thiadiazole (i) -endo-3- [4- (Trifluoromethoxy)benzyloxy] -4- (1-azabicyclo[ 3 . 2 .l]octyl-6-oxy)-1, 2, 5-thiadiazole (i)-endo-3- (4-Fluorobutoxy)-4-(1-azabicyclo[3 .2 .l]octyl-6-oxy)-1,2,5-thiadiazole (i) - end o-3 - ( 4- tert -Butylbenzyloxy)-4-(1-azabicyclo [3 . 2 .1] octyl-6-oxy)-1,2,5-thiadiazole ~ endo-3-(1-Cyclopropylethoxy)-4-(1-azabicyclo [3 . 2 .1] octyl-6-oxy)-1,2,S-thiadiazole (i) -endo-3- (2-Cyclohexylethoxy)-4-(1-azabicyclo[3. 2 .1] octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(3-Methyl-2-butenyloxy)-4-(1-azabicyclo[3. 2 .1] octyl-6-oxy)-1,2,5-thiadiazole (i) -endo-3- (4-Cyclohexylbutoxy)-4-(1-azabicyclo [3 . 2 .1] octyl-6-oxy)-1,2,5-thiadiazole (i) - endo-3 - ( 3-Butyn-2-oxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1, 2, 5- thiadiazole (i)-endo-3-(3-Methyl-3-phenylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(3-Fluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole CA 0223930l 1998-06-02 W O 97/20819 PCT~US96/19229 (i) -endo-3- [3- (2-Thienyl)propoxy]-4-(1-azabicyclo[3.2.1] octyl-6-oxy)-1, 2,5-thiadiazole (+) -3- (2-[4-Fluorophenoxy]ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy~-1,2,5-thiadiazole li)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-sutylthio-4-hydroxy-1,2,5-thiadiazole 3-(2-[3-{1,2,5-Thi~ 70yloxy} ]ethoxy)-4-~1-azabicyclo[2.2.2]octyl -3 -oxy ) -1, 2,5-thiadiazole and (+)Exo-3-Butylthio-4- (1-azabicyclor2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole.
Preferred compounds o~ Formula I are selected from the group consisting o~:
(+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-1,2,5-oxadiazole, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(2,2,3,3,4,4,4-heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-oxadiazole, 3-3Q methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-pentylthio-4-(1-azabicyclo[2.2.2]ocytl-3-oxy)-1,2,5-oxadiazole, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-oxadiazole, 3-butylthio-4-(3-azetidinyloxy)-1,2,5-oxadiazole, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-oxadiazole, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-butylthio-4-~3-+-endo-(1-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-hexyloxy-4-[6-i-endo-(2-azabicyclo[2.2.2locyloxy)]-1,2,5-oxadiazole, 3-~4,4,~-trifluorobutylthio)-4-[2-+-exo-(7-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-(2-phenoxyethylthio)-4-[3-~-endo-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(5-hexenyloxy)-4-[7-+-endo-(2-azabicyclo[2.2.1]heptyloxy)~-1,2,5-oxadiazole, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, and 3-cyclobutylmethyl-4-[2-+-endo-(8-azabicyclo[3.2.1~octyloxy)]-1,2,5-oxadiazole.
Some prefered characteristics of compound of Formula I for the composition are:
A) W is S;
B) r is 1 or 2;
C) G is selected from het-l and het-5;
D) G is unsaturated E) G is het-4;
F) G is an azabicycle having 7 ring carbon atoms and a nitrogen atom;
G) G is het-6;
H) r is 0;
I) R iS selected from halogen, -oR5y~ -SR5Y, -oR5ZY, -SR5ZY, -oR5ZR4, -SR5ZR4, -oR4, and -SR4;
J) W is O;
K) m is l;
L) n is l;
M) p is 2;
N) G is het-3 O~ G is het-2 P) a compound of Formula I
Q) a compound of Formula I
R) a compound of Formula I
wherein W is oxygen or sulphur;
R is selected from the group consisting of hydrogen, amino, halogen, NHR5, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4, C3_10-W O 97/20819 PCT~US96/19229 cycloalkyl, C4_l2-(cycloalkylalkyl), -Z-C3_l0-cycloalkyl and -Z-C4_l2-(cycloalkylalkyl); R4 is selected from the group consisting of Cl-ls-alkyl~ c2-ls-alkenylt and C2-15-alkynyl, each of which is optionally substituted with one S or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, -CN, Cl-4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; or R is phenyl or benzyloxycarbonyl, each o~ which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -CN, Cl_4-alkyl, Cl_4-alko~y, -OCF3, -CF3, -CONH2 and -CSNH2; or R is selected from the group consisting of -oR5y~ -SR5Y, oR5-Z-Y, -SR5ZY, -o-R5-Z-R4 and -S-R5-Z-R4;
Z is oxygen or sulphur;
R5 is selected from the group consisting of Cl_ls-alkyl, C2_1s-alkenyl, and C2_1s-alkynyl;
Y iS a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
~N ~ ~ 3 hst-l het-2 het-3het-4 R~R~ Cm ~
het-~ het-6 het-7 . -70-or G can optionally be substituted C3-Cg cycloalkyl wherein the substitution is -NR6R7;
R6 and R7 independently are selected from the group consisting of hydrogen and C1_6-alkyl; or R6 and R7 together wlth the nitrogen atom optionally form a 4- to 6-member rlng;
R1 and R2 independently are selected from the group consisting of hydrogen, C1_1s-alkyl, C2_s-alkenyl, C2_s-alkynyl, C1_10-alkoxy, and C1_s-alkyl substituted with a subsituent independently selected from the group consisting of -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, and phenyl;
R3 is selected from the group consisting of hydrogen, C1_s-alkyl, C2_s-alkenyl and C2_s-alkynyl;
R6 is selected from the group consisting of hydrogen and C1_6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond;
provided that when W is O and G is a saturated azabicyclic group having from 7 to 11 ring carbon atoms and a nitrogen atom wherein the nitrogen atom is separated from the W atom by 2 to 3 ring carbon atoms;
or a pharmaceutically acceptable salt or solvate thereof;
S) The G substituent is selected from the group consisting of ~ , ~ , R3 R3-N~ ~ and ~N.
T) The G substituent is CA 0223930l l998-06-02 W O 97n~819 PCT~US96/19229 ~, U) R is selected from the group consisting of -SR4 , SoR4 , -So2R4 , substituted benzyloxycarbonyl wherein the substituents are one or more independently selected from the group consisting of -CN, -OCF3, -CF3, -CONH2 and -CSNH2;
or C3_l0-cycloalkyl, c4-l2-(cycloalkylalkyl)~ -Z-C3_l0-cycloalkyl and -Z-C4_12-(cycloalkylalkyl).
V) R is selected from the group consisting of R4, C3-1o -cycloalkyl, C4_12-(cycloalkylal}~l), -z-C3_l~-cycloalkyl and -Z-C4_12-(cycloalkylalkyl); and R~ is selected from the group consisting of substituted Cs_ls-alkyl, optionally substituted C2_1s-alkenyl, and optionally substituted C2-1s-alkynyl, wherein such substituent is one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, Cl_~-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2.
W) G is selected from the group consisting of het-4, het-7, het-6 wherein n=2; het-3 wherein one of n and m is 0 or 2; and het-3 wherein the I or I group is attached at the bridgehead of het-3.
Especially preferred compounds of this invention have the characteristics of A-F,P; A-F,Q; characteristics of A, G, H, M, F; characteristics of G-O,Q; or the characteristics of G-J,M,P; or G-J,M,Q. The characteristics of R and S may be particularly preferred.
Further, especially preferred R groups include phenyl, benzyloxycarbonyl, -oR5y ~ - SR5Y, oR5-Z-Y, -SR5ZY, -o-R4-z-R5 or -S-R4-Z-R5, -SoR4, C3_l0-çycloalkyl, C4_l2-(cycloalkylalkyl), -Z-C3_l0-cycloalkyl and -Z-C4-l2-(cycloalkylalkyl) wherein Z is oxygen or sulphur, R5 iS Cl_ 15-alkYl, C2-l5-alkenyl~ C2-ls-alkynyll Y is a 5 or 6 W O 97/20819 PCT~US96/19229 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereo~, R4 iS Cl-15-alkYl~ C2-5-alkenyl~ and C2_1s-alkynyl.
Further, especially preferred G groups include the following heterocycles:
~ ~ ~ I 3 ~ .
l3 R3 R3 R3-N ~ R3-N ~ ~
, , N ; wherein the point of attachment to the -(CH2)r-W- group is as indicated Some particularly pre~erred G groups include R3 R , ~ , and N , It is another preferred embodiment of this invention that G is not an azabicycle, particularly when W is oxygen.
Additionally, another embodiment of this invention which can be preferred is that when W is O and G
is alkyl, R is not halogen.
The invention will now be described in further detail with reference to the following examples. Many compounds of Formula I' can be prepared using the methods and procedures illustrated by the following examples. The examples are provided ~or illustrative purposes, and are not to be construed as limiting the scope of the invention in any way. The NSAIDS can be purchased from commercial vendors or prepared using methods that are well known in the art.
EXAMPLE
3-Chloro-4-(1-butvlthio)-1.2,5-thiadiazole Cyanogen (36 g, 0.69 mol) was bubbled into ether (250 mL) maintained at -10~C. To the solution was added dropwise diethylamine (3 mL) followed by dropwise addition of 1-butylthiol (47 mL, 0.64 mol) at such a rate that the temperature did not exceed -5~C. The reaction was maintained below 0~C for 5 h then stirred at ambient overnight. Ether was distilled from the reaction until the pot temperature reached 50~C. The reaction was cooled to ambient and then added dropwise to a solution of sulfur monochloride (55 mL, 0.688 mol) in DMF (50 mL) that was cooled to 5~C. Cooling was removed and reaction was stirred overnight. The reaction was cooled in an ice-water bath and excess sulfur monochloride destroyed by careful addition of H2O while maint~;n;n~ the temperature below 40~C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The a~ueous fraction was extracted with hexane (3 X) and the combined extracts and triturants were washed with H20, aqueous NaHCO3, brine, dried, and the solvent evaporated. The W O 97/20819 PCT~JS96/19229 residue was distilled at 2 mm Hg to give a yellow liquid (24.6 g), b.p. 105-110~C. (Compound 1).
3-Chloro-4-butYlsulfon~1-1,2,5-thiadiazole A solution of OxoneTM (12 g, 0.0195 mol) in H20 (60 mL) was vigorous stirred as 3-chloro-4-butylthio-1,2,5-thiadiazole (2.1 g, 0.01 mol) in THF (30 mL) was added dropwise. After 24 h, the THF was evaporated and the residue extracted with ether (3X). Extracts were washed with H2O, dried, and solvent evaporated to give a clear liquid. Radial chromatography eluting with 30 %
EtOAc/hexane gave a colorless liquid (2.3 g). (Compound 2).
3-Chloro-4-ethvlthio-1,2,5-thiadiazole Cyanogen (36 g, 0.69 mol) was bubbled into ether (250 rnL) maintained at -10~C. To the solution was added dropwise diethylamine (3 mL) followed by dropwise addition of ethanethiol (47 mL, 0.64 mol) at such a rate that the temperature did not exceed -5~C. The reaction was maintained below 0~C for 5 h then stirred at ambient temperature overnight. Ether was distilled from the reaction until the pot temperature reached 50~C. The reaction was cooled to ambient and then added dropwise to a solution of sulfur monochloride (125 mL, 1.56 mol) in DMF
(150 mL) that was cooled to 5~C. Cooling was removed and the reaction was stirred overnight. The reaction was cooled in an EtOH-ice bath as the excess sulfur monochloride was destroyed by dropwise addition of water while maintaining the temperature below 35~C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The aqueous fraction was extracted with hexane (3 X) and the combined extracts and triturants W O 97/20819 PCTnUS96/19229 were washed with H2O, aqueous NaHCO3, brine, dried, and the solvent evaporated. The brown liquid residue was distilled at 3 mm Hg to give a yellow liquid (80.2 g), b.p. 91-96~C.
(Compound 3).
3-Chloro-4-ethylsulfonyl-1,2,5-thiadi~zole A solution of Oxone (84 g, 0.137 mol) in H2O (400 mL) was rapidly stirred as 3-chloro-a-ethylthio-1,2,5-thiadiazole (12.2 g, 0.067 mol) in THF (200 mL) was added.
After stirring overnight, the THF wag evaporated and the residue extracted with ether (3x). The extracts were washed with H2O, aqueous NaHCO3, and brine then the solvent dried and evaporated to give a clear liquid (13.6 g). (Compound 4).
E~AMPLE 5 (~)-3-Methoxy-4-(1-az~hicvclor2.2.2loctvl-3-oxy)-1,2.5-thiadiazole A solution of 1-azabicyclo[2.2.2]octan-3-ol (1.36 g, 0.0104 mol) in THF (20 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (7.4 mL, 0.0118 mol).
To this solution was added 3-methoxy-4-methanesulfonyl-1,2,5-thiadiazole (2.08 g, 0.0107 mol) in THF (40 mL), the reaction heated to 40~C for 2 h, and then stirred at ambient temperature overnight. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution was made basic and extracted with EtOAc. The extracts were washed with ~ H2O, dried, and the solvent evaporated. The residue was purified by radial chromatography (2.5 % EtOH-0.25 % NH40H-CHCl3) to give a clear oil. The HCl salt of the oil (0.85 g) crystallized from MeOH-EtOAc, m.p. 197-198~C. (Compound 5).
W O 97/20819 PCT~US96/19229 (+)-3-~thoxv-4-(1-azabicvclo r2 .2.2loctvl-3-oxv3-1,2,5-thiadiazole A solution of 1-azabicyclo[2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF (50 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (3.7 mL, 0.0059 mol).
To this solution was added 3-ethoxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0048 mol) in THF (12 mL) and the reaction heated to 60~C for 5 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution was made basic and extracted with ether. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (0.47 g) crystallized from 2-propanol, m.p. 212-213~C. (Compound 6).
l~)-3-Pro~vloxv-4-(1-azabicvclor2.2.2loctvl-3-oxv)-1.2,5-thiadiazole A solution of 1-azabicyclo[2.2.2]octan-3-ol (1.1 g, 0.0087 mol) in THF (75 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (5.0 mL, 0.008 mol). To this solution was added 3-propyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.3 g, 0.0059 mol) in THF (15 mL) and the reaction heated to 60~C for 4 h. The solvent was evaporated, the residue acidified with 1 N HC1, and the mixture extracted with ether. The aqueous solution was made basic and extracted with EtOAc. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (0.59 g) crystallized ~rom 2-propanol, m.p. 218-219~C. (Compound 7).
W O 97/20819 PCTnUS96/19229 (+)-3-Butvloxv-4-(l-azabicvclo r 2.2.2loctvl-3-oxv)-1,2,5-thiadiazole .
A solution of l-azabicyclo[2.2.2]octan-3-ol (2.2 g, O.016~ mol) in THF (25 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (10.8 mL, 0.0173 mol). To this solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.98 g, 0.084 mol) in THF (25 mL) and the reaction heated to 52~C for 3.5 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous solution was made basic and extracted with EtOAc. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (2.0 g) crystallized from CHCl3-EtOAc-ether, m.p. 204-205~C. (Compound 8).
(i)-3-Pentvloxv-4-(1 -azabicvclor2.2.2loctvl-3-oxv)-1,2,5-thiadiazole A solution of l-azabicyclo r 2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF (50 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (3.7 mL, 0.0059 mol).
To this solution was added 3-pentyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.004 mol) in THF (10 mL) and the reaction heated to 60~C ~or 4 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution was made basic and extracted with ether. The extracts were washed ~ with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (0.75 g) crystallized from EtOAc, m.p. 171-172~C. (Compound 9).
CA 0223930l l998-06-02 W O 97/20819 PCT~US96/19229 (+)-3-Hexvloxv-4-(1-azabicvclo r2 ~ 2.2loctvl-3-oxv)-1,2,5-thiadiazole A solution of l-azabicyclo[2.2.2~octan-3-ol (2.2 g, 0.0168 mol) in THF (25 mL) was treated dropwise with 1. 6 M n-butyllithium in hexane (10.8 mL, 0. 0173 mol). To this solution was added 3-hexyloxy-4-methanesulfonyl-1,2,5-thiadiazole (2.2 g, 0.004 mol) in THF (25 mL) and the reaction heated to 52~C for 3. 5 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous solution was made basic and extracted with ether. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (1.76 g) crystallized from EtOAc, m.p. 165-166~C. (Compound 10).
(+)-3-~4-Methvl~entvloxv) 4-(1-azabicvclo~2.2.2l-octvl-3-oxv)-1.2,5-thiadiazole A solution of l-azabicyclo[2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF (50 mL) was treated dropwise with 1. 6 M n-butyllithium in hexane (3.7 mL, 0. 0059 mol).
To this solution was added 3-(4-methylpentyloxy)-4-methanesulfonyl-l, 2, 5-thiadiazole (1.2 g, 0.00 4 5 mol) in THF (10 mL) and the reaction heated to reflux for 6 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous solution was made basic and extracted with ether. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (1.1 g) crystallized from EtOAc, m.p. 179-180~C. (Compound 11).
W O 97/20819 PCT~US96/19229 EXAMP~E 12 (+)-3-Chloro-4-(1-azabicvclor2.2.2loctvl-3-oxv)-1,2,5-thi~diazole .~
A solution of l-azabicyclo~2.2.2]octan-3-ol (1.1 g, 0.0084 mol) in THF (25 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (5.4 mL, 0.0086 mol). This solution was added dropwise to a solution of 3-chloro-4-butylsul~onyl-1,2,5-thladiazole (2.1 g, 0.0086 mol) in THF
(15 mL) at such a rate that the temperature did not exceed 32~C. After stirring for 3 days, the reaction was treated with H20 (10 mL), diluted with ether (100 mL), and extracted with 1 N HCl (25 mL). The aqueous solution was washed with ether, made basic, and extracted with ether.
The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (2.5 ~ EtOH-0.25 % NH40H-CHCl3) to give a straw colored liquid (1.1 g). The oxalate salt (0.39 g) crystallized from MeOH-EtOAc, m.p.
154-156~C. (Compound 12).
Alternative s~nthe~is o~ (+)-3-Chloro-4-(1-~zabicvclor2.2.2loctvl-3-oxv)-1,2,5-thiadiazole:
A solution of l-azabicyclo~2.2.2]octan-3-ol (1.2 g, 0.0092 mol) in THF (25 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (5.9 mL, 0.00~5 mol). The solution was cooled to -8~C and a solution of 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF
(15 mL) was added dropwise. After 15 min, cooling was removed and the reaction stirred overnight. The reaction was treated with H2O (10 mL), diluted with ether (100 mL), ~ and extracted with 1 N HCl (25 mL). The aqueous solution was washed with ether, made basic, and extracted with Y ether. The extracts were dried and the solvent evaporated to give crude (compound 12) (1.05 g) as a brownish liquid.
w o 97nO819 PCTrUS96/19229 Alternative sYnthesis o~ (+)-3-Chloro-4-(1-~z~hicyclor2.2.2loctyl-3-oxy)-l~2~5-thiadiazole:
A mixture of 1-azabicyclo[2.2.2]octan-3-ol (12.7 S g, 0.1 mol), triethylamine ~0.3 mL), and CHC13 (150 mL) was cooled to 5~C and cyanogen (7.25 g, 0.139 mol) bubbled into the mixture. The reaction was stirred another hour then allowed to come to ambient temperature overnight. The solvent was evaporated, the residue dissolved in DMF ~20 mL), and the solution added dropwise to a solution of S2Cl2 (47.3 g, 0.35 mol) in DMF (30 mL) that was cooled in an ice-water bath. After addition, cooling was removed and reaction exothermed to 32~C. After 5 h, reaction cooled and excess S2C12 destroyed by careful addition of H20. The reaction was diluted with more H2O (300 mL) and the aqueous solution decanted from the sulfur residue. The sulfur residue was triturated with H2O and the combined aqueous solutions evaporated to a small volume (150 mL). The solution was washed with ether and then made basic with 50 % NaOH while maintaining the temperature below 30 ~C. The mixture was extracted with CHCl3, the extracts dried, and the solvents thoroughly evaporated. The residue was suspended in ether, dried, filtered and the solvent evaporated to give (compound 12~ (18.1 g) as a yellow oil that slowly solidified.
EXAMPL~ 13 (+)-3-Propvlthio-~-(1-azabicyclo r 2.2.2loctyl-3-oxy)-1,2,5-thi~i~zole A solution of the crude compound 12 (1.67 g, O.0068 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.8 g, 0.0075 mol). After ~0 min, 1-bromopropane (1.25 g, 0.010 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and CA 0223930l l998-06-02 extracted with ether. The ex~racts were dried and the solvent evaporated to give a straw-colored liquid. The HCl salt (1.28 g) crystallized from CHCl3-EtOAc-ether, m.p.
174-176~C. (Compound 13).
EXAMPhE 14 (~)-3-Butvlthio-4~ az~hicvclo r2 .2.2loctvl-3-oxv)-~,2,5-thiadiazole A solution of the crude compound 12 (1.8 g, 0.0073 mol) in DMF (25 m~) was treated portionwise with freshly ground flaked Na2S-9H20 (1.94 g, 0.0081 mol). After 1 h, l-iodobutane (2 g, 0.011 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-coloured li~uid. The HCl salt (1. 82 g) crystallized from CHCl3-EtOAc-ether, m.p.
151-153~C. (Compound 14).
EXAMPLE lS
(+)-3-Pentvlthio-4-(1-azabicvclo r 2. 2. 2loctvl-3-oxv)-1,2 5-thiadi~zole A solution of the crude compound 12 (1.67 g, Q.0068 mol) in DMF (25 mL) was treated portionwise with ~reshly ground flaked Na2S-9H2O (1.8 g, 0.0075 mol). After 1 h, l-bromopentane (1.53 g, 0.010 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidi~ied with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and - extracted with ether. The extracts were dried and the solvent evaporated to give a straw-coloured li~uid. The HCl salt (1.07 g) crystallized from CHCl3-EtOAc-ether, m.p.
186-187~C. (Compound 15).
W O 97/20819 PCTrUS96/19229 EX~iMPLE 16 ~S)-3-Pentvlthio-4-(1-azabicvclo r 2.2.2loctvl-3-oxv)-1.2,5-thiadiazole A solution of tS)-l-azabicyclo[ 2.2.2] octan-3-ol (2.0 g, 0.0157 mol) in THF (40 mL) was cooled to 10~C as 1.6 M n-butyllithium in hexane (10 mL, 0.016 mol) was added dropwise. The resulting mixture was treated with 3-chloro-ethylsulfonyl-1,2,5-thiadiazole (3.34 g, 0.0157 mol) in THF
(25 mL) and stirred for 16 h. The reaction was treated with H20 (10 mL), ether (170 mL) and extracted with 1 N HCl (43 mL). The aqueous fraction was washed with ether, made ~asic, and extracted with ether. The extracts were dried and the solvent evaporated to give an oil (1.7 g). The oil was dissolved in DMF (25 mL), treated portionwise with freshly ground flaked Na2S-9H2O (1.83 g, 0.0076 mol), and heated (40~C). After 1.25 h, l-bromopentane (1.58 g, 0.0105 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N
HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid that was purified by radial chromatography (5% EtOH-0.5% NH40H-CHCl3). The HCl salt (0.87 g) crystallized from CHCl3-EtOAc-ether, m.p. 194-195~C, [~]D = 25.41~ (EtOH).
(Compound 16).
(i)-3-Hexvlthio-4-~1-azabic~clo r2 .2.2loctvl-3-oxv)-1,2,5-thiadiazole A solution o~ the crude compound 12 (1.8 g, 0.0073 mol) in DMF (25 mL) was treated portionwise with freshly ground ~laked Na2S-9H2O (1.94 g, 0.0081 mol). After 1 h, l-iodohexane (2.3 g, 0.011 mol~ was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid. The HCl salt (1.0 g) crystallized from CHCl3-EtOAc-ether, m.p. 165-~ 167~C. (Compound 17).
~XAMPLE 18 (~)-3-(3,3-DimethvlbutYlthio)-4-(1-azabicvclo r 2.2.21-octvl-3-oxv)-1 ~,5-thi~diazole A solution of the crude (compound 12) (1. 05 g, 0.0043 mol) in DMF (25 mL) was treated portionwise with ~reshly groun~ flaked Na2S-9H2O (1.24 g, 0.0051 mol). A~ter 1 h, 1-bromo-3,3-dimethylbutane (1.18 g, 0.007 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid. The HCl salt (0.41 g) crystallized from CHCl3-EtOAc-ether, m.p.
189-190~C. (Compound 18).
(+)-3-(2-(2-Thienvlthio)ethvlthio)-4-(1-azabicvclo-r2.2.2loctvl-3-oxv)-1.2.5-thiadiazole A solution of the crude (compound 12) (1.0 g, 0.0041 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O ~1.1 g, 0.0045 mol). After 1 h, 1-chloro-2-(2-thienylthio)ethane (1.1 g, 0.0062 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by flash CA 0223930l l998-06-02 W O 97/20819 PCTrUS96/19229 chromatography (10% EtOH-1% NH40H-CHC13) to give a liquid.
The HCl salt (0. 88 g) crystallized from ether, m.p. 179.5-181~C. (Compound 19).
EXAMPLE a o (+)-3-(2,2,3,3,3-Pentafluoro~ro~ylth;o)-4-(1-~zabicvclo-r2.2~2loctyl-3-oxv)-l~2~5-th;~;azole A solution of the crude (compound 12) (0.5 g, 0.002 mol) in DMF (15 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (0.53 g, 0.0022 mol). After 1 h, 1-methanesulfonoxy-2,2,3,3,3-pentafluoropropane (0.003 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N
HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by flash chromatography (5% EtOH-0.5% NH40H-CHC13) to give a liquid. The HCl salt (0.016 g) crystallized from ether, m.p. 138-140~C. (Compound 20).
(i)-3-(3-~2-Thienvl)~ro~vlthio)-4-(1-~z~hicvclo r 2.2.2l-octyl-3-oxy)-1.2.5-thi~ zole A solution of the crude (compound 12) (0.6 g, 0.0024 mol) in DMF (15 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (0.6 g, 0.0027 mol). After 1 h, 1-chloro-3-(2-thienyl)propane (0.6 g, 0.0036 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by flash chromatography (10% EtOH-1% NH40H-CHC13) to give a liquid.
The HCl salt (0.16 g) crystallized from EtOH-EtOAc, m.p.
194-196~C. (Compound 21).
W O 97/20819 PCT~US96/19229 3-Butvlthio-4-((1-~z~hicvclo r 2.2.2loctan-3-vl)-methoxv)-1,2.5-thiadiazole A solution of 3-hydroxymethyl-1-azabicyclo[2.2.2]octane (1.4 g, 0.01 mol) in THF (30 mL) was treated with 1.6 M n-butyllithium in hexane (6.5 mL, 0.0104 mol). The mixture was cooled to 10~C, and 3-chloro-4-ethylsul~onyl-1,2,5-thiadiazole (2.21 g, 0.0104 mol) in THF (10 mL) was added dropwise. Cooling was removed and the reaction stirred overnight. The reaction was treated with H2O, diluted with ether, and extracted with 1 N HCl (25 mL). The acidic extracts were washed with ether, made basic, and extracted with ether. The extracts were dried and the solvent evaporated to give an orange liquid (1.82 g). The liquid was dissolved in DMF (32 mL) and treated with freshly ground ~1aked Na2S-9H2O (2.5 g, 0.0104 mol) in portions.
After 55 min, the reaction was treated with l-iodobutane (2.6 g, 0.014 mol) and warmed to 44~C overnight. The solvent was e~aporated, the residue acidi~ied with 1 N HCl, and the mixture extracted with EtOAc-ether (1:1). The aqueous fraction was made basic and extracted with ether.
The ether was dried, the solvent evaporated, and the residue purified by radial chromatography (5% EtOH-0.5 NH40H-CHC13) to give a liquid. The HCl salt (0.84 g) crystallized from EtOAc-ether, m.p. 170-171~C. (Compound 22).
(+)-exo-3-Pentvlthio-4-(1-azabicvclor3.2.1loctvl-6-oxv)-1.2,5-thiadiazole and (~)-Fndo-3-~entvlthio-4-(1-azabicvclor3.2.1l- octvl-6-oxv)-1,2,5-thiadiazole A solution of the endo/exo mixture of 1-azabicyclo~3.2.1]octan-6-ol (1.95 g, 0.0153 mol, ref.
Sternbach, L. H.; Kaiser, S. J. Amer. Chem. Soc. lg52, 74, W O 97~0819 PCT~US96/19229 2215-2218.) in THF (25 mL) was treated with 1.6 M n-butyllithium in hexane (9.6 mL, 0.0153 mol). When the mixture had cooled to ambient temperature, 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole t2.96 g, 0.014 mol) in THF
(15 m~) was added dropwise and the reaction stirred overnight. The reaction was treated with H2O, diluted with ether, and extracted with 1 N HCl (32 mL). The acidic extract was made basic, extracted with ether, the extracts dried, and the solvent evaporated to give an orange li~uid (1.25 g). The liquid was dissolved in DMF (25 mL) and treated with freshly ground flaked Na2S-9H2O (1.82 g, 0.0076 mol) in portions. After 40 min, l-bromopentane (1.55 g, 0.0103 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue acidi~ied, and the mixture extracted with ether. The aqueous fraction was made basic, extracted with ether, the extracts dried, and the solvent evaporated. The residue was purified by radial chromatography (2.5% EtOH-0.25% NH40H-CHCl3) to first elute the exo isomer as a liquid. The HCl salt (0.26 g), crystallized from EtOAc, m.p. 159-160~C.
(Compound 23). Further elution provided the endo isomer as a liquid. The HCl salt (0.23 g) crystallized from EtOAc, m.p. 1~0-193~C. (Compound 24).
(~)-endo-3-Butvloxv-4-(1-azabicvclo r2 .2.1lhe~tvl-3-oxv)-1,2.5-thiadiazole A solution of a mixture of (+)-endo and (+)-exo-l-azabicyclo[2.2.1]heptan3-ol (0.5 g, 0.0044 mol)(Ref. J.
Ora. Chem. 1969, 34, 3674-3676) in THF (20 mL) was cooled in an ice-water bath and ~reated dropwise with 1.6 M n-butyllithium in hexane (2.8 mL, 0.0044 mol). Cooling was removed, 3-butyloxy-~-methanesul~onyl-1,2,5-thiadiazole (1.4 g, 0.0059 mol) was added, and the reaction heated to reflux ~or 6 h. The solvent was evaporated, the residue CA 0223930l l998-06-02 W O 97/20819 PCTnUS96/19229 acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution was made basic and extracted with EtOAc. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. R~; Al chromatography (5% EtOH, 0.5% NH40~, CHCl3) eluted the title compound as the more polar of the two UV active spots. The HCl salt o~ the title compound (0.5 g) crystallized from EtOAc with a quarter mole of H2O, m.p.
161.5-163~C. tCompound 25).
EXAMP~E 25 (~)-Fxo-3-butvloxv-4-(1-azabicvclo~2.2.1lhe~tvl-3-oxv)-1,2.5-thiadiazole Rechromatography of the mixed fractions from the isolation of ~compound 25) (5% EtOH, 0.5% NH40H, CHC13) gave the less polar W active material. The HCl salt (0.036 g) crystallized from EtOAc with a ~uarter mole of water, m.p. 156-157~C. (Compound 26).
EXAMPLE a 6 ~)-3-Butvloxv-4-(3-~vrrolidinvloxv)-1.2.5-thi~diazole A suspension of NaH (0.066 g, 0.0028 mol) in THF
(25 mL) was treated with l-t-butylcarbamoyl-3-hydroxypyrrolidine (Ref. Svn. Commun. 15, 587.) (0.5 g, 0.0027 mol) and the reaction warmed to 50~C for 30 min.
After cooling to ambient temperature, 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (0.55 g, 0.0027 mol) in TH~ (5 mL) was added and the reaction heated to reflux for 2.5 h. The solvent was evaporated, the residue treated with ice-water, and the mixture extracted with ether. The extracts were washed with brine, dried, and the solvent evaporated. The residue was dissolved in ether (50 mL) and treated with a slow stream of HCl for 5 min. After stirring overnight, the reaction was extracted with cold water. The a~ueous was washed with ether, made basic, and extracted W O 97/20819 PCT~US96119229 with EtOAc. The extracts were washed with brine, dried, and the solvent evaporated to give a clear oil. The HCl salt (0.42 g) crystallized from EtOAc, m.p. 127-128~C. (Compound 27).
EXAMPLE 27(i)-3-Butvloxv-4-(1-methvl-3-~vrrolidinvloxv)-1.2,5-thiaai~zole A solution of l-methyl-3-pyrrolidinol (0.6 g, 0.0059 mol) in THF (20 mL) was treated with 1.6 M n-butyllithium in hexane (3.1 mL), 0.005 mol). To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0042 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The aqueous fraction was made basic, extracted with EtOAc, and the extracts washed with water. The extracts were dried and the solvent evaporated to give a liquid. The HCl salt (0.7 g) crystallized from EtOAc, m.p. 157-158~C.
(Compound 28).
~ 3-Butvlthio-4-(1-methvl-3-~i~eridvloxv)-1,2,5-thiadiazole A solution of 3-hydroxy-1-methylpiperidine (1.12 g, 0.0095 mol) in THF (25 mL) was treated with 1. 6 M n-butyllithium in hexane (5.9 mL, 0.0095 mol). The mixture was cooled to 8~C and treated dropwise with 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF
(20 mL). The cooling was removed and the reaction stirred overnight. The mixture was treated with H2O, acidified with 1 N HCl and diluted with ether. The aqueous fraction was washed with ether, made basic, and extracted with ether.
The extracts dried and solvent evaporated to give a brown li~uid (1.95 g). The liquid was dissolved in DMF (38 mL) W O 97/20819 PCT~US96/19229 and treated with freshly ground flaked Ma2S-9H2O (2.98 g, 0.0124 mol) in portions. After 1 h, the mixture was treated with l-iodobutane (3.1 g, 0.0169 mol) and stirred 64 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution - was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give an orange liquid.
Purification by radial chromatography (2.5% EtOH-0.25%
NH40H-CHC13) gave a liquid whose HCl salt (1.4 g) crystallized from CHCl3-EtOAc-ether, m.p. 141-142~C.
~Compound 29)~
EXAMP~E 29 3-Rlltvlthio-4-(1-methvl-4-pi~eridvloxv)-1~2~ ~-tl~ zol e A solution of 4-hydroxy-1-methylpiperidine (1.12 g, 0.0095 mol) in THF (25 mL) was treated with 1.6 M n-butyllithium in hexane (5.9 mL, 0.0095 mol). The mixture was cooled to 8~C and treated dropwise with 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF
(20 mL). The cooling was removed and the reaction stirred overnight. The mixture was treated with H2O, acidified with 1 N HCl, and diluted with ether. The aqueous fraction was washed with ether, made basic, and extracted with ether.
The extracts dried and solvent evaporated to give a brown liquid (1.52 g). The liquid was dissolved in DMF ~30 mL) and treated with freshly ground flaked Na2S-9H2O (2.32 g, 0.0097 mol) in portions. After 50 min, the mixture was treated with l-iodobutane (2.4 g, 0.013 mol) and stirred for 63 h. The solvent was evaporated, the residue acidified with dilute HCl, and the mixture extracted with ether. The ~ aqueous fraction was made basic and extracted with ether.
The extracts were dried and the solvent evaporated to give ~ 1.3 g li~uid. The HCl salt (1.3 g) crystallized from EtOAc-ether, m.p. 140-142~C. (Compound 30).
W O 97~0819 PCTnJS96/19229 EXAMPtS)-3-ButvloxY-4-(1 -methvl-2-~vrrolidinvlmethoxv)-1.2.5-thiadi~ole A solution of (S)-l-methyl-2-pyrrolidinemethanol (0.86, 0.0075 mol) in THF (20 mL) was treated with 1.6 M n-butyllithium in hexane (4.7 mL, 0.0075 mol). To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.2 g, 0.005 mol) and the reaction heated to reflux for 6.5 h. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with EtOAc.
The extracts were washed with water, dried, and the solvent evaporated to give a liquid. The HCl salt (0.72 g) crystallized from EtOAc, m.p. 115-116~C. (Compound 31).
(S)-3-ButYloxv-~-l2-~vrrolidinvlmethoxv~ 2~5-thiadiazole A solution of (S)-l-butyloxycarbonyl-2-pyrrolidinemethanol (1.21, 0.006 mol) in THF (5 mL) was added to a suspension of 60% Na~ in oil (0.24 g, 0.006 mol) in THF (30 mL). After 1 h, the mixture was heated to gentle reflux for 1 h. To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1 g, 0.0042 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue treated with cold H2O, and the mixture extracted with EtOAc. The extracts were dried and treated with a stream of dry HCl for 3 min. After another hour, the solvent was evaporated, the residue treated with cold H2O, and the mixture extracted with ether. The aqueous fraction was made basic and extracted with EtOAc. The extracts were washed with water, dried, and the solvent evaporated to give a li~uid. The HCl salt (0.72 g) crystallized from EtOAc, m.p. 99-100~C. (Compound 32).
CA 0223930l l998-06-02 W O 97/20819 PCT~US96/19229 ~ --91--EXA~MPLE 3 a 3-Butvloxv-4- (2-(dimethvlamino)ethoxv)-1.2,5-thiadiazole A so lution of 2-dimethylaminoethanol (0.67 g, 0.0075 mol) in THF (20 mL) was treated with 1.6 M n-c butyllithium in hexane (4.7 mL, 0.0075 mol). To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole tl.2 g, 0.005 mol) and the reaction heated to reflux for 6 h. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with EtOAc.
The extracts were washed with water, dried, and the solvent evaporated to give a clear oil. The HCl salt (0.94 g) recrystallized from EtOAc to give a white solid, m.p. 97-98~C. (Compound 33).
3-Rutvlthio-4-(2-(diethvlamino)ethoxv)-1~2~5-thiadiazole A solution of 2-diethyl~minoethanol (1.11 g, 0.009~ mol) in THF (25 mL) was treated with 1.6 M n-butyllithium in hexane (5.9 mL, 0.0095 mol). The mixture was cooled to 8~C and treated dropwise with 3-chloro-4-ethylsulfonyl-1,2,5thiadiazole (1.83 g, 0.0086 mol) in THF
(20 mL). The cooling was removed and the reaction stirred overnight. The mixture was treated with H2O, acidified with 1 N HCl, and diluted with ether. The a(aueous fraction was washed with ether, made basic, and extracted with ether.
The extracts dried and solvent evaporated to give a brown liguid (1.6 g). The li~uid was dissolved in DMF ~30 mL) and treated with freshly ground flaked Na2S-9H2O (2.43 g, 0.010 ~ mol) in portions. After 50 min, the mixture was treated with l-iodobutane (2.52 g, 0.0137 mol) and stirred for 46 r h. The solvent was evaporated, the residue acidified with dilute HCl, and the mixture extracted with ether. The aqueous fraction was made basic and extracted with ether.
The extracts were dried, the solvent evaporated, and the W O 97/20819 PCTrUS96/19229 residue purified by radial chromatography (5% EtOH-0.5%
NH~OH-CHC13) to give a li~uid. The HCl salt ~1.15 g) crystallized from EtOAc-ether, m.p. 95-97~C. (Compound 34).
EXA~PL~ 34 3-Butvloxv-4-(2-(trimethvlamino)ethoxv)-1 2.5-thiadiazole iodide A solution of (compound 33) (from Q.5 g, 0.0018 mol of the HCl salt) in FtOAC (30 mL) was treated with CH3I
(0.3 mL) and stirred overnight. The precipitant was collected, washed with EtOAc, and dried to give a white solid (0.64 g), m.p. 137-138~C. (Compound 35).
E:XAMPLE 35 3-Rlltvloxv-~-(2-(dimethvlamino)ethvlthio)-1,2.5-thia~;~zole A suspension of 2-dimethylaminoethanthiol hydrochloride (0.57 g, 0.004 mol) in THF (25 mL) was treated with 1.6 M n-butyllithium in hexane (5 mL, 0.008 mol). To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,~-thiadiazole (0.71 g, 0.003 mol) and the reaction heated to reflux for 2 h followed by stirring at ambient temperature overnight. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were washed with water, dried, and the solvent evaporated. The residue was purified by radial chromatography (5% EtOH-0.5% NH40H-CHCl3) to give a tan liquid. The HCl salt (0.22 g) recrystallized from EtOAc to give a white solid, m.p. 108-109~C. (Compound 36).
CA 0223930l l998-06-02 W O 97/20~19 PCT~US96/19Z29 -~3-EXA~P~E 36 3-ChlorQ-4~ ~ro~vlthio)-1,2,5-thiadiazole cyanogen (34 g, 0.65 mol) was bubbled into ether (250 mL) maintained at -10~C. To the solution was added dropwise diethylamine (3 mL) followed bv dropwise addition of l-propanethiol (57 mL, 0.63 mol) in ether (25 mL) at such a rate that the temperature did not exceed -5~C. After ~ h, cooling was removed and the reaction stirred overnight. Ether was distilled ~rom the reaction until the pot temperature reached 50~C. The reaction was cooled to ambient and added dropwise to a solution of sul~ur monochloride (125 mL, 1.56 mol) in DMF (125 mL) that was cooled in an ice-water bath. Cooling was removed and the reaction allowed to exotherm to 35~C, recooled to below 3û~C, then stirred overnight. The reaction was cooled in EtOH-ice and the excess sul~ur monochloride carefully destroyed by dropwise addition o~ H20 (200 mL) such that the temperature did not exceed 30~C. The mixture was extracted with hexane, the extracts washed with brine, dried, and the solvent e~raporated. The residue was distilled at 1.5 mm Hg to give a yellow lisluid (98.6 g), b.p. 84-94~C. (Compound 37).
(R)-3-Pentvlth;o-4~ azabicvclor2.2.210ctvl-3-oxv)-1.2,5-thiadiazole A solution o~ (R)-l-azabicyclo[2.2.2]octan-3-ol (3.0 g, 0.0236 mol) in THF (40 mL) was cooled to 10~C as 1.6 M n-butyllithium in hexane (15 mL, 0.024 mol) was added ~ ~ropwise. The resulting mixture was treated with 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (5.01 g, 0.0236 mol) in THF (5 mL) and stirred ~or 22 h. The reaction was treated with H20 (10 mL), ether (170 mL) and extracted with 1 N HCl (35 mL). The a~[ueous ~raction was washed with ether, made basic, and extracted with ether. The extracts were dried WO 97nO819 PCT~US96/19229 ~ -94-and the solvent evaporated to give an oil (2.35 g). The oil was dissolved in DMF (35 mL), treated portionwise with ~reshly ground flaked Na2S-9H20 (2.53 g, 0.0105 mol), and heated (40~C). A~ter 1.25 h, 1-bromopentane (2.18 g, 0.0145 mol) was added and the reaction stirred overnight at 38~C.
The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid that was purified by radial chromatography (596 EtOH-0.5% NH40H-CHCl3), The HCl salt (1.68 g) crystallized from CHC13-EtOAc, m.p. 195-196~C, [a]D = -24.6~ (EtOH).
(Compound 38).
(~)-3-(4-Methvl~entvlthio)-4-(1-azabicvclo r 2.2.2loct~1-3-oxv)-1.2,5-thiadiazole A solution of the crude (compound 12) (1.65 g, 0.0067 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H20 (1.83 g, 0.0076 mol). After 1 h, 1-bromo-4-methylpentane (1.73 g, 0.0105 mol) was added and the reaction stirred three days at 40~C. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored lic;[uid that was purified by radial chromatography (5% EtO~-0.5% NH40H-CHCl3). The HCl salt (0.74 g) crystallized from CHCl3-EtOAc-ether, m.p. 183-185~C. (Compound 39).
EXA(+)-3-(3-Phenvl~ro~vlthio)-4-(1-azabicyclor2.2.2loctvl-3-oxv)-1.2,5-thiadiazole A solution of the crude (compound 12) (0.9 g, 0.0037 mol) in DMF (25 mL) was treated portionwise with _9~ _ freshly ground flaked Na2S-9~2O (0.97 g, 0.004 mol). After 1 h, 1-bromo-3-phenylpropane (1.11 g, 0.056 mol) was added and the reaction stirred 17 h at 50~C. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid that was purified by radial chromatography (2.5% EtOH-0.25% NH40H-CHC13). The HCl salt (0.42 g) crystallized from CHCl3-EtOAc-ether, m.p. 210-212~C. (Compound 40).
(+)-3-(~-Cyanobenzylthio)-4-(1-az~h-cyclo r 2.2.2loctvl-3-oxY)-l~2~5-thiadia~ole A solution of the crude (compound 12) (1.15 g, O.0047 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.68 g, 0.007 mol). After 1 h, 4-cyanobenzyl bromide (1.85 g, 0.0g4 mol) was added and the reaction stirred 22 h. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid that was purified by radial chromatography (5% EtOH-0.5% NH40H-CHCl3). The HCl salt (0.12 g) crystallized from CHCl3-EtOAc-ether, m.p. 211-213~C. (Compound 41).
(+)-3-(4-Flllorobenzylthio)-4~ z~hicyclor2.2.2loctyl-3-oxv)-1,2,5-th;~diazole A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.68 g, 0.007 mol). After 1 h, 4-fluorobenzyl chloride (1.37 g, 0.094 mol) was added and the reaction stirred 22 h. The solvent was evaporated, W O 97/20819 PCT~US96/19229 the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored li~uid that was purified by radial chromatography (5% EtOH-0.5% NH40H-CHC13). The HCl salt (0.89 g) crystallized from MeOH-EtOAc-ether, m.p. 236-237~C. (Compound 42).
(+)-3-(2-Phenvlethvlthio)-4-(1 -azabicvclor2.2.21Octvl-3-oxv)-1 2 5-thi~;azole A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF (25 mL) wa~ treated portionwise with freshly ground flaked Na2S-9~2O (1.68 g, 0.007 mol). After 1 h, the reaction was cooled to -30~C and treated with dropwise with 1-bromo-2-phenylethane (1.75 g, 0.095 mol) in DMF (22 mL). The cooling was removed after 1 h and the reaction stirred 22 h. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored li~uid that was purified 3~y radial chromatography (5% EtOH-0.5% NH40H-CHC13). The HCl salt ~0.53 g) crystallized from MeOH-EtOAc-ether, m.p. 181-183~C. (Compound 43).
(+)-3-~2-Phenvloxvethvlthio)-4-(1-a~abicvclo r 2.2.2loctvl-3-oxv)- 1,2.5-thiadiazole A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF ~25 mL) was treated portionwise with freshly ground flaked Na2~-9H2O ~1.68 g, 0.007 mol). After 1 h, the reaction was cooled to -50~C and treated with dropwise with 1-bromo-2-phenyloxyethane (1.90 g, 0.0095 mol) in DMF (22 mL). The cooling was removed after 1 h and w o 97nO819 PCT~US96/19229 the reaction stirred 22 h. Another solution of bromo-2-phenyloxyethane (1.90 g, 0.0095 mol) in DMF (5 mL) was added in two portions with cooling to -30~C. After 2 h, the solvent was evaporated, the residue was acidified with 1 N
HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with CHCl3. The extracts were dried and the solvent evaporated to give a straw-colored li~uid that was purified by radial chromatography (5% EtOH-O.5% NH40H-CHC13). The HCl salt (1.29 g) crystallized ~rom MeOH-EtOAc-ether, m.p. 193-194~C. (Compound 44).
endo-3-~utvloxv-4-(N-methvl-8-azabicvclo r 3.2.1loctvl-3-oxv)-1.2,5-thi~di~zole A solution of tropine ~1.36 g, 0.0094 mol) in THF (25 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (5.9 mL, 0.000g5 mol~. To this solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (2.04 g, 0.0086 mol) in THF (25 mL) and the reaction heated to 40~C
for 19 h. The solution was treated with H2O (40 mL), 5 N
HCl (5.5 mL), and ether (150 mL), the a~ueous layer separated and made basic. The a~ueous solution was extracted with ether, the extracts dried, and the solvent evaporated to give a clear oil. The oil was purified by radial chromatography (5% EtOH-0.5% NH40H-CHCl3) and the HCl salt (1.49 g) crystallized from CHCl3-EtOAc-ether, m.p.
168-169~C. (Compound 45).
(+)-exo-3-Butvloxv-4-(6-(N-methvl-8-azabicvclor3.2.110ctan-3-onoxv))-1 2,5-thiadiazole A suspension of NaH (0.11 g, 0.00275 mol) in THF
(25 mL) was treated with ~+)-exo-6-hydroxytropinone (1.36 g, 0.0094 mol) and the reaction heated to 50~C for 1 h. To this solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-W O 97/20819 PCT~US96/19229 thiadiazole (0.55 g, 0.0027 mol) and the reaction heated to reflux for 2 h. The solvent was evaporated, the residue suspended in ice-water, acidified, and the mixture extracted with ether. The aqueous layer was made basic, was extracted with ether, the extracts washed with brine, dried, and the solvent evaporated to give a clear oil. The oil was purified by radial chromatography (2.5% EtoH-o.25%
NH40H-CHCl3) and the HCl salt (0.325 g) crystallized from EtOAc, m.p. 178-179~C. (Compound 46).
(+)-exo-3-Chloro-4-~1-azabicvclor3.2.1loctvl-6-oxsr)-1,2.5-th;adiazole and(~t)-endo-3-chloro-4-(l-azabicvclo r3.2.1 octvl-6-oxv)-1.2,5-thia~iazole A solution of the endo/exo mixture of 1-azabicyclo[3.2.1]octan-6-ol (13 g, 0.102 mol, ref.
Sternbach, L. H.; Kaiser, S. J. Amer. ~hem. Soc. ls5a , 74, 2215-2218), triethylamine (0.3 mL), and CHCl3 (100 mL) was cooled to 3~C and cyanogen (7.7 g, 0.148 mol) bubbled into the solution. After 1 h, the cooling was removed, the reaction stirred another 3 h, and the solvent evaporated.
The residue was dissolved in D~qF (30 mL) and added dropwise to a solution of S2C12 (47.3 g, 0.35 mol) in DMF (30 mL) that was cooled in an ice-water bath. Cooling was removed, the reaction stirred overnight, and, after further cooling, the excess S2C12 carefully destroyed with H2O. The mixture was diluted with H2O (200 mL), the aqueous solution decanted, and the sulfur residue triturated with H2O. The combined a~eous solutions were evaporated to a ~mall volume (150 mL) and extracted with hexane. The aqueous solution was cooled, made basic with 50% NaOH, and extracted with CHCl3. The extracts were dried, the solvent thoroughly evaporated, the residue suspended in ether and filtered. Evaporation of the solvent gave a brown liquid (12.76 g), a 0.8 g sample of which was purified by radial chromatography (10% EtOH-196 NH4oH-cHcl3)~ The exo isomer _99 _ eluted first and was converted to an HCl salt (0.1 g) that crystallized from acetone, m.p. 226~C, dec. (compound 47).
Further elution provided the endo isomer that crystallized as an HCl salt (0.2 g) from 2-propanol, m.p. 199.5-201~C.
(Compound 48).
EXAMP~E 47 (+)-endo-3-(4-cvanobenzvlthio)-4-(1-azabicvclor3.2.1loctvl -6-oxv)-1,2,5-thiadiazole A solution of the crude mixture of (compound 47) and (compound 48) (2.3 g, 0.0094 mol) in DMF (34 mL) was treated portionwise with freshly ground flaked Na2~-9H2O
(3.36 g, 0.014 mol). After 2 h, the reaction was cooled to -30~C and treated with dropwise with 4-cyanobenzyl bromide (3.7 g, 0.0189 mol) in ~qF (34 mL). The cooling was removed and after 1.5 h, the reaction was treated with 5 N NaOH (4 mL). The solvents were evaporated, the residue dissolved in a mixture of CHCl3 and H2O, the CHCl3 extract separated, and washed with H2O. The organic extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (5% EtOH-0.5% NH4OH-EtOAc) to give the endo isomer. The HCl salt (0.31 g) crystallized from MeOH-EtOAc-ether, m.p. 250-251~C. (Compound 49).
3-RutYloxY-4-(3-azetidinYloxy)-l~2~5-thiadiazole A suspension of NaH (0.24 g, 0.006 mol) in THF
(30 mL) was treated with l-t-butylcarbamoyl-3-hydroxyazetidine (1.1 g, 0.006 mol), the reaction stirred 1 h, followed by addition of 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0042 mol) in THF (5 mL). The reaction was heated to reflux for 4 h, the solvent evaporated, the residue treated with ice-water, and the mixture extracted with EtOAc. The extracts were dried and treated with a slow stream of HCl for 3 min. After 0.5 h, W O 97/20819 PCT~US96/19229 the solvent was evaporated, the residue treated with ice-water, and the solution extracted with ether. The aqueous phase was made basic, extracted with EtOAc, the extracts washed with brine, dried, and the solvent evaporated to give a clear oil. The ~Cl salt (0.77 g) crystallized from 2-propanol, m.p. 167-168.5~C. (Compound 50).
EXAMP~E 49 3-Rlltvlthio-4-(3-azetidinvloxv)-1.2,5-thiadiazole A suspension of NaH (0.24 g, 0.006 mol) in THF
(30 mL) was treated with 1-t-butylcarbamoyl-3-hydroxyazetidine (1.6 g, 0.0092 mol), and the reaction stirred 1 h. After cooling to 8~C, 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.96 g, 0.0092 mol) in THF
(5 mL) was added, the reaction stirred 30 min, cooling removed for 30 min, and the reaction heated to 35~C for 45 min. Heating was removed, the reaction stirred overnight, and the solvent evaporated. The residue was suspended in cold water, the mixture extracted with EtOAc, the extracts washed with brine, dried, and the solvent evaporated to give a tan li~uid, (2.98 g). A DMF (30 mL) solution of the liquid was treated with freshly ground flaked Na2s-9H2o (3.3 g, 0.0138 mol). After 1 h, l-iodobutane (2.1 mL) was added, the reaction stirred 2 h, diluted with cold water, and extracted with ether. The ether was dried, the solvent evaporated, the residue dissolved in EtOAc, and the solution treated with a stream o~ dry HCl ~or 5 min. After 1 h, the reaction was treated with icewater and the organic solvent evaporated. The aqueous solution was extracted with ether, made basic, and extracted with EtOAc. The EtOAc extracts were dried and the solvent evaporated to give a tan liquid that was purified by radial chromatography (10%
EtOH-1% NH40H-CHC13). The HC1 salt (0.41 g) crystallized from EtOAc, m.p. 138-139~C. (Compound 51).
EXAMP~E 50 (+)-trans-3-Butvloxv-4-(2-dimethYlaminoc~clo~entvloxY)-1,2,5-thiadiazole A suspension of NaH (0.25 g, 0.006 mol) in THF
(30 mL) was treated with (+)-trans-dimethylaminocyclopentanol (0.8 g, 0.006 mol), the reaction heated to reflux 1 h, followed by addition of 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0042 mol), and the heating continued overnight. The solvent was evaporated, the residue suspended in cold water, and the mixture acidified. The solution was extracted with ether, made basic, and extracted with EtOAc. The EtOAc extracts were washed with brine, dried, the solvent evaporated, and the residue purified by radial chromatography (10% EtOH-1%
NH40H-CHCl3). The HCl salt (0.98 g) crystallized from EtOAc, m.p. 148-149~C. (Compound 52).
(+)-3-~utvlthio-4-t3-~vrrolidinvloxv)-1,2.5-thiadia~ole A suspension of NaH (0.22 g, 0.009 mol) in THF
(30 mL) was treated with (+)-l-t-butylcarbamoyl-3-hydroxypyrrolidine (1.73 g, 0.0092 mol), and the reaction heated to reflux for 35 min. After cooling to 10~C, 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole ~1.96 g, 0.0092 mol) in TEF ( 5 mL) was added, cooling was removed, and the reaction heated to 35~C for 16 h. The reaction was diluted with H2O, ether added, and the ether extract separated. The ether extract was washed with H2O, dried, and the solvent evaporated to give a tan liquid, (3.05 g). A DMF (42 mL) solution of the li~uid was treated with freshly ground flaked Na2S-9H2O (3.3 g, 0.0138 mol). After 1 h, 1-iodobutane (3.42 g, 0.0186 mol) was added, and the reaction stirred at 40~C for 16 h. The solvent was evaporated, the residue diluted with cold water, and the mixture extracted with ether. The ether was dried, the solvent evaporated, W O 97/20819 PCT~US96/19229 the residue dissolved in ether, and the solution treated with a stream of dry HCl for 5 min. After 66 h, the reaction was treated with ice-water and the organic solvent evaporated. The aqueous solution was extracted with ether, made basic, and extracted with ether. The ether extracts were dried and the solvent evaporated to give a tan liquid that was purified by radial chromatography (5% EtOH-0.5%
NH4OH-CHCl3). The HCl salt (0.67 g) crystallized from EtOAc, m.p. 99-100.5~C. (Compound 53).
l-Chloro-2-(2-~h1O-5-trifluoromethvlthienvl)ethane A solution of 2 -trifluoromethylthiophene (1. 2 g, 0.0105 mol, J. Fluorine Chem. 1990, 46, 445-459) in THF
(10 mL) was cooled to -40~C as 1.6 M n-butyllithium in hexane (6.5 mL, 0.0103 mol) was added dropwise. After 2 h, the reaction was cooled to -78~C and S (0.32 g, 0.01 mol) was added and the reaction stirred 2 h. Cooling was removed and when temperature reached 0~C, the reaction was quenched with H2O and dilute NaOH. The mixture was extracted with ether, the aqueous phase acidified, and the mixture extracted with ether. The final ether extracts were dried and the solvent evaporated to give 2 g of material. This was added to a mixture of KOH (0.6 g, 0.011 mol), N(butyl)4HSO4 (0.3 g, 0.001 mol), and 1-bromo-2-chloroethane (1. 4 g, 0.01 mol) in THF (20 mL) and the reaction stirred at ambient overnight. The mixture was poured into H2O, extracted with CH2C12, the extracts dried, and the solvent evaporated. The residue was purified by flash chromatography (5% EtOAc-hexane) to give a liquid (0.42 g). ~Compound 54).
W O 97/20819 PCT~US96/19229 ~XAMPL~ 53 ~+)-3-(2-(2-Thio-5-tri~luorometh~lthienvl)ethvlthio)-4-(1-~zabicvclor2.Z.2loctvl-3-oxv)-1.2.5-thiadiazole ..
A solution o~ the crude (compound 12) (0.37 g, 0.0015 mol) in DMF (8 mL) was treated portionwise with freshly ground ~1aked Na2S-9H2O (0.41 g, 0.0017 mol). After 1 h, 1-chloro-2-(2-thio-5-tri~luoromethylthienyl) ethane (0.42 g, 0.0017 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidi~ied with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether.
The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (10% EtOH-l~
NH40H-CHC13) to give a liquid. The oxalate salt (0.107 g) crystallized from 2-propanol, m.p. 65-69~C. (Compound 55).
EXAMP~E 54 2Q 2-(5-(2-Thienvl)thio~hene)thiol A solution o~ 2-(2-thienyl)thiophene (10 g, o.a602 mol) in THF (50 mL) was cooled to -40~C as 1.6 M n-butyllithium in hexane (37.2 mL, 0.0595 mol) was added dropwise. After 2 h, the reaction was cooled to -78~C and S
(1.8 g, 0.0575 mol) was added and the reaction stirred 2 h.
Cooling was removed and when temperature reached 0~C, the reaction was quenched with H2O and dilute NaOH. The mixture was extracted with ether, the aqueous phase acidi~ied, and 3~ the mixture extracted with ether. The ~inal ether extracts were dried and the solvent evaporated to give 9.9 g of material. (Compound 56).
~XANP~E 55 (+)-3-(2-(5-(2-Thienvl)thienvl)thio)-4-(1 -~z~hicvclor2.2.2loctvl-3-oxv)-1~2~5-thiadiazo1e A mixture of 2-(5-(2-thienyl)thiophene)thiol (1.2 g, 0.0061 mol), potassium t-butoxide (0.5 g, 0. 0045 mol), and a trace of 18-Crown-6 in THF (90 mL) was stirred for 1.5 h. To the solution was added (compound 12) (1.0 g, 0.0041 mol) and the reaction heated to reflux overnight.
The reaction was poured into H2O, extracted with ether, the extracts dried, and the solvent evaporated. The residue was purified by flash chromatography (5% EtOH-0.5% NH40H-CHC13) and the oxalate salt (0.41 g) crystallized from acetone, m.p. 215~C, dec. (Compound 57).
EX~MPLE 56 :l-chloro-2- ~2-(5- (2-thienvl)thienvl)thio)ethane Crude 2-(5-(2-thienyl)thiophene)thiol (3 g, 0.0152 mol) was added to a mixture of KOH ~0.93 g, 0.0166 mol), N(butyl)4HS04 (0.51 g, 0.0015 mol), and 1-bromo-2-chloroethane (2.2 g, 0.0152 mol) in THF (100 mL) and the reaction stirred at ambient overnight. The mixture was poured into H2O, extracted with CH2C12, the extracts dried, and the solvent evaporated to give the desired product (3.5 g). (Compound 58).
EXl~MPLE 57 (~)-3-(2-(2-(5-(2-Thienvl)thienvl)thio)ethvlthio)-4-(1-~z~hicvclo r 2.2.21Octvl-3-oxv)-1~2~5-thi~diazo1e A solution of the crude (compound 12) (0.5 g, 0.002 mol) in DMF (10 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (0.55 g, 0.0023 mol). After 1 h, 1-chloro-2-(2-(5-(2-thienyl)thienyl3thio)ethane (0.6 g, 0.0023 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was W O 97~0819 PCT~US96/19229 acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether.
The extracts were dried, the solvent evaporated, and the residue purified by flash chromatography (5% EtOH-0.5%
NH40H-CHCl3) to give a liquid. The oxalate salt (0.43 g) crystallized ~rom acetone, m.p. 102-105~C. (Compound 59).
(+)-3-(2-Thienvl)thio)-4-(l-azabicYclor2.2.210ctvl-3-oxv)-1,2,5-thiadiazole A mixture of 2-thiophenethiol ~0.42 g, 0.0036 mol) and K2C03 (0.5g g, 0.0043 mol), in DMF (20 mL) was heated at 60~C for 3 h. To the solution was added (compound 12) (0.89 g, 0.0036 mol) and the reaction heated overnight.
The reaction was poured into 1 N HCl (50 mL), extracted with ether, the agueous phase made basic, and the mixture extracted with EtOAc. The EtOAc extracts were dried, the solvent evaporated, and the residue purified by flash chromatography ~5% EtOH-0.5% NH40H-CHC13). The oxalate salt (0.095 g) crystallized from acetone, m.p. 133-136~C.
~Compound 60).
(+)-3-(3-N-(2-Thiazol;donvl)~ro~vlthio)-4-(1-azabicvclo-r ~ . 2.21octvl-3-oxv)1.2,5-thiadlazole A solution of the crude (compound 12) ~0.5 g, 0.002 mol) in DMF ~10 mL) was treated portionwise with freshly ground flaked Na2S-9H20 (0.55 g, 0.0023 mol). After 1 h, 1-chloro-3-N-~2-thiazolidone) propane (0.41 g, 0.0023 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N
HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (10% EtOH-1% NH40H-CHC13) to give a W O 97/20819 PCT~US96/1922 li~uid. The oxalate salt (0.148 g) crystallized from acetone-ether, m.p. 70--75~C. (Compound 61).
EXAMP~L 60 (~)exo-Methvl-7-hvdroxv-2-azabicvclo r 2.2.2loct-5-ene-2-c~rboxvlate A solution of 2.1 g (8.4 mmol) methyl 7-acetoxy-7-cyano-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (J. Ora.
~hem. 1989, ~, 2893) in 25 mL ethanol and 5 mL H20 was cooled in an ice bath. To this mixture was added 2.4 g (42 mmol) KOH followed by 0.65 g (17 mmol) NaBH4. After 15 min.
the ice bath was removed and the reaction was stirred for 16 h. The reaction was ~uenched by addition of 25 mL H
and then concentrated under vacuum. To the residue was added 25 mL H20 and the mixture was extracted three times with 50 mL portions of EtOAc. The combined extracts were dried over NaCl/Na2SO4 and evaporated under vacuum. The residue was chromatographed (25% EtOAc/hexane) on silica gel to give 1.47 g of exo methyl 7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate and 135 mg of endo methyl 7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate. (Compound 62).
EXA~PLE 61 (+)exo-Methvl-6-hvdroxY-2-azabicYclor2.2.2loctane-2-c~rboxYlate A solution of 1.47 g (8 mmol) exo methyl 7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate and 0.15 g 5% Pd/C in 50 mL methanol was hydrogenated at 50 psi on a Parr shaker for 5 h at room temperature. Removal of the catalyst by filtration followed by evaporation under vacuum afforded 1.43 g. (Compound 63).
W ~ 97120819 PCT~US96/19229 EX~MPLE 62 (+)3-Butvlthio-4-(exo-2-methoxvc~rbonvl-2-~z~hic~clo r2 .2.2loct-6-vloxv)-l~2~5-thiadiazole A
To a solution of 1.3 g (7.1 mmol) exo methyl 6-hydroxy-2-aza~icyclo[2.2.2loctane-2-carboxylate and 0.80 g (7.1 mmol) potassium t-butoxide in 20 mL of THF was added 1.5 9 (7.1 mmol) 3-chloro-4-butylthio-1,2,5-thiadiazole.
After stirring the mixture at room temperature for 20 h, 50 mL of brine was added and the solution was extracted five times with 50 mL portions of EtOAc. The combined extracts were dried over NaCl/Na2SO4 and evaporated under vacuum.
Chromatography over silica gel (25% EtOAc/hexane) afforded 1.42 g. (Compound 64).
(+)3-Butvlthio-4-~exo-2-azabicvclor2.2.2loct-6-vloxv)-1,2,5-thia~lazole Trimethylsilyliodide 0.70 mL (4.9 mmol) was added to a solution of 3-butylthio-4-(exo-2-methoxycarbonyl-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole in 10 mL of CH2C12. After stirring for 5 h at room temperature, the solution was evaporated under vacuum.
10 mL of saturated NaHCO3 was added and the solution was extracted three times with 20 mL portions of EtOAc. The combined extracts were dried over NaCl/Na2SO4 and evaporated under vacuum. The residue was chromatographed over silica gel (10% EtOH, 1% NH40H-CHCl3) and the resulting oil converted to its oxalate salt.
Recrystallization from EtOH/EtOAc afforded 789 mg (mp. 148-150~C). (Compound 65).
W O 97~0819 PCTAUS96/19229 3-Amino-4-butvlthio-1,2,5-thiadiazole A 1.04 g sample of 3-chloro-4-butylthio-1,2,5-thiadiazole was dissolved in 20 mL of THF and added to a 50 mL reaction vessel. The mixture was cooled to 0~C. A 10 mL
sample of sodium bis(trimethylsilyl)amide in THF (1.0 M) was added dropwise to the reaction vessel. The mixture was stirred at 0~C. The reaction was quenched using 50 mh water upon desired completion of reaction. The pH of the mixture was adjusted to 2.0 using HCl. The mixture was stirred ~or 15 min. and then adjusted to pH = 11 using NaOH. The mixture was extracted using ether. The organic layers were combined, dried, and filtered. The filtrate was concentrated to dryness. The resulting product was purified using column chromatography. Yield: 1.07 g (65%). The N,N-bis(trimethylsilyl)-3-amino-4-butylthio-1,2,5-thiadiazole was suspended in 3N HCl and heated to about 50~C. The mixture was stirred for 3 h. The pH was adjusted to 11 using NaOH. The mixture was extracted using t-butylmethyl ester. The organics were combined, dried, filtered and concentrated to dryness. Yield: 0.43 g (45%). (Compound 66). The process substantially as described was repeated to yield 82% of the desired 3-amino-4-butylthio-1,2,5-thiadiazole.
3-Bromo-4-hutvlth;o-1.2,5-thiadiazole A 0.42 g sample of cupric bromide, 0.28 isoamyl nitrite and 6 mL acetonitrile were added to a 25 mL
reaction vessel. The mixture was warmed to 65~C. The acetonitrile mixture was added to a 4 m1 acetonitrile solution containing 0.30 g 4-amino-3-butylthio-1,2,5-thiadiazole. The mixture was stirred for 30 min. at 65~.
The mixture was cooled to room temperature and quenched W O 97/20819 PCT~US96/19229 with 50 mL of 1 N HC1. The organic layers were combined, dried, filtered and concentrated to dryness. Yield: 0.38 g (94~). The resulting material was purified using column chromatography to yield 0.30 g (73%) of material. (Compound 67).
The process substantially as described above was completed using copper(I) iodide (0.61 9) to provide 3-iodo-4-butylthio-1,2,5-thiadiazole. Yield: 0.23 g (48~).
(Compound 68).
~Y~le 66 (i)3~(2~2r3~3~4~4~4-he~tafluorobutvloxv)-4-r-3-(1-az~h;cvclor2.2.2loctvloxv)l-1,2,5-thiadiazole A solution of potassium t-butoxide (1.6g, 0.0143 mol) in THF (12 mL) was treated with 2,2,3,3,4,4,4-heptafluorobutanol ( 2 mL, 0.016 mol). After 5 min, Compound 12 (0.75 g, 0.Q03 mol) was added, the reaction stirred 2 h followed by heating to re~lux for 1.5 h. After stirring at ambient temperature overnight and heating to reflux for another 1.5 h, the solvent was evaporated, the residue suspended in H2O, and the mixture extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (20 %
EtOH-2 % N~40H-CHCl3) to give an oil. The hydrochloride salt crystallized from EtOAc with a half mole of H2O as a flocculent white solid (0.43 g), m.p. 168.5-169.5 ~C.
(Compound 69).
Example 67 (+)3-(1-Butvlthio)-4-~endo--6-(1-~z~hicvclor3.2.1loctvloxv)l-1~2~5-thi~diazole A solution o~ potassium t-butoxide (0.62 g, 0.0055 mol) in THF (12 mL) was treated with endo-1-azabicyclo[3.2.1~octan-6-ol (0.64 g, 0.005 mol). After 5 W O 97/20819 PCT~US96/19229 min, 3-chloro-4-(1-butylthio)-1,2,5-thiadiazole ~1.2 g, 0.0057 mol) was added. After stirring overnight, the solvent was evaporated, the residue diluted with H2O, acidified, and extracted with ether. The a~ueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was purified by radial chromatography (20 % EtoH-2 % NH40H-CHC13). The HCl salt crystallized from EtOAc to give a white solid (0.68 g), m.p. 201-202 ~C dec.
(Compound 70).
Exam~le 68 l+)3-(3-Phenvl~roDvlthio)-4-rendo--6-(1-az~h;cvclor3.2.1loctvloxy)l-1.2,5-thiadiazole A solution of Compound 48 (0.9 g, 0.0037 mol) in DMF t25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (0.97 g, 0.004 mol). After 2 h, the reaction was treated with dropwise with l-bromo-3-phenylpropane (1.11 g, 0.0059 mol), the reaction stirred 3.25 h, followed by dropwise addition of additional l-bromo-3-phenylpropane (1.11 g, 0.0059 mol) in DMF (5 mL). A~ter stirring overnight, the solvents were evaporated, the residue suspended in H2O, acidified, and the mixture extracted with ether. The aqueous phase was made basic, extracted with CHCl3, the extracts dried, and the solvent evaporated. The residue purified by radial chromatography (MeOH:EtOAc:NH40H/15:30:1) to give an oil. The HCl salt (0.41 g) crystallized from CHC13-EtOAc-ether, m.p. 178-179 ~C. (Compound 72) W O 97/20819 PCT~US96/19229 ~Y~m~le 69 (i)3- r 3-(4-Fluoro~henvl)~ro~vlthiol-4- r -3-(1-~abicvclo r 2.2.21OctvloxY)l-1,2,5-thiadiazole - A solution of the crude Compound 12 (1.15 g, 0.0047 mol) in DMF ~20 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.68 g, 0.007 mol). After 1 h, 1-chloro-3-(4-fluorophenyl)propane (1.63 g, 0.0095 mol) in DMF (2 mL) was added dropwise and the reaction stirred 2.5 days. The reaction was then treated with additional 1-chloro-3-(4-fluorophenyl)propane (0.815 g, 0.00~7 mol) and warmed at 35 ~C for 6 h. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (MeOH:EtOAc:NH40~/15:30:1). The HCl salt (0.19 g) crystallized from CHC13-EtOAc-ether, m.p. 189-191 ~C. (Compound 73) ~YA~le 70 (+)3-r3-r4-(Trifluorom~thvl)~henYll~ro~vlthio~-4-r-3- ~-~hicvclo r 2.2.2loctvloxv)l-1,2,5-thiadiazole A solution of the Compound 12 (1.15 g, 0.0047 mol) in DMF
(20 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.68 g, 0.007 mol). After 2 h, the reaction was cooled to -35 ~C, treated dropwise with l-bromo-3-[4-(trifluoromethyl)phenyl)propane (2.53 g, 0.0095 mol) in DMF
(30 mL), and the reaction stirred 2 h. Cooling was removed, reaction stirred 3.5 h, and again cooled to -35 ~C. The reaction was then treated with additional l-bromo-3-[4-(trifluoromethyl)phenyl)propane (1.75 g, 0.0043 mol) in DMF (5 mL), cooling removed, and reaction stirred over night. Additional l-bromo-3-[4-W O 97/20819 PCT~US96/19229 (trifluoromethyl)phenyl)propane (0.75 g, 0.0028 mol) in DMF
(5 mL) was added and stirring continued for 1.5 h. The solvent was evaporated, the residue suspended in H2O, and the mixture extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (MeOH:EtOAc:NH40H/15:30:1). The HCl salt (0.32 g) crvstallized from CHCl3-EtOAc-ether, m.p. 182-184 ~C. (Compound 74) Example 71 3-(1-Butvl~m;no)-4-r(+.-)-3-(1-azabicvclor2.2.2loctvloxv)l-1,2,5-thia~;~zole A mixture of Compound 12 (1.15 g, 0.0047 mol) and 1-butylamine (20 mL) was heated to reflux for 22 h. The solvent was evaporated, residue suspended in H2O, the mixture acidified, and extracted with ether. The aqueous phase was made basic, extracted with EtOAc, extracts dried, and solvent evaporated. Purification by radial chromatography (MeOH:EtOAc:NH40H/15:30:1) and conversion to a HCl salt gave a solid partial hydrate (0.046 g), m.p.
193-195 ~C. (Compound 75) Exam~le 72 Cvanoaen butvloxv;~;de A solution of 1-butanol (92 mL, 1 mol) and triethylamine (3 mL) was cooled to -8 ~C and cyanogen (58 g, 1.12 mol) was slowly bubbled through the solution while maintA;n;n~ the temperature below 2 ~C. The reaction mixture was then distilled at 7 mm Hg to give a clear liquid (119.4 g) b.p. 43-49 ~C. (Compound 76).
W O 97120819 PCTrUS96119229 ~YA _ le 73 3-Chloro-4-butvloxv-1,2,5-thiadiazole A solution of DMF (400 mL) and sulfur monochloride (230 mL) was cooled to 5 ~C and Compound 76 (119.4 g, 0.95 mol) was added dropwise such that the temperature did not exceed 10 ~C. Cooling was removed and the reaction was stirred over night. The reaction was cooled in an ice-water bath and the excess sulfur monochloride destroyed by dropwise addition of H2O such that the temperature did not exceed 30 ~C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The aqueous ~raction was extracted with hexane (3 x) and the combined extracts and triturants were washed with H2O, aqueous NaHCO3, brine, dried, and the solvent e~aporated. The yellow liquid residue was distilled at 14 mm Hg to give a clear liquid (153 g), b.p. 120-125 ~C. (Compound 77) ~Y~m~le 74 3-Methylthio-4-butylo~-1,2,5-thiadiazole A solution of Compound 77 (6 g, 0.031 mol) in DMF (75 m~) was rapidly'stirred as ground flaked Na2S-~ ~2~
(8 g, 0.034 mol) was added. After 1 h, CH3I (3 mL, 0.048 mol) was added and the reaction stirred 30 min. Ice-water (150 mL) was added to the reaction and the mixture extracted with hexane (3 X). The extracts were washed with H2O (2 X), dried and the solvent evaporated to give a clear liquid (6.04 g). (Compound 78) ~YA _ le 75 3-Methylsulfonyl-4-butvlox~-1,2.5-thiadiazole To a solution of oxone (18.4 g, 0.03 mol) in H2O
(100 mL) was added dropwise compound 78 (3 g, 0.0147 mol) in THF (45 mL). After stirring overnight, the organics CA 0223930l l998-06-02 W O 971208~9 PCTnUS96/19229 were evaporated and the residue extracted with ether (3 x)~
The extracts were washed with H2O (2 X), dried, and the solvent evaporated. The residue was puri~ied by radial chromatography eluting with 50 % EtOAc-hexane to give a clear colorless liquid (2.93 g) that solidified on st~n~lng, m.p. 39-40 ~C. (Compound 79) Example 76 3-Methvlth;o-4-hexvloxv-1,2,5-thiadiazole A solution of 3-chloro-4-hexyloxy-1,2,5-thiadiazole (CA 60, 2796e, 1964) ( 1.1 g, 0.005 mol) in DMF
(30 mL~ was rapidly stirred as ground flaked Na2S-9 H2O
(1.5 g, 0.00625 mol) was added. After stirring overnight, CH3I (2 mL ) was added and the reaction stirred 30 min.
Ice-water (150 mL) was added to the reaction and the mixture extracted with ether (2 X). The extracts were washed with H2O (2 x)~ dried and the solvent evaporated to give a clear li~uid (1.025 g). (Compound 80) ~Y~ _le 77 3-Methvlsulfonvl-4-hexvlox~-1,2,5-thiadiazole To a solution of Oxone (18.4 g, 0.03 mol) in H2O
(100 mL) was added dropwise Compound 80 (3.4 g, 0. 0147 mol) in THF (50 mL). After stirring for three days, the organics were evaporated and the residue extracted with ether (3 X). The extracts were washed with H2O ~2 X), dried, and the solvent evaporated. The residue was purified by radial chromatograph~ eluting with 50 % EtOAc-hexane to give a clear colorless li~uid (3.58 g).
(Compound 81) CA 0223930l l998-06-02 W O 97/20819 PCT~US96/19229 ~Y~ _ le 78 Cvanoqen ~ro~vloxvimi~e A solution of l-propanol (40 mL, 0. 536 mol) and triethylamine (1. 5 mL) was cooled to -8 ~C and cyanogen (36 - g, 0.69 mol) was slowly bubbled through the solution while maintaining the temperature below 2 ~C. The reaction mixture was then distilled at 20 mm Hg to give a clear liquid ( 59 g) b.p. 63-64 ~C. (Compound 82) ~YA _ le 79 3-C~lloro-4-~ro~vloxv-1,2,5-thiadiazole A solution of DMF (180 mL) and sulfur monochloride (120 mL, 1. 5 mol) was cooled to 5 ~C and Compound 82 (59 g, 0.527 mol) was added dropwise such that the temperature did not exceed 10 ~C. Cooling was removed and the reaction was stirred over night. The reaction was cooled in an ice-water bath and the excess sulfur monochloride destroyed by dropwise addition of H2O such that the temperature did not exceed 30 ~C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The aqueous fraction was extracted with hexane (3 X) and the combined extracts and triturants were washed with H2O, aqueous NaHCO3, brine, dried, and the solvent evaporated. The yellow liquid residue was distilled at 15 mm Hg to give a clear liquid (79.g g), b.p. 103-106 ~C. (compound 83) ~YAm~le 80 3-Methvlthio-4-~ro~vloxv-1,2,5-thiadiazole A solution o~ Compound 83 (11.1 g, 0.062 mol) in DMF (150 mL) was rapidly stirred as ground ~laked Na2S-9 H2O (16.4 g, 0.068 mol) was added. After 1 h, CH3I (6 mL, 0.096 mol) was added and the reaction stirred 30 min. Ice-water (300 mL) was added to the reaction and the mixture extracted with hexane (3 X). The extracts were washed with H2O (2 X), dried and the solvent evaporated to give a clear liguid (11.02 g). (Compound 84) ~Y~ _le 81 ~)-3-(4,4,4-Tri~luorobutvloxv)-4-(1-~z~hicvclor2.2.2loctvl-3-oxv)-1,2,5-thiadiazole A solution o~ 4,4,4-trifluorobutanol (0.75 g) in THF (20 mL) was cooled to 0 ~C and potassium t-butoxide (0.65 g) was added. A~ter 5 min, a solution of Compound 102 (0.6 g) in THF (5 mL) was added and the reaction stirred one hour. The reaction was guenched with 5N HCl (1.5 mL) and the solvent evaporated. The residue was suspended in water and extracted with ether. The aqueous phase was made basic and extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromotography eluting with 20%-EtOH-1%-NH40H-CHCl3 to give a clear oil. The HCl salt was recrystallized ~rom EtOAc-ether to give a white solid, m.p.
3~ 122-124 ~C (0.43 g). (Compound 104).
CA 0223930l l998-06-02 W O 97/20819 PCTnUS96/19229 Example 82 (+)-endo-3-Pro~vlsulfonvl-4~ azabicvclor3.2.1loctvl-6-oxv)-1,2,5-thiadiazole A solution of (+)-endo-3-propylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (5.7 g) in 1 N HCl (24 mL) was cooled in ice-watér and Oxone (36.8 g) in H2O (75 mL) was added dropwise over 5 min. Cooling was removed and after 5 h, excess oxidant was destroyed with NaHSO3. The reaction was poured into ice and the pH
adjusted to 12. The mixture was extracted with EtOAc, the extracts washed with water, the solvent dried, and the solvent evaporated to give analytically pure (+)-endo-3-propylsul~onyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole as an oil (4.6 g). (Compound 166).
R~AMpT~ 83 (+/-) -3-ButvloxY-4- (1 -;Iz~h;cvclor2,2,210ctvl-3-ox~) -1,2,5-oxadiazole A suspension o~ 3,4-diphenylsulfonyl-1,2,5-oxadiazole oxide (4.6 g, 0.126 mol, Ref. J.Chem. Soc. 1964, 904.) in l-butanol (400 mL) was heated to 55-60 C as a solution of sodium l-butyloxide (0.3 g Na, 40 mL l-butanol) was added dropwise. After 1 h, the solvent was evaporated, residue was treated with H2O, and the mixture extracted with ether (3X).
The extracts were washed with H2O, dried, and the solvent evaporated to give a white solid (3.15 g). The solid was heated to re~lux overnight in P(OCH3)3 (30 mL) then poured into ice-H2O containing HCl (6 mL, 5N). The mixture was extracted with ether, the extracts washed with brine, dried, and the solvent evaporated to give a yellow li~uid. Radial ~ chromatography (15% EtOAc/hexane) gave a clear liquid (1.85 g). The li~uid was dissolved in THF (30 mL) and added dropwise to a mixture prepared from 1-azabic~clo~2.2.2]octan-3-ol(1.85 g 0.014 mol), THF (20 mL), W O 97/20819 PCT~US96/19229 and 1.6 M n-butyl lithium in hexane (8.4 mL, 0.013 mol). The reaction was then warmed to 52 C for 5 h. The cooled reaction was acidified with dilute HCl and diluted wit ether.
the aqueous fraction was washed with ether, made basic, and extracted with ether. The extracts were dried and evaporated to give a clear liquid. The HCl salt ~1.4 g) crvstallized from CHCl3-EtOAc-ether, m.p. 186-188 C.
(Compound 1).
E~AMpLE 1 ' (+) -endo-2- (4-Methvl-3-~entenvlthio~-3-(1-~zabicvclor3.2.11Octvl-6-oxv)~vrazine Obtained from Compound 19 and 1-bromo-4-methyl-3-pentene in 8% yield as a foam. (Compound 43).
~XAMPT~ 2' (+/-)-3-Chloro-2-(1-azabicvclor2.2.2loctvl-3-oxv)~vrazine A solution of 1-azabicyclo[2.2.2]octan-3-ol (5 g, 0.039 mol) in THF (400 mL) was treated with 1.6 M n-butyllithium in hexane (25 mL, 0.04 mol). After 1 h, the solution was cooled in an ice-water bath and 2,3-dichloropyrazine (6.6 g, 0.044 mol) in THF (30 mol) was added in one portion. Cooling was removed and after 30 min., the reaction was heated to reflux for 2.5 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous fraction was made basic and extracted with ether. The extracts were washed with water, dried, and the solvent evaporated to give a tacky solid. Recr,vstallization from ether gave a yellow solid (1.74 g), m.p. 112.5-114 C. (Compound 2).
~AMPL 3 (+/-)-3-Butvloxv-2-(l-azabicvclor2.2.21octvl-3-oxv)~vrazine W O g7/20819 PC~US96/19229 A solution of sodium butyloxide (0.25 g Na, Q.O109 mol, 1-butanol, 30 mL) was added to (compound 2) (0.48 g, 0.002 mol), the reaction stirred overnight, then heated to 80 C for 4 h. The solution was acidified and the solvent evaporated. The residue was suspended in H20, extracted with ether, and the aqueous solution made basic. The aqueous fraction was extracted with EtOAc, the extracts washed with H20, dried, and the solvent evaporated to give a yellow oil.
The HCl salt (0.32 g) crystallized from EtOAc as a white powder, m.p. 150-151 C. (Compound 3).
,~MPLE 4' (~/-)-3-Pro~vloxv-2-(1-azabicvclor2.2.2loctvl-3-oxv)~Yrazine To a solution of lithium 1-propyloxide (7 mL 1.6 M
n-butyllithium, O.011 mol, 1-propanol, 30 mL) was added (compound 2) (0.63 g, 0.0026 mol) and the reaction heated to reflux for 6 h. The solvent was evaporated, the residue suspended in H20, and the mixture extracted with EtOAc. The extracts were washed with H20, dried, and the solvent evaporated to give an oil. The HC1 salt (0.34 g) crystallized from acetone as a tan solid, m.p. 186-l90 C.
~Compound 4).
MPLE S ' (+/-)-3-Hexvloxv-2-(1-azabicvclor2.2.2loctvl-3-oxv)~vr~zine TO a solution of lithium 1-hexyloxide (7.8 mL 1.6 M
n-butyllithium, 0.013 mol, 1-hexanol, 20 mL) was added (compound 2) (0.6 g, 0.0025 mol) and the reaction heated to 80 C overnight. The solution was cooled, treated with 1 N
HCl (15 mL) and the solvent evaporated. The residue was suspended in H20, the mixture washed with ether, and made basic. The aqueous fraction was extracted with EtOAc, the ~ extracts dried, and the solvent evaporated to give an oil.
The HC1 salt (0.34 g) crystallized from EtOAc as a hemihydrate, m.p. 162-164 C. (Compound 5).
CA 0223930l l998-06-02 W O 97/20819 PCTAJSg6/19229 ~MPT.R 6' (+/-~-3-Butylth-o-2-(1-azabicvclor2.2.2loctyl-3-oxv)Dyr~zine A solution of l-butanethiol (1.1 mL) in THF (100 mL) was treated with 1.6 M n-butyl lithium in hexane ~4.7 mL, 0.0075 mol). After 10 min, (compound 2) (0.6 g, 0.0025 mol) was added and the reaction heated to reflux for 3 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The ether was dried and the solvent evaporated to give a clear liquid.
The HCl salt (0.59 g) crystallized from EtOAc as white crystals, m.p. 192-lg3-C (Compound 6).
~MPLE 7' (+/-)-3-Pentylthio-2-(1-azabicyclor2.2.2loctvl-3 -QXY) ~vrazine A solution of l-pentanethiol (1.2 mL) in THF (50 mL) was treated with 1.6 M n-butyl lithium in hexane (4.7 mL, 0.0075 mol). After 10 min, (compound 2) (0.6 g, 0.0025 mol) was added and the reaction heated to reflux for 2 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The a~ueous was made basic and extracted with EtOAc. The EtOAc was dried and the solvent evaporated to give a clear liquid. The HCl salt (0.44 g) crystallized from EtOAc, m.p. 169-171-C
(Compound 7).
~MPT.~ 8' (+/-)-2-(1-Azabicyclo r 2.2.2loctyl-3-oxv)~vrazine A suspension of 60% NaH in oil (1 g, 0.025 mol) in DMF (30 mL) was treated with l-azabicyclo[2. 2.2] octan-3-ol (3 .28 g, 0.025 mol) and the mixture heated to 50 C for 65 min. The mixture was treated dropwise with 2-chloropyrazine t3.16 g, 0 .027 mol) and heating continued for 3 h. ~Ieating was discontinued and the reaction stirred overnight. The solvent was evaporated, the residue treated with water, acidified, and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (30% MeOH-EtOAc-trace NH40H) to give an oil. The HCl salt (2.07 g) crystallized from MeOH-EtOAc, m.p. 256-258 C
(Compound 8).
~;!X'I~MPT.lZ 9 ~
(+/-)-3-(1-Pentvloxv)-2-(1-azabicvclo r 2.2.21 octvl-3-oxv)~vrazine To a solution of lithium 1-pentoxide (1.6 M n-butyllithium, 7.6 mL, 0.012 mol, 1-pentanol, 20 mL) was added (Compound 2) (0.58 g, 0.0024 mol) and the reaction heated to 90 C overnight. The solution was acidi~ied and the solvent evaporated. The residue was suspended in H20, extracted with ether, and the aqueous solution made basic. the aqueous fraction was extracted with EtOAc, the extracts washed with H20, dried, and the solvent evaporated to give an oil. The oil was purified by raidal chromatography (10% EtOH-1% NH40H-CHC13) and the HC1 salt (0.2 g) crystallized from EtOAc as a white powder, m.p. 163-165-C (Compound 9).
~ MpLE 10 ' (+/-)-3-MethoxY-2-tl-azabicvclor2.2.2loctvl-3-oxv)Dyrazine To a solution of sodium methoxide (Na, 0.4 g, 0.0174 mol, methanol, 25 mL) was added (compound 2) (0.8 g, 0.0033 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue suspended in H20, and the mixture extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (10% EtOH-1% MH40H-CHCl3). The HCl salt (0.34 g) crystallized from 2-propanol as a hemihydrate, m.p. 215-218-C. (Compound 10).
W O 97~20819 PCT~US96/19229 EXAMPT~ 11' (+/-)-3-Fthoxv-2-(1-~z~hicvclor2.2.2loctvl-3-oxv)~vrazine To a solution of sodium ethoxide (Na, 0.4 g, 0.0174 mol, ethanol, 25 mL) was added (compound 2) (0.8 g, 0.0033 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue suspended in H2O, and the mixture extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatograph~ (10% EtOH-l % NH40H-CHCl3). The HCl salt (0.086 g) crystallized from 2-propanol, m.p. 215-218-C.
(Compound 11).
~MPLE 12' ~+/-)-3-(1-Hexvlthio)-2-(1-azabicvclo r 2.2.2loctvl-3-oxv)~vr~zine A solution of l-hexanethiol (1.4 mL) in THF (50 mL) was treated with 1.6 M n-butyllithium in hexane (4.7 mL, 0.0075 mol). After 10 min, (compound 2) (0.6 g, 0.0025 mol) was added and the reaction heated to re~lux for 4 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with EtOAc. The EtOAc was dried and the solvent evaporated to give a clear li~uid.
The HCl salt (0.57 g) crystallized from EtOAc, m.p. 171-174 C
(Compound 12).
~XAMPLE 13~
(+/-)-3-Methvlthio-2-(1-azabicvclo~2.2.2loctvl-3-oxv)~vra~ine A suspension of NaH (0.42 g, 0.018 mol) in DMF ~25 mL) was treated with 5.19 M methanethiol in DMF ( 6.44 mL, 0.033 mol). After 10 min, (compound 2) (0.8 g, 0.0033 mol) was added and the reaction heated to 50 C ~or 3 h. The reaction was cooled, acidified, and the solvent evaporated.
The residue was suspended in cold water, extracted with ether, the a~ueous made basic, and the mixture extracted with W O 97/20Xl9 PCT~US96/19229 EtOAc. The EtOAc was dried and the solvent evaporated to give a clear liquid. The HCl salt (0.63 g) crystallized from MeOH-EtOAc, m.p. 243-247 C. (Compound 13).
.
~X~MPT.~ 1~
- (+/-)-3-Ethvlthio-2-~1-azabicvclor2.2.2loctYl-3-oxv)~vrazine A solution o~ ethanethiol (2.6 mL) in THF (90 mL) was treated with 1.6 M n-butyllithium in hexane (9 mL, 0.0167 mol). After 15 min, (compound 2) (0.6 g, 0.0025 mol) was added and the reaction heated to reflux for 4 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with EtOAc. The EtOAc was dried, the solvent evaporated, and the residue purified by radial chromatography (5% EtOH-0.5% NH40HCHCl3). The HCl salt (0.48 g) crystallized from EtOAc, m.p. 269-272 C. (Compound 14).
~AMPLE 15' (+/-)-3-(1-Pro~vlthio-2-(1-azabi CYClO r 2.2.2loctvl-3-oxv)~vrazine A solution of l-propanethiol (2.7 mL) in THF ~90 mL) was treated with 1.6 M n-butyllithium in hexane (7 mL, 0.0117 mol). After 15 min, (compound 2) (0.7 g, 0.0029 mol) was added and the reaction heated to reflux for 4 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with EtO~c. The EtOAc was dried, the solvent evaporated to give an oil. The HCl salt (0.76 g) crystallized from MeOH-EtOAc, m.p. 231-234-C.
(Compound 15).
-12~-~AMPT.~ 16' (~/-)-3-(l-Heptylthio-2-(l-az~hicvclor2.2.2~octyl-3-oxv)~vr~zine A solution of l-heptanethiol (4.9 mL) in THF (90 mL) was treated with 1.6 M n-butyllithium in hexane (7 mL, 0.0117 mol). After 15 min, (compound 2) (0.7 g, 0.0029 mol) was added and the reaction heated to reflux for 4 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with EtOAc. The EtOAc was dried, the solvent evaporated to give an oil. The HCl salt (0.767 g) crystallized from MeOH-EtOAc as a hemihydrate, m.p. 169-173 C. (Compound 16).
~MP~E 17' 3-(1-Butylthio-2-(2-(dimeth~lamino)ethoxy)Dyrazine A solution of 2-dimethylaminoethanol (2.13 mL, 0.021 mol) in THF (130 mL) was treated with 1.6 M n-butyllithium in hexane (13.1 mL, 0.021 mol) with cooling in an ice-water bath. To the solution was added 2,3-dichloropyrazine (3.13 g, 0.021 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with EtOAc.
The extracts were washed with water, dried, and the solvent evaporated to give a clear oil (3.86 g). The oil was added to a solution of lithium l-butanethioxide (1.6 M n-butanethioxide (1.6 M n-butYllithium, 17 mL, 0.0273 mol, 1-butanethiol, 19.7 mL, 0.184 mol) in THF (100 mL), the reaction heated to reflux for 2 h, heating removed, and the reaction stirred over the weekend. The solvent was evaporated, the residue dissolved in dilute HCl, and the mixture extracted with ether. The aqueous phase was made basic, extracted with EtOAc, the extracts dried, and the solvent evaporated. The residue was purified by radial 9 PCTnJS96/19229 chromatography (5% EtOH-0.5% NH4OH-CHC13) to give an oil (3.4 g). The HCl salt crystallized from EtOAc to give a white solid, m.p. 120-123'C. (Compound 17).
~AMPT.~ 18' - 3-(1-Butvlthio)-2-(2-(trimethvlamino)ethoxv)~yrazine iodide A solution of (compound 17) (0.7 g, 0.0028 mol) in EtOAc (40 mL) was treated with iodomethane (O.~ mL) and the reaction stirred overnight. The white solid (1.04 g) was collected by filtration and dried, m.p. 140-142 C. (Compound 18).
~MPT.~ 19 ~
3-Cl~loro-2-rendo-(+.-)-6-(1-azabicyclo r 3.2.1loctyloxy)l-~yrazine A solution of potassium t-butoxide (0.62 g, 0.0055 mol) in THF (10 mL) was treated with endo-(+,-)-l-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol). After 5 min, 2,3-dichloropyrazine (2 g, 0.0134 mol) was added and the reaction stirred overnight. The reaction was diluted with H2O, acidified, and extracted with ether. The aqueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was purified by radial chromatography (20 % EtOH-2 %
NH40H-CHCl3) to give an oil. The HCl salt crystallized from acetone (0.44 g), m.p. 200 ~C dec. (Compound 19).
~mn le 20' 3-Meth~yl-2- r endo-(+,-)-6-(1-azabicyclo r 3.2.1loctyloxy)l-pyrazlne -A solution of potassium t-butoxide (0.62 g, 0.0055 mol) in THF (10 mL) was treated with endo-(+,-)-l-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol). After 5 W O 97/20819 PCTAUS~6/19229 min, reaction was cooled in an ice-water bath and 2-chloro-3-methylpyrazine (1.3 g, 0.01 mol) was added in a single portion. Cooling was removed and the reaction stirred for 3 days. The solvent was evaporated, the residue diluted with H20, acidified, and extracted with ether. The aqueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was converted to an HCl salt and recrystallized from 2-propanol to give a floculant powder (0.5 g), m.p. 240 ~C
dec. (Compound 20).
~m~ le 21' 2 - r endo-(~,-)-6-(1-azabicvclo r 3.2.1loctvloxv)l-~vrazine A solution o~ potassium t-butoxide (0.62 g, 0.0055 mol) in THF (10 mL) was treated with endo-(+,-)-l-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol). A~ter 5 min, reaction was cooled in an ice-water bath and 2-chloro-3-methylpyrazine (1.2 g, 0.01 mol) was added in a single portion. Cooling was removed and the reaction stirred 4 h.
The solvent was evaporated, the residue diluted with H2O, acidified, and extracted with ether. The a~ueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The solid residue was converted to an HCl salt and recrystallized ~rom 2-propanol to give a white solid (0.92 g), m.p. 250 ~C
dec. (Compound 21).
Exam~le 22~
6-Chloro-2-rendo-(+.-)-6-(1-azabicvclor3.2.1loctvloxv)l-~vrazine A solution of potassium t-butoxide (0.62 g, 0.0055 mol) in THF ~10 mL) was treated with endo-(+,-)-l-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol). A~ter 5 min, reaction was cooled in an ice-water bath and 2,6-dichloropyrazine (1 g, 0.0067 mol) was added in a single CA 0223930l l998-06-02 WO 97/20819 PCTrUS96/19229 portion. Cooling was removed and the reaction stirred over night. The solvent was evaporated, the resldue diluted with H2O, acidified, and extracted with ether. The aqueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The - residue was purified by radial chromatography (20 % EtOH-2 %
NH40H-CHCl3) . The HCl salt cr~stallized from acetone to give a white solid (0.33 g), m.p. 211-213 ~C dec. (Compound 22).
Ex~m~le 23 ' 3~ butvloxv)-2-rendo-(+,-)-6-~1-,~zabicvclo r 3 . 2.1loctvloxv)l-~vrazine A solution of potassium t-butoxide (1 g, 0.0089 mol) in THF
(20 mL) was treated with l-butanol (1 mL). After 5 min, reaction was cooled in an ice-water bath and Compound 19 (0.65 g, 0.0027 mol) in THF (10 mL) was added. Cooling was removed and the reaction stirred for 3 days. The solvent was evaporated, the residue diluted with H2O, acidified, and extracted with ether. The aqueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was purified bv radial chromatography (20 % EtOH-2 % NH40H-CHCl3). The HCl salt crvstallized from EtOAc to give a white solid (0.23 g), m.p. 171.5-172.5 ~C dec.(Compound 23) ~am~le 24~
3-(1-butvlthio~-2-rendo-(+,-)-6-(1-azabicvclor3.2.11 octvloxv)l-~vrazine A solution of potassium t-butoxide (1 g, 0.0089 mol) in THF (20 mL) was cooled in ice-water and treated with l-butanethiol (1 mL). After 5 min, cooling was removed and ~ Compound 19 (0.6 g, 0.0025 mol) in THF (10 mL) was added.
After stirring overnight, the solvent was evaporated, the residue diluted with H2O, acidified, and extracted with ether. The a~ueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was purified by radial chromatography (20 % EtOH-2 % NH40H-CHC13). The HCl salt crystallized from EtOAc to give a white solid (0.64 g), m.p.
157-158 ~C dec. (Compound 24).
Example 25~
endo-(8-Methvl-8-azabicvclo r 3.2.1loctYl-3-oxY)~vrazine A solution of potassium tert-butoxide (0.62 g) in THF (15 mL) was treated with tropine (0.7 g). After 5 min, the reaction was cooled in ice-water and chloropyrazine (1.2 g) was added.
The cooling was removed and the reaction stirred over night.
The solvent was evaporated, the residue dissolved in cold 1 N
HCl, and the mixture exracted with ether. The aqueous fraction was made basic, extracted with EtOAc, the extracts washed with water, brine, the solvent dried, and the solvent evaporated. The residue was purified by radial chromatography eluting with 20%-EtOH-2~-NH40H-CHC13 to give endo-(8-methyl-8-azabicyclo[3.2.1~octyl-3-oxy)pyrazine (0.6 g) that was isolated as a HCl salt that crystallized from 2-propanol, m.p. 240 ~C, dec. (Compound 25).
Exam~le 2~' ~-t2-Dimethvlaminoethoxv)~vrazine A solution of 2-dimethylaminoethanol (1 mL) in THF (20 mL) was treated with potassium tert-butoxide (1.2 g). After 5 min, chloropyrazine (2 g) was added and the reaction stirred 2 h. The solvent was evaporated, the residue suspended in cold water, the mixture acidified, and the mixture extracted with ether. The aqueous fraction was made ~asic and extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography eluting with 10%-EtOH-1%-NH~OH-CHC13 to give 2-(2-dimethylaminoethoxy)pyrazine (1.3 g). The HCl salt W O 97/20819 PCTrUS96/19229 crystallized from 2-propanol as a white solid, m.p. 151-153 ~C. (Compound 26).
., Example 27~
2-(2-Trimethvlaminoethoxv)~vrazine iodide A solution of the free base of Compound 26 (0.7 g) in EtOAc (40 mL) was treated with methyl iodide (1 mL) and the reaction stirred over night. The resulting solid was collected and dried to give 2- (2-trimethylaminoethoxy)pyrazine iodide as a off white solid (1.34 g), m.p. 164 ~C, dec. (Compound 27).
Exam~le as 1 (S)-2-(1-Methvl-2-~vrroli~nvlmethoxv)~vrazine A solution of (SJ-l-methyl-2-pyrrolidinemethanol (1.15 g) in THF (45 mL) was treated with potassium tert-butoxide (1.2 g).
After 10 min, chloropyrazine was added and the reaction stirred for 1.5 h. The reaction was quenched with 5 N HCl (4 mL) and the solvent evaporated. The residue was suspended in water and extracted with ether. The aqueous fraction was made basic and extracted with CHC13. The extracts were dried, the solvent evaporated, and the residue puri~ied by radial chromatography eluting with 20%-EtOH-2%-NH40H-CHCl3 to give (S)-2~ methyl-2-pyrrolidinylmethoxy)pyrazine (1.1).
The HCl salt crystallized from EtOAc as a white solid, m.p.
121-122 ~C. (Compound 28) W O 97/20819 PCTrUS96/19229 ~xample 29~
(+)-endo-2-Pro~Ylthio-3-(1-azabicvclo r3 . 2.1loctvl-6-oxv)~vrazine Potassium t-butoxide (0.9 g, 8 mmoles) was added at 0~ C. to propanethiol (0.61 g, 8 mmoles) in 20 ml THF and stirred for 5 min. Compound 19 (0.5 g, 2 mmoles) was added and the reaction stirred for 24 hr at room tempera~ure. 200 ml of 1 N
HCl was added and the aqueous solution washed with ethyl acetate. The pH was adjusted to 12Ø The product was extracted with ethyl acetate, dried over sodium sulfate and evaporated. The HCl salt was ~ormed in ether and ~iltered to yield (~)- endo-2 -propylthio-3-(1-azabicyclo[3.2.1]octyl-6-oxy)pyrazine hydrochloride (0.38 g), m.p. 159-160 ~C.
(Compound 29) The following compounds were prepared in substantially the same manner as Compound 29 by substituting the appropriate alkyl~hiol ~or propanethiol.
~Y~le 30' (+)-endo-2-Pentvlthio-3-(1-azabicvclor3.2.1loctvl-6-oxv)~vrazine Obtained from Compound 19 and pentanethiol in 60% yield, m.p.
159-160 ~C. (Compound 30).
~Y~m~le 31' (i)-endo-2-(2-Methvl~ro~vlthio)-3-(1-az~hicYclor3.2.1loctvl-6-oxY)~vrazine Obtained from Compound 19 and 2-methylpropanethiol in 8%
yield, m.p. 142-143 ~C. (Compound 31).
CA 0223930l l998-06-02 W o 97/208l9 PCT~US96/19229 ~xample 32' (+) -endo-2-7~thvlthio-3- (1-azabicvclo r3 . 2 .lloctvl-6-oxv)~vrazine Obtained from Compound 19 and ethanethiol in 53% yield, m.p.
196-197 ~C. (Compound 32).
Example 33~
( + ) - endo- 2-(2,2,2,-Trifluoroethvlthio)-3-(1-10azabicvclo r3 . 2 .lloctvl-6-oxv)~vrazine Obtained from Compound 19 and 2, 2, 2 -trifluoroethanethiol in 14% yield, m.p. 116-117 ~C. (Compound 33).
15Examl?le 34' (*~ - endo-2 - ( trans-2 -Butenvlthio)-3 - ( 1-azabicvclo r 3 .2.1loctvl-6-oxv)~vrazine Obtained from Compound 19 and trans-2-butenethiol in 13%
yield, m.p. 128-130 ~C. (Compound 34).
Example 35' (+) -er~do-2- (4,4,4-Trifluorobutvlthio)-3-(1-az~hicvclo r 3. 2 . 11 octvl-6-oxv)~Yrazine Obtained from Compound 19 and 4,4,4-trifluorobutanethiol in 30% yield, m.p. 173-174 ~C. (Compound 35 ) .
Example 36l 30(~) -endo-2- (2-~ro~envlthio)-3-(1-azabicvclo r3 . 2 .lloctvl-6-oxv)~vrazine obtained from Compound 19 and 2-propenethiol in 70% yield, - m.p. 254-255 ~C. (Compound 36).
WO 97/20819 PCT~US96/19229 Example 37 ' ( + ) - endo- 2 - ( 3-Methvlbutvlthio~-3-(1-azabicvclo r 3.2.1loctvl-6-oxv)~vrazine obtained from Compound 19 and 3-methylbutanethiol in 26%
yield, m.p. 174-176 ~C. (Compound 37).
Examp 1 e 3 8 ' (+) -endo-2- (4-TrifluoromethoxYbenzvlthio)-3-(1-~z~hicvclo r 3.2.1loctvl-6-oxY)~vrazine Obtained from Compound 19 and 4-trifluoromethoxybenzylthiol in 57% yield, m.p. 175-176 ~C. (Compound 38).
~Y~m~le 39' (+) -~ndo-2 -Pro~vlthio-6-(1-azabicvclo r 3. 2 . 11 octvl-6-oxv)~Yrazine Obtained from Compound 22 and propanethiol in 11% yield as a 2Q foam. (Compound 39).
Bxam~le 40 ' (~) -endo-2- (2.2 .2-TrifluoroethYlthio)-6- (1-az~hicvclo r3 . 2 .lloctvl-6-oxv)~yrazine Obtained from Compound 22 and 2,2,2-trifluoroethanethiol in 7% yield, m.p. 125-126 ~C. (Compound 40).
~y~mrle 41' (+) -endo-2- (2-Methoxvethvl~hio)-3-(1-azabicvclo r3 . 2.1loctvl-6-oxv)~Yrazine Compound 19 (1.15 g, 4.7 mmoles) and sodium sulfide (Na2S-9H20), 1.68 g, 7 mmoles) were heated in 30 ml DMF
at 50~ C. for 3.5 hr, cooled to 0~ C. and 2-Bromoethylmethylether (1.3 g, 9 mmoles) added. The reaction was stirred at room temperature overnight and diluted with W O 97/20819 PCT~US96/19229 ethyl acetate and 100 ml o~ 5 N HCl. The aqueous layer was washed with ethyl acetate and the pH adiusted to 12Ø The product was extracted with ethyl acetate , dried over sodium sulfate, condensed and purified by HPLC eluted with 9496CHC13/
5% ethanol/ 1% ammonium hydroxide. The HCl salt was formed in ether and filtered to give (+) -endo-2- (2-Methoxyethylthio) -3-(l-azabicyclo[3.2.1]octyl-6-oxy)pyrazine hydrochloride (0.3 g), m.p. 165-166 ~C. (Compound 41).
The following compounds were prepared in substantially the same manner as Compound 41 substituting the appropriate alkylhalide for 2-bromoethylmethylether.
Fxample 42' t+) -endo-2- ( 3-Phenvl-2-~ro~envlthio)-3-~1-aza~icvclor3.2.1loctvl-6-oxv)~vrazine Obtained from Compound 19 and cinnamyl bromide in 36% yield, m.p. 16~-167 ~C. (Compound 42).
Examp le 43' Alternate Synthesis of Com~ound 19 A sample o~ (+)-~ endo) -l-Azabicyclo[3.2.1]octan-6-ol (3.0 g, 23.6 mmoles, was added to a stirred solution of potassium t-butoxide (2.9 g, 26 mmoles) in 60 ml THF at room temperature. The reaction was cooled to 5 ~C and 2,3-dichloropyrazine (7.03 g, 47 mmoles) in 15 ml THF was added.
The solution was stirred at room temperature for 2 hrs, condensed, and diluted with water and ethyl acetate. The organic solution was dried and condensed. Puri~ication by HPLC eluting with 94% CHC13, 5~ ethanol, 1 % ammonium hydroxide yielded 4.9 g, (Compound 19).
Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical ~cience, 66, 2 (1977) which are known to the skilled artisan. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
W O 97/20819 PCT~US96/19229 The compounds of Formula I~ can be prepared using the chemical processes illustrated in Scheme I. The starting materials for the illustrated process are commercially available or may be prepared using methods known to the skilled artisan S~h~m~ T
1. HSR/Et2NH N N Oxidize N N
2. S2Hal2 ~ l ~
Hal l SR Hal 2 SO2R
l.HOR/Et3N
2~s2Hal2 \ G-(CH2)r-W-h+
G-(CH2)~-W-h+\
~ (CH2) r-w-h+ ~/ w~Hal Hal 3 OR ~ S
G-(CH2) r l~h+2s/MeI Y~ N\\ /N
2.0xidize \\ //~ l.Et3N
NCCN
G-(CH2)r-W 5 (ols)R4 2~s2Hal2 N ~ G-(CH2)r-OH
\ ~ --(CH2)r--W-h~
As used in Scheme I, R, h+, and G are as de~ined supra. As used in Scheme I, the term ~Hal~ refers to Cl, Br, and R9S02. Preferred oxidizing agents for the process of Scheme I include oxone and sodium periodate. Oxone is an especially preferred oxidizing agent for the process of Scheme I. Compounds of Formula 3, as illustrated in Scheme I wherein the OR group is replaced by an R4 group, can be prepared using methods well known in the art. See for example, U.S. Patent Number 5,~43,345.
W O 97/20819 PCTnU~96/19229 -21~
Further, compounds of Formula I may be prepared using the process illustrated in the following Scheme II
Scheme II
~ K2CO3 ~ ~
G(CH2)r-W P G(CHa)r~W SR4 (especially desired oxidize h+QR if P is Cl; W is o;
~ r is O) G(CH2)r~W QR24 G(CH2)r~W R25 As used in Scheme II, Q may be N, o or S; R24 is selected from the group consisting of hydrogen, R4, R5, R6, and R7; R25 is selected from the group consisting of SoR4 and So2R4; all other meanings are as defined supra .
Additional compounds of Formula I may be prepared using the process illustrated by Scheme III.
W ~nh~m~ III
G ~H2)r \ /
S amine ~ G- (CH2)r ~ / jS
Hal N 6 reduction G~(CH2)r \ ~
~ N
As used in Scheme III, Hal, W, r, and G are as defined supra . As used in Scheme III, R22 and R23 are independently selected from the group consisting of hydrogen, R6 and R7.
Certain intermediates of the present invention may be prepared using the process illustrated in Scheme IV.
~ w o g7nO819 PCTnUS96~192~9 .scheme IV
~ ~ ~ R~ OR~ si)(Rl3~l~ls si~
Cl R NRl5Rl6 R
1. HCl 2. Nitrosate Cu(Br,I) ~< /~
Br, I 11 As used in Scheme IV, R8, Si, R10~R11~ Rl2, R13, R14, R15', R15 and R16 are as defined supra. For example, R8N[(R10R11Rl2Si)(R13R14Rl5~Si) may be, but is not limited to lithium bis(tri-2-propylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, lithium bis(tri-2-propylsilyl)amide, sodium bis(ethyldimethylsilyl)amide, potassium bis(1-propylethylmethylsilyl~amide, lithium bis(tri-phenylsilyl)amide, sodium bis(tri-phenylmethylsilyl)amide, potassium bis(2-butyl-2-propylmethylsilyl)amide, lithium (tri-2-propylsilyl)(2-butyldiethylsilyl)amide, sodium (trimethylsilyl)(triphenylsilyl)amide, potassium (dimethyl phenylsilyl)(ethyldimethylsilyl)amide, and the like. Most preferably, R15 and R16 are each hydrogen when the process of Scheme III is used for preparing a compound of 11 from a compound of 10. The intermediate 10 may be nitrosated using standard nitrosating procedures. A preferred W O 97/20819 PCTrUS96/19229 nitrosating agent is isoamyl nitrite; however, other known nitrosating agents are appropriate. As used in Scheme III, the term "Cu(sr,I)" refers to copper (I) bromide, copper (II) bromide, or copper (I) iodide. The artisan will recognize that the copper (I) bromide, copper (II) bromide, or copper ( I) iodide reagent shall determine the substitution on the product of the process illustrated in Scheme III.
Certain compounds of this invention may more preferably be prepared by a process using a hydroxyalkylamine (G-OH) wherein G has the meaning defined supra. in the presence of a phosphorus(III) compound and a diester of azodicarboxylate to give the l,2,5-thiadiazoyloxyalkylamine as illustrated by Scheme V.
Scheme v ~ N + G---OH p~l~)3 ~ N
R' ll R' ~N
Co2R3' The G groups are as defined supra. The R'is selected from the group consisting of hydrogen, halogen, NR6R7, R4, -oR4, -SR4, -soR4, -S02R~, C3-1o-cycloalkyl, C4-12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl);
R4 is selected from the group consisting of Cl_ls-alkyl, C2-15-alkenYl, C2-ls-alkynyl~ each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cl_4-alkyl, Cl_4-alkoxy, -OCF3, or -CF3; or R~ is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more independently W O 97/20819 PCT~US96/19229 selected from the group consisting of halogen, -CN, C1-4-alkyl, C1_4-alkoxy, -OCF3, and -CF3; or R' selected from the group consisting of -oR5Y, -SR5Y, oR5 Z-Y, -SR5ZY, -o-R5-Z-R4 and -S-R5-Z-R4;
Z is oxygen or sulphur;
R5 iS selected from the group consisting of C1_1s-alk~
C2_1s-alkenyl, and C2_1s-alkynyl;
Y is a 5 or 6 membered heterocyclic group:
R1~ is selected from the group consisting of phenyl, C1_1s-alkyl, C2_s-alkenyl, C2_s-alkynyl and (NR2')3;
R2 and R3 are independently selected from the group consisting of hydrogen, C1_1s-alkyl, C2_s-alkenyl, C2_s-alkynyl, and C1_s-alkyl substituted with one or more selected from the group consisting of halogen and phenyl;
W is oxygen or sulphur;
R6, and R7 independently are C1_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 are independently selected from hydrogen, C1-1s-alkyl, C2_s-alkenyl, C2_s-alkynyl, C1_10-alkoxy, and C1_s-alkyl substituted with one or more independently selected from the group consisting of -COR6 , halogen, and phenyl;
R6 is hydrogen or C1-C3 alkyl;
R3 is selected from the group consisting of C1_s-alk~l, C2-s-alkenyl and C2_s-alkynyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or ~;
....... is a single or double bond.
Preferred R1' groups include phenyl, C1_1s-alkyl, and (NR2 ~3. The process of Scheme IV is particularly advantageous because the process provides a method for inverting the stereochemistry at the carbon bearing the hydroxyl group in G.
W O 97/20819 PCT~US96/19229 Another new process illustrated by Scheme VI, involves the sequential reaction of 3,4-dihydroxy-1,2,5-thiadiazole with G-OH wherein G is defined as defined supra.
in the presence o~ a phosphorous(III) compounds and a diester of azodicarboxylate to give an unisolated hydrox~-1, 2,5-thiadiazole ether I'' followed by reaction of I'' with R~OH
where R4 is defined as supra. with phosphorous(III) compounds and a diester of azodicarboxylate to give the diethers of 3,4-dihydroxy-1,2,5-thiadiazole which are useful as muscarinic agonists and antagonists. (See, Org. Prep. &
Procedures 1969, 1, 255-258) The substituents illustrated in Scheme VI are as defined supra.
Scheme VI
G- OH
~_ CO2R2 ~ ~ N
OH N _ OH
~ P(Rl )3 CO2R3 R40H ,N
R4 ~ OH P(R~)3 ~ N
11 oR41 II N
Co2R3 Alternatively, the order of addition of the alcohols may be reversed as shown above to yive unisolated hydroxy-1,2,5-thiadiazole ether II which is subsequently converted to the same final muscarinic active compound.
W O 97/20819 PCT~US96/19229 The process illustrated by Scheme VII encompases the reaction of a phenol or hydroxyheteroaryl compound with compound III in the presence of a phosphorus(III) compound and a diester of azodicarboxylate to give compound IV.
S~heme VII
Aryl - OH
or Heteroa~yl- OH
P(Rl~)3 G ~ CE2 ) r w~ G ~ CH2 ~ r~w~
R6l ~ IV OAryl III Co2R3 (OHeteroaryl) In compound III, G(CH2)rW is as defined supra. and R6 is selected from the group consisting of R7, -oR7, -SR7, -SoR7, -So2R7~ C3_10-cycloalkyl, C4_12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl);
R7 is Cl_ls-alkyl, C2_1s-alkenyl, C2_1s-alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, -CN, Cl_4-alkyl, cl_4-alkoxy~
-OCF3, and -CF3;
provided that at least one alkyl atom of R6' is substituted with a hydroxyl group or R6'is a substituent selected from the group consisting of -oR8Y, -SR8Y, oR8-z-y~ -SR8ZY, -o-R
Z-R7 and -S-R8-Z-R7 wherein each -oR8Y, -SR8Y, oR8-Z-Y, -SR8ZY, -o-R8-z-R7 and -S-R8-Z-R7 is substituted with a alkylhydroxyl;
Y is a 5 or 6 membered heterocyclic group;
z is oxygen or sulphur;
R8 iS Cl_l5-alkyl, C2_1s-alkenyl, C2_1s-alkynyl;
W O 97/20819 PCT~US96/19229 aryl and heteroaryl is optionally substituted with one or more independently selected from the group consisting of halogen, -C~, Cl_4-alkyl, Cl_4-alkoxy, Cl_4-alkylthio, Cl-4-alkylsulfone, Cl_4-al~ylsulfoxide, -OCF3, NO2, N(R7)2, and -CF3; heteroaryl group is a 5 or 6 membered heterocycle containing one to four N, O, or S atomS or a combination thereof.
Another process of this inVention, illustrated by Scheme VIII, is the synthesis of 3-hydroxy-4-alkylthio-1,2,5-thiadiazoles by treating 3-halo-4-alkylthio-1,2,5-thiadiazoles with aqueous alkaline metal hydroxides in the preSence or absence o~ a dipolar aprotic solvent. In this scheme, Hal has the meanings defined supra. and M is an alkali metal, W iS O or S.
Scheme VI~I
~-'' \ MOH ~ ~ ~
Hal ~ HaO ( opt ) ~N
WRR ~Rr RR is hydrogen, R4, C3_l0-cycloalkyl~ C4-12-(cycloalkylalkyl), R4-Z-C3_1o-cycloalkyl and R4-Z-C4_12-(cycloalkylalkyl);
R4 is selected from the group consisting of Cl_ls-alkyl, C2_1s-alkenyl, and C2-1s-alkynyl, each of which iS
optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted With one or more selected from the group consisting of halogen, Cl_4-alkyl, Cl_4-alkoxy, and -CF3; or RR is phenyl or benzyloxycarbonyl, each of which is optionally substituted With one or more selected from the W O 97/20819 PCT~US96/19229 group consisting of halogen, Cl_4-alkyl, Cl_4-alkoxy, and -CF3; or RR is R~-oR5Y R4-SR5Y, R4-oR5-z-y, R4-SR5ZY, R4_o_R5_z_R4 or R4-S-R5-Z-;
z is oxygen or sulphur;
R5 is selected from the group consisting of C1_1s-alkyl, C2_1s-alkenyl, and C2_1s-alkynyl;
Y is a 5 or 6 membered heterocyclic group; and R6, and R7 independently are hydrogen, C1_6-alkyl, or R6 and R7 together with the nitrogen atom optionally form a 4-to 6-member ring;
R1 and R2 independently are hydrogen, C1-1s-alkYl, C2-s-alkenyl, C2_s-alkynyl, C1_10-alkoxy, C1_s-alkyl substituted with -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R6 is hydrogen or C1-C3 alkyl;
W is O or S;
Hal is selected from Cl, Br, F, I, and if W is O then Hal may be SO2R4 ;
R4' is Cl-C3 alkyl or phenyl.
The compounds (11) are useful intermediates for the preparation of 1, 2, 5-thiadiazole compounds. The artisan will recognize that the intermediates 11 are useful for preparing 1,2,5-thiadiazole compounds as illustrated by the processes of Schemes I, II, and III.
When the G substituent contains a secondary nitrogen protected by a protecting group, the protecting group may be removed using standard methods known to the skilled artisan. An especially preferred protecting group is carbamate. One particularly useful reference concerning protecting groups is Greene, Protectina Grou~s in Ora~nic Svnthesis, (John Wiley & Sons, New York, 1981).
Compounds of this invention may be prepared by the process illustrated in Scheme II
W O 97/20819 PCT~US96/19229 Scl~
N G(CH?)rWh ~ N
~ he artisan will recognize that the starting materials for the process of Scheme II are commercially available or can be prepared using methods familiar to the skilled artisan.
Compounds of Formula I wherein R iS an R4 group, can be prepared using methods well known in the art. See for example, U.S. Patent Number 5,043,345.
Further, compounds of Formula I may be prepared using the process illustrated in the following Scheme III
Scheme m N~O~N 1. Na2S OI NaSH and ~O~
~ 2. RX N N
G(CH2~W P (especially desired G(cH2),-W 8R~
if PisCl;WisO;
r is 0) o~idize h+QR
N~ ~N
Q(CH2b~W QR2~ G(CH ~,-W R~
As used in Scheme III, Q may be N, o or S; R24 is selected from the group consisting of hydrogen, R~, R5, R6, and R7; R25is selected from the group consisting of SoR4 and So2R4; all other meanings are as defined supra.
Additional compounds o~ Formula I may be prepared using the process illustrated by Scheme IV.
W O 97/20819 PCT~US96/19229 SchemerV
G~CH~ ~ N~ amineG~CH~r ~/0 N NR22R2~
..
reduction ~W~N
N
As used in Scheme IV, Hal, W, r, and G are as defined supra . As used in Scheme IV, R22 and R23 are independently selected from the group consisting of hydrogen, R6 and R7.
Compounds of Formula I' can be prepared by a) reacting a compound of formula II
G~CH~fW ~ N ~
Cl \ N II
wherein G, W and r have the me;~ning de~ined above with h+QR
wherein h+ is an alkoxide metal; Q is O or S and R has the me~ning defined above, or b) reacting a compound of formula III or IV
P R III;
~ N~R
I
p ~ N IV;
wherein P is R9SO2 or halogen; R9 is Cl_g straight or branched chain alkyl or aryl; and R has the meaning defined above;
with G-(CH2)r-W-~h+ wherein h+, G, W and r have the meanings defined above.
The compounds of Formula I' can be prepared as described supra. and by using the chemical processes illustrated in Scheme I. The starting materials for the illustrated process are commercially available or may be prepared using methods known to the skilled artisan.
Scbeme I
Hal~
G(CH2~,Wh~ H~ J G(CH~),W ;~¢ ~
\~;~¢I'q R R40- b+
R4S' h+
G(CH~),W ~L
CA 0223930l l998-06-02 W O 97/20819 PCTnUS96/19229 As used in Scheme I, R, h+, and G are as defined supra. As used in Scheme I, the term ~Hal~ refers to Cl, sr, I, and R9so2.
When the G substituent contains a secondary nitrogen protected by a protecting group, the protecting group may be removed using standard methods known to the skilled artisan. An especially preferred protecting group is carbamate. One particularly useful reference concerning protecting groups is Greene, Protectina Grou~s in Oraanic Svnthes;s. (John Wiley & So~s, New York, lg81).
Certain compounds of this invention may more preferredly be prepared using the process of Scheme V.
Scheme v SH ~ ~ ~ O
Cl KOC(CH333 ~
Potassium t-butoxide or another appropriate alkali metal base was added at about 0~ C. to an alkylthiol in THF and stirred.
The haloopyra~ine was added and the reaction stirred at about room temperature. A sample of about 1 N acid was added and the aqueous solution washed. The pH was adjusted to about 12Ø The product was extracted, dried and evaporated. The salt was optionally formed using standard methods.
Certain of the compounds of this invention can more preferredly be prepared using the process illustrated by Scheme VI.
.
W O 97/20819 PCT~US96/19229 ~cheIne VI
~OH THF ~ ~ Na2S ~ O
KOC(CH~)3 ~ ~ "~~
Cl N~ ~ )= N DMF \~ = N
!1 (CH2)20CH3 Cl N' The alcohol was added to a mixture of potassium t-butoxide in THF at about room temperature. The reaction was cooled to about 5~ C. The 2,3-dichloropyrazine in THF was S added to the mixture. The reaction mixture was stirred at about room temperature for about 2 hrs, condensed, diluted with water and ethyl acetate. The organic solution was dried and condensed. The chloropyrazine derivative and sodium sulfide ~Na2S 9H2O), were heated in DMF at about 50~ C. for about 3.5 hr, cooled to about 0~ C. Then 2-Bromoethylmethyl-ether was added. The reaction was stirred at about room temperature overnight and diluted with ethyl acetate and about 5 N acid. The aqueous layer was washed and the pH
adjusted to about 12Ø The product was extracted, dried, condensed and purified by HPLC. The salt form of the product was optionally formed using standard methods.
The term '~analgesic dose", as used herein, represents an amount of compound necessary to prevent or treat a human susceptible to or suffering from pain following administration to such human. The active compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment o~ adult hllm~n~, the range o~ about 0.05 to about 100 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, W O 97~0819 PCT~US96/19229 weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
While the present compounds are preferably administered orally to hllm~n~ susceptible to or suffering from anxiety, the compounds may also be ~min;stered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes. such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
The term "NSAIDS", as used herein, represents a nonsteroidal anti-inflammatory drug which can be identified as such by the skilled artisan. For example, the Merck M~n~ , 16th Edition, Merck Research Laboratories (1990) pp 1308 - 1309 provide well known examples of NSAIDS. The term is intended to include, but is not limited to salicylates such as aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac. Especially preferred NSAIDS include aspirin, ibuprofen, and naproxen.
Alternative preferred NSAIDS are indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
Particularly preferred NSAIDS include aspirin and ibuprofen.
The salicylates may include acetylsalicylic acid, sodium acetylsalicylic acid, calcium acetylsalicylic acid, salicylic acid, and sodium salicylate. An especially preferred NSAID
is ibuprofen.
The term "acetaminophen", as used herein, shall have the art accepted me~n;ng and refers to N-(4-Hydroxyphenyl)acetamide and 4~-hydroxyacetanilide. The compound is claimed in U.S. Patent No. 2,998,450 and is known to the skilled artisan.
W O 97/20819 PCT~US96/19229 The term ~central alpha-adrenergic active compounds", as used herein, represents a compound having central alpha-adrenergic receptor activity. The most pre~erred central alpha-adrenergic active compound is clonidine or a pharmaceutically acceptable salt thereof having the chemical name: 2-(2,6-dichlorophenylamino)-2-imidazoline.
Clonidine is known to be useful for treating hypertension. see Physicians~ Desk Re~erence, 45th Ed.
(1991) p. 673.
The term "opioid", as used herein, represents opioid analgesics and antagonists including natural opioid analgesics, synthetic opioid analgesics, opioid antagonists and opioid agonist-antagonists. Preferred an opioid compounds are selected from the group consisting of morphine, codeine, meperidine, meth~one, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton~s cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabllph;ne, and buprenorphine. More preferred opioid compounds are selected ~rom the group consisting of codeine, nabuphine, naloxone, and naltrexone.
Preferred an opioid compounds are morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, bromptonls cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
Especially preferred opioid compounds are selected from the group con~isting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
Particularly preferred opioid compound~ are selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine. The especially particularly preferred opioid compounds are selected from morphine and codeine.
W O 97/20819 PCT~US96/19229 As used herein, the phrase "one or more" most preferredly refers to one; however, two, three, or more may be used.
We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with non-steroidal antiinflammatory agents (NSAIDS). More specifically, the invention provides a method of treating pain in hllm~n~ using a specified known compounds (collectively referred to herein as "selected muscarinic compoundsll) in combination with a NSAIDS to provide a synergistic ef~ect. The Selected Muscarinic Compounds are believed to be active based on activity at muscarinic cholinergic receptors; however, the present invention is in no way limited by the mechanism o~
action.
We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with acetaminophen.
More specifically, the invention provides a method of treating pain in hllm~n~ using a specified Selected Muscarinic Compounds in combination with acet~minophen to provide a synergistic effect.
Further, we have discovered that a group of compounds having muscarinic cholinergic activity can be particularly useful for treating pain when used in combination with central alpha-adrenergic active compounds.
More specifically, the invention provides a method of treating pain in humans using Selected Muscarinic Compounds in combination with a central alpha-adrenergic active compound to provide a synergistic effect.
Oral combinations of aspirin with codeine or other narcotic analgesics are known to provide additive analgesic effects in man. The Pharmacological Basis of Therapeutics, 5th edition, Macmillan Publishing Co., 1975, pp 325-358.
The present invention further envisions that one or more Selected Muscarlnic Compounds may be used at one time in the composition of this invention to provide the desired analgesic effect.
In the composition of this invention a Selected Muscarinic Compound and NSAIDS compound are combined in a weight ratio of Compound to NSAIDS of from about 1 to about 1000 .
A preferred composition is a weight ratio of Compound to NSAIDS of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A
further preferred ratio may be from about 1 to about 10. A
final preferred ratio may be from about 1 to about 3.
There are many NSAIDS known in the literature and to the skilled artisan.
In the composition of this invention a Selected Muscarinic Compound and acetaminophen are combined in a weight ratio of Selected Muscarinic Compound to acetaminophen of from about 1 to about 1000.
A preferred composition is a weight ratio of Selected Muscarinic Compound to acet~m;nophen of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The Selected Muscarinic Compounds are effective over a wide dosage range; however, it is de~irable to administer a dosage that is as low as possible. The amount of NSAIDS present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage. The amount of acetaminophen present in the composition is adjusted as described above in ratio to the Selected Muscarinic compound dosage.
In the composition of this invention a Selected Muscarinic Compound selected and one or more opioid compounds are combined in a weight ratio of Selected Muscarinic Compound to opioid compound of from about 1 to about 1000.
WO 97/20819 PCT~US96/19229 A preferred composition is a weight ratio of Selected Muscarinic Compound to opioid compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be ~rom about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The amount of opioid compound present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage.
However, for each composition claimed herein, it will be understood that the amount of the Selected Muscarinic Compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of ~elected Muscarinic Compound to be administered, the age, weight, and response of the individual patient, the severity of the patient~s symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. While the present compounds are preferably administered orally to hllmAn~ susceptible to or suffering from pain, the compounds may also be administered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes. Such formulations may be designed to provide delayed or controlled release using formulation techni~ues which are known in the art.
Transdermal formulations cont~;ning the composition claimed herein most preferably deliver the active substances in an effective amount for from about three days to about seven days. However, for chronic pain such as arthritis or cancer pain, a transdermal delivery of from about three days to up to about two weeks is desirable. Alternatively, it may be preferred to deliver the claimed compositions transdermally in an e~fective amount for from about one day to about three days.
AS used herein the ~erm ~treating~ includes prophylaxis o~ a physical and/or mental condition or amelioration or ~llmln~tion of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
The Selected Muscarinic Compounds employed in the invention are not believed to act via the GABA/benzodiazepine, 5HT1A, or Dl receptor systems in hl~m~ns.
Rather, the activity of the present Selected Muscarinic Compounds as analgesic agents is believed to be based upon modulation of muscarinic cholinergic receptors. However, the mechanism by which the present compounds function is not necessarily the mechanism stated supra., and the present invention is not limited by any mode of operation.
Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts lis~ed in ~ournal of Pharmaceutic~l Science, 66, 2 (1977) which are known to the skilled artisan. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
The dosage administered will, of course, vary depending on known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of the symptoms, kind of W O 97/20819 PCT~US96/19229 concurrent treatment, fre~uency of treatment, and the effect desired. Usually, the daily dosage can be such that the active ingredient is ~mlnistered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight Selected Muscarinic Compound and from about 0.6 to about 200 mg/kg of NSAIDS.
Compositions suitable for internal administration contain from about one half (0.5) milligrams to about 600 milligrams of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of from about 0.5%
to about 95% by weight based on the total weight of the composition.
For compositions containing acet~m;nophen, usually, the daily dosage can be such that the active ingredient is ~m; n; stered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Selected Muscarinic Compound and from about 0.6 to about 200 mg/kg of acetaminophen.
Typical compositions include a compound of Selected Muscarinic Compound and one or more NSAIDSs, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, W O 97/20819 PCT~US96/19229 alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
Typical compositions include a Selected Muscarinic Compound and acetaminophen, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used, as described above.
A preferred composition is a weight ratio of Selected Muscarinic Compound to central alpha-adrenergic active compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The Selected Muscarinic Compounds are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible. The amount of central alpha-adrenergic active compound present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage.
Usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Selected W O 97/20819 PCT~US96/19229 -43- .
Muscarinic ompound and from about 0.6 to about 200 mg/kg of central alpha-adrenergic active compound.
Typical compositions include a Selected Muscarinic Compound and one or more central alpha-adrenergic active compounds, associated with apharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the ~orm of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation o~ pharmaceutical compositions may be used.
The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsi~iers, salt for in~luencing osmotic pressure, bu~ers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
For parenteral application, particularly suitable are injectable solutions or suspensions, 2~ preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, andtor potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
Generally, the compositions of this invention are dispensed in unit form comprising from about 0.1 to about 300 mg in a pharmaceutically acceptable carrier per unit dosage.
The compositions of this invention may be suitable for administration to an ~nim~l, Such animals include both domestic ~nim~l S, for example livestock, W O 97/20819 PCT~US96/19229 laboratory animals, and household pets, and non-domestic ~nim~ls such as wildlife. More preferredly, the animal is a vertebrate. Most pre~erredly, a composition of this invention shall be ~min;stered to a m~mm~l, It iS
especially preferred that the animal is a domestic m~mmAl or a human. The most preferred mammal is a human. For such domestic ~nim~l purposes, a composition of this invention may be administered as a feed additive.
The following models and assays are useful for illustrating the effectiveness of the compositions claimed herein.
Nocice~tive ~ain model:
Acetic acid-induced writhing: A standard procedure for detecting and comparing the analgesic activity of different classes of analgesic drugs for which there is a good correlation with human analgesic activity is the prevention of acetic acid-induced writhing in mice. Mice, are subcutaneously ~m; n; stered various doses of the claimed composition and are injected injected intraperitoneally with acetic acid (0.5% solution, 10 ml/kg) 5 min prior to a designated observation period. For scoring purposes a ~writhe~ is indicated by whole body stretching or contraction of the abdomen during the observation period beginning 5 min after receiving the acetic acid. Inhibition of writhing behavior is demonstrative of analgesic activity.
See, Haubrich, D.R., Ward, S.J., Baizman, E., Bell, M.R., Bradford, J., Ferrari, R., Miller, M., Perrone, M., Pierson, A.K., Saelens, J.K. and Luttinger, D.:
Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
Neuro~thic Da~ n model:
Sciatic ner~e li~ation model: Rats are anesthetized and a nerve ligation procedure performed. The common sciatic nerve is exposed and 4 ligatures tied loosely around it with W O 97/20819 PCTnJS96/l9Z29 about 1 mm spacing. One day to 10 weeks after surgery, the nociceptive testing is performed. Responses to noxious heat are determined by placing the rats in a chamber with a clear glass floor and aiming at the plantar surface of the affected foot a radiant heat source from beneath the floor. Increased latency to withdraw the hindpaw is demonstrative of analgesic activity. Responses to normally innocuous mechanical stimuli is determined by placing the rats in a chamber with a screen floor and stimulating the plantar surface of the hind paw with graduated von Frey hairs which are c~l;hrated by ~he grams of force required to bend them. ~ats with sciatic nerve ligation respond to lower grams of mechanical stimulation b~r reflexive withdrawal of the foot than unoperated rats. This response to stimuli which are normally innocuous is termed allodynia. Increases in the grams o~
mechanical force required to produce foot withdrawal is demonstrative of antiallodynic activity.
See, Bennett, G.J. and Xie, Y.-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107.
See also, Lee, Y.-W., Chaplan, S.R. and Yaksh, T.L.:
Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neuroci Lett 186 (1995) 111-114.
Formalin paw test: Rats are anesthetized and when there is a loss of spontaneous movement the rats are injected subcutaneously in the dorsal surface of the hindpaw with 50 ul of 5% formalin solution using a 30 gauge needle. Rats are then individually placed in an open Plexiglas chamber for observation, and within a maximum interval of 1 to 2 min, the ~nlm~l displays recovery from anesthesia with spontaneous activity and normal motor function. Pain behavior is ~uantified by periodically counting the incidents of spontaneous flinching/shaking of the injected paw. The flinches are counted for l-min periods at 1- to 2-, 5- to 6-and 5min intervals during the interval from 10 to 60 min.
CA 0223930l l998-06-02 W O 97/20819 PCTrUS96/19229 Inhibition of the pain behavior is demonstrative of an analgesic activity.
See, Malm~erg, A.B. and Yaksh, T.L.: Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. The Journal of Pharmacology and Experimental Therapeutics 263 (1992) 136-146.
InflA~m~torY ~ain model:
srewer~ yeast-induced hyperalgesia (Randall-Selitto ~est): TO assess nociceptive threshold in rats, ascending pressure is applied gradually to the paw with a motor driven weight of a Ugo sasile Analgesy Meter. Rats respond to the pressure by either pulling free of the device, struggling or vocalizing. Hyperalgesia is induced by a hind paw subplantar injection of 0.1 ml of 1% suspension of brewerls yeast in 0.9~ saline. The composition of this invention is a~m;n;~tered at varying times ( 0 - 4 hr) after injection of brewerls yeast and pressure threshold ~or the inflamed paw again determined at varying times. Increases in the pressure which produces a behavioral response is demonstrative of analgesic activity.
See, Haubrich, D.R., Ward, S.J., Baizman, E., Bell, M.R., Bradford, J., Ferrari, R., Miller, M., Perrone, M., Pierson, A.K., Saelens, J.K. and Luttinger, D.:
Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
Utilitv Test Metho~
The unexpectedly enhanced analgesic activity of the composition of the invention is evidenced by tests intially conducted on mice. Male mice are fasted for 16-22 hours and weighed. Mice weighing from about 18-22 grams at the time of testing are used for the following studies.
All mice are dosed se~uentially by the oral route with suspensions of a composition of this invention. Doses are coded using a code unknown to the observer.
W O 97/20819 PCT~JS96/19229 A stock suspension of the test composition is prepared by mixing the active ingredients with about 40 mL
o~ an aqueous vehicle containing about 2% Tween 80 (R), a pharmacological dispersant and containing 100% polysorbate 80, and 1% by weight Methocel (R) MC powder, and containing 100% methylcellulose, in distilled water. The mixture may be sonicated for about 10 to about 15 seconds using an ultrasound sytem. All dosing suspensions are prepared by dilution of the stock suspension with Methocel/Tween 80.
All suspensions are used within two hours of preparation.
Mouse Writhina Test An accepted standard for detecting and comparing the analgesic activity of different classes of analgesic compounds for which there is a good correlation with human analgesic activity is the prevention of phenyl-p-benzoquinone induced writhing in mice. [H. slumberg et al.
Proc. Soc. Exp. biol. Med., 118, 763-766 (1965)].
Mice, treated with various doses of Selected Muscarinic Compound, composition or vehicle are injected intraperitoneally with a standard challenge dose of phenyl-p-benzoquinone 5 minutes prior to a designated observation period. The pheyl-p-benzoquinone is prepared as about 0.1 mg/ml solution in about 5% by volume of ethanol in water.
The writhing dose is 1.25 mg/kg injected at a volume of about 0.25ml/lOg. For scoring purposes a ~writhe~ is indicated by whole body stretching or contracting of the abdomen during an observation period beginning about five minutes after the phenyl-p-benzoquinone dose.
All ED50 values and their 95% confidence limits are determined using accepted numerical methods. For example, see W.F. Thompson, Bacteriolo~ical Rev., 11, 115-145 (1947). The interaction of the dosages on phenyl-p-benzoquinone induced writhing in mice is demonstrated by the Loewe isobologram (S. Loewe, Pharm. Rev. 9, 237-242 (1957).
W O 97120819 PCT~US96/19229 The solid line connecting the ED50 dosages of Selected Muscarinic Compound (alone) and Synergis~ic Analgesic as claimed herein (alone) represents the ~ED50 addition line" which indicates the expected location of the ED50's for Selected Muscarinic Compound and classical analagesic combinations if simple additivity were to describe their combined effects. The 95% confidence range for the ED50 addition line is shown by the area between the broken lines above and below the ED50 addition line.
According to Loewe's isobolic theory, if the analgesic effects are simply additive to one another, then the expected location of the ED50's of the Selected Muscarinic Compound and Synergistic Analgesic component of each fixed dosage ratio would be contained within or overlap the region of the ED5~ addition line. Combination ED50'S located significantly below the ED50 addition line would represent unexpectedly enhanced analgesic activity and combination ED50'S located above the line would represent unexpected ~;m;n; shed analgesic effect.
One method to establish the significance of such unexpected enhanced or ~;m;n;shed activity is to calculate the best fitting polynomial regression line to the observed ED50'S using standard mathematical techniques.
Such experiments demonstrate that compositions comprised of a Selected Muscarinic Compound and one or more Synergistic Analgesics provides a statistically significant synergistic analgesic effect.
Preferred compounds of Formula I' are selected from the group consisting of:
(+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-pyrazine, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(2,2,3,3,4,4,4-3 5 heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-pyrazine, 3-methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-pentylthio-4-(1-W O 97/20819 PCT~US96/19229 azabicyclo[2.2.2]ocytl-3-oxy)-pyrazine, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-pyrazine, 3-butylthio-4-(3-azetidinyloxy)-pyrazine, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-pyrazine, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-butylthio-4-[3-+-endo-(1-azabicyclo~2.2.13heptyloxy)]-pyrazine, 3-hexyloxy-4-[6-i--endo-(2-azabicyclo[2.2.2]ocyloxy)]-pyrazine, 3-~4,4,4-trifluorobuty]thio)-4-[2-+-exo-(7-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-(2-phenoxyethylthio)-4-[3-i--endo-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(5-hexenyloxy)-4-[7-+-endo-(2-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, and 3-cyclobutylmethyl-4-[2-~--endo-(8-azabicyclo[3.2.1]octyloxy)]-pyrazine.
Some examples of compounds of Formula I' for use in the present analgesic composition include, but are not limited to: 2-[exo-(~/-)-3-[1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-butylthio-2-(1-azabicyclo[2.2.2]ocytl-3-oxy)]pyrazine, 3-butyloxy-2-[3-+-endo-(l-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-butynyloxy)-2-[6-~-endo-(1-azabicyclo[3.2.1]octyloxy)pyrazine, 3-hexylthio-2-[6-+-exo-(2-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(3-phenylpropyny]thio)-2-[2-+-exo-(7-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-methylthioethoxy)-2-[3-i--exo-(1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-propargyl-2-[4-(1-azabicyclo[2.2.1]heptyloxy)]pyrazine, and 3-cyclopropylmethylthio-2-[2-+-exo-(8-azabicyclo[3.2.1]octyloxy)]pyrazine.
For analgesic use, Compounds of Formula I may be preferred. Alternatively, compounds of Formula I' may be preferred. Alternatively, Compounds of Formula Il may be preferred.
W097~0819 PCTAJS96/19229 Some prefered characteristics of compounds of Formula I' for use in the present analgesic composition are:
A) W is S;
B) r is 1 or 2;
C) G is selected from het-l and het-5;
D) G is unsaturated;
E) G is het-4;
F) G is an azabicycle having 7 ring carbon atoms and a nitrogen atom;
G) G is het-6;
H) r is 0;
I) R iS selected from halogen, -oR5Y, -SR5Y, oR5ZY -SR5ZY -oR5ZR4, -SR5ZR4, -oR4, and -SR4;
J) W is O;
K) m is l;
L) n is l;
M) p is 2;
N) G is het-3 O) G is het-2 P) a compound of Formula I' Q) a compound of Formula I' wherein W is oxygen or sulphur;
R is selected from the group consisting of hydrogen, amino, halogen, NHR6, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4, C3_10~
cycloalkyl, C4_12-(cycloalkylalkyl), -Z-C3_10-cycloalkyl and -Z-C4_12- (cycloalkylalkyl); R4 iS selected from the group consisting of Cl_ls-alkyl, C2-ls-alkenyl~ and C2-15-alkynyl, each of which is optionally su~stituted with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, -CN, Cl-4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of W O 97/20819 PCTAUS96/lg229 halogen, -CN, C1_4-alkyl, c1_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; or R is selected i~rom the group consisting o~ -oR5Y, -SR5Y, oR5-Z-Y, -SR5ZY, -o-R5-Z-R4 and -S-R5-Z-R4;
Z is oxygen or sulphur;
R5 is selected from the group consisting of C1_1s-alkyl, C2_1s-alkenyl, and C2_1s-alkynyl;
Y is a 5 or 6 membered heterocyclic group; and G is selected from one o~ the ~ollowing azacyclic or azabicyclic ring systems:
~ ~ R~
h~t-1 het-2 het-3 het-4 R ~ ~ R ~ ~2 het-5 het-6 het-7 or G can optionally be substituted C3-Cg cycloalkyl wherein the substitution is -NR6R7;
R6 and R7 independently are se:Lected ~rom the group consisting of hydrogen and C1_6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;~ 20 R1 and R2 independently are selected from the group consisting of hydrogen, C1_1s-alkyl, C2_s-alkenyl, C2_s-al~ynyl, C1_1o-alkoxy, and C1_s-alkyl substituted with a subsituent independently selected ~rom the group consisting of -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, and phenyl;
W O 97/20819 PCT~US96119229 R3 is selected from the group consisting of hydrogen, Cl-s-alkyl, C2_s-alkenyl and C2_s-alkynyl;
R6' is selected from the group consisting of hydrogen and C1_6-alkyl;
n is Q, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
~ is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond;
provided that when w is o and G is a saturated azabicyclic group having from 7 to 11 ring carbon atoms and a nitrogen atom wherein the nitrogen atom is separated from the W atom by 2 to 3 ring carbon atoms;
or a pharmaceutically acceptable salt or solvate thereof;
R) The G substituent is selected from the group consisting of .
N R3--N~-- ~N
, , and S) The G substituent is W O 97/20819 PCTrUS96/19229 T) R is selected from the group consisting of -SR4 , SoR4', -S02R4', substituted benzyloxycarbonyl wherein the su~stitue~ts are one or more independently selected from the group consisting of -CN, -OCF3, -CF3, -CoNH2 and -CSNH2;
or C3_10-cycloalkyl, C4_12-~cycloalkylalkyl), -Z-C3_10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl).
U) R is selected from the group consisting of R4, C3_10-cycloalkyl, C4_12-(cycloalkylalkyl), -Z-C3-1o-cycloalkyl and -Z-C4_12-(cycloalkylalkyl); and R4 is selected from the group consisting o~ substituted Cs_1s-alkyl, optionally substituted C2_1s-alkenyl, and optionally substituted C2_1s-alkynyl, wherein such substituent is one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more substituents ~elected from the group consisting of halogen, -CN, C1_4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2.
v~ G is selected from the group consisting of het-4, het-7, het-6 wherein n=2; het-3 wherein one of n and m is 0 or 2; and het-3 wherein the I or I' group is attached at tlle bridgehead of het-3.
Especially preferred compounds of this invention have the characteristics of A-F,P; A-F,Q; characteristics of A, G, H, M, F; characteristics of G-O,Q; or the characteristics of G-J,M,P; or G-J,M,Q. The characteristics of R and S may be particularly preferred.
Further, especially preferred R groups include phenyl, benzyloxycarbonyl, -oR5Y, -SR5Y, oR5-Z-Y, -SR5ZY, -o-R4-z-R5 or -S-R4-Z-R5, -SoR4~ c3 10-cycloalkyl, C4_l2-(cycloalkylalkyl), -Z-C3_10-cycloalkyl and -Z-C4_12-(cycloalkylalkyl) wherein Z is oxygen or sulphur, R5 is C1_ l5-alkyl, C2_15-alkenyl~ C2_1s-alkynyl, Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, R4 is Cl_ls-alkyl, C2_ 15-al]~enY1, and C2_1s-alkynyl.
W O 97/20819 PCTrUS96/19229 Pre~erred compounds o~ Formula I1l are any one or more selected from the group consisting of:
(i)-3-Methoxy-4-(1-azabicyclo~2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Ethox~-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Propyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Butyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Pentyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Hexyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(4-Methylpentyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Chloro-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Propylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Butylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (S)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, W O 97/20819 PCT~US96/19229 (i)-3-Hexylthio-4-(1-azabicyclo[2.2.2]octyl-3-oAYy)-1,2,5-thiadiazole, (i)-3-(3,3-Dimethylbutylthio)-4-(1-azabicyclo~2.2.2]octyl-3-oxy) ~lr 2,5-thiadiazole, A
~i)-3-(2-(2-Thienylthio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (+)-3-(2,2,3,3,3-Penta~luoropropylthio)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-(2-Thienyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-sutylthio-4-((l-azabicyclo[2.2.2]octan-3-yl)methoAyy) 1,2,5-thiadiazole, (i)-Exo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (+)-Endo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (i)-Endo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole, (i)-Exo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole, (i)-3-Butyloxy-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-Butyloxy-4-(1-methyl-3-pyrrolidinyloxy)-1,2,5-thiadiazole, (+)-3-Butylthio-4-(1-methyl-3-piperidyloxy)-1,2,5-thiadiazole, wo 97nO819 PCTrUS96/19229 3-Butylthio-4-(1-methyl-4-piperidyloxy)-1,2,5-thiadiazole, (S)-3-sutyloxy-4-(1-methyl-2-pyrrolidinylmethoxy)-1,2,5-thiadiazole, (S)-3-sutyloxy-4-(2-pyrrolidinylmethoxy)-1,2,5-thiadiazole, 3-sutyloxy-4-(2-(dimethylamino)ethoxy)-1,2,5-thiadiazole, 3-Butylthio-4-(2-(diethylamino)ethoxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(2-(trimethylamino)ethoxy)-1,2,5-thiadiazole iodide, (R)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(4-Methylpentylthio)-4-(1-azabicyclo[2.2.2]octyl-3-2~ oxy)-1,2,5-thiadiazole, (~)-3-(3-Phenylpropylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(4-Cyanobenzylthio)-4-(1-azabicyclo~2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(4-Fluorobenzylthio)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5- thiadiazole, (~)-3-(2-Phenylethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (+)-3-(2-Phenyloxyethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, W O 97~0819 PCT~US96/19229 Endo-3-~utyloxy-4-(N-methyl-8-azabicyclo[3.2.1]octyl-3-oxy)-1,2,5-thiadiazole, (i)-Exo-3-butyloxy-4-~6-(N-methyl-8-azabicyclo[3.2.1]octan-3-onoxy))-1,2,5-thiadiazole, (i)-Exo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (+)-Endo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (i)-Endo-3-(4-cyanobenzylthio)-4-(1-azabicyclo~3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(3-azetidinyloxy)-1,2,S-thiadiazole, 3-Butylthio-4-(3-azetidinyloxy)-1,2,5-thiadiazole, (i)-Tran~-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole, (i)-3-Butylthio-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (i)-3-(2-(2-(5-(2-Thienyl)thienyl)thio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(2-(5-(2-Thienyl)thienyl)thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (i)-3-(3-N-(2-Thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5-thiadiazole, (i)3-Butylthio-4-(exo-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole, =
W O 97/20819 PCT~US96119229 (~)3-(2,2,3,3,4,4,4-heptafluorobutyloxy)-4-r-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole, (+)3-(1-butylthio)-4-[endo-6-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-thiadiazole, (i)3-(3-phenylpropylthio)-4-[endo-6-(1-azabicyclo-[3.2.1]octyloxy)]-1,2,5-thiadiazole (i)3-[3-(4-fluorophenyl)propylthio]-4-[-3-(1-azabicyclo-[2.2.2]octyloxy)]-1,2,5-thiadiazole (~)3-{3-[4-(trifluoromethyl)phenyl]propylthio}-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (i)3-(1-sutylamino)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (i)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-Butylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-Propylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-(4,4,4-Trifluorobutyloxy)-4-~1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-(2-Butynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[2.2.23octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Phenylpropynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Butenyloxy)-4-(1-azabicyclor2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-Methoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-sutynoxy)-4-(1-azabicycloE2.2.2~octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-(Methylthio)ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Chloropropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole -(i)-3-(4-Fluorobutyloxy)-4-(1-azabicyclo[2.2.2~octyl-3-oxy)-1,2,5-thiadiazole ~ 3-(2-[4-Chlorophenoxy]ethoxy)-4-(1-azabicyclo~2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-[2-methoxy-5-pyridyl]propyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(trans-3-Chloro-2-propenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-[4-Fluorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy~-1,2,5-thiadiazole (i)-3-(4-Pentenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Fluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-(Cyclobutylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3,3,3,2,2-Pentafluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-[Phenylthio]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-[1-napthyloxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-[4-sromophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(2-Hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-Butylthio-4-hydroxy-1,2,5-thiadiazole w o 97nO819 PCT~US96/19229 (+)Exo-3-sutylthio-4~ azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[3-{1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2~octyl-3-oxy3-1,2,5-thiadiazole (i)-exo-3-sutyloxy-4-(7-azabicyclo ~2 . 2 .1] heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-sutyloxy-4-(3-piperidinyloxy)-1,2,5-thiadiazole 3-sutyloxy-4-( cis-lR-2 -aminocyclopentanoxy)-1,2,5-thiadiazole (i)-endo-3-Hexyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1, 2, 5-thiadiazole (5S,6S) -endo-3 -Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole f~R, 6R) -endo-3 -Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-trans-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1, 2, 5-thiadiazole (+)-cis-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole (+)-trans-3-Butylthio-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole 3-Butylthio-4-(2-dimethylaminoethoxy)-1,2,5-thiadiazole (+)-trans-3-Butylthio-4-(N-tert-butylcarboxy-4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole W O 97/20819 PCT~US96/19229 trans-3-Butylthio-4- (4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole (i) -endo-3-Butyloxy-4- (1-azabicyclo[3. 2.1]octyl-6-oxy)-1,2,5-thiadiazole ~+)-3 -(4-Phenylbutylthio)-4-( 1-azabicyclo[ 2.2. 2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3- (3-Phenyl-2-propenylthio) -4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-[4-Fluorophenyl]propan-3-onethio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+)-3-(3-[N-Phenothiazinyl]propylthio)-4-~1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (:~:) -3-(3-[4-Fluorophenyl]-3-[4-fluorophenoxy]propylthio)-4-(l-azabicyclo[2.2. 2~ octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(3-Phenyl-3-[4-trifluoromethylphe~oxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (i)-3-(4,4,4-Trifluorobutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[3-Pyridyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-endo-3- (2-Phenoxyethylthio)-4-(1-azabicyclo [3. 2.1]octyl-6-oxy)-1,2,5-thiadiazole (i) -exo-3 -Propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole W O 97/208~9 PCTAUS96/19229 (+)-exo-3- Propylsulfonyl-4-~2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (+)-exo-3- (4,4,4-Trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(4,4, 4-Trifluorobutyloxy) -4- (2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (+) -exo-3- (Hexyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(4,4, 4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (+)-exo-3- (2-[Fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (+)-exo-3- (2-[Fluorophenoxy]ethylthio)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-Propylthio-4- (1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i) -endo-3 -Propylsulfonyl-4-(1-azabicyclo [3. 2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4, 4-Tri~luorobutoxy)-4-(1-azabicyclo[ 3. 2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3- (2-Butynyloxy)-4-(1-azabicyclo [3.2.1] octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-(trans-2 -Butenyloxy)-4-(1-3 5 azabicyclo[3.2.1]octyl-5-oxy)-1,2,5-thiadiazole (i)-endo-3-(2-Methylthioethoxy)-4-(1-azabicyclo~3.2.1]octyl-6-oxy)-1,2,5-thiadiazole ~i)-endo-3-(2-(4-Methyl-1,3-thiazol-5-yl)ethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(4-Methylthiobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole ~i)-endo-3-(2-Thienylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(2-Cyclohexenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(3-Pentynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(3-Hexynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Chloropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) -endo-3- [2-(2-Napthalyl)ethoxy]-4~
azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-t4-Chloro-~-cyclopropyl-benzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(4-Methyl-3-pentenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+) -endo-3 - (Cyclopropylmethoxy)-4-(1-azabicyclo [3 . 2 .1] octyl-6-oxy)-1,2,5-thladiazole (+)-endo-3-(2-Methoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole -(+) -endo-3- (3-Butenyloxy)-4-~1-azabicyclo [3 .2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole ~ endo-3-(3-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+) -endo-3- (4,4,4, 3, 3, 2,2-Heptafluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-[2-(3-Trifluoromethylphenyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-[2-(2-Thienyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+) - endo-3 - ( 3, 3, 3, 2,2,Pentafluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(4-n-sutylbenzyloxy)-4-(1-~ azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole ( i ) - end o- 3-[3-(4-Methoxyphenyl)propoxy]-4-(1-azabicyclo [3 . 2.1]octyl-6-oxy)-1,2,5-thiadiazole W O 97/20819 PCT~US96/19229 (i) -endo-3- (4-Fluorobenzyloxy)-4-(1-azabicyclo [3 . 2.1]octyl-6-oxy)-1,2,5-thiadiazole (i) -endo-3- (2, 4-Di~luorobenzyloxy)-4~
azabicyclo [3 . 2 .1] octyl-6-oxy)-1, 2, 5-thiadiazole (i) -endo-3- [4- (Trifluoromethoxy)benzyloxy] -4- (1-azabicyclo[ 3 . 2 .l]octyl-6-oxy)-1, 2, 5-thiadiazole (i)-endo-3- (4-Fluorobutoxy)-4-(1-azabicyclo[3 .2 .l]octyl-6-oxy)-1,2,5-thiadiazole (i) - end o-3 - ( 4- tert -Butylbenzyloxy)-4-(1-azabicyclo [3 . 2 .1] octyl-6-oxy)-1,2,5-thiadiazole ~ endo-3-(1-Cyclopropylethoxy)-4-(1-azabicyclo [3 . 2 .1] octyl-6-oxy)-1,2,S-thiadiazole (i) -endo-3- (2-Cyclohexylethoxy)-4-(1-azabicyclo[3. 2 .1] octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(3-Methyl-2-butenyloxy)-4-(1-azabicyclo[3. 2 .1] octyl-6-oxy)-1,2,5-thiadiazole (i) -endo-3- (4-Cyclohexylbutoxy)-4-(1-azabicyclo [3 . 2 .1] octyl-6-oxy)-1,2,5-thiadiazole (i) - endo-3 - ( 3-Butyn-2-oxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1, 2, 5- thiadiazole (i)-endo-3-(3-Methyl-3-phenylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(3-Fluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole CA 0223930l 1998-06-02 W O 97/20819 PCT~US96/19229 (i) -endo-3- [3- (2-Thienyl)propoxy]-4-(1-azabicyclo[3.2.1] octyl-6-oxy)-1, 2,5-thiadiazole (+) -3- (2-[4-Fluorophenoxy]ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy~-1,2,5-thiadiazole li)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-sutylthio-4-hydroxy-1,2,5-thiadiazole 3-(2-[3-{1,2,5-Thi~ 70yloxy} ]ethoxy)-4-~1-azabicyclo[2.2.2]octyl -3 -oxy ) -1, 2,5-thiadiazole and (+)Exo-3-Butylthio-4- (1-azabicyclor2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole.
Preferred compounds o~ Formula I are selected from the group consisting o~:
(+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-1,2,5-oxadiazole, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(2,2,3,3,4,4,4-heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-oxadiazole, 3-3Q methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-pentylthio-4-(1-azabicyclo[2.2.2]ocytl-3-oxy)-1,2,5-oxadiazole, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-oxadiazole, 3-butylthio-4-(3-azetidinyloxy)-1,2,5-oxadiazole, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-oxadiazole, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-butylthio-4-~3-+-endo-(1-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-hexyloxy-4-[6-i-endo-(2-azabicyclo[2.2.2locyloxy)]-1,2,5-oxadiazole, 3-~4,4,~-trifluorobutylthio)-4-[2-+-exo-(7-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-(2-phenoxyethylthio)-4-[3-~-endo-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(5-hexenyloxy)-4-[7-+-endo-(2-azabicyclo[2.2.1]heptyloxy)~-1,2,5-oxadiazole, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, and 3-cyclobutylmethyl-4-[2-+-endo-(8-azabicyclo[3.2.1~octyloxy)]-1,2,5-oxadiazole.
Some prefered characteristics of compound of Formula I for the composition are:
A) W is S;
B) r is 1 or 2;
C) G is selected from het-l and het-5;
D) G is unsaturated E) G is het-4;
F) G is an azabicycle having 7 ring carbon atoms and a nitrogen atom;
G) G is het-6;
H) r is 0;
I) R iS selected from halogen, -oR5y~ -SR5Y, -oR5ZY, -SR5ZY, -oR5ZR4, -SR5ZR4, -oR4, and -SR4;
J) W is O;
K) m is l;
L) n is l;
M) p is 2;
N) G is het-3 O~ G is het-2 P) a compound of Formula I
Q) a compound of Formula I
R) a compound of Formula I
wherein W is oxygen or sulphur;
R is selected from the group consisting of hydrogen, amino, halogen, NHR5, NR6R7, R4, -oR4, -SR4, -SoR4, -So2R4, C3_10-W O 97/20819 PCT~US96/19229 cycloalkyl, C4_l2-(cycloalkylalkyl), -Z-C3_l0-cycloalkyl and -Z-C4_l2-(cycloalkylalkyl); R4 is selected from the group consisting of Cl-ls-alkyl~ c2-ls-alkenylt and C2-15-alkynyl, each of which is optionally substituted with one S or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, -CN, Cl-4-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; or R is phenyl or benzyloxycarbonyl, each o~ which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -CN, Cl_4-alkyl, Cl_4-alko~y, -OCF3, -CF3, -CONH2 and -CSNH2; or R is selected from the group consisting of -oR5y~ -SR5Y, oR5-Z-Y, -SR5ZY, -o-R5-Z-R4 and -S-R5-Z-R4;
Z is oxygen or sulphur;
R5 is selected from the group consisting of Cl_ls-alkyl, C2_1s-alkenyl, and C2_1s-alkynyl;
Y iS a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
~N ~ ~ 3 hst-l het-2 het-3het-4 R~R~ Cm ~
het-~ het-6 het-7 . -70-or G can optionally be substituted C3-Cg cycloalkyl wherein the substitution is -NR6R7;
R6 and R7 independently are selected from the group consisting of hydrogen and C1_6-alkyl; or R6 and R7 together wlth the nitrogen atom optionally form a 4- to 6-member rlng;
R1 and R2 independently are selected from the group consisting of hydrogen, C1_1s-alkyl, C2_s-alkenyl, C2_s-alkynyl, C1_10-alkoxy, and C1_s-alkyl substituted with a subsituent independently selected from the group consisting of -OH, -COR6 , CH2-OH, halogen, -NH2, carboxy, and phenyl;
R3 is selected from the group consisting of hydrogen, C1_s-alkyl, C2_s-alkenyl and C2_s-alkynyl;
R6 is selected from the group consisting of hydrogen and C1_6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
....... is a single or double bond;
provided that when W is O and G is a saturated azabicyclic group having from 7 to 11 ring carbon atoms and a nitrogen atom wherein the nitrogen atom is separated from the W atom by 2 to 3 ring carbon atoms;
or a pharmaceutically acceptable salt or solvate thereof;
S) The G substituent is selected from the group consisting of ~ , ~ , R3 R3-N~ ~ and ~N.
T) The G substituent is CA 0223930l l998-06-02 W O 97n~819 PCT~US96/19229 ~, U) R is selected from the group consisting of -SR4 , SoR4 , -So2R4 , substituted benzyloxycarbonyl wherein the substituents are one or more independently selected from the group consisting of -CN, -OCF3, -CF3, -CONH2 and -CSNH2;
or C3_l0-cycloalkyl, c4-l2-(cycloalkylalkyl)~ -Z-C3_l0-cycloalkyl and -Z-C4_12-(cycloalkylalkyl).
V) R is selected from the group consisting of R4, C3-1o -cycloalkyl, C4_12-(cycloalkylal}~l), -z-C3_l~-cycloalkyl and -Z-C4_12-(cycloalkylalkyl); and R~ is selected from the group consisting of substituted Cs_ls-alkyl, optionally substituted C2_1s-alkenyl, and optionally substituted C2-1s-alkynyl, wherein such substituent is one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, Cl_~-alkyl, Cl_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2.
W) G is selected from the group consisting of het-4, het-7, het-6 wherein n=2; het-3 wherein one of n and m is 0 or 2; and het-3 wherein the I or I group is attached at the bridgehead of het-3.
Especially preferred compounds of this invention have the characteristics of A-F,P; A-F,Q; characteristics of A, G, H, M, F; characteristics of G-O,Q; or the characteristics of G-J,M,P; or G-J,M,Q. The characteristics of R and S may be particularly preferred.
Further, especially preferred R groups include phenyl, benzyloxycarbonyl, -oR5y ~ - SR5Y, oR5-Z-Y, -SR5ZY, -o-R4-z-R5 or -S-R4-Z-R5, -SoR4, C3_l0-çycloalkyl, C4_l2-(cycloalkylalkyl), -Z-C3_l0-cycloalkyl and -Z-C4-l2-(cycloalkylalkyl) wherein Z is oxygen or sulphur, R5 iS Cl_ 15-alkYl, C2-l5-alkenyl~ C2-ls-alkynyll Y is a 5 or 6 W O 97/20819 PCT~US96/19229 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereo~, R4 iS Cl-15-alkYl~ C2-5-alkenyl~ and C2_1s-alkynyl.
Further, especially preferred G groups include the following heterocycles:
~ ~ ~ I 3 ~ .
l3 R3 R3 R3-N ~ R3-N ~ ~
, , N ; wherein the point of attachment to the -(CH2)r-W- group is as indicated Some particularly pre~erred G groups include R3 R , ~ , and N , It is another preferred embodiment of this invention that G is not an azabicycle, particularly when W is oxygen.
Additionally, another embodiment of this invention which can be preferred is that when W is O and G
is alkyl, R is not halogen.
The invention will now be described in further detail with reference to the following examples. Many compounds of Formula I' can be prepared using the methods and procedures illustrated by the following examples. The examples are provided ~or illustrative purposes, and are not to be construed as limiting the scope of the invention in any way. The NSAIDS can be purchased from commercial vendors or prepared using methods that are well known in the art.
EXAMPLE
3-Chloro-4-(1-butvlthio)-1.2,5-thiadiazole Cyanogen (36 g, 0.69 mol) was bubbled into ether (250 mL) maintained at -10~C. To the solution was added dropwise diethylamine (3 mL) followed by dropwise addition of 1-butylthiol (47 mL, 0.64 mol) at such a rate that the temperature did not exceed -5~C. The reaction was maintained below 0~C for 5 h then stirred at ambient overnight. Ether was distilled from the reaction until the pot temperature reached 50~C. The reaction was cooled to ambient and then added dropwise to a solution of sulfur monochloride (55 mL, 0.688 mol) in DMF (50 mL) that was cooled to 5~C. Cooling was removed and reaction was stirred overnight. The reaction was cooled in an ice-water bath and excess sulfur monochloride destroyed by careful addition of H2O while maint~;n;n~ the temperature below 40~C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The a~ueous fraction was extracted with hexane (3 X) and the combined extracts and triturants were washed with H20, aqueous NaHCO3, brine, dried, and the solvent evaporated. The W O 97/20819 PCT~JS96/19229 residue was distilled at 2 mm Hg to give a yellow liquid (24.6 g), b.p. 105-110~C. (Compound 1).
3-Chloro-4-butYlsulfon~1-1,2,5-thiadiazole A solution of OxoneTM (12 g, 0.0195 mol) in H20 (60 mL) was vigorous stirred as 3-chloro-4-butylthio-1,2,5-thiadiazole (2.1 g, 0.01 mol) in THF (30 mL) was added dropwise. After 24 h, the THF was evaporated and the residue extracted with ether (3X). Extracts were washed with H2O, dried, and solvent evaporated to give a clear liquid. Radial chromatography eluting with 30 %
EtOAc/hexane gave a colorless liquid (2.3 g). (Compound 2).
3-Chloro-4-ethvlthio-1,2,5-thiadiazole Cyanogen (36 g, 0.69 mol) was bubbled into ether (250 rnL) maintained at -10~C. To the solution was added dropwise diethylamine (3 mL) followed by dropwise addition of ethanethiol (47 mL, 0.64 mol) at such a rate that the temperature did not exceed -5~C. The reaction was maintained below 0~C for 5 h then stirred at ambient temperature overnight. Ether was distilled from the reaction until the pot temperature reached 50~C. The reaction was cooled to ambient and then added dropwise to a solution of sulfur monochloride (125 mL, 1.56 mol) in DMF
(150 mL) that was cooled to 5~C. Cooling was removed and the reaction was stirred overnight. The reaction was cooled in an EtOH-ice bath as the excess sulfur monochloride was destroyed by dropwise addition of water while maintaining the temperature below 35~C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The aqueous fraction was extracted with hexane (3 X) and the combined extracts and triturants W O 97/20819 PCTnUS96/19229 were washed with H2O, aqueous NaHCO3, brine, dried, and the solvent evaporated. The brown liquid residue was distilled at 3 mm Hg to give a yellow liquid (80.2 g), b.p. 91-96~C.
(Compound 3).
3-Chloro-4-ethylsulfonyl-1,2,5-thiadi~zole A solution of Oxone (84 g, 0.137 mol) in H2O (400 mL) was rapidly stirred as 3-chloro-a-ethylthio-1,2,5-thiadiazole (12.2 g, 0.067 mol) in THF (200 mL) was added.
After stirring overnight, the THF wag evaporated and the residue extracted with ether (3x). The extracts were washed with H2O, aqueous NaHCO3, and brine then the solvent dried and evaporated to give a clear liquid (13.6 g). (Compound 4).
E~AMPLE 5 (~)-3-Methoxy-4-(1-az~hicvclor2.2.2loctvl-3-oxy)-1,2.5-thiadiazole A solution of 1-azabicyclo[2.2.2]octan-3-ol (1.36 g, 0.0104 mol) in THF (20 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (7.4 mL, 0.0118 mol).
To this solution was added 3-methoxy-4-methanesulfonyl-1,2,5-thiadiazole (2.08 g, 0.0107 mol) in THF (40 mL), the reaction heated to 40~C for 2 h, and then stirred at ambient temperature overnight. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution was made basic and extracted with EtOAc. The extracts were washed with ~ H2O, dried, and the solvent evaporated. The residue was purified by radial chromatography (2.5 % EtOH-0.25 % NH40H-CHCl3) to give a clear oil. The HCl salt of the oil (0.85 g) crystallized from MeOH-EtOAc, m.p. 197-198~C. (Compound 5).
W O 97/20819 PCT~US96/19229 (+)-3-~thoxv-4-(1-azabicvclo r2 .2.2loctvl-3-oxv3-1,2,5-thiadiazole A solution of 1-azabicyclo[2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF (50 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (3.7 mL, 0.0059 mol).
To this solution was added 3-ethoxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0048 mol) in THF (12 mL) and the reaction heated to 60~C for 5 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution was made basic and extracted with ether. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (0.47 g) crystallized from 2-propanol, m.p. 212-213~C. (Compound 6).
l~)-3-Pro~vloxv-4-(1-azabicvclor2.2.2loctvl-3-oxv)-1.2,5-thiadiazole A solution of 1-azabicyclo[2.2.2]octan-3-ol (1.1 g, 0.0087 mol) in THF (75 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (5.0 mL, 0.008 mol). To this solution was added 3-propyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.3 g, 0.0059 mol) in THF (15 mL) and the reaction heated to 60~C for 4 h. The solvent was evaporated, the residue acidified with 1 N HC1, and the mixture extracted with ether. The aqueous solution was made basic and extracted with EtOAc. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (0.59 g) crystallized ~rom 2-propanol, m.p. 218-219~C. (Compound 7).
W O 97/20819 PCTnUS96/19229 (+)-3-Butvloxv-4-(l-azabicvclo r 2.2.2loctvl-3-oxv)-1,2,5-thiadiazole .
A solution of l-azabicyclo[2.2.2]octan-3-ol (2.2 g, O.016~ mol) in THF (25 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (10.8 mL, 0.0173 mol). To this solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.98 g, 0.084 mol) in THF (25 mL) and the reaction heated to 52~C for 3.5 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous solution was made basic and extracted with EtOAc. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (2.0 g) crystallized from CHCl3-EtOAc-ether, m.p. 204-205~C. (Compound 8).
(i)-3-Pentvloxv-4-(1 -azabicvclor2.2.2loctvl-3-oxv)-1,2,5-thiadiazole A solution of l-azabicyclo r 2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF (50 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (3.7 mL, 0.0059 mol).
To this solution was added 3-pentyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.004 mol) in THF (10 mL) and the reaction heated to 60~C ~or 4 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution was made basic and extracted with ether. The extracts were washed ~ with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (0.75 g) crystallized from EtOAc, m.p. 171-172~C. (Compound 9).
CA 0223930l l998-06-02 W O 97/20819 PCT~US96/19229 (+)-3-Hexvloxv-4-(1-azabicvclo r2 ~ 2.2loctvl-3-oxv)-1,2,5-thiadiazole A solution of l-azabicyclo[2.2.2~octan-3-ol (2.2 g, 0.0168 mol) in THF (25 mL) was treated dropwise with 1. 6 M n-butyllithium in hexane (10.8 mL, 0. 0173 mol). To this solution was added 3-hexyloxy-4-methanesulfonyl-1,2,5-thiadiazole (2.2 g, 0.004 mol) in THF (25 mL) and the reaction heated to 52~C for 3. 5 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous solution was made basic and extracted with ether. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (1.76 g) crystallized from EtOAc, m.p. 165-166~C. (Compound 10).
(+)-3-~4-Methvl~entvloxv) 4-(1-azabicvclo~2.2.2l-octvl-3-oxv)-1.2,5-thiadiazole A solution of l-azabicyclo[2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF (50 mL) was treated dropwise with 1. 6 M n-butyllithium in hexane (3.7 mL, 0. 0059 mol).
To this solution was added 3-(4-methylpentyloxy)-4-methanesulfonyl-l, 2, 5-thiadiazole (1.2 g, 0.00 4 5 mol) in THF (10 mL) and the reaction heated to reflux for 6 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous solution was made basic and extracted with ether. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. The HCl salt of the oil (1.1 g) crystallized from EtOAc, m.p. 179-180~C. (Compound 11).
W O 97/20819 PCT~US96/19229 EXAMP~E 12 (+)-3-Chloro-4-(1-azabicvclor2.2.2loctvl-3-oxv)-1,2,5-thi~diazole .~
A solution of l-azabicyclo~2.2.2]octan-3-ol (1.1 g, 0.0084 mol) in THF (25 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (5.4 mL, 0.0086 mol). This solution was added dropwise to a solution of 3-chloro-4-butylsul~onyl-1,2,5-thladiazole (2.1 g, 0.0086 mol) in THF
(15 mL) at such a rate that the temperature did not exceed 32~C. After stirring for 3 days, the reaction was treated with H20 (10 mL), diluted with ether (100 mL), and extracted with 1 N HCl (25 mL). The aqueous solution was washed with ether, made basic, and extracted with ether.
The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (2.5 ~ EtOH-0.25 % NH40H-CHCl3) to give a straw colored liquid (1.1 g). The oxalate salt (0.39 g) crystallized from MeOH-EtOAc, m.p.
154-156~C. (Compound 12).
Alternative s~nthe~is o~ (+)-3-Chloro-4-(1-~zabicvclor2.2.2loctvl-3-oxv)-1,2,5-thiadiazole:
A solution of l-azabicyclo~2.2.2]octan-3-ol (1.2 g, 0.0092 mol) in THF (25 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (5.9 mL, 0.00~5 mol). The solution was cooled to -8~C and a solution of 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF
(15 mL) was added dropwise. After 15 min, cooling was removed and the reaction stirred overnight. The reaction was treated with H2O (10 mL), diluted with ether (100 mL), ~ and extracted with 1 N HCl (25 mL). The aqueous solution was washed with ether, made basic, and extracted with Y ether. The extracts were dried and the solvent evaporated to give crude (compound 12) (1.05 g) as a brownish liquid.
w o 97nO819 PCTrUS96/19229 Alternative sYnthesis o~ (+)-3-Chloro-4-(1-~z~hicyclor2.2.2loctyl-3-oxy)-l~2~5-thiadiazole:
A mixture of 1-azabicyclo[2.2.2]octan-3-ol (12.7 S g, 0.1 mol), triethylamine ~0.3 mL), and CHC13 (150 mL) was cooled to 5~C and cyanogen (7.25 g, 0.139 mol) bubbled into the mixture. The reaction was stirred another hour then allowed to come to ambient temperature overnight. The solvent was evaporated, the residue dissolved in DMF ~20 mL), and the solution added dropwise to a solution of S2Cl2 (47.3 g, 0.35 mol) in DMF (30 mL) that was cooled in an ice-water bath. After addition, cooling was removed and reaction exothermed to 32~C. After 5 h, reaction cooled and excess S2C12 destroyed by careful addition of H20. The reaction was diluted with more H2O (300 mL) and the aqueous solution decanted from the sulfur residue. The sulfur residue was triturated with H2O and the combined aqueous solutions evaporated to a small volume (150 mL). The solution was washed with ether and then made basic with 50 % NaOH while maintaining the temperature below 30 ~C. The mixture was extracted with CHCl3, the extracts dried, and the solvents thoroughly evaporated. The residue was suspended in ether, dried, filtered and the solvent evaporated to give (compound 12~ (18.1 g) as a yellow oil that slowly solidified.
EXAMPL~ 13 (+)-3-Propvlthio-~-(1-azabicyclo r 2.2.2loctyl-3-oxy)-1,2,5-thi~i~zole A solution of the crude compound 12 (1.67 g, O.0068 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.8 g, 0.0075 mol). After ~0 min, 1-bromopropane (1.25 g, 0.010 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and CA 0223930l l998-06-02 extracted with ether. The ex~racts were dried and the solvent evaporated to give a straw-colored liquid. The HCl salt (1.28 g) crystallized from CHCl3-EtOAc-ether, m.p.
174-176~C. (Compound 13).
EXAMPhE 14 (~)-3-Butvlthio-4~ az~hicvclo r2 .2.2loctvl-3-oxv)-~,2,5-thiadiazole A solution of the crude compound 12 (1.8 g, 0.0073 mol) in DMF (25 m~) was treated portionwise with freshly ground flaked Na2S-9H20 (1.94 g, 0.0081 mol). After 1 h, l-iodobutane (2 g, 0.011 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-coloured li~uid. The HCl salt (1. 82 g) crystallized from CHCl3-EtOAc-ether, m.p.
151-153~C. (Compound 14).
EXAMPLE lS
(+)-3-Pentvlthio-4-(1-azabicvclo r 2. 2. 2loctvl-3-oxv)-1,2 5-thiadi~zole A solution of the crude compound 12 (1.67 g, Q.0068 mol) in DMF (25 mL) was treated portionwise with ~reshly ground flaked Na2S-9H2O (1.8 g, 0.0075 mol). After 1 h, l-bromopentane (1.53 g, 0.010 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidi~ied with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and - extracted with ether. The extracts were dried and the solvent evaporated to give a straw-coloured li~uid. The HCl salt (1.07 g) crystallized from CHCl3-EtOAc-ether, m.p.
186-187~C. (Compound 15).
W O 97/20819 PCTrUS96/19229 EX~iMPLE 16 ~S)-3-Pentvlthio-4-(1-azabicvclo r 2.2.2loctvl-3-oxv)-1.2,5-thiadiazole A solution of tS)-l-azabicyclo[ 2.2.2] octan-3-ol (2.0 g, 0.0157 mol) in THF (40 mL) was cooled to 10~C as 1.6 M n-butyllithium in hexane (10 mL, 0.016 mol) was added dropwise. The resulting mixture was treated with 3-chloro-ethylsulfonyl-1,2,5-thiadiazole (3.34 g, 0.0157 mol) in THF
(25 mL) and stirred for 16 h. The reaction was treated with H20 (10 mL), ether (170 mL) and extracted with 1 N HCl (43 mL). The aqueous fraction was washed with ether, made ~asic, and extracted with ether. The extracts were dried and the solvent evaporated to give an oil (1.7 g). The oil was dissolved in DMF (25 mL), treated portionwise with freshly ground flaked Na2S-9H2O (1.83 g, 0.0076 mol), and heated (40~C). After 1.25 h, l-bromopentane (1.58 g, 0.0105 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N
HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid that was purified by radial chromatography (5% EtOH-0.5% NH40H-CHCl3). The HCl salt (0.87 g) crystallized from CHCl3-EtOAc-ether, m.p. 194-195~C, [~]D = 25.41~ (EtOH).
(Compound 16).
(i)-3-Hexvlthio-4-~1-azabic~clo r2 .2.2loctvl-3-oxv)-1,2,5-thiadiazole A solution o~ the crude compound 12 (1.8 g, 0.0073 mol) in DMF (25 mL) was treated portionwise with freshly ground ~laked Na2S-9H2O (1.94 g, 0.0081 mol). After 1 h, l-iodohexane (2.3 g, 0.011 mol~ was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid. The HCl salt (1.0 g) crystallized from CHCl3-EtOAc-ether, m.p. 165-~ 167~C. (Compound 17).
~XAMPLE 18 (~)-3-(3,3-DimethvlbutYlthio)-4-(1-azabicvclo r 2.2.21-octvl-3-oxv)-1 ~,5-thi~diazole A solution of the crude (compound 12) (1. 05 g, 0.0043 mol) in DMF (25 mL) was treated portionwise with ~reshly groun~ flaked Na2S-9H2O (1.24 g, 0.0051 mol). A~ter 1 h, 1-bromo-3,3-dimethylbutane (1.18 g, 0.007 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid. The HCl salt (0.41 g) crystallized from CHCl3-EtOAc-ether, m.p.
189-190~C. (Compound 18).
(+)-3-(2-(2-Thienvlthio)ethvlthio)-4-(1-azabicvclo-r2.2.2loctvl-3-oxv)-1.2.5-thiadiazole A solution of the crude (compound 12) (1.0 g, 0.0041 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O ~1.1 g, 0.0045 mol). After 1 h, 1-chloro-2-(2-thienylthio)ethane (1.1 g, 0.0062 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by flash CA 0223930l l998-06-02 W O 97/20819 PCTrUS96/19229 chromatography (10% EtOH-1% NH40H-CHC13) to give a liquid.
The HCl salt (0. 88 g) crystallized from ether, m.p. 179.5-181~C. (Compound 19).
EXAMPLE a o (+)-3-(2,2,3,3,3-Pentafluoro~ro~ylth;o)-4-(1-~zabicvclo-r2.2~2loctyl-3-oxv)-l~2~5-th;~;azole A solution of the crude (compound 12) (0.5 g, 0.002 mol) in DMF (15 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (0.53 g, 0.0022 mol). After 1 h, 1-methanesulfonoxy-2,2,3,3,3-pentafluoropropane (0.003 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N
HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by flash chromatography (5% EtOH-0.5% NH40H-CHC13) to give a liquid. The HCl salt (0.016 g) crystallized from ether, m.p. 138-140~C. (Compound 20).
(i)-3-(3-~2-Thienvl)~ro~vlthio)-4-(1-~z~hicvclo r 2.2.2l-octyl-3-oxy)-1.2.5-thi~ zole A solution of the crude (compound 12) (0.6 g, 0.0024 mol) in DMF (15 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (0.6 g, 0.0027 mol). After 1 h, 1-chloro-3-(2-thienyl)propane (0.6 g, 0.0036 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by flash chromatography (10% EtOH-1% NH40H-CHC13) to give a liquid.
The HCl salt (0.16 g) crystallized from EtOH-EtOAc, m.p.
194-196~C. (Compound 21).
W O 97/20819 PCT~US96/19229 3-Butvlthio-4-((1-~z~hicvclo r 2.2.2loctan-3-vl)-methoxv)-1,2.5-thiadiazole A solution of 3-hydroxymethyl-1-azabicyclo[2.2.2]octane (1.4 g, 0.01 mol) in THF (30 mL) was treated with 1.6 M n-butyllithium in hexane (6.5 mL, 0.0104 mol). The mixture was cooled to 10~C, and 3-chloro-4-ethylsul~onyl-1,2,5-thiadiazole (2.21 g, 0.0104 mol) in THF (10 mL) was added dropwise. Cooling was removed and the reaction stirred overnight. The reaction was treated with H2O, diluted with ether, and extracted with 1 N HCl (25 mL). The acidic extracts were washed with ether, made basic, and extracted with ether. The extracts were dried and the solvent evaporated to give an orange liquid (1.82 g). The liquid was dissolved in DMF (32 mL) and treated with freshly ground ~1aked Na2S-9H2O (2.5 g, 0.0104 mol) in portions.
After 55 min, the reaction was treated with l-iodobutane (2.6 g, 0.014 mol) and warmed to 44~C overnight. The solvent was e~aporated, the residue acidi~ied with 1 N HCl, and the mixture extracted with EtOAc-ether (1:1). The aqueous fraction was made basic and extracted with ether.
The ether was dried, the solvent evaporated, and the residue purified by radial chromatography (5% EtOH-0.5 NH40H-CHC13) to give a liquid. The HCl salt (0.84 g) crystallized from EtOAc-ether, m.p. 170-171~C. (Compound 22).
(+)-exo-3-Pentvlthio-4-(1-azabicvclor3.2.1loctvl-6-oxv)-1.2,5-thiadiazole and (~)-Fndo-3-~entvlthio-4-(1-azabicvclor3.2.1l- octvl-6-oxv)-1,2,5-thiadiazole A solution of the endo/exo mixture of 1-azabicyclo~3.2.1]octan-6-ol (1.95 g, 0.0153 mol, ref.
Sternbach, L. H.; Kaiser, S. J. Amer. Chem. Soc. lg52, 74, W O 97~0819 PCT~US96/19229 2215-2218.) in THF (25 mL) was treated with 1.6 M n-butyllithium in hexane (9.6 mL, 0.0153 mol). When the mixture had cooled to ambient temperature, 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole t2.96 g, 0.014 mol) in THF
(15 m~) was added dropwise and the reaction stirred overnight. The reaction was treated with H2O, diluted with ether, and extracted with 1 N HCl (32 mL). The acidic extract was made basic, extracted with ether, the extracts dried, and the solvent evaporated to give an orange li~uid (1.25 g). The liquid was dissolved in DMF (25 mL) and treated with freshly ground flaked Na2S-9H2O (1.82 g, 0.0076 mol) in portions. After 40 min, l-bromopentane (1.55 g, 0.0103 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue acidi~ied, and the mixture extracted with ether. The aqueous fraction was made basic, extracted with ether, the extracts dried, and the solvent evaporated. The residue was purified by radial chromatography (2.5% EtOH-0.25% NH40H-CHCl3) to first elute the exo isomer as a liquid. The HCl salt (0.26 g), crystallized from EtOAc, m.p. 159-160~C.
(Compound 23). Further elution provided the endo isomer as a liquid. The HCl salt (0.23 g) crystallized from EtOAc, m.p. 1~0-193~C. (Compound 24).
(~)-endo-3-Butvloxv-4-(1-azabicvclo r2 .2.1lhe~tvl-3-oxv)-1,2.5-thiadiazole A solution of a mixture of (+)-endo and (+)-exo-l-azabicyclo[2.2.1]heptan3-ol (0.5 g, 0.0044 mol)(Ref. J.
Ora. Chem. 1969, 34, 3674-3676) in THF (20 mL) was cooled in an ice-water bath and ~reated dropwise with 1.6 M n-butyllithium in hexane (2.8 mL, 0.0044 mol). Cooling was removed, 3-butyloxy-~-methanesul~onyl-1,2,5-thiadiazole (1.4 g, 0.0059 mol) was added, and the reaction heated to reflux ~or 6 h. The solvent was evaporated, the residue CA 0223930l l998-06-02 W O 97/20819 PCTnUS96/19229 acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution was made basic and extracted with EtOAc. The extracts were washed with H2O, dried, and the solvent evaporated to give a clear oil. R~; Al chromatography (5% EtOH, 0.5% NH40~, CHCl3) eluted the title compound as the more polar of the two UV active spots. The HCl salt o~ the title compound (0.5 g) crystallized from EtOAc with a quarter mole of H2O, m.p.
161.5-163~C. tCompound 25).
EXAMP~E 25 (~)-Fxo-3-butvloxv-4-(1-azabicvclo~2.2.1lhe~tvl-3-oxv)-1,2.5-thiadiazole Rechromatography of the mixed fractions from the isolation of ~compound 25) (5% EtOH, 0.5% NH40H, CHC13) gave the less polar W active material. The HCl salt (0.036 g) crystallized from EtOAc with a ~uarter mole of water, m.p. 156-157~C. (Compound 26).
EXAMPLE a 6 ~)-3-Butvloxv-4-(3-~vrrolidinvloxv)-1.2.5-thi~diazole A suspension of NaH (0.066 g, 0.0028 mol) in THF
(25 mL) was treated with l-t-butylcarbamoyl-3-hydroxypyrrolidine (Ref. Svn. Commun. 15, 587.) (0.5 g, 0.0027 mol) and the reaction warmed to 50~C for 30 min.
After cooling to ambient temperature, 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (0.55 g, 0.0027 mol) in TH~ (5 mL) was added and the reaction heated to reflux for 2.5 h. The solvent was evaporated, the residue treated with ice-water, and the mixture extracted with ether. The extracts were washed with brine, dried, and the solvent evaporated. The residue was dissolved in ether (50 mL) and treated with a slow stream of HCl for 5 min. After stirring overnight, the reaction was extracted with cold water. The a~ueous was washed with ether, made basic, and extracted W O 97/20819 PCT~US96119229 with EtOAc. The extracts were washed with brine, dried, and the solvent evaporated to give a clear oil. The HCl salt (0.42 g) crystallized from EtOAc, m.p. 127-128~C. (Compound 27).
EXAMPLE 27(i)-3-Butvloxv-4-(1-methvl-3-~vrrolidinvloxv)-1.2,5-thiaai~zole A solution of l-methyl-3-pyrrolidinol (0.6 g, 0.0059 mol) in THF (20 mL) was treated with 1.6 M n-butyllithium in hexane (3.1 mL), 0.005 mol). To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0042 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The aqueous fraction was made basic, extracted with EtOAc, and the extracts washed with water. The extracts were dried and the solvent evaporated to give a liquid. The HCl salt (0.7 g) crystallized from EtOAc, m.p. 157-158~C.
(Compound 28).
~ 3-Butvlthio-4-(1-methvl-3-~i~eridvloxv)-1,2,5-thiadiazole A solution of 3-hydroxy-1-methylpiperidine (1.12 g, 0.0095 mol) in THF (25 mL) was treated with 1. 6 M n-butyllithium in hexane (5.9 mL, 0.0095 mol). The mixture was cooled to 8~C and treated dropwise with 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF
(20 mL). The cooling was removed and the reaction stirred overnight. The mixture was treated with H2O, acidified with 1 N HCl and diluted with ether. The aqueous fraction was washed with ether, made basic, and extracted with ether.
The extracts dried and solvent evaporated to give a brown li~uid (1.95 g). The liquid was dissolved in DMF (38 mL) W O 97/20819 PCT~US96/19229 and treated with freshly ground flaked Ma2S-9H2O (2.98 g, 0.0124 mol) in portions. After 1 h, the mixture was treated with l-iodobutane (3.1 g, 0.0169 mol) and stirred 64 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous solution - was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give an orange liquid.
Purification by radial chromatography (2.5% EtOH-0.25%
NH40H-CHC13) gave a liquid whose HCl salt (1.4 g) crystallized from CHCl3-EtOAc-ether, m.p. 141-142~C.
~Compound 29)~
EXAMP~E 29 3-Rlltvlthio-4-(1-methvl-4-pi~eridvloxv)-1~2~ ~-tl~ zol e A solution of 4-hydroxy-1-methylpiperidine (1.12 g, 0.0095 mol) in THF (25 mL) was treated with 1.6 M n-butyllithium in hexane (5.9 mL, 0.0095 mol). The mixture was cooled to 8~C and treated dropwise with 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF
(20 mL). The cooling was removed and the reaction stirred overnight. The mixture was treated with H2O, acidified with 1 N HCl, and diluted with ether. The aqueous fraction was washed with ether, made basic, and extracted with ether.
The extracts dried and solvent evaporated to give a brown liquid (1.52 g). The liquid was dissolved in DMF ~30 mL) and treated with freshly ground flaked Na2S-9H2O (2.32 g, 0.0097 mol) in portions. After 50 min, the mixture was treated with l-iodobutane (2.4 g, 0.013 mol) and stirred for 63 h. The solvent was evaporated, the residue acidified with dilute HCl, and the mixture extracted with ether. The ~ aqueous fraction was made basic and extracted with ether.
The extracts were dried and the solvent evaporated to give ~ 1.3 g li~uid. The HCl salt (1.3 g) crystallized from EtOAc-ether, m.p. 140-142~C. (Compound 30).
W O 97~0819 PCTnJS96/19229 EXAMPtS)-3-ButvloxY-4-(1 -methvl-2-~vrrolidinvlmethoxv)-1.2.5-thiadi~ole A solution of (S)-l-methyl-2-pyrrolidinemethanol (0.86, 0.0075 mol) in THF (20 mL) was treated with 1.6 M n-butyllithium in hexane (4.7 mL, 0.0075 mol). To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.2 g, 0.005 mol) and the reaction heated to reflux for 6.5 h. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with EtOAc.
The extracts were washed with water, dried, and the solvent evaporated to give a liquid. The HCl salt (0.72 g) crystallized from EtOAc, m.p. 115-116~C. (Compound 31).
(S)-3-ButYloxv-~-l2-~vrrolidinvlmethoxv~ 2~5-thiadiazole A solution of (S)-l-butyloxycarbonyl-2-pyrrolidinemethanol (1.21, 0.006 mol) in THF (5 mL) was added to a suspension of 60% Na~ in oil (0.24 g, 0.006 mol) in THF (30 mL). After 1 h, the mixture was heated to gentle reflux for 1 h. To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1 g, 0.0042 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue treated with cold H2O, and the mixture extracted with EtOAc. The extracts were dried and treated with a stream of dry HCl for 3 min. After another hour, the solvent was evaporated, the residue treated with cold H2O, and the mixture extracted with ether. The aqueous fraction was made basic and extracted with EtOAc. The extracts were washed with water, dried, and the solvent evaporated to give a li~uid. The HCl salt (0.72 g) crystallized from EtOAc, m.p. 99-100~C. (Compound 32).
CA 0223930l l998-06-02 W O 97/20819 PCT~US96/19229 ~ --91--EXA~MPLE 3 a 3-Butvloxv-4- (2-(dimethvlamino)ethoxv)-1.2,5-thiadiazole A so lution of 2-dimethylaminoethanol (0.67 g, 0.0075 mol) in THF (20 mL) was treated with 1.6 M n-c butyllithium in hexane (4.7 mL, 0.0075 mol). To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole tl.2 g, 0.005 mol) and the reaction heated to reflux for 6 h. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with EtOAc.
The extracts were washed with water, dried, and the solvent evaporated to give a clear oil. The HCl salt (0.94 g) recrystallized from EtOAc to give a white solid, m.p. 97-98~C. (Compound 33).
3-Rutvlthio-4-(2-(diethvlamino)ethoxv)-1~2~5-thiadiazole A solution of 2-diethyl~minoethanol (1.11 g, 0.009~ mol) in THF (25 mL) was treated with 1.6 M n-butyllithium in hexane (5.9 mL, 0.0095 mol). The mixture was cooled to 8~C and treated dropwise with 3-chloro-4-ethylsulfonyl-1,2,5thiadiazole (1.83 g, 0.0086 mol) in THF
(20 mL). The cooling was removed and the reaction stirred overnight. The mixture was treated with H2O, acidified with 1 N HCl, and diluted with ether. The a(aueous fraction was washed with ether, made basic, and extracted with ether.
The extracts dried and solvent evaporated to give a brown liguid (1.6 g). The li~uid was dissolved in DMF ~30 mL) and treated with freshly ground flaked Na2S-9H2O (2.43 g, 0.010 ~ mol) in portions. After 50 min, the mixture was treated with l-iodobutane (2.52 g, 0.0137 mol) and stirred for 46 r h. The solvent was evaporated, the residue acidified with dilute HCl, and the mixture extracted with ether. The aqueous fraction was made basic and extracted with ether.
The extracts were dried, the solvent evaporated, and the W O 97/20819 PCTrUS96/19229 residue purified by radial chromatography (5% EtOH-0.5%
NH~OH-CHC13) to give a li~uid. The HCl salt ~1.15 g) crystallized from EtOAc-ether, m.p. 95-97~C. (Compound 34).
EXA~PL~ 34 3-Butvloxv-4-(2-(trimethvlamino)ethoxv)-1 2.5-thiadiazole iodide A solution of (compound 33) (from Q.5 g, 0.0018 mol of the HCl salt) in FtOAC (30 mL) was treated with CH3I
(0.3 mL) and stirred overnight. The precipitant was collected, washed with EtOAc, and dried to give a white solid (0.64 g), m.p. 137-138~C. (Compound 35).
E:XAMPLE 35 3-Rlltvloxv-~-(2-(dimethvlamino)ethvlthio)-1,2.5-thia~;~zole A suspension of 2-dimethylaminoethanthiol hydrochloride (0.57 g, 0.004 mol) in THF (25 mL) was treated with 1.6 M n-butyllithium in hexane (5 mL, 0.008 mol). To the solution was added 3-butyloxy-4-methanesulfonyl-1,2,~-thiadiazole (0.71 g, 0.003 mol) and the reaction heated to reflux for 2 h followed by stirring at ambient temperature overnight. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were washed with water, dried, and the solvent evaporated. The residue was purified by radial chromatography (5% EtOH-0.5% NH40H-CHCl3) to give a tan liquid. The HCl salt (0.22 g) recrystallized from EtOAc to give a white solid, m.p. 108-109~C. (Compound 36).
CA 0223930l l998-06-02 W O 97/20~19 PCT~US96/19Z29 -~3-EXA~P~E 36 3-ChlorQ-4~ ~ro~vlthio)-1,2,5-thiadiazole cyanogen (34 g, 0.65 mol) was bubbled into ether (250 mL) maintained at -10~C. To the solution was added dropwise diethylamine (3 mL) followed bv dropwise addition of l-propanethiol (57 mL, 0.63 mol) in ether (25 mL) at such a rate that the temperature did not exceed -5~C. After ~ h, cooling was removed and the reaction stirred overnight. Ether was distilled ~rom the reaction until the pot temperature reached 50~C. The reaction was cooled to ambient and added dropwise to a solution of sul~ur monochloride (125 mL, 1.56 mol) in DMF (125 mL) that was cooled in an ice-water bath. Cooling was removed and the reaction allowed to exotherm to 35~C, recooled to below 3û~C, then stirred overnight. The reaction was cooled in EtOH-ice and the excess sul~ur monochloride carefully destroyed by dropwise addition o~ H20 (200 mL) such that the temperature did not exceed 30~C. The mixture was extracted with hexane, the extracts washed with brine, dried, and the solvent e~raporated. The residue was distilled at 1.5 mm Hg to give a yellow lisluid (98.6 g), b.p. 84-94~C. (Compound 37).
(R)-3-Pentvlth;o-4~ azabicvclor2.2.210ctvl-3-oxv)-1.2,5-thiadiazole A solution o~ (R)-l-azabicyclo[2.2.2]octan-3-ol (3.0 g, 0.0236 mol) in THF (40 mL) was cooled to 10~C as 1.6 M n-butyllithium in hexane (15 mL, 0.024 mol) was added ~ ~ropwise. The resulting mixture was treated with 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (5.01 g, 0.0236 mol) in THF (5 mL) and stirred ~or 22 h. The reaction was treated with H20 (10 mL), ether (170 mL) and extracted with 1 N HCl (35 mL). The a~[ueous ~raction was washed with ether, made basic, and extracted with ether. The extracts were dried WO 97nO819 PCT~US96/19229 ~ -94-and the solvent evaporated to give an oil (2.35 g). The oil was dissolved in DMF (35 mL), treated portionwise with ~reshly ground flaked Na2S-9H20 (2.53 g, 0.0105 mol), and heated (40~C). A~ter 1.25 h, 1-bromopentane (2.18 g, 0.0145 mol) was added and the reaction stirred overnight at 38~C.
The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid that was purified by radial chromatography (596 EtOH-0.5% NH40H-CHCl3), The HCl salt (1.68 g) crystallized from CHC13-EtOAc, m.p. 195-196~C, [a]D = -24.6~ (EtOH).
(Compound 38).
(~)-3-(4-Methvl~entvlthio)-4-(1-azabicvclo r 2.2.2loct~1-3-oxv)-1.2,5-thiadiazole A solution of the crude (compound 12) (1.65 g, 0.0067 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H20 (1.83 g, 0.0076 mol). After 1 h, 1-bromo-4-methylpentane (1.73 g, 0.0105 mol) was added and the reaction stirred three days at 40~C. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored lic;[uid that was purified by radial chromatography (5% EtO~-0.5% NH40H-CHCl3). The HCl salt (0.74 g) crystallized from CHCl3-EtOAc-ether, m.p. 183-185~C. (Compound 39).
EXA(+)-3-(3-Phenvl~ro~vlthio)-4-(1-azabicyclor2.2.2loctvl-3-oxv)-1.2,5-thiadiazole A solution of the crude (compound 12) (0.9 g, 0.0037 mol) in DMF (25 mL) was treated portionwise with _9~ _ freshly ground flaked Na2S-9~2O (0.97 g, 0.004 mol). After 1 h, 1-bromo-3-phenylpropane (1.11 g, 0.056 mol) was added and the reaction stirred 17 h at 50~C. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid that was purified by radial chromatography (2.5% EtOH-0.25% NH40H-CHC13). The HCl salt (0.42 g) crystallized from CHCl3-EtOAc-ether, m.p. 210-212~C. (Compound 40).
(+)-3-(~-Cyanobenzylthio)-4-(1-az~h-cyclo r 2.2.2loctvl-3-oxY)-l~2~5-thiadia~ole A solution of the crude (compound 12) (1.15 g, O.0047 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.68 g, 0.007 mol). After 1 h, 4-cyanobenzyl bromide (1.85 g, 0.0g4 mol) was added and the reaction stirred 22 h. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored liquid that was purified by radial chromatography (5% EtOH-0.5% NH40H-CHCl3). The HCl salt (0.12 g) crystallized from CHCl3-EtOAc-ether, m.p. 211-213~C. (Compound 41).
(+)-3-(4-Flllorobenzylthio)-4~ z~hicyclor2.2.2loctyl-3-oxv)-1,2,5-th;~diazole A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF (25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.68 g, 0.007 mol). After 1 h, 4-fluorobenzyl chloride (1.37 g, 0.094 mol) was added and the reaction stirred 22 h. The solvent was evaporated, W O 97/20819 PCT~US96/19229 the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored li~uid that was purified by radial chromatography (5% EtOH-0.5% NH40H-CHC13). The HCl salt (0.89 g) crystallized from MeOH-EtOAc-ether, m.p. 236-237~C. (Compound 42).
(+)-3-(2-Phenvlethvlthio)-4-(1 -azabicvclor2.2.21Octvl-3-oxv)-1 2 5-thi~;azole A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF (25 mL) wa~ treated portionwise with freshly ground flaked Na2S-9~2O (1.68 g, 0.007 mol). After 1 h, the reaction was cooled to -30~C and treated with dropwise with 1-bromo-2-phenylethane (1.75 g, 0.095 mol) in DMF (22 mL). The cooling was removed after 1 h and the reaction stirred 22 h. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried and the solvent evaporated to give a straw-colored li~uid that was purified 3~y radial chromatography (5% EtOH-0.5% NH40H-CHC13). The HCl salt ~0.53 g) crystallized from MeOH-EtOAc-ether, m.p. 181-183~C. (Compound 43).
(+)-3-~2-Phenvloxvethvlthio)-4-(1-a~abicvclo r 2.2.2loctvl-3-oxv)- 1,2.5-thiadiazole A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF ~25 mL) was treated portionwise with freshly ground flaked Na2~-9H2O ~1.68 g, 0.007 mol). After 1 h, the reaction was cooled to -50~C and treated with dropwise with 1-bromo-2-phenyloxyethane (1.90 g, 0.0095 mol) in DMF (22 mL). The cooling was removed after 1 h and w o 97nO819 PCT~US96/19229 the reaction stirred 22 h. Another solution of bromo-2-phenyloxyethane (1.90 g, 0.0095 mol) in DMF (5 mL) was added in two portions with cooling to -30~C. After 2 h, the solvent was evaporated, the residue was acidified with 1 N
HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with CHCl3. The extracts were dried and the solvent evaporated to give a straw-colored li~uid that was purified by radial chromatography (5% EtOH-O.5% NH40H-CHC13). The HCl salt (1.29 g) crystallized ~rom MeOH-EtOAc-ether, m.p. 193-194~C. (Compound 44).
endo-3-~utvloxv-4-(N-methvl-8-azabicvclo r 3.2.1loctvl-3-oxv)-1.2,5-thi~di~zole A solution of tropine ~1.36 g, 0.0094 mol) in THF (25 mL) was treated dropwise with 1.6 M n-butyllithium in hexane (5.9 mL, 0.000g5 mol~. To this solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (2.04 g, 0.0086 mol) in THF (25 mL) and the reaction heated to 40~C
for 19 h. The solution was treated with H2O (40 mL), 5 N
HCl (5.5 mL), and ether (150 mL), the a~ueous layer separated and made basic. The a~ueous solution was extracted with ether, the extracts dried, and the solvent evaporated to give a clear oil. The oil was purified by radial chromatography (5% EtOH-0.5% NH40H-CHCl3) and the HCl salt (1.49 g) crystallized from CHCl3-EtOAc-ether, m.p.
168-169~C. (Compound 45).
(+)-exo-3-Butvloxv-4-(6-(N-methvl-8-azabicvclor3.2.110ctan-3-onoxv))-1 2,5-thiadiazole A suspension of NaH (0.11 g, 0.00275 mol) in THF
(25 mL) was treated with ~+)-exo-6-hydroxytropinone (1.36 g, 0.0094 mol) and the reaction heated to 50~C for 1 h. To this solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-W O 97/20819 PCT~US96/19229 thiadiazole (0.55 g, 0.0027 mol) and the reaction heated to reflux for 2 h. The solvent was evaporated, the residue suspended in ice-water, acidified, and the mixture extracted with ether. The aqueous layer was made basic, was extracted with ether, the extracts washed with brine, dried, and the solvent evaporated to give a clear oil. The oil was purified by radial chromatography (2.5% EtoH-o.25%
NH40H-CHCl3) and the HCl salt (0.325 g) crystallized from EtOAc, m.p. 178-179~C. (Compound 46).
(+)-exo-3-Chloro-4-~1-azabicvclor3.2.1loctvl-6-oxsr)-1,2.5-th;adiazole and(~t)-endo-3-chloro-4-(l-azabicvclo r3.2.1 octvl-6-oxv)-1.2,5-thia~iazole A solution of the endo/exo mixture of 1-azabicyclo[3.2.1]octan-6-ol (13 g, 0.102 mol, ref.
Sternbach, L. H.; Kaiser, S. J. Amer. ~hem. Soc. ls5a , 74, 2215-2218), triethylamine (0.3 mL), and CHCl3 (100 mL) was cooled to 3~C and cyanogen (7.7 g, 0.148 mol) bubbled into the solution. After 1 h, the cooling was removed, the reaction stirred another 3 h, and the solvent evaporated.
The residue was dissolved in D~qF (30 mL) and added dropwise to a solution of S2C12 (47.3 g, 0.35 mol) in DMF (30 mL) that was cooled in an ice-water bath. Cooling was removed, the reaction stirred overnight, and, after further cooling, the excess S2C12 carefully destroyed with H2O. The mixture was diluted with H2O (200 mL), the aqueous solution decanted, and the sulfur residue triturated with H2O. The combined a~eous solutions were evaporated to a ~mall volume (150 mL) and extracted with hexane. The aqueous solution was cooled, made basic with 50% NaOH, and extracted with CHCl3. The extracts were dried, the solvent thoroughly evaporated, the residue suspended in ether and filtered. Evaporation of the solvent gave a brown liquid (12.76 g), a 0.8 g sample of which was purified by radial chromatography (10% EtOH-196 NH4oH-cHcl3)~ The exo isomer _99 _ eluted first and was converted to an HCl salt (0.1 g) that crystallized from acetone, m.p. 226~C, dec. (compound 47).
Further elution provided the endo isomer that crystallized as an HCl salt (0.2 g) from 2-propanol, m.p. 199.5-201~C.
(Compound 48).
EXAMP~E 47 (+)-endo-3-(4-cvanobenzvlthio)-4-(1-azabicvclor3.2.1loctvl -6-oxv)-1,2,5-thiadiazole A solution of the crude mixture of (compound 47) and (compound 48) (2.3 g, 0.0094 mol) in DMF (34 mL) was treated portionwise with freshly ground flaked Na2~-9H2O
(3.36 g, 0.014 mol). After 2 h, the reaction was cooled to -30~C and treated with dropwise with 4-cyanobenzyl bromide (3.7 g, 0.0189 mol) in ~qF (34 mL). The cooling was removed and after 1.5 h, the reaction was treated with 5 N NaOH (4 mL). The solvents were evaporated, the residue dissolved in a mixture of CHCl3 and H2O, the CHCl3 extract separated, and washed with H2O. The organic extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (5% EtOH-0.5% NH4OH-EtOAc) to give the endo isomer. The HCl salt (0.31 g) crystallized from MeOH-EtOAc-ether, m.p. 250-251~C. (Compound 49).
3-RutYloxY-4-(3-azetidinYloxy)-l~2~5-thiadiazole A suspension of NaH (0.24 g, 0.006 mol) in THF
(30 mL) was treated with l-t-butylcarbamoyl-3-hydroxyazetidine (1.1 g, 0.006 mol), the reaction stirred 1 h, followed by addition of 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0042 mol) in THF (5 mL). The reaction was heated to reflux for 4 h, the solvent evaporated, the residue treated with ice-water, and the mixture extracted with EtOAc. The extracts were dried and treated with a slow stream of HCl for 3 min. After 0.5 h, W O 97/20819 PCT~US96/19229 the solvent was evaporated, the residue treated with ice-water, and the solution extracted with ether. The aqueous phase was made basic, extracted with EtOAc, the extracts washed with brine, dried, and the solvent evaporated to give a clear oil. The ~Cl salt (0.77 g) crystallized from 2-propanol, m.p. 167-168.5~C. (Compound 50).
EXAMP~E 49 3-Rlltvlthio-4-(3-azetidinvloxv)-1.2,5-thiadiazole A suspension of NaH (0.24 g, 0.006 mol) in THF
(30 mL) was treated with 1-t-butylcarbamoyl-3-hydroxyazetidine (1.6 g, 0.0092 mol), and the reaction stirred 1 h. After cooling to 8~C, 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.96 g, 0.0092 mol) in THF
(5 mL) was added, the reaction stirred 30 min, cooling removed for 30 min, and the reaction heated to 35~C for 45 min. Heating was removed, the reaction stirred overnight, and the solvent evaporated. The residue was suspended in cold water, the mixture extracted with EtOAc, the extracts washed with brine, dried, and the solvent evaporated to give a tan li~uid, (2.98 g). A DMF (30 mL) solution of the liquid was treated with freshly ground flaked Na2s-9H2o (3.3 g, 0.0138 mol). After 1 h, l-iodobutane (2.1 mL) was added, the reaction stirred 2 h, diluted with cold water, and extracted with ether. The ether was dried, the solvent evaporated, the residue dissolved in EtOAc, and the solution treated with a stream o~ dry HCl ~or 5 min. After 1 h, the reaction was treated with icewater and the organic solvent evaporated. The aqueous solution was extracted with ether, made basic, and extracted with EtOAc. The EtOAc extracts were dried and the solvent evaporated to give a tan liquid that was purified by radial chromatography (10%
EtOH-1% NH40H-CHC13). The HC1 salt (0.41 g) crystallized from EtOAc, m.p. 138-139~C. (Compound 51).
EXAMP~E 50 (+)-trans-3-Butvloxv-4-(2-dimethYlaminoc~clo~entvloxY)-1,2,5-thiadiazole A suspension of NaH (0.25 g, 0.006 mol) in THF
(30 mL) was treated with (+)-trans-dimethylaminocyclopentanol (0.8 g, 0.006 mol), the reaction heated to reflux 1 h, followed by addition of 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0042 mol), and the heating continued overnight. The solvent was evaporated, the residue suspended in cold water, and the mixture acidified. The solution was extracted with ether, made basic, and extracted with EtOAc. The EtOAc extracts were washed with brine, dried, the solvent evaporated, and the residue purified by radial chromatography (10% EtOH-1%
NH40H-CHCl3). The HCl salt (0.98 g) crystallized from EtOAc, m.p. 148-149~C. (Compound 52).
(+)-3-~utvlthio-4-t3-~vrrolidinvloxv)-1,2.5-thiadia~ole A suspension of NaH (0.22 g, 0.009 mol) in THF
(30 mL) was treated with (+)-l-t-butylcarbamoyl-3-hydroxypyrrolidine (1.73 g, 0.0092 mol), and the reaction heated to reflux for 35 min. After cooling to 10~C, 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole ~1.96 g, 0.0092 mol) in TEF ( 5 mL) was added, cooling was removed, and the reaction heated to 35~C for 16 h. The reaction was diluted with H2O, ether added, and the ether extract separated. The ether extract was washed with H2O, dried, and the solvent evaporated to give a tan liquid, (3.05 g). A DMF (42 mL) solution of the li~uid was treated with freshly ground flaked Na2S-9H2O (3.3 g, 0.0138 mol). After 1 h, 1-iodobutane (3.42 g, 0.0186 mol) was added, and the reaction stirred at 40~C for 16 h. The solvent was evaporated, the residue diluted with cold water, and the mixture extracted with ether. The ether was dried, the solvent evaporated, W O 97/20819 PCT~US96/19229 the residue dissolved in ether, and the solution treated with a stream of dry HCl for 5 min. After 66 h, the reaction was treated with ice-water and the organic solvent evaporated. The aqueous solution was extracted with ether, made basic, and extracted with ether. The ether extracts were dried and the solvent evaporated to give a tan liquid that was purified by radial chromatography (5% EtOH-0.5%
NH4OH-CHCl3). The HCl salt (0.67 g) crystallized from EtOAc, m.p. 99-100.5~C. (Compound 53).
l-Chloro-2-(2-~h1O-5-trifluoromethvlthienvl)ethane A solution of 2 -trifluoromethylthiophene (1. 2 g, 0.0105 mol, J. Fluorine Chem. 1990, 46, 445-459) in THF
(10 mL) was cooled to -40~C as 1.6 M n-butyllithium in hexane (6.5 mL, 0.0103 mol) was added dropwise. After 2 h, the reaction was cooled to -78~C and S (0.32 g, 0.01 mol) was added and the reaction stirred 2 h. Cooling was removed and when temperature reached 0~C, the reaction was quenched with H2O and dilute NaOH. The mixture was extracted with ether, the aqueous phase acidified, and the mixture extracted with ether. The final ether extracts were dried and the solvent evaporated to give 2 g of material. This was added to a mixture of KOH (0.6 g, 0.011 mol), N(butyl)4HSO4 (0.3 g, 0.001 mol), and 1-bromo-2-chloroethane (1. 4 g, 0.01 mol) in THF (20 mL) and the reaction stirred at ambient overnight. The mixture was poured into H2O, extracted with CH2C12, the extracts dried, and the solvent evaporated. The residue was purified by flash chromatography (5% EtOAc-hexane) to give a liquid (0.42 g). ~Compound 54).
W O 97/20819 PCT~US96/19229 ~XAMPL~ 53 ~+)-3-(2-(2-Thio-5-tri~luorometh~lthienvl)ethvlthio)-4-(1-~zabicvclor2.Z.2loctvl-3-oxv)-1.2.5-thiadiazole ..
A solution o~ the crude (compound 12) (0.37 g, 0.0015 mol) in DMF (8 mL) was treated portionwise with freshly ground ~1aked Na2S-9H2O (0.41 g, 0.0017 mol). After 1 h, 1-chloro-2-(2-thio-5-tri~luoromethylthienyl) ethane (0.42 g, 0.0017 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidi~ied with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether.
The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (10% EtOH-l~
NH40H-CHC13) to give a liquid. The oxalate salt (0.107 g) crystallized from 2-propanol, m.p. 65-69~C. (Compound 55).
EXAMP~E 54 2Q 2-(5-(2-Thienvl)thio~hene)thiol A solution o~ 2-(2-thienyl)thiophene (10 g, o.a602 mol) in THF (50 mL) was cooled to -40~C as 1.6 M n-butyllithium in hexane (37.2 mL, 0.0595 mol) was added dropwise. After 2 h, the reaction was cooled to -78~C and S
(1.8 g, 0.0575 mol) was added and the reaction stirred 2 h.
Cooling was removed and when temperature reached 0~C, the reaction was quenched with H2O and dilute NaOH. The mixture was extracted with ether, the aqueous phase acidi~ied, and 3~ the mixture extracted with ether. The ~inal ether extracts were dried and the solvent evaporated to give 9.9 g of material. (Compound 56).
~XANP~E 55 (+)-3-(2-(5-(2-Thienvl)thienvl)thio)-4-(1 -~z~hicvclor2.2.2loctvl-3-oxv)-1~2~5-thiadiazo1e A mixture of 2-(5-(2-thienyl)thiophene)thiol (1.2 g, 0.0061 mol), potassium t-butoxide (0.5 g, 0. 0045 mol), and a trace of 18-Crown-6 in THF (90 mL) was stirred for 1.5 h. To the solution was added (compound 12) (1.0 g, 0.0041 mol) and the reaction heated to reflux overnight.
The reaction was poured into H2O, extracted with ether, the extracts dried, and the solvent evaporated. The residue was purified by flash chromatography (5% EtOH-0.5% NH40H-CHC13) and the oxalate salt (0.41 g) crystallized from acetone, m.p. 215~C, dec. (Compound 57).
EX~MPLE 56 :l-chloro-2- ~2-(5- (2-thienvl)thienvl)thio)ethane Crude 2-(5-(2-thienyl)thiophene)thiol (3 g, 0.0152 mol) was added to a mixture of KOH ~0.93 g, 0.0166 mol), N(butyl)4HS04 (0.51 g, 0.0015 mol), and 1-bromo-2-chloroethane (2.2 g, 0.0152 mol) in THF (100 mL) and the reaction stirred at ambient overnight. The mixture was poured into H2O, extracted with CH2C12, the extracts dried, and the solvent evaporated to give the desired product (3.5 g). (Compound 58).
EXl~MPLE 57 (~)-3-(2-(2-(5-(2-Thienvl)thienvl)thio)ethvlthio)-4-(1-~z~hicvclo r 2.2.21Octvl-3-oxv)-1~2~5-thi~diazo1e A solution of the crude (compound 12) (0.5 g, 0.002 mol) in DMF (10 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (0.55 g, 0.0023 mol). After 1 h, 1-chloro-2-(2-(5-(2-thienyl)thienyl3thio)ethane (0.6 g, 0.0023 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was W O 97~0819 PCT~US96/19229 acidified with 1 N HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether.
The extracts were dried, the solvent evaporated, and the residue purified by flash chromatography (5% EtOH-0.5%
NH40H-CHCl3) to give a liquid. The oxalate salt (0.43 g) crystallized ~rom acetone, m.p. 102-105~C. (Compound 59).
(+)-3-(2-Thienvl)thio)-4-(l-azabicYclor2.2.210ctvl-3-oxv)-1,2,5-thiadiazole A mixture of 2-thiophenethiol ~0.42 g, 0.0036 mol) and K2C03 (0.5g g, 0.0043 mol), in DMF (20 mL) was heated at 60~C for 3 h. To the solution was added (compound 12) (0.89 g, 0.0036 mol) and the reaction heated overnight.
The reaction was poured into 1 N HCl (50 mL), extracted with ether, the agueous phase made basic, and the mixture extracted with EtOAc. The EtOAc extracts were dried, the solvent evaporated, and the residue purified by flash chromatography ~5% EtOH-0.5% NH40H-CHC13). The oxalate salt (0.095 g) crystallized from acetone, m.p. 133-136~C.
~Compound 60).
(+)-3-(3-N-(2-Thiazol;donvl)~ro~vlthio)-4-(1-azabicvclo-r ~ . 2.21octvl-3-oxv)1.2,5-thiadlazole A solution of the crude (compound 12) ~0.5 g, 0.002 mol) in DMF ~10 mL) was treated portionwise with freshly ground flaked Na2S-9H20 (0.55 g, 0.0023 mol). After 1 h, 1-chloro-3-N-~2-thiazolidone) propane (0.41 g, 0.0023 mol) was added and the reaction stirred overnight. The solvent was evaporated, the residue was acidified with 1 N
HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (10% EtOH-1% NH40H-CHC13) to give a W O 97/20819 PCT~US96/1922 li~uid. The oxalate salt (0.148 g) crystallized from acetone-ether, m.p. 70--75~C. (Compound 61).
EXAMP~L 60 (~)exo-Methvl-7-hvdroxv-2-azabicvclo r 2.2.2loct-5-ene-2-c~rboxvlate A solution of 2.1 g (8.4 mmol) methyl 7-acetoxy-7-cyano-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (J. Ora.
~hem. 1989, ~, 2893) in 25 mL ethanol and 5 mL H20 was cooled in an ice bath. To this mixture was added 2.4 g (42 mmol) KOH followed by 0.65 g (17 mmol) NaBH4. After 15 min.
the ice bath was removed and the reaction was stirred for 16 h. The reaction was ~uenched by addition of 25 mL H
and then concentrated under vacuum. To the residue was added 25 mL H20 and the mixture was extracted three times with 50 mL portions of EtOAc. The combined extracts were dried over NaCl/Na2SO4 and evaporated under vacuum. The residue was chromatographed (25% EtOAc/hexane) on silica gel to give 1.47 g of exo methyl 7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate and 135 mg of endo methyl 7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate. (Compound 62).
EXA~PLE 61 (+)exo-Methvl-6-hvdroxY-2-azabicYclor2.2.2loctane-2-c~rboxYlate A solution of 1.47 g (8 mmol) exo methyl 7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate and 0.15 g 5% Pd/C in 50 mL methanol was hydrogenated at 50 psi on a Parr shaker for 5 h at room temperature. Removal of the catalyst by filtration followed by evaporation under vacuum afforded 1.43 g. (Compound 63).
W ~ 97120819 PCT~US96/19229 EX~MPLE 62 (+)3-Butvlthio-4-(exo-2-methoxvc~rbonvl-2-~z~hic~clo r2 .2.2loct-6-vloxv)-l~2~5-thiadiazole A
To a solution of 1.3 g (7.1 mmol) exo methyl 6-hydroxy-2-aza~icyclo[2.2.2loctane-2-carboxylate and 0.80 g (7.1 mmol) potassium t-butoxide in 20 mL of THF was added 1.5 9 (7.1 mmol) 3-chloro-4-butylthio-1,2,5-thiadiazole.
After stirring the mixture at room temperature for 20 h, 50 mL of brine was added and the solution was extracted five times with 50 mL portions of EtOAc. The combined extracts were dried over NaCl/Na2SO4 and evaporated under vacuum.
Chromatography over silica gel (25% EtOAc/hexane) afforded 1.42 g. (Compound 64).
(+)3-Butvlthio-4-~exo-2-azabicvclor2.2.2loct-6-vloxv)-1,2,5-thia~lazole Trimethylsilyliodide 0.70 mL (4.9 mmol) was added to a solution of 3-butylthio-4-(exo-2-methoxycarbonyl-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole in 10 mL of CH2C12. After stirring for 5 h at room temperature, the solution was evaporated under vacuum.
10 mL of saturated NaHCO3 was added and the solution was extracted three times with 20 mL portions of EtOAc. The combined extracts were dried over NaCl/Na2SO4 and evaporated under vacuum. The residue was chromatographed over silica gel (10% EtOH, 1% NH40H-CHCl3) and the resulting oil converted to its oxalate salt.
Recrystallization from EtOH/EtOAc afforded 789 mg (mp. 148-150~C). (Compound 65).
W O 97~0819 PCTAUS96/19229 3-Amino-4-butvlthio-1,2,5-thiadiazole A 1.04 g sample of 3-chloro-4-butylthio-1,2,5-thiadiazole was dissolved in 20 mL of THF and added to a 50 mL reaction vessel. The mixture was cooled to 0~C. A 10 mL
sample of sodium bis(trimethylsilyl)amide in THF (1.0 M) was added dropwise to the reaction vessel. The mixture was stirred at 0~C. The reaction was quenched using 50 mh water upon desired completion of reaction. The pH of the mixture was adjusted to 2.0 using HCl. The mixture was stirred ~or 15 min. and then adjusted to pH = 11 using NaOH. The mixture was extracted using ether. The organic layers were combined, dried, and filtered. The filtrate was concentrated to dryness. The resulting product was purified using column chromatography. Yield: 1.07 g (65%). The N,N-bis(trimethylsilyl)-3-amino-4-butylthio-1,2,5-thiadiazole was suspended in 3N HCl and heated to about 50~C. The mixture was stirred for 3 h. The pH was adjusted to 11 using NaOH. The mixture was extracted using t-butylmethyl ester. The organics were combined, dried, filtered and concentrated to dryness. Yield: 0.43 g (45%). (Compound 66). The process substantially as described was repeated to yield 82% of the desired 3-amino-4-butylthio-1,2,5-thiadiazole.
3-Bromo-4-hutvlth;o-1.2,5-thiadiazole A 0.42 g sample of cupric bromide, 0.28 isoamyl nitrite and 6 mL acetonitrile were added to a 25 mL
reaction vessel. The mixture was warmed to 65~C. The acetonitrile mixture was added to a 4 m1 acetonitrile solution containing 0.30 g 4-amino-3-butylthio-1,2,5-thiadiazole. The mixture was stirred for 30 min. at 65~.
The mixture was cooled to room temperature and quenched W O 97/20819 PCT~US96/19229 with 50 mL of 1 N HC1. The organic layers were combined, dried, filtered and concentrated to dryness. Yield: 0.38 g (94~). The resulting material was purified using column chromatography to yield 0.30 g (73%) of material. (Compound 67).
The process substantially as described above was completed using copper(I) iodide (0.61 9) to provide 3-iodo-4-butylthio-1,2,5-thiadiazole. Yield: 0.23 g (48~).
(Compound 68).
~Y~le 66 (i)3~(2~2r3~3~4~4~4-he~tafluorobutvloxv)-4-r-3-(1-az~h;cvclor2.2.2loctvloxv)l-1,2,5-thiadiazole A solution of potassium t-butoxide (1.6g, 0.0143 mol) in THF (12 mL) was treated with 2,2,3,3,4,4,4-heptafluorobutanol ( 2 mL, 0.016 mol). After 5 min, Compound 12 (0.75 g, 0.Q03 mol) was added, the reaction stirred 2 h followed by heating to re~lux for 1.5 h. After stirring at ambient temperature overnight and heating to reflux for another 1.5 h, the solvent was evaporated, the residue suspended in H2O, and the mixture extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (20 %
EtOH-2 % N~40H-CHCl3) to give an oil. The hydrochloride salt crystallized from EtOAc with a half mole of H2O as a flocculent white solid (0.43 g), m.p. 168.5-169.5 ~C.
(Compound 69).
Example 67 (+)3-(1-Butvlthio)-4-~endo--6-(1-~z~hicvclor3.2.1loctvloxv)l-1~2~5-thi~diazole A solution o~ potassium t-butoxide (0.62 g, 0.0055 mol) in THF (12 mL) was treated with endo-1-azabicyclo[3.2.1~octan-6-ol (0.64 g, 0.005 mol). After 5 W O 97/20819 PCT~US96/19229 min, 3-chloro-4-(1-butylthio)-1,2,5-thiadiazole ~1.2 g, 0.0057 mol) was added. After stirring overnight, the solvent was evaporated, the residue diluted with H2O, acidified, and extracted with ether. The a~ueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was purified by radial chromatography (20 % EtoH-2 % NH40H-CHC13). The HCl salt crystallized from EtOAc to give a white solid (0.68 g), m.p. 201-202 ~C dec.
(Compound 70).
Exam~le 68 l+)3-(3-Phenvl~roDvlthio)-4-rendo--6-(1-az~h;cvclor3.2.1loctvloxy)l-1.2,5-thiadiazole A solution of Compound 48 (0.9 g, 0.0037 mol) in DMF t25 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (0.97 g, 0.004 mol). After 2 h, the reaction was treated with dropwise with l-bromo-3-phenylpropane (1.11 g, 0.0059 mol), the reaction stirred 3.25 h, followed by dropwise addition of additional l-bromo-3-phenylpropane (1.11 g, 0.0059 mol) in DMF (5 mL). A~ter stirring overnight, the solvents were evaporated, the residue suspended in H2O, acidified, and the mixture extracted with ether. The aqueous phase was made basic, extracted with CHCl3, the extracts dried, and the solvent evaporated. The residue purified by radial chromatography (MeOH:EtOAc:NH40H/15:30:1) to give an oil. The HCl salt (0.41 g) crystallized from CHC13-EtOAc-ether, m.p. 178-179 ~C. (Compound 72) W O 97/20819 PCT~US96/19229 ~Y~m~le 69 (i)3- r 3-(4-Fluoro~henvl)~ro~vlthiol-4- r -3-(1-~abicvclo r 2.2.21OctvloxY)l-1,2,5-thiadiazole - A solution of the crude Compound 12 (1.15 g, 0.0047 mol) in DMF ~20 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.68 g, 0.007 mol). After 1 h, 1-chloro-3-(4-fluorophenyl)propane (1.63 g, 0.0095 mol) in DMF (2 mL) was added dropwise and the reaction stirred 2.5 days. The reaction was then treated with additional 1-chloro-3-(4-fluorophenyl)propane (0.815 g, 0.00~7 mol) and warmed at 35 ~C for 6 h. The solvent was evaporated, the residue was acidified with 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (MeOH:EtOAc:NH40~/15:30:1). The HCl salt (0.19 g) crystallized from CHC13-EtOAc-ether, m.p. 189-191 ~C. (Compound 73) ~YA~le 70 (+)3-r3-r4-(Trifluorom~thvl)~henYll~ro~vlthio~-4-r-3- ~-~hicvclo r 2.2.2loctvloxv)l-1,2,5-thiadiazole A solution of the Compound 12 (1.15 g, 0.0047 mol) in DMF
(20 mL) was treated portionwise with freshly ground flaked Na2S-9H2O (1.68 g, 0.007 mol). After 2 h, the reaction was cooled to -35 ~C, treated dropwise with l-bromo-3-[4-(trifluoromethyl)phenyl)propane (2.53 g, 0.0095 mol) in DMF
(30 mL), and the reaction stirred 2 h. Cooling was removed, reaction stirred 3.5 h, and again cooled to -35 ~C. The reaction was then treated with additional l-bromo-3-[4-(trifluoromethyl)phenyl)propane (1.75 g, 0.0043 mol) in DMF (5 mL), cooling removed, and reaction stirred over night. Additional l-bromo-3-[4-W O 97/20819 PCT~US96/19229 (trifluoromethyl)phenyl)propane (0.75 g, 0.0028 mol) in DMF
(5 mL) was added and stirring continued for 1.5 h. The solvent was evaporated, the residue suspended in H2O, and the mixture extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (MeOH:EtOAc:NH40H/15:30:1). The HCl salt (0.32 g) crvstallized from CHCl3-EtOAc-ether, m.p. 182-184 ~C. (Compound 74) Example 71 3-(1-Butvl~m;no)-4-r(+.-)-3-(1-azabicvclor2.2.2loctvloxv)l-1,2,5-thia~;~zole A mixture of Compound 12 (1.15 g, 0.0047 mol) and 1-butylamine (20 mL) was heated to reflux for 22 h. The solvent was evaporated, residue suspended in H2O, the mixture acidified, and extracted with ether. The aqueous phase was made basic, extracted with EtOAc, extracts dried, and solvent evaporated. Purification by radial chromatography (MeOH:EtOAc:NH40H/15:30:1) and conversion to a HCl salt gave a solid partial hydrate (0.046 g), m.p.
193-195 ~C. (Compound 75) Exam~le 72 Cvanoaen butvloxv;~;de A solution of 1-butanol (92 mL, 1 mol) and triethylamine (3 mL) was cooled to -8 ~C and cyanogen (58 g, 1.12 mol) was slowly bubbled through the solution while maintA;n;n~ the temperature below 2 ~C. The reaction mixture was then distilled at 7 mm Hg to give a clear liquid (119.4 g) b.p. 43-49 ~C. (Compound 76).
W O 97120819 PCTrUS96119229 ~YA _ le 73 3-Chloro-4-butvloxv-1,2,5-thiadiazole A solution of DMF (400 mL) and sulfur monochloride (230 mL) was cooled to 5 ~C and Compound 76 (119.4 g, 0.95 mol) was added dropwise such that the temperature did not exceed 10 ~C. Cooling was removed and the reaction was stirred over night. The reaction was cooled in an ice-water bath and the excess sulfur monochloride destroyed by dropwise addition of H2O such that the temperature did not exceed 30 ~C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The aqueous ~raction was extracted with hexane (3 x) and the combined extracts and triturants were washed with H2O, aqueous NaHCO3, brine, dried, and the solvent e~aporated. The yellow liquid residue was distilled at 14 mm Hg to give a clear liquid (153 g), b.p. 120-125 ~C. (Compound 77) ~Y~m~le 74 3-Methylthio-4-butylo~-1,2,5-thiadiazole A solution of Compound 77 (6 g, 0.031 mol) in DMF (75 m~) was rapidly'stirred as ground flaked Na2S-~ ~2~
(8 g, 0.034 mol) was added. After 1 h, CH3I (3 mL, 0.048 mol) was added and the reaction stirred 30 min. Ice-water (150 mL) was added to the reaction and the mixture extracted with hexane (3 X). The extracts were washed with H2O (2 X), dried and the solvent evaporated to give a clear liquid (6.04 g). (Compound 78) ~YA _ le 75 3-Methylsulfonyl-4-butvlox~-1,2.5-thiadiazole To a solution of oxone (18.4 g, 0.03 mol) in H2O
(100 mL) was added dropwise compound 78 (3 g, 0.0147 mol) in THF (45 mL). After stirring overnight, the organics CA 0223930l l998-06-02 W O 971208~9 PCTnUS96/19229 were evaporated and the residue extracted with ether (3 x)~
The extracts were washed with H2O (2 X), dried, and the solvent evaporated. The residue was puri~ied by radial chromatography eluting with 50 % EtOAc-hexane to give a clear colorless liquid (2.93 g) that solidified on st~n~lng, m.p. 39-40 ~C. (Compound 79) Example 76 3-Methvlth;o-4-hexvloxv-1,2,5-thiadiazole A solution of 3-chloro-4-hexyloxy-1,2,5-thiadiazole (CA 60, 2796e, 1964) ( 1.1 g, 0.005 mol) in DMF
(30 mL~ was rapidly stirred as ground flaked Na2S-9 H2O
(1.5 g, 0.00625 mol) was added. After stirring overnight, CH3I (2 mL ) was added and the reaction stirred 30 min.
Ice-water (150 mL) was added to the reaction and the mixture extracted with ether (2 X). The extracts were washed with H2O (2 x)~ dried and the solvent evaporated to give a clear li~uid (1.025 g). (Compound 80) ~Y~ _le 77 3-Methvlsulfonvl-4-hexvlox~-1,2,5-thiadiazole To a solution of Oxone (18.4 g, 0.03 mol) in H2O
(100 mL) was added dropwise Compound 80 (3.4 g, 0. 0147 mol) in THF (50 mL). After stirring for three days, the organics were evaporated and the residue extracted with ether (3 X). The extracts were washed with H2O ~2 X), dried, and the solvent evaporated. The residue was purified by radial chromatograph~ eluting with 50 % EtOAc-hexane to give a clear colorless li~uid (3.58 g).
(Compound 81) CA 0223930l l998-06-02 W O 97/20819 PCT~US96/19229 ~Y~ _ le 78 Cvanoqen ~ro~vloxvimi~e A solution of l-propanol (40 mL, 0. 536 mol) and triethylamine (1. 5 mL) was cooled to -8 ~C and cyanogen (36 - g, 0.69 mol) was slowly bubbled through the solution while maintaining the temperature below 2 ~C. The reaction mixture was then distilled at 20 mm Hg to give a clear liquid ( 59 g) b.p. 63-64 ~C. (Compound 82) ~YA _ le 79 3-C~lloro-4-~ro~vloxv-1,2,5-thiadiazole A solution of DMF (180 mL) and sulfur monochloride (120 mL, 1. 5 mol) was cooled to 5 ~C and Compound 82 (59 g, 0.527 mol) was added dropwise such that the temperature did not exceed 10 ~C. Cooling was removed and the reaction was stirred over night. The reaction was cooled in an ice-water bath and the excess sulfur monochloride destroyed by dropwise addition of H2O such that the temperature did not exceed 30 ~C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The aqueous fraction was extracted with hexane (3 X) and the combined extracts and triturants were washed with H2O, aqueous NaHCO3, brine, dried, and the solvent evaporated. The yellow liquid residue was distilled at 15 mm Hg to give a clear liquid (79.g g), b.p. 103-106 ~C. (compound 83) ~YAm~le 80 3-Methvlthio-4-~ro~vloxv-1,2,5-thiadiazole A solution o~ Compound 83 (11.1 g, 0.062 mol) in DMF (150 mL) was rapidly stirred as ground ~laked Na2S-9 H2O (16.4 g, 0.068 mol) was added. After 1 h, CH3I (6 mL, 0.096 mol) was added and the reaction stirred 30 min. Ice-water (300 mL) was added to the reaction and the mixture extracted with hexane (3 X). The extracts were washed with H2O (2 X), dried and the solvent evaporated to give a clear liguid (11.02 g). (Compound 84) ~Y~ _le 81 ~)-3-(4,4,4-Tri~luorobutvloxv)-4-(1-~z~hicvclor2.2.2loctvl-3-oxv)-1,2,5-thiadiazole A solution o~ 4,4,4-trifluorobutanol (0.75 g) in THF (20 mL) was cooled to 0 ~C and potassium t-butoxide (0.65 g) was added. A~ter 5 min, a solution of Compound 102 (0.6 g) in THF (5 mL) was added and the reaction stirred one hour. The reaction was guenched with 5N HCl (1.5 mL) and the solvent evaporated. The residue was suspended in water and extracted with ether. The aqueous phase was made basic and extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromotography eluting with 20%-EtOH-1%-NH40H-CHCl3 to give a clear oil. The HCl salt was recrystallized ~rom EtOAc-ether to give a white solid, m.p.
3~ 122-124 ~C (0.43 g). (Compound 104).
CA 0223930l l998-06-02 W O 97/20819 PCTnUS96/19229 Example 82 (+)-endo-3-Pro~vlsulfonvl-4~ azabicvclor3.2.1loctvl-6-oxv)-1,2,5-thiadiazole A solution of (+)-endo-3-propylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (5.7 g) in 1 N HCl (24 mL) was cooled in ice-watér and Oxone (36.8 g) in H2O (75 mL) was added dropwise over 5 min. Cooling was removed and after 5 h, excess oxidant was destroyed with NaHSO3. The reaction was poured into ice and the pH
adjusted to 12. The mixture was extracted with EtOAc, the extracts washed with water, the solvent dried, and the solvent evaporated to give analytically pure (+)-endo-3-propylsul~onyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole as an oil (4.6 g). (Compound 166).
R~AMpT~ 83 (+/-) -3-ButvloxY-4- (1 -;Iz~h;cvclor2,2,210ctvl-3-ox~) -1,2,5-oxadiazole A suspension o~ 3,4-diphenylsulfonyl-1,2,5-oxadiazole oxide (4.6 g, 0.126 mol, Ref. J.Chem. Soc. 1964, 904.) in l-butanol (400 mL) was heated to 55-60 C as a solution of sodium l-butyloxide (0.3 g Na, 40 mL l-butanol) was added dropwise. After 1 h, the solvent was evaporated, residue was treated with H2O, and the mixture extracted with ether (3X).
The extracts were washed with H2O, dried, and the solvent evaporated to give a white solid (3.15 g). The solid was heated to re~lux overnight in P(OCH3)3 (30 mL) then poured into ice-H2O containing HCl (6 mL, 5N). The mixture was extracted with ether, the extracts washed with brine, dried, and the solvent evaporated to give a yellow li~uid. Radial ~ chromatography (15% EtOAc/hexane) gave a clear liquid (1.85 g). The li~uid was dissolved in THF (30 mL) and added dropwise to a mixture prepared from 1-azabic~clo~2.2.2]octan-3-ol(1.85 g 0.014 mol), THF (20 mL), W O 97/20819 PCT~US96/19229 and 1.6 M n-butyl lithium in hexane (8.4 mL, 0.013 mol). The reaction was then warmed to 52 C for 5 h. The cooled reaction was acidified with dilute HCl and diluted wit ether.
the aqueous fraction was washed with ether, made basic, and extracted with ether. The extracts were dried and evaporated to give a clear liquid. The HCl salt ~1.4 g) crvstallized from CHCl3-EtOAc-ether, m.p. 186-188 C.
(Compound 1).
E~AMpLE 1 ' (+) -endo-2- (4-Methvl-3-~entenvlthio~-3-(1-~zabicvclor3.2.11Octvl-6-oxv)~vrazine Obtained from Compound 19 and 1-bromo-4-methyl-3-pentene in 8% yield as a foam. (Compound 43).
~XAMPT~ 2' (+/-)-3-Chloro-2-(1-azabicvclor2.2.2loctvl-3-oxv)~vrazine A solution of 1-azabicyclo[2.2.2]octan-3-ol (5 g, 0.039 mol) in THF (400 mL) was treated with 1.6 M n-butyllithium in hexane (25 mL, 0.04 mol). After 1 h, the solution was cooled in an ice-water bath and 2,3-dichloropyrazine (6.6 g, 0.044 mol) in THF (30 mol) was added in one portion. Cooling was removed and after 30 min., the reaction was heated to reflux for 2.5 h. The solvent was evaporated, the residue acidified with 1 N HCl, and the mixture extracted with ether. The aqueous fraction was made basic and extracted with ether. The extracts were washed with water, dried, and the solvent evaporated to give a tacky solid. Recr,vstallization from ether gave a yellow solid (1.74 g), m.p. 112.5-114 C. (Compound 2).
~AMPL 3 (+/-)-3-Butvloxv-2-(l-azabicvclor2.2.21octvl-3-oxv)~vrazine W O g7/20819 PC~US96/19229 A solution of sodium butyloxide (0.25 g Na, Q.O109 mol, 1-butanol, 30 mL) was added to (compound 2) (0.48 g, 0.002 mol), the reaction stirred overnight, then heated to 80 C for 4 h. The solution was acidified and the solvent evaporated. The residue was suspended in H20, extracted with ether, and the aqueous solution made basic. The aqueous fraction was extracted with EtOAc, the extracts washed with H20, dried, and the solvent evaporated to give a yellow oil.
The HCl salt (0.32 g) crystallized from EtOAc as a white powder, m.p. 150-151 C. (Compound 3).
,~MPLE 4' (~/-)-3-Pro~vloxv-2-(1-azabicvclor2.2.2loctvl-3-oxv)~Yrazine To a solution of lithium 1-propyloxide (7 mL 1.6 M
n-butyllithium, O.011 mol, 1-propanol, 30 mL) was added (compound 2) (0.63 g, 0.0026 mol) and the reaction heated to reflux for 6 h. The solvent was evaporated, the residue suspended in H20, and the mixture extracted with EtOAc. The extracts were washed with H20, dried, and the solvent evaporated to give an oil. The HC1 salt (0.34 g) crystallized from acetone as a tan solid, m.p. 186-l90 C.
~Compound 4).
MPLE S ' (+/-)-3-Hexvloxv-2-(1-azabicvclor2.2.2loctvl-3-oxv)~vr~zine TO a solution of lithium 1-hexyloxide (7.8 mL 1.6 M
n-butyllithium, 0.013 mol, 1-hexanol, 20 mL) was added (compound 2) (0.6 g, 0.0025 mol) and the reaction heated to 80 C overnight. The solution was cooled, treated with 1 N
HCl (15 mL) and the solvent evaporated. The residue was suspended in H20, the mixture washed with ether, and made basic. The aqueous fraction was extracted with EtOAc, the ~ extracts dried, and the solvent evaporated to give an oil.
The HC1 salt (0.34 g) crystallized from EtOAc as a hemihydrate, m.p. 162-164 C. (Compound 5).
CA 0223930l l998-06-02 W O 97/20819 PCTAJSg6/19229 ~MPT.R 6' (+/-~-3-Butylth-o-2-(1-azabicvclor2.2.2loctyl-3-oxv)Dyr~zine A solution of l-butanethiol (1.1 mL) in THF (100 mL) was treated with 1.6 M n-butyl lithium in hexane ~4.7 mL, 0.0075 mol). After 10 min, (compound 2) (0.6 g, 0.0025 mol) was added and the reaction heated to reflux for 3 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The ether was dried and the solvent evaporated to give a clear liquid.
The HCl salt (0.59 g) crystallized from EtOAc as white crystals, m.p. 192-lg3-C (Compound 6).
~MPLE 7' (+/-)-3-Pentylthio-2-(1-azabicyclor2.2.2loctvl-3 -QXY) ~vrazine A solution of l-pentanethiol (1.2 mL) in THF (50 mL) was treated with 1.6 M n-butyl lithium in hexane (4.7 mL, 0.0075 mol). After 10 min, (compound 2) (0.6 g, 0.0025 mol) was added and the reaction heated to reflux for 2 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with ether. The a~ueous was made basic and extracted with EtOAc. The EtOAc was dried and the solvent evaporated to give a clear liquid. The HCl salt (0.44 g) crystallized from EtOAc, m.p. 169-171-C
(Compound 7).
~MPT.~ 8' (+/-)-2-(1-Azabicyclo r 2.2.2loctyl-3-oxv)~vrazine A suspension of 60% NaH in oil (1 g, 0.025 mol) in DMF (30 mL) was treated with l-azabicyclo[2. 2.2] octan-3-ol (3 .28 g, 0.025 mol) and the mixture heated to 50 C for 65 min. The mixture was treated dropwise with 2-chloropyrazine t3.16 g, 0 .027 mol) and heating continued for 3 h. ~Ieating was discontinued and the reaction stirred overnight. The solvent was evaporated, the residue treated with water, acidified, and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (30% MeOH-EtOAc-trace NH40H) to give an oil. The HCl salt (2.07 g) crystallized from MeOH-EtOAc, m.p. 256-258 C
(Compound 8).
~;!X'I~MPT.lZ 9 ~
(+/-)-3-(1-Pentvloxv)-2-(1-azabicvclo r 2.2.21 octvl-3-oxv)~vrazine To a solution of lithium 1-pentoxide (1.6 M n-butyllithium, 7.6 mL, 0.012 mol, 1-pentanol, 20 mL) was added (Compound 2) (0.58 g, 0.0024 mol) and the reaction heated to 90 C overnight. The solution was acidi~ied and the solvent evaporated. The residue was suspended in H20, extracted with ether, and the aqueous solution made basic. the aqueous fraction was extracted with EtOAc, the extracts washed with H20, dried, and the solvent evaporated to give an oil. The oil was purified by raidal chromatography (10% EtOH-1% NH40H-CHC13) and the HC1 salt (0.2 g) crystallized from EtOAc as a white powder, m.p. 163-165-C (Compound 9).
~ MpLE 10 ' (+/-)-3-MethoxY-2-tl-azabicvclor2.2.2loctvl-3-oxv)Dyrazine To a solution of sodium methoxide (Na, 0.4 g, 0.0174 mol, methanol, 25 mL) was added (compound 2) (0.8 g, 0.0033 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue suspended in H20, and the mixture extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography (10% EtOH-1% MH40H-CHCl3). The HCl salt (0.34 g) crystallized from 2-propanol as a hemihydrate, m.p. 215-218-C. (Compound 10).
W O 97~20819 PCT~US96/19229 EXAMPT~ 11' (+/-)-3-Fthoxv-2-(1-~z~hicvclor2.2.2loctvl-3-oxv)~vrazine To a solution of sodium ethoxide (Na, 0.4 g, 0.0174 mol, ethanol, 25 mL) was added (compound 2) (0.8 g, 0.0033 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue suspended in H2O, and the mixture extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatograph~ (10% EtOH-l % NH40H-CHCl3). The HCl salt (0.086 g) crystallized from 2-propanol, m.p. 215-218-C.
(Compound 11).
~MPLE 12' ~+/-)-3-(1-Hexvlthio)-2-(1-azabicvclo r 2.2.2loctvl-3-oxv)~vr~zine A solution of l-hexanethiol (1.4 mL) in THF (50 mL) was treated with 1.6 M n-butyllithium in hexane (4.7 mL, 0.0075 mol). After 10 min, (compound 2) (0.6 g, 0.0025 mol) was added and the reaction heated to re~lux for 4 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with EtOAc. The EtOAc was dried and the solvent evaporated to give a clear li~uid.
The HCl salt (0.57 g) crystallized from EtOAc, m.p. 171-174 C
(Compound 12).
~XAMPLE 13~
(+/-)-3-Methvlthio-2-(1-azabicvclo~2.2.2loctvl-3-oxv)~vra~ine A suspension of NaH (0.42 g, 0.018 mol) in DMF ~25 mL) was treated with 5.19 M methanethiol in DMF ( 6.44 mL, 0.033 mol). After 10 min, (compound 2) (0.8 g, 0.0033 mol) was added and the reaction heated to 50 C ~or 3 h. The reaction was cooled, acidified, and the solvent evaporated.
The residue was suspended in cold water, extracted with ether, the a~ueous made basic, and the mixture extracted with W O 97/20Xl9 PCT~US96/19229 EtOAc. The EtOAc was dried and the solvent evaporated to give a clear liquid. The HCl salt (0.63 g) crystallized from MeOH-EtOAc, m.p. 243-247 C. (Compound 13).
.
~X~MPT.~ 1~
- (+/-)-3-Ethvlthio-2-~1-azabicvclor2.2.2loctYl-3-oxv)~vrazine A solution o~ ethanethiol (2.6 mL) in THF (90 mL) was treated with 1.6 M n-butyllithium in hexane (9 mL, 0.0167 mol). After 15 min, (compound 2) (0.6 g, 0.0025 mol) was added and the reaction heated to reflux for 4 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with EtOAc. The EtOAc was dried, the solvent evaporated, and the residue purified by radial chromatography (5% EtOH-0.5% NH40HCHCl3). The HCl salt (0.48 g) crystallized from EtOAc, m.p. 269-272 C. (Compound 14).
~AMPLE 15' (+/-)-3-(1-Pro~vlthio-2-(1-azabi CYClO r 2.2.2loctvl-3-oxv)~vrazine A solution of l-propanethiol (2.7 mL) in THF ~90 mL) was treated with 1.6 M n-butyllithium in hexane (7 mL, 0.0117 mol). After 15 min, (compound 2) (0.7 g, 0.0029 mol) was added and the reaction heated to reflux for 4 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with EtO~c. The EtOAc was dried, the solvent evaporated to give an oil. The HCl salt (0.76 g) crystallized from MeOH-EtOAc, m.p. 231-234-C.
(Compound 15).
-12~-~AMPT.~ 16' (~/-)-3-(l-Heptylthio-2-(l-az~hicvclor2.2.2~octyl-3-oxv)~vr~zine A solution of l-heptanethiol (4.9 mL) in THF (90 mL) was treated with 1.6 M n-butyllithium in hexane (7 mL, 0.0117 mol). After 15 min, (compound 2) (0.7 g, 0.0029 mol) was added and the reaction heated to reflux for 4 h. The solvent was evaporated, the residue acidified with cold dilute HCl, and the mixture extracted with ether. The aqueous was made basic and extracted with EtOAc. The EtOAc was dried, the solvent evaporated to give an oil. The HCl salt (0.767 g) crystallized from MeOH-EtOAc as a hemihydrate, m.p. 169-173 C. (Compound 16).
~MP~E 17' 3-(1-Butylthio-2-(2-(dimeth~lamino)ethoxy)Dyrazine A solution of 2-dimethylaminoethanol (2.13 mL, 0.021 mol) in THF (130 mL) was treated with 1.6 M n-butyllithium in hexane (13.1 mL, 0.021 mol) with cooling in an ice-water bath. To the solution was added 2,3-dichloropyrazine (3.13 g, 0.021 mol) and the reaction heated to reflux overnight. The solvent was evaporated, the residue acidified with cold 1 N HCl, and the mixture extracted with ether. The a~ueous was made basic and extracted with EtOAc.
The extracts were washed with water, dried, and the solvent evaporated to give a clear oil (3.86 g). The oil was added to a solution of lithium l-butanethioxide (1.6 M n-butanethioxide (1.6 M n-butYllithium, 17 mL, 0.0273 mol, 1-butanethiol, 19.7 mL, 0.184 mol) in THF (100 mL), the reaction heated to reflux for 2 h, heating removed, and the reaction stirred over the weekend. The solvent was evaporated, the residue dissolved in dilute HCl, and the mixture extracted with ether. The aqueous phase was made basic, extracted with EtOAc, the extracts dried, and the solvent evaporated. The residue was purified by radial 9 PCTnJS96/19229 chromatography (5% EtOH-0.5% NH4OH-CHC13) to give an oil (3.4 g). The HCl salt crystallized from EtOAc to give a white solid, m.p. 120-123'C. (Compound 17).
~AMPT.~ 18' - 3-(1-Butvlthio)-2-(2-(trimethvlamino)ethoxv)~yrazine iodide A solution of (compound 17) (0.7 g, 0.0028 mol) in EtOAc (40 mL) was treated with iodomethane (O.~ mL) and the reaction stirred overnight. The white solid (1.04 g) was collected by filtration and dried, m.p. 140-142 C. (Compound 18).
~MPT.~ 19 ~
3-Cl~loro-2-rendo-(+.-)-6-(1-azabicyclo r 3.2.1loctyloxy)l-~yrazine A solution of potassium t-butoxide (0.62 g, 0.0055 mol) in THF (10 mL) was treated with endo-(+,-)-l-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol). After 5 min, 2,3-dichloropyrazine (2 g, 0.0134 mol) was added and the reaction stirred overnight. The reaction was diluted with H2O, acidified, and extracted with ether. The aqueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was purified by radial chromatography (20 % EtOH-2 %
NH40H-CHCl3) to give an oil. The HCl salt crystallized from acetone (0.44 g), m.p. 200 ~C dec. (Compound 19).
~mn le 20' 3-Meth~yl-2- r endo-(+,-)-6-(1-azabicyclo r 3.2.1loctyloxy)l-pyrazlne -A solution of potassium t-butoxide (0.62 g, 0.0055 mol) in THF (10 mL) was treated with endo-(+,-)-l-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol). After 5 W O 97/20819 PCTAUS~6/19229 min, reaction was cooled in an ice-water bath and 2-chloro-3-methylpyrazine (1.3 g, 0.01 mol) was added in a single portion. Cooling was removed and the reaction stirred for 3 days. The solvent was evaporated, the residue diluted with H20, acidified, and extracted with ether. The aqueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was converted to an HCl salt and recrystallized from 2-propanol to give a floculant powder (0.5 g), m.p. 240 ~C
dec. (Compound 20).
~m~ le 21' 2 - r endo-(~,-)-6-(1-azabicvclo r 3.2.1loctvloxv)l-~vrazine A solution o~ potassium t-butoxide (0.62 g, 0.0055 mol) in THF (10 mL) was treated with endo-(+,-)-l-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol). A~ter 5 min, reaction was cooled in an ice-water bath and 2-chloro-3-methylpyrazine (1.2 g, 0.01 mol) was added in a single portion. Cooling was removed and the reaction stirred 4 h.
The solvent was evaporated, the residue diluted with H2O, acidified, and extracted with ether. The a~ueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The solid residue was converted to an HCl salt and recrystallized ~rom 2-propanol to give a white solid (0.92 g), m.p. 250 ~C
dec. (Compound 21).
Exam~le 22~
6-Chloro-2-rendo-(+.-)-6-(1-azabicvclor3.2.1loctvloxv)l-~vrazine A solution of potassium t-butoxide (0.62 g, 0.0055 mol) in THF ~10 mL) was treated with endo-(+,-)-l-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol). A~ter 5 min, reaction was cooled in an ice-water bath and 2,6-dichloropyrazine (1 g, 0.0067 mol) was added in a single CA 0223930l l998-06-02 WO 97/20819 PCTrUS96/19229 portion. Cooling was removed and the reaction stirred over night. The solvent was evaporated, the resldue diluted with H2O, acidified, and extracted with ether. The aqueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The - residue was purified by radial chromatography (20 % EtOH-2 %
NH40H-CHCl3) . The HCl salt cr~stallized from acetone to give a white solid (0.33 g), m.p. 211-213 ~C dec. (Compound 22).
Ex~m~le 23 ' 3~ butvloxv)-2-rendo-(+,-)-6-~1-,~zabicvclo r 3 . 2.1loctvloxv)l-~vrazine A solution of potassium t-butoxide (1 g, 0.0089 mol) in THF
(20 mL) was treated with l-butanol (1 mL). After 5 min, reaction was cooled in an ice-water bath and Compound 19 (0.65 g, 0.0027 mol) in THF (10 mL) was added. Cooling was removed and the reaction stirred for 3 days. The solvent was evaporated, the residue diluted with H2O, acidified, and extracted with ether. The aqueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was purified bv radial chromatography (20 % EtOH-2 % NH40H-CHCl3). The HCl salt crvstallized from EtOAc to give a white solid (0.23 g), m.p. 171.5-172.5 ~C dec.(Compound 23) ~am~le 24~
3-(1-butvlthio~-2-rendo-(+,-)-6-(1-azabicvclor3.2.11 octvloxv)l-~vrazine A solution of potassium t-butoxide (1 g, 0.0089 mol) in THF (20 mL) was cooled in ice-water and treated with l-butanethiol (1 mL). After 5 min, cooling was removed and ~ Compound 19 (0.6 g, 0.0025 mol) in THF (10 mL) was added.
After stirring overnight, the solvent was evaporated, the residue diluted with H2O, acidified, and extracted with ether. The a~ueous phase was made basic and extracted with EtOAc, the extracts dried, washed with brine, dried, and the solvent evaporated. The residue was purified by radial chromatography (20 % EtOH-2 % NH40H-CHC13). The HCl salt crystallized from EtOAc to give a white solid (0.64 g), m.p.
157-158 ~C dec. (Compound 24).
Example 25~
endo-(8-Methvl-8-azabicvclo r 3.2.1loctYl-3-oxY)~vrazine A solution of potassium tert-butoxide (0.62 g) in THF (15 mL) was treated with tropine (0.7 g). After 5 min, the reaction was cooled in ice-water and chloropyrazine (1.2 g) was added.
The cooling was removed and the reaction stirred over night.
The solvent was evaporated, the residue dissolved in cold 1 N
HCl, and the mixture exracted with ether. The aqueous fraction was made basic, extracted with EtOAc, the extracts washed with water, brine, the solvent dried, and the solvent evaporated. The residue was purified by radial chromatography eluting with 20%-EtOH-2~-NH40H-CHC13 to give endo-(8-methyl-8-azabicyclo[3.2.1~octyl-3-oxy)pyrazine (0.6 g) that was isolated as a HCl salt that crystallized from 2-propanol, m.p. 240 ~C, dec. (Compound 25).
Exam~le 2~' ~-t2-Dimethvlaminoethoxv)~vrazine A solution of 2-dimethylaminoethanol (1 mL) in THF (20 mL) was treated with potassium tert-butoxide (1.2 g). After 5 min, chloropyrazine (2 g) was added and the reaction stirred 2 h. The solvent was evaporated, the residue suspended in cold water, the mixture acidified, and the mixture extracted with ether. The aqueous fraction was made ~asic and extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography eluting with 10%-EtOH-1%-NH~OH-CHC13 to give 2-(2-dimethylaminoethoxy)pyrazine (1.3 g). The HCl salt W O 97/20819 PCTrUS96/19229 crystallized from 2-propanol as a white solid, m.p. 151-153 ~C. (Compound 26).
., Example 27~
2-(2-Trimethvlaminoethoxv)~vrazine iodide A solution of the free base of Compound 26 (0.7 g) in EtOAc (40 mL) was treated with methyl iodide (1 mL) and the reaction stirred over night. The resulting solid was collected and dried to give 2- (2-trimethylaminoethoxy)pyrazine iodide as a off white solid (1.34 g), m.p. 164 ~C, dec. (Compound 27).
Exam~le as 1 (S)-2-(1-Methvl-2-~vrroli~nvlmethoxv)~vrazine A solution of (SJ-l-methyl-2-pyrrolidinemethanol (1.15 g) in THF (45 mL) was treated with potassium tert-butoxide (1.2 g).
After 10 min, chloropyrazine was added and the reaction stirred for 1.5 h. The reaction was quenched with 5 N HCl (4 mL) and the solvent evaporated. The residue was suspended in water and extracted with ether. The aqueous fraction was made basic and extracted with CHC13. The extracts were dried, the solvent evaporated, and the residue puri~ied by radial chromatography eluting with 20%-EtOH-2%-NH40H-CHCl3 to give (S)-2~ methyl-2-pyrrolidinylmethoxy)pyrazine (1.1).
The HCl salt crystallized from EtOAc as a white solid, m.p.
121-122 ~C. (Compound 28) W O 97/20819 PCTrUS96/19229 ~xample 29~
(+)-endo-2-Pro~Ylthio-3-(1-azabicvclo r3 . 2.1loctvl-6-oxv)~vrazine Potassium t-butoxide (0.9 g, 8 mmoles) was added at 0~ C. to propanethiol (0.61 g, 8 mmoles) in 20 ml THF and stirred for 5 min. Compound 19 (0.5 g, 2 mmoles) was added and the reaction stirred for 24 hr at room tempera~ure. 200 ml of 1 N
HCl was added and the aqueous solution washed with ethyl acetate. The pH was adjusted to 12Ø The product was extracted with ethyl acetate, dried over sodium sulfate and evaporated. The HCl salt was ~ormed in ether and ~iltered to yield (~)- endo-2 -propylthio-3-(1-azabicyclo[3.2.1]octyl-6-oxy)pyrazine hydrochloride (0.38 g), m.p. 159-160 ~C.
(Compound 29) The following compounds were prepared in substantially the same manner as Compound 29 by substituting the appropriate alkyl~hiol ~or propanethiol.
~Y~le 30' (+)-endo-2-Pentvlthio-3-(1-azabicvclor3.2.1loctvl-6-oxv)~vrazine Obtained from Compound 19 and pentanethiol in 60% yield, m.p.
159-160 ~C. (Compound 30).
~Y~m~le 31' (i)-endo-2-(2-Methvl~ro~vlthio)-3-(1-az~hicYclor3.2.1loctvl-6-oxY)~vrazine Obtained from Compound 19 and 2-methylpropanethiol in 8%
yield, m.p. 142-143 ~C. (Compound 31).
CA 0223930l l998-06-02 W o 97/208l9 PCT~US96/19229 ~xample 32' (+) -endo-2-7~thvlthio-3- (1-azabicvclo r3 . 2 .lloctvl-6-oxv)~vrazine Obtained from Compound 19 and ethanethiol in 53% yield, m.p.
196-197 ~C. (Compound 32).
Example 33~
( + ) - endo- 2-(2,2,2,-Trifluoroethvlthio)-3-(1-10azabicvclo r3 . 2 .lloctvl-6-oxv)~vrazine Obtained from Compound 19 and 2, 2, 2 -trifluoroethanethiol in 14% yield, m.p. 116-117 ~C. (Compound 33).
15Examl?le 34' (*~ - endo-2 - ( trans-2 -Butenvlthio)-3 - ( 1-azabicvclo r 3 .2.1loctvl-6-oxv)~vrazine Obtained from Compound 19 and trans-2-butenethiol in 13%
yield, m.p. 128-130 ~C. (Compound 34).
Example 35' (+) -er~do-2- (4,4,4-Trifluorobutvlthio)-3-(1-az~hicvclo r 3. 2 . 11 octvl-6-oxv)~Yrazine Obtained from Compound 19 and 4,4,4-trifluorobutanethiol in 30% yield, m.p. 173-174 ~C. (Compound 35 ) .
Example 36l 30(~) -endo-2- (2-~ro~envlthio)-3-(1-azabicvclo r3 . 2 .lloctvl-6-oxv)~vrazine obtained from Compound 19 and 2-propenethiol in 70% yield, - m.p. 254-255 ~C. (Compound 36).
WO 97/20819 PCT~US96/19229 Example 37 ' ( + ) - endo- 2 - ( 3-Methvlbutvlthio~-3-(1-azabicvclo r 3.2.1loctvl-6-oxv)~vrazine obtained from Compound 19 and 3-methylbutanethiol in 26%
yield, m.p. 174-176 ~C. (Compound 37).
Examp 1 e 3 8 ' (+) -endo-2- (4-TrifluoromethoxYbenzvlthio)-3-(1-~z~hicvclo r 3.2.1loctvl-6-oxY)~vrazine Obtained from Compound 19 and 4-trifluoromethoxybenzylthiol in 57% yield, m.p. 175-176 ~C. (Compound 38).
~Y~m~le 39' (+) -~ndo-2 -Pro~vlthio-6-(1-azabicvclo r 3. 2 . 11 octvl-6-oxv)~Yrazine Obtained from Compound 22 and propanethiol in 11% yield as a 2Q foam. (Compound 39).
Bxam~le 40 ' (~) -endo-2- (2.2 .2-TrifluoroethYlthio)-6- (1-az~hicvclo r3 . 2 .lloctvl-6-oxv)~yrazine Obtained from Compound 22 and 2,2,2-trifluoroethanethiol in 7% yield, m.p. 125-126 ~C. (Compound 40).
~y~mrle 41' (+) -endo-2- (2-Methoxvethvl~hio)-3-(1-azabicvclo r3 . 2.1loctvl-6-oxv)~Yrazine Compound 19 (1.15 g, 4.7 mmoles) and sodium sulfide (Na2S-9H20), 1.68 g, 7 mmoles) were heated in 30 ml DMF
at 50~ C. for 3.5 hr, cooled to 0~ C. and 2-Bromoethylmethylether (1.3 g, 9 mmoles) added. The reaction was stirred at room temperature overnight and diluted with W O 97/20819 PCT~US96/19229 ethyl acetate and 100 ml o~ 5 N HCl. The aqueous layer was washed with ethyl acetate and the pH adiusted to 12Ø The product was extracted with ethyl acetate , dried over sodium sulfate, condensed and purified by HPLC eluted with 9496CHC13/
5% ethanol/ 1% ammonium hydroxide. The HCl salt was formed in ether and filtered to give (+) -endo-2- (2-Methoxyethylthio) -3-(l-azabicyclo[3.2.1]octyl-6-oxy)pyrazine hydrochloride (0.3 g), m.p. 165-166 ~C. (Compound 41).
The following compounds were prepared in substantially the same manner as Compound 41 substituting the appropriate alkylhalide for 2-bromoethylmethylether.
Fxample 42' t+) -endo-2- ( 3-Phenvl-2-~ro~envlthio)-3-~1-aza~icvclor3.2.1loctvl-6-oxv)~vrazine Obtained from Compound 19 and cinnamyl bromide in 36% yield, m.p. 16~-167 ~C. (Compound 42).
Examp le 43' Alternate Synthesis of Com~ound 19 A sample o~ (+)-~ endo) -l-Azabicyclo[3.2.1]octan-6-ol (3.0 g, 23.6 mmoles, was added to a stirred solution of potassium t-butoxide (2.9 g, 26 mmoles) in 60 ml THF at room temperature. The reaction was cooled to 5 ~C and 2,3-dichloropyrazine (7.03 g, 47 mmoles) in 15 ml THF was added.
The solution was stirred at room temperature for 2 hrs, condensed, and diluted with water and ethyl acetate. The organic solution was dried and condensed. Puri~ication by HPLC eluting with 94% CHC13, 5~ ethanol, 1 % ammonium hydroxide yielded 4.9 g, (Compound 19).
Claims (41)
1. A composition for treating pain comprising an analgesic dose of a First Compound selected from the group consisting of:
Formula I
Formula I
, wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, MHR6, MR6R7, R4, -OR4, -SR4, -SOR4, -SO2R4, C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4-12-(cycloalkylalkyl) wherein R4 is C1-5-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y, OR5-Z-Y, -SR5ZY, -O-R5-Z-R4 or -S-R5-Z-R4 wherein z is oxygen or sulphur, R5 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
or G can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, C1-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6' is hydrogen, C1-6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
~ is a single or double bond; and Formula I1' wherein W' is oxygen or sulfur;
R' is hydrogen, amino, halogen, NHR6' , NR6' R7' , R4' , -OR4' , -SR4 , -SOR4 , -SO2R4 , C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z'-C3-10-cycloalkyl and -Z' -C4-12-(cycloalkylalkyl) wherein R4' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is -OR5' Y', -SR5' Y', OR5' -Z'-Y', -SR5' Z'Y', -O-R5'-Z-R4' or -S-R5'-Z'-R4' wherein Z' is oxygen or sulphur, R5 is C1-15 -alkyl, C2-is-alkenyl, C2-is-alkynyl, and Y' is a 5 or 6 membered heterocyclic group; and G' is selected from one of the following azacyclic or azabicyclic ring systems:
or G' can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6'R7';
R6' and R7' independently are hydrogen, C1-6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6'' , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6'' is hydrogen, C1-15-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
~ is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof;
and one or more Synergistic Analgesics in a weight ratio of First Compound to Synergistic Analgesic of from about 1 to about 1000.
Formula I
Formula I
, wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, MHR6, MR6R7, R4, -OR4, -SR4, -SOR4, -SO2R4, C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4-12-(cycloalkylalkyl) wherein R4 is C1-5-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y, OR5-Z-Y, -SR5ZY, -O-R5-Z-R4 or -S-R5-Z-R4 wherein z is oxygen or sulphur, R5 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
or G can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, C1-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6' is hydrogen, C1-6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
~ is a single or double bond; and Formula I1' wherein W' is oxygen or sulfur;
R' is hydrogen, amino, halogen, NHR6' , NR6' R7' , R4' , -OR4' , -SR4 , -SOR4 , -SO2R4 , C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z'-C3-10-cycloalkyl and -Z' -C4-12-(cycloalkylalkyl) wherein R4' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is -OR5' Y', -SR5' Y', OR5' -Z'-Y', -SR5' Z'Y', -O-R5'-Z-R4' or -S-R5'-Z'-R4' wherein Z' is oxygen or sulphur, R5 is C1-15 -alkyl, C2-is-alkenyl, C2-is-alkynyl, and Y' is a 5 or 6 membered heterocyclic group; and G' is selected from one of the following azacyclic or azabicyclic ring systems:
or G' can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6'R7';
R6' and R7' independently are hydrogen, C1-6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6'' , CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6'' is hydrogen, C1-15-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
~ is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof;
and one or more Synergistic Analgesics in a weight ratio of First Compound to Synergistic Analgesic of from about 1 to about 1000.
2. A composition as claimed by Claim 1 wherein the First Compound is selected from the group consisting of Formula I1 and Formula I; or a pharmaceutically acceptable salt or solvate thereof.
3. A composition as claimed by Claim 1 wherein the Synergistic Analgesic is a nonsteroidal anti-inflammatory drug,
4. A composition as claimed by Claim 3 wherein the nonsteroidal anti-inflammatory drug is selected from the group consisting of indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
5. A composition as claimed by Claim 3 wherein the nonsteroidal anti-inflammatory drug is ibuprofen.
6. A composition as claimed by Claim 3 wherein the First Compound is selected from the group consisting of Formula I and Formula I1', or a pharmaceutically acceptable salt or solvate thereof.
7. A composition as claimed by Claim 3 wherein the First Compound is selected from the group consisting of (~)-3-Methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (~)-3-Ethoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (~)-3-Propyloxy-4-(1-azabicyclo[2.2.2]octyl-3-Oxy) -1,2,5-thiadiazole, (~)-3-Butyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (~)-3-Pentyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (~)-3-Hexyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(4-Methylpentyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Chloro-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (~)-3-Propylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (~)-3-Butylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (~)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (S)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Hexylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy) -1,2,5-thiadiazole, (~)-3-(3,3-Dimethylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (+)-3-(2-(2-Thienylthio)ethylthio)-4-(1-azabicylo [2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~) 3-(2,2,3 3 3,3-Pentafluoropropylthio) -4-(1- azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-(2-Thienyl)propylthio) -4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Butylthio-4-((1-azabicyclo[2.2.2]octan-3-yl)methoxy)-1,2,5-thiadiazole, (~)-Exo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole, (~)-Exo-3-butyloxy-4-tl-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Butyloxy-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-Butyloxy-4-(1-methyl-3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-Butylthio-4-(1-methyl-3-piperidyloxy)-1,2,5-thiadiazole, 3-Butylthio-4-(1-methyl-4-piperidyloxy)-1,2,5-thiadiazole, (S)-3-Butyloxy-4-(1-methyl-2-pyrrolidinylmethoxy)-1,2,5-thiadiazole, (S)-3-Butyloxy-4-(2-pyrrolidinylmethoxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(2-(dimethylamino)ethoxy)-1,2,5-thiadiazole, 3-Butylthio-4-(2-(diethylamino)ethoxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(2-(trimethylamino)ethoxy)-1,2,5-thiadiazole iodide, (R)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(4-Methylpentylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-Phenylpropylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(4-Cyanobenzylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(4-Fluorobenzylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5- thiadiazole, (~)-3-(2-Phenylethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(2-Phenyloxyethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, Endo-3-butyloxy-4-(N-methyl-8-azabicyclo[3.2.1]octyl-3-oxy)-1,2,5-thiadiazole, (~)-Exo-3-butyloxy-4-(6-(N-methyl-8-azabicyclo[3.2.1]
octan-3-onoxy))-1,2,5-thidiazole, (~)-Exo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-(4-cyanobenzylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(3-azetidinyloxy)-1,2,5-thiadiazole, 3-Butylthio-4-(3-azetidinyloxy)-1,2,5-thiadiazole, (~)-Trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole, (~)-3-Butylthio-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-(2-(2-(5-(2-Thienyl)thienyl)thio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(2-(5-(2-Thienyl)thienyl)thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-N-(2-Thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)3-Butylthio-4-(exo-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole, (~)3-(2,2,3,3,4,4,4-heptafluorobutyloxy)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole, (~)3-(1-butylthio)-4-[endo-6-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-thiadiazole, (~)3-(3-phenylpropylthio)-4-[endo-6-(1-azabicyclo-[3.2.1]octyloxy)]-1,2,5-thiadiazole (~)3-[3-(4-fluorophenyl)propylthio]-4-[-3-(1-azabicyclo-[2.2.2]octyloxy)]-1,2,5-thiadiazole (~)3-{3-[4-(trifluoromethyl)phenyl]propylthio}-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (~)3-(1-Butylamino)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (~)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Butylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Propylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4,4,4-Trifluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Butynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenylpropynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Methoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Butynoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-(Methylthio)ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Chloropropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4-Fluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Chlorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[2-methoxy-5-pyridyl]propyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(trans-3-Chloro-2-propenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Fluorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4-Pentenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Fluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(Cyclobutylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3,3,3,2,2-Pentafluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[Phenylthio]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[1-napthyloxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Bromophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-Butylthio-4-hydroxy-1,2,5-thiadiazole (~)Exo-3-Butylthio-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[3-{1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-exo-3-Butyloxy-4-(7-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-Butyloxy-4-(3-piperidinyloxy)-1,2,5-thiadiazole 3-Butyloxy-4-(cis-1R-2-aminocyclopentanoxy)-1,2,5-thiadiazole (~)-endo-3-Hexyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (5S, 6S)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (5R , 6R)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-trans-3-sutylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole (~) -cis-3 -Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole (~)-trans-3-Butylthio-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole 3-Butylthio-4-(2-dimethylaminoethoxy)-1,2,5-thiadiazole (~)-trans-3-Butylthio-4-(N-tert-butylcarboxy-4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole (~)-trans-3-Butylthio-4-(4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole (~)-endo-3-Butyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-3-(4-Phenylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenyl-2-propenylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[4-Fluorophenyl]propan-3-onethio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3 - [N-Phenothiazinyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3- (3- [4-Fluorophenyl]-3-[4-fluorophenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenyl-3-[4-trifluoromethylphenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4,4,4-Trifluorobutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3- (3- [3-Pyridyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~) -endo-3- (2-Phenoxyethylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-Propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3- Propylsulfonyl-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(Hexyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3- (2-[Fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(2-[Fluorophenoxy]ethylthio)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3 -Propylthio-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-Propylsulfonyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4, 4, 4-Trifluorobutoxy)-4-(1-azabicyclo [3.2.1] octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) -endo-3- (trans-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3- (2-Methylthioethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2- (4-Methyl-1,3-thiazol-5-yl)ethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1, 2, 5-thiadiazole (~)-endo-3-(4-Methylthiobenzyloxy)-4-(1-azabicyclo [3.2.1] octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2 -Thienylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1, 2, 5-thiadiazole (~)-endo-3-(2-Cyclohexenyloxy)-4-(1-azabicyclo[3.2.1] octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Pentynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Hexynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Chloropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3- [2-(2-Napthalyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Chloro-a-cyclopropyl-benzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Methyl-3-pentenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) -endo-3-(Cyclopropylmethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Methoxyethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3 -Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) - endo-3 - ( 2-Cyclopropylethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4,4,3,3,2,2-Heptafluorobutoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[2-(3-Trifluoromethylphenyl)ethoxy]-4-(1-azabicyclo [3.2.1] octyl-6-oxy)-1, 2, 5-thiadiazole (~)-endo-3-[2-(2-Thienyl)ethoxy]-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1, 2, 5-thiadiazole (~)-endo-3-(3,3,3,2,2,Pentafluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Phenoxyethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-n-Butylbenzyloxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[3-[4-Methoxyphenyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Fluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2,4-Difluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[4-(Trifluoromethoxy)benzyloxy]-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Fluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3- (4-tert-Butylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(1-Cyclopropylethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Cyclohexylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Methyl-2-butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-cyclohexylbutoxy)-4-(1-azabicyclot3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Butyn-2-oxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Methyl-3-phenylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Fluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[3-t2-Thienyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-3-(2-t4-Fluorophenoxy]ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Methylthioethyl)-4-(1-azabicyclot2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(1-Azabicyclot2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-Butylthio-4-hydroxy-1,2,5-thiadiazole (~)-3-(2-{3-[1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-1,2,5-oxadiazole, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(2,2,3,3,4,4,4-heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-oxadiazole, 3-methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-pentylthio-4-(1-azabicyclo[2.2.2]ocytl-3-oxy)-1,2,5-oxadiazole, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-oxadiazole, 3-butylthio-4-(3-azetidinyloxy)-1,2,5-oxadiazole, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-oxadiazole, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-butylthio-4-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-hexyloxy-4-[6-~-endo-(2-azabicyclo[2.2.2]ocyloxy)]-1,2,5-oxadiazole, 3-(4,4,4-trifluorobutylthio)-4-[2-~-exo-(7-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-(2-phenoxyethylthio)-4-[3-~-endo-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(5-hexenyloxy)-4-[7-~-endo-(2-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-cyclobutylmethyl-4-[2-~-endo-(8-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, (+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-pyrazine, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(2,2,3,3,4,4,4-heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-pyrazine, 3-methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-pentylthio-4-(1-azabicyclo[2.2.2]ocytl-3-oxy)-pyrazine, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-pyrazine, 3-butylthio-4-(3-azetidinyloxy)-pyrazine, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyc][2.2.2]octyl-3-oxy)-pyrazine, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-pyrazine, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-butylthio-4-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-hexyloxy-4-[6-~-endo-(2-azabicyclo[2.2.2]ocyloxy)]-pyrazine, 3-(4,4,4-trifluorobuty]thio)-4-[2-~-exo-(7-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-(2-phenoxyethylthio)-4-[3-~-endo-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(5-hexenyloxy)-4-[7-~-endo-(2-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, and 3-cyclobutylmethyl-4-[2-~-endo-(8-azabicyclo[3.2.1]octyloxy)]-pyrazine.
2-[exo-(+/-)-3-[1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-butylthio-2-(1-azabicyclo[2.2.2]ocytl-3-oxy)]pyrazine, 3-butyloxy-2-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-butynyloxy)-2-[6-~-endo-(1-azabicyclo[3.2.1]octyloxy)pyrazine, 3-hexylthio-2-[6-~-exo-(2-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(3-phenylpropynylthio)-2-[2-~-exo-(7-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-methylthioethoxy)-2-[3-~-exo-(1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-propargyl-2-[4-(1-azabicyclo[2.2.1]heptyloxy)}pyrazine, and 3-cyclopropylmethylthio-2-[2-~-exo-(8-azabicyclo[3.2.1]octyloxy)]pyrazine; or a pharmaceutically acceptable salt or solvate thereof.
octan-3-onoxy))-1,2,5-thidiazole, (~)-Exo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-(4-cyanobenzylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(3-azetidinyloxy)-1,2,5-thiadiazole, 3-Butylthio-4-(3-azetidinyloxy)-1,2,5-thiadiazole, (~)-Trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole, (~)-3-Butylthio-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-(2-(2-(5-(2-Thienyl)thienyl)thio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(2-(5-(2-Thienyl)thienyl)thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-N-(2-Thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)3-Butylthio-4-(exo-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole, (~)3-(2,2,3,3,4,4,4-heptafluorobutyloxy)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole, (~)3-(1-butylthio)-4-[endo-6-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-thiadiazole, (~)3-(3-phenylpropylthio)-4-[endo-6-(1-azabicyclo-[3.2.1]octyloxy)]-1,2,5-thiadiazole (~)3-[3-(4-fluorophenyl)propylthio]-4-[-3-(1-azabicyclo-[2.2.2]octyloxy)]-1,2,5-thiadiazole (~)3-{3-[4-(trifluoromethyl)phenyl]propylthio}-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (~)3-(1-Butylamino)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (~)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Butylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Propylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4,4,4-Trifluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Butynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenylpropynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Methoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Butynoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-(Methylthio)ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Chloropropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4-Fluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Chlorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[2-methoxy-5-pyridyl]propyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(trans-3-Chloro-2-propenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Fluorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4-Pentenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Fluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(Cyclobutylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3,3,3,2,2-Pentafluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[Phenylthio]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[1-napthyloxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Bromophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-Butylthio-4-hydroxy-1,2,5-thiadiazole (~)Exo-3-Butylthio-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[3-{1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-exo-3-Butyloxy-4-(7-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-Butyloxy-4-(3-piperidinyloxy)-1,2,5-thiadiazole 3-Butyloxy-4-(cis-1R-2-aminocyclopentanoxy)-1,2,5-thiadiazole (~)-endo-3-Hexyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (5S, 6S)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (5R , 6R)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-trans-3-sutylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole (~) -cis-3 -Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole (~)-trans-3-Butylthio-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole 3-Butylthio-4-(2-dimethylaminoethoxy)-1,2,5-thiadiazole (~)-trans-3-Butylthio-4-(N-tert-butylcarboxy-4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole (~)-trans-3-Butylthio-4-(4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole (~)-endo-3-Butyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-3-(4-Phenylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenyl-2-propenylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[4-Fluorophenyl]propan-3-onethio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3 - [N-Phenothiazinyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3- (3- [4-Fluorophenyl]-3-[4-fluorophenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenyl-3-[4-trifluoromethylphenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4,4,4-Trifluorobutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3- (3- [3-Pyridyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~) -endo-3- (2-Phenoxyethylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-Propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3- Propylsulfonyl-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(Hexyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3- (2-[Fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(2-[Fluorophenoxy]ethylthio)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3 -Propylthio-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-Propylsulfonyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4, 4, 4-Trifluorobutoxy)-4-(1-azabicyclo [3.2.1] octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) -endo-3- (trans-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3- (2-Methylthioethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2- (4-Methyl-1,3-thiazol-5-yl)ethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1, 2, 5-thiadiazole (~)-endo-3-(4-Methylthiobenzyloxy)-4-(1-azabicyclo [3.2.1] octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2 -Thienylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1, 2, 5-thiadiazole (~)-endo-3-(2-Cyclohexenyloxy)-4-(1-azabicyclo[3.2.1] octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Pentynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Hexynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Chloropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3- [2-(2-Napthalyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Chloro-a-cyclopropyl-benzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Methyl-3-pentenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) -endo-3-(Cyclopropylmethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Methoxyethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3 -Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) - endo-3 - ( 2-Cyclopropylethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4,4,3,3,2,2-Heptafluorobutoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[2-(3-Trifluoromethylphenyl)ethoxy]-4-(1-azabicyclo [3.2.1] octyl-6-oxy)-1, 2, 5-thiadiazole (~)-endo-3-[2-(2-Thienyl)ethoxy]-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1, 2, 5-thiadiazole (~)-endo-3-(3,3,3,2,2,Pentafluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Phenoxyethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-n-Butylbenzyloxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[3-[4-Methoxyphenyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Fluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2,4-Difluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[4-(Trifluoromethoxy)benzyloxy]-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Fluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3- (4-tert-Butylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(1-Cyclopropylethoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Cyclohexylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Methyl-2-butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-cyclohexylbutoxy)-4-(1-azabicyclot3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Butyn-2-oxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Methyl-3-phenylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Fluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[3-t2-Thienyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-3-(2-t4-Fluorophenoxy]ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Methylthioethyl)-4-(1-azabicyclot2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(1-Azabicyclot2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-Butylthio-4-hydroxy-1,2,5-thiadiazole (~)-3-(2-{3-[1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-1,2,5-oxadiazole, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(2,2,3,3,4,4,4-heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-oxadiazole, 3-methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-pentylthio-4-(1-azabicyclo[2.2.2]ocytl-3-oxy)-1,2,5-oxadiazole, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-oxadiazole, 3-butylthio-4-(3-azetidinyloxy)-1,2,5-oxadiazole, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-oxadiazole, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-butylthio-4-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-hexyloxy-4-[6-~-endo-(2-azabicyclo[2.2.2]ocyloxy)]-1,2,5-oxadiazole, 3-(4,4,4-trifluorobutylthio)-4-[2-~-exo-(7-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-(2-phenoxyethylthio)-4-[3-~-endo-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(5-hexenyloxy)-4-[7-~-endo-(2-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-cyclobutylmethyl-4-[2-~-endo-(8-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, (+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-pyrazine, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(2,2,3,3,4,4,4-heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-pyrazine, 3-methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-pentylthio-4-(1-azabicyclo[2.2.2]ocytl-3-oxy)-pyrazine, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-pyrazine, 3-butylthio-4-(3-azetidinyloxy)-pyrazine, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyc][2.2.2]octyl-3-oxy)-pyrazine, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-pyrazine, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-butylthio-4-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-hexyloxy-4-[6-~-endo-(2-azabicyclo[2.2.2]ocyloxy)]-pyrazine, 3-(4,4,4-trifluorobuty]thio)-4-[2-~-exo-(7-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-(2-phenoxyethylthio)-4-[3-~-endo-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(5-hexenyloxy)-4-[7-~-endo-(2-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, and 3-cyclobutylmethyl-4-[2-~-endo-(8-azabicyclo[3.2.1]octyloxy)]-pyrazine.
2-[exo-(+/-)-3-[1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-butylthio-2-(1-azabicyclo[2.2.2]ocytl-3-oxy)]pyrazine, 3-butyloxy-2-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-butynyloxy)-2-[6-~-endo-(1-azabicyclo[3.2.1]octyloxy)pyrazine, 3-hexylthio-2-[6-~-exo-(2-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(3-phenylpropynylthio)-2-[2-~-exo-(7-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-methylthioethoxy)-2-[3-~-exo-(1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-propargyl-2-[4-(1-azabicyclo[2.2.1]heptyloxy)}pyrazine, and 3-cyclopropylmethylthio-2-[2-~-exo-(8-azabicyclo[3.2.1]octyloxy)]pyrazine; or a pharmaceutically acceptable salt or solvate thereof.
8. A composition as claimed by Claim 1 wherein the Synergistic Analgesic is an opioid.
9. A composition as claimed by Claim 8 wherein the First Compound is selected from the group consisting of Formula I and Formula I1' or a pharmaceutically acceptable salt or solvate thereof.
10. A composition as claimed by Claim 8 wherein the First Compound is Formula I' or a pharmaceutically acceptable salt or solvate thereof.
11. A composition as claimed by Claim 8 wherein the First Compound is selected from the group consisting of (~)-3-Ethoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Propyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Butyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Pentyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Hexyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(4-Methylpentyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Chloro-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Propylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Butylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (S)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Hexylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3,3-Dimethylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(2-(2-Thienylthio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(2,2,3,3,3-Pentafluoropropylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-(2-Thienyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Butylthio-4-((1-azabicyclo[2.2.2]octan-3-yl)methoxy)-1,2,5-thiadiazole, (~)-Exo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Exo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole, (~)-Exo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole, (~)-3-Butyloxy-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-Butyloxy-4-(1-methyl-3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-Butylthio-4-(1-methyl-3-piperidyloxy)-1,2,5-thiadiazole, 3-Butylthio-4-(1-methyl-4-piperidyloxy)-1,2,5-thiadiazole, (S)-3-Butyloxy-4-(1-methyl-2-pyrrolidinylmethoxy)-1,2,5-thiadiazole, (S)-3-sutyloxy-4-(2-pyrrolidinylmethoxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(2-(dimethylamino)ethoxy)-1,2,5-thiadiazole, 3-Butylthio-4-(2-(diethylamino)ethoxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(2-(trimethylamino)ethoxy)-1,2,5-thiadiazole iodide, (R)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(4-Methylpentylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-Phenylpropylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(4-Cyanobenzylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(4-Fluorobenzylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5- thiadiazole, (~)-3-(2-Phenylethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(2-Phenyloxyethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, Endo-3-butyloxy-4-(N-methyl-8-azabicyclo[3.2.1]octyl-3-oxy)-1,2,5-thiadiazole, (~)-Exo-3-butyloxy-4-(6-(N-methyl-8-azabicyclo[3.2.1]octan-3-onoxy))-1,2,5-thiadiazole, (~)-Exo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, (~)-Endo-3-(4-cyanobenzylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole, 3-Butyloxy-4-(3-azetidinyloxy)-1,2,5-thiadiazole, 3-Butylthio-4-(3-azetidinyloxy)-1,2,5-thiadiazole, (~)-Trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole, (~)-3-Butylthio-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole, (~)-3-(2-(2-(5-(2-Thienyl)thienyl)thio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(2-(5-(2-Thienyl)thienyl) thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)-3-(3-N-(2-Thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, (~)3-Butylthio-4-(exo-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole, (~)3-(2,2,3,3,4,4,4-heptafluorobutyloxy)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole, (~)3-(1-butylthio)-4-[endo-6-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-thiadiazole, (~)3-(3-phenylpropylthio)-4-[endo-6-(1-azabicyclo-[3.2.1]octyloxy)]-1,2,5-thiadiazole (~)3-[3-(4-fluorophenyl)propylthio]-4-[-3-(1-azabicyclo-[2.2.2]octyloxy)]-1,2,5-thiadiazole (~)3-{3-{4-(trifluoromethyl)phenyl]propylthio}-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (~)3-(1-Butylamino)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole; and (~)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Butylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Propylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4,4,4-Trifluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Butynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenylpropynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Methoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Butynoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-(Methylthio)ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Chloropropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4-Fluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Chlorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[2-methoxy-5-pyridyl]propyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(trans-3-Chloro-2-propenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Fluorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4-Pentenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Fluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(Cyclobutylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3,3,3,2,2-Pentafluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[Phenylthio]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[1-napthyloxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Bromophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-Butylthio-4-hydroxy-1,2,5-thiadiazole (~)Exo-3-Butylthio-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-[3-{1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-exo-3-Butyloxy-4-(7-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole (~)-3-Butyloxy-4-(3-piperidinyloxy)-1,2,5-thiadiazole 3-Butyloxy-4-(cis-1R-2-aminocyclopentanoxy)-1,2,5-thiadiazole (~)-endo-3-Hexyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (5S, 6S) -endo-3 -Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (5R,6R)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-trans-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole (~)-cis-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole (~)-trans-3-Butylthio-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole 3-Butylthio-4-(2-dimethylaminoethoxy)-1,2,5-thiadiazole (~)-trans-3-Butylthio-4-(N-tert-butylcarboxy-4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole (~)-trans-3-Butylthio-4-(4-hydroxy-pyrollidin-3-oxy)-1.2.5-thiadiazole (~)-endo-3-Butyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-3-(4-Phenylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenyl-2-propenylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[4-Fluorophenyl]propan-3-onethio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[N-Phenothiazinyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[4-Fluorophenyl]-3-[4-fluorophenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-Phenyl-3-[4-trifluoromethylphenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(4,4,4-Trifluorobutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(3-[3-Pyridyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Phenoxyethylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-Propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-Propylsulfonyl-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(Hexyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(2-[Fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-exo-3-(2-[Fluorophenoxy]ethylthio)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-Propylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-Propylsulfonyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4,4-Trifluorobutoxy)-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Methylthioethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-(4-Methyl-1,3-thiazol-5-yl)ethoxyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Methylthiobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Thienylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Cyclohexenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Pentynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Hexynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Chloropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[2-(2-Napthalyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Chloro-.alpha.-cyclopropyl-benzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Methyl-3-pentenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (i)-endo-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~) -endo-3-(2-Methoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4,4,4,3,3,2,2-Heptafluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[2-(3-Trifluoromethylphenyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[2-(2-Thienyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3,3,3,2,2,Pentafluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-n-Butylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[3-(4-Methoxyphenyl)propoxy]-4-(1-azabicyclo [3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (+)-endo-3-(4-Fluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2,4-Difluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[4-(Trifluoromethoxy)benzyloxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-Fluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-tert-Butylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(1-Cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(2-Cyclohexylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Methyl-2-butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(4-cyclohexylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Butyn-2-oxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Methyl-3-phenylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-(3-Fluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-endo-3-[3-(2-Thienyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole (~)-3-(2-[4-Fluorophenoxy]ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (~)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole 3-Butylthio-4-hydroxy-1,2,5-thiadiazole (~)-3-(2-[3-{1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole (+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-1,2,5-oxadiazole, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(2,2,3,3,4,4,4-heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-oxadiazole, 3-methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-pentylthio-4-(1-azabicyclo[2.2.2]ocytl-3-oxy)-1,2,5-oxadiazole, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-oxadiazole, 3-butylthio-4-(3-azetidinyloxy)-1,2,5-oxadiazole, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-oxadiazole, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-oxadiazole, 3-butylthio-4-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-hexyloxy-4-[6-~-endo-(2-azabicyclo[2.2.2]ocyloxy)]-1,2,5-oxadiazole, 3-(4,4,4-trifluorobutylthio)-4-[2-~-exo-(7-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-(2-phenoxyethylthio)-4-[3-~-endo-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-(5-hexenyloxy)-4-[7-~-endo-(2-azabicyclo[2.2.1]heptyloxy)]-1,2,5-oxadiazole, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, 3-cyclobutylmethyl-4-[2-~-endo-(8-azabicyclo[3.2.1]octyloxy)]-1,2,5-oxadiazole, (+/-)-3-butylthio-4-(azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, (+/-)-3-(2-butyloxy)-4-[(+/-)-3-azabicyclo[2.2.2]octyloxy)-pyrazine, (+/-)-3-butyloxy-4-[endo-(+/-)-6-[1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(2,2,3,3,4,4,4-heptaflurorobutyloxy)-4-[(+/-)-3-(1-azabicyclo[2.2.2]octyloxy)]-pyrazine, 3-methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-pentylthio-4-(1-azabicyclo[2.2.2]ocytl-3-oxy)-pyrazine, trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-pyrazine, 3-butylthio-4-(3-azetidinyloxy)-pyrazine, 3-(3-N-(2-thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-pyrazine, 3-(2-2-thio-5-trifluoromethylthienyl)ethylthio)-4-azabicyclo[2.2.2]octyl-3-oxy)-pyrazine, 3-butylthio-4-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-hexyloxy-4-[6-~-endo-(2-azabicyclo[2.2.2]ocyloxy)]-pyrazine, 3-(4,4,4-trifluorobutylthio)-4-[2-~-exo-(7-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-(2-phenoxyethylthio)-4-[3-~-endo-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, 3-(5-hexenyloxy)-4-[7-i-endo-(2-azabicyclo[2.2.1]heptyloxy)]-pyrazine, 3-butyl-4-[5-(1-azabicyclo[3.2.1]octyloxy)]-pyrazine, and 3-cyclobutylmethyl-4-[2-~-endo-(8-azabicyclo[3.2.1]octyloxy)]-pyrazine.
2-[exo-(+/-)-3-[1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-butylthio-2-(1-azabicyclo[2.2.2]ocytl-3-oxy)]pyrazine, 3-butyloxy-2-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-butynyloxy)-2-[6-~-endo-(1-azabicyclo[3.2.1]octyloxy)pyrazine, 3-hexylthio-2-[6-~-exo-(2-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(3-phenylpropynylthio)-2-[2-+-exo-(7-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-methylthioethoxy)-2-[3-~-exo-(1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-propargyl-2-[4-(1-azabicyclo[2.2.1]heptyloxy)]pyrazine, and 3-cyclopropylmethylthio-2-[2-~-exo-(8-azabicyclo[3.2.1]octyloxy)]pyrazine; or a pharmaceutically acceptable salt thereof.
2-[exo-(+/-)-3-[1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-butylthio-2-(1-azabicyclo[2.2.2]ocytl-3-oxy)]pyrazine, 3-butyloxy-2-[3-~-endo-(1-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-butynyloxy)-2-[6-~-endo-(1-azabicyclo[3.2.1]octyloxy)pyrazine, 3-hexylthio-2-[6-~-exo-(2-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(3-phenylpropynylthio)-2-[2-+-exo-(7-azabicyclo[2.2.1]heptyloxy)]pyrazine, 3-(2-methylthioethoxy)-2-[3-~-exo-(1-azabicyclo[3.2.1]octyloxy)]pyrazine, 3-propargyl-2-[4-(1-azabicyclo[2.2.1]heptyloxy)]pyrazine, and 3-cyclopropylmethylthio-2-[2-~-exo-(8-azabicyclo[3.2.1]octyloxy)]pyrazine; or a pharmaceutically acceptable salt thereof.
12. A composition as claimed by Claim 8 wherein the opioid is selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
13. A composition as claimed by Claim 8 wherein the opioid is selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
14. A composition as claimed by Claim 8 wherein the opioid is selected from the group consisting of propoxyphene, methadone, hydrocodone, hydromorphine, and codeine.
15. A composition as claimed by Claim 1 wherein the Synergistic Analgesic is acetaminophen.
16. A composition as claimed by Claim 15 wherein the First Compound is selected from the group consisting of Formula I and Formula I1'; or a pharmaceutically acceptable salt or solvate thereof.
17. A composition as claimed by Claim 15 wherein the First Compound is Formula I'; or a pharmaceutically acceptable salt thereof.
18. A composition as claimed by Claim 1 wherein the Synergistic Analgesic is an alpha-adrenergic compound.
19. A composition as claimed by Claim 18 wherein the First Compound is selected from the group consisting of Formula I and Formula I1'; or a pharmaceutically acceptable salt or solvate thereof.
20. A composition as claimed by Claim 19 wherein the First Compound is Formula I'; or a pharmaceutically acceptable salt thereof.
21. A method for treating pain comprising administering an analgesic dose of a composition comprising a a First Compound selected from the group consisting of:
Formula I
, Formula I' , wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, NHR6, NR6R7, R4, -OR4, -SR4, -SOR4, -SO2R4, C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4-12-(cycloalkylalkyl) wherein R4 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y, OR5-Z-Y, -SR5ZY, -O-R5-Z-R4 or -S-R5-Z-R4 wherein Z is oxygen or sulphur, R5 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
or G can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, C1-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1- and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6' is hydrogen, C1-6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
~ is a single or double bond; and Formula I1' wherein W' is oxygen or sulfur;
R' is hydrogen, amino, halogen, NHR6', NR6'R7', R4', -OR4' , -SR4', -SOR4', -SO2R4', C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z'-C3-10-cycloalkyl and -Z'-C4-12-(cycloalkylalkyl) wherein R4' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is -OR5'Y', -SR5'Y', OR5'-Z'-Y', -SR5'Z'Y', -O-R5'-Z-R4' or -S-R5'-Z'-R4' wherein Z' is oxygen or sulphur, R5' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y' is a 5 or 6 membered heterocyclic group; and G' is selected from one of the following azacyclic or azabicyclic ring systems:
or G' can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6'R7';
R6' and R7' independently are hydrogen, C1-6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6'', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6'' is hydrogen, C1-15-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof;
and one or more Synergistic Analgesics in a weight ratio of First Compound to Synergistic Analgesic of from about 1 to about 1000.
Formula I
, Formula I' , wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, NHR6, NR6R7, R4, -OR4, -SR4, -SOR4, -SO2R4, C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4-12-(cycloalkylalkyl) wherein R4 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y, OR5-Z-Y, -SR5ZY, -O-R5-Z-R4 or -S-R5-Z-R4 wherein Z is oxygen or sulphur, R5 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
or G can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, C1-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1- and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6' is hydrogen, C1-6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
~ is a single or double bond; and Formula I1' wherein W' is oxygen or sulfur;
R' is hydrogen, amino, halogen, NHR6', NR6'R7', R4', -OR4' , -SR4', -SOR4', -SO2R4', C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z'-C3-10-cycloalkyl and -Z'-C4-12-(cycloalkylalkyl) wherein R4' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is -OR5'Y', -SR5'Y', OR5'-Z'-Y', -SR5'Z'Y', -O-R5'-Z-R4' or -S-R5'-Z'-R4' wherein Z' is oxygen or sulphur, R5' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y' is a 5 or 6 membered heterocyclic group; and G' is selected from one of the following azacyclic or azabicyclic ring systems:
or G' can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6'R7';
R6' and R7' independently are hydrogen, C1-6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6'', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6'' is hydrogen, C1-15-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof;
and one or more Synergistic Analgesics in a weight ratio of First Compound to Synergistic Analgesic of from about 1 to about 1000.
22. A method as claimed by Claim 21 wherein the First Compound is selected from the group consisting of Formula I and Formula I1'; or a pharmaceutically acceptable salt or solvate thereof.
23. A method as claimed by Claim 21 wherein the Synergistic Analgesic is a nonsteroidal anti-inflammatory drug.
24. A method as claimed by Claim 23 wherein the nonsteroidal anti-inflammatory drug is selected from the group consisting of indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
25. A method as claimed by Claim 23 wherein the nonsteroidal anti-inflammatory drug is ibuprofen.
26. A method as claimed by Claim 23 wherein the First Compound is selected from the group consisting of Formula I and Formula I1'; or a pharmaceutically acceptable salt or solvate thereof.
27. A method as claimed by Claim 21 wherein the Synergistic Analgesic is an opioid.
28. A method as claimed by Claim 27 wherein the First Compound is selected from the group consisting of Formula I and Formula I1'; or a pharmaceutically acceptable salt or solvate thereof.
29. A method as claimed by Claim 27 wherein the First Compound is Formula I'; or a pharmaceutically acceptable salt thereof.
30. A method as claimed by Claim 27 wherein the opioid is selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
31. A method as claimed by Claim 27 wherein the opioid is selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
32. A method as claimed by Claim 27 wherein the opioid is selected from the group consisting of propoxyphene, methadone, hydrocodone, hydromorphine, and codeine.
33. A method as claimed by Claim 21 wherein the Synergistic Analgesic is acetaminophen.
34. A method as claimed by Claim 33 wherein the First Compound is selected from the group consisting of Formula I and Formula I1'; or a pharmaceutically acceptable salt or solvate thereof.
35. A method as claimed by Claim 21 wherein the Synergistic Analgesic is an alpha-adrenergic compound.
36. A method as claimed by Claim 35 wherein the First Compound is selected from the group consisting of Formula I and Formula I1'; or a pharmaceutically acceptable salt or solvate thereof.
37. The use of a First Compound selected from the group consisting of:
Formula I
, Formula I' , wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, NHR6, NR6R7, R4, -OR4, -SR4, -SOR4, -SO2R4, C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4-12-(cycloalkylalkyl) wherein R4 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y, OR5-Z-Y, -SR5ZY, -O-R5-Z-R4 or -S-R5-Z-R4 wherein Z is oxygen or sulphur, R5 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
or G can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, C1-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6' is hydrogen, C1-6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
is a single or double bond; and Formula I1' wherein W' is oxygen or sulfur;
R' is hydrogen, amino, halogen, NHR6', NR6'R7', R4', -OR4', -SR4', -SOR4', -SO2R4', C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z'-C3-10-cycloalkyl and -Z'-C4-12-(cycloalkylalkyl) wherein R4' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is -OR5'Y', -SR5'Y', OR5'-Z'-Y', -SR5'Z'Y', -O-R5'-Z-R4' or -S-R5'-Z'-R4' wherein Z' is oxygen or sulphur, R5' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y' is a 5 or 6 membered heterocyclic group; and G' is selected from one of the following azacyclic or azabicyclic ring systems:
or G' can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6'R7';
R6' and R7' independently are hydrogen, C1-6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6'', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6'' is hydrogen, C1-15-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of Compound to Synergistic Analgesic of from about 1 to about 1000 for the manufacture of a medicament for therapeutic application in the treatment of pain.
Formula I
, Formula I' , wherein W is oxygen or sulphur;
R is hydrogen, amino, halogen, NHR6, NR6R7, R4, -OR4, -SR4, -SOR4, -SO2R4, C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z-C3-10-cycloalkyl and -Z-C4-12-(cycloalkylalkyl) wherein R4 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y, OR5-Z-Y, -SR5ZY, -O-R5-Z-R4 or -S-R5-Z-R4 wherein Z is oxygen or sulphur, R5 is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group; and G is selected from one of the following azacyclic or azabicyclic ring systems:
or G can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are hydrogen, C1-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6' is hydrogen, C1-6-alkyl;
n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
is a single or double bond; and Formula I1' wherein W' is oxygen or sulfur;
R' is hydrogen, amino, halogen, NHR6', NR6'R7', R4', -OR4', -SR4', -SOR4', -SO2R4', C3-10-cycloalkyl, C4-12-(cycloalkylalkyl), -Z'-C3-10-cycloalkyl and -Z'-C4-12-(cycloalkylalkyl) wherein R4' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, each of which is optionally substituted with one or more halogen(s), -CF3, -CN, Y', phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CF3, -CONH2 or -CSNH2; or R' is -OR5'Y', -SR5'Y', OR5'-Z'-Y', -SR5'Z'Y', -O-R5'-Z-R4' or -S-R5'-Z'-R4' wherein Z' is oxygen or sulphur, R5' is C1-15-alkyl, C2-15-alkenyl, C2-15-alkynyl, and Y' is a 5 or 6 membered heterocyclic group; and G' is selected from one of the following azacyclic or azabicyclic ring systems:
or G' can optionally be substituted C3-C8 cycloalkyl or optionally substituted C1-6-alkyl wherein the substitution is -NR6'R7';
R6' and R7' independently are hydrogen, C1-6-alkyl; or R6' and R7' together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, C1-10-alkoxy, C1-5-alkyl substituted with -OH, -COR6'', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R3 is hydrogen, C1-5-alkyl, C2-5-alkenyl or C2-5-alkynyl;
R6'' is hydrogen, C1-15-alkyl n is 0, 1 or 2;
m is 0, 1 or 2;
p is 0, 1 or 2;
q is 1 or 2;
r is 0, 1 or 2;
is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of Compound to Synergistic Analgesic of from about 1 to about 1000 for the manufacture of a medicament for therapeutic application in the treatment of pain.
38. A use as claimed by Claim 37 wherein the Synergistic Analgesic is an opioid.
39. A use as claimed by Claim 37 wherein the Synergistic Analgesic is acetaminophen.
40. A use as claimed by Claim 37 wherein the Synergistic Analgesic is a nonsteroidal anti-inflammatory drug.
41. A use as claimed by Claim 37 wherein the Synergistic Analgesic is an alpha-adrenergic compound.
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US951095P | 1995-12-06 | 1995-12-06 | |
| US828095P | 1995-12-06 | 1995-12-06 | |
| US827495P | 1995-12-06 | 1995-12-06 | |
| US827995P | 1995-12-06 | 1995-12-06 | |
| US827595P | 1995-12-06 | 1995-12-06 | |
| US827695P | 1995-12-06 | 1995-12-06 | |
| US827095P | 1995-12-06 | 1995-12-06 | |
| US827395P | 1995-12-06 | 1995-12-06 | |
| US60/008,273 | 1995-12-06 | ||
| US60/008,270 | 1995-12-06 | ||
| US60/008,279 | 1995-12-06 | ||
| US60/008,276 | 1995-12-06 | ||
| US60/008,280 | 1995-12-06 | ||
| US60/008,275 | 1995-12-06 | ||
| US60/009,510 | 1995-12-06 | ||
| US60/008,274 | 1995-12-06 | ||
| PCT/US1996/019229 WO1997020819A1 (en) | 1995-12-06 | 1996-12-05 | Composition for treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2239301A1 true CA2239301A1 (en) | 1997-06-12 |
Family
ID=27573941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002239301A Abandoned CA2239301A1 (en) | 1995-12-06 | 1996-12-05 | Composition for treating pain |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5998434A (en) |
| EP (1) | EP0874828A4 (en) |
| AU (1) | AU1128297A (en) |
| CA (1) | CA2239301A1 (en) |
| WO (1) | WO1997020819A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3055397A (en) * | 1996-04-23 | 1997-11-12 | Eli Lilly And Company | Heterocyclic compounds |
| JP4489940B2 (en) * | 1997-12-19 | 2010-06-23 | アボット・ラボラトリーズ | Heterocyclic ether and thioether compounds useful in the control of chemical synaptic transmission |
| PL193273B1 (en) | 1997-12-22 | 2007-01-31 | Euro Celtique Sa | Opioidic agonistic/antagonistic combinations |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| DE60004835T2 (en) | 1999-06-04 | 2004-06-09 | Eli Lilly And Co., Indianapolis | 7-oxo-2-azabicyclo [2.2.1] heptanes as a selective muscarinic receptor antagonist |
| CN1423559A (en) | 2000-02-08 | 2003-06-11 | 欧罗赛铁克股份有限公司 | Controlled-release compositions containing opioid agonist and antagonist |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
| DE60238756D1 (en) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | OPIOID CONTAINING ARZNEIFORM AGAINST MISUSE |
| US7943173B2 (en) | 2001-07-18 | 2011-05-17 | Purdue Pharma L.P. | Pharmaceutical combinations of oxycodone and naloxone |
| WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| DE60232417D1 (en) | 2001-08-06 | 2009-07-02 | Euro Celtique Sa | OPIOID AGONIST FORMULATIONS WITH FREEZER AND SEQUESTRATED ANTAGONIST |
| DE10141650C1 (en) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate |
| US20030092724A1 (en) * | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
| CA2478523A1 (en) | 2002-04-05 | 2003-10-16 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
| EP2422772A3 (en) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
| US20040192715A1 (en) * | 2003-02-05 | 2004-09-30 | Mark Chasin | Methods of administering opioid antagonists and compositions thereof |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| US20050038062A1 (en) * | 2003-04-14 | 2005-02-17 | Burns Lindsay H. | Methods and materials for the treatment of pain comprising opioid antagonists |
| TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| DE602004031124D1 (en) | 2003-08-13 | 2011-03-03 | Neurosearch As | NEW CHINUCLIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE |
| US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| BRPI0405520A (en) * | 2004-10-21 | 2006-06-13 | Cmax Otimizacao De Resultados | new diclofenac-derived drugs containing donor heterocycles, inflammation composition and treatment method |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| HUE032156T2 (en) | 2006-06-19 | 2017-09-28 | Alpharma Pharmaceuticals Llc | Pharmaceutical compositions |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| US20080026054A1 (en) * | 2007-04-27 | 2008-01-31 | Nectid Inc. | Novel anelgesic combination |
| US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| ES2706407T3 (en) | 2009-03-10 | 2019-03-28 | Euro Celtique Sa | Immediate-release pharmaceutical compositions comprising oxycodone and naloxone |
| SG188307A1 (en) | 2010-09-23 | 2013-04-30 | Abbvie Inc | Monohydrate of an azaadamantane derivative |
| AU2014295042B2 (en) | 2013-07-23 | 2017-03-30 | Mundipharma Pty Limited | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| PL3639828T3 (en) | 2013-12-24 | 2022-05-02 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) for treating acute liver failure |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1307790C (en) * | 1987-08-04 | 1992-09-22 | Ian Anthony Cliffe | Ethers |
| US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| YU84791A (en) * | 1990-05-19 | 1994-06-10 | Boehringer Ingelheim Kg. | BICYCLIC 1-AZA-CYCLOALKAL |
| DK198590D0 (en) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE |
| US5527813A (en) * | 1990-08-21 | 1996-06-18 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
| US5418240A (en) * | 1990-08-21 | 1995-05-23 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
| US5376668A (en) * | 1990-08-21 | 1994-12-27 | Novo Nordisk A/S | Heterocyclic compounds |
| WO1993014089A1 (en) * | 1992-01-13 | 1993-07-22 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
| US6265419B1 (en) * | 1993-12-21 | 2001-07-24 | Novo Nordisk A/S | Method of treating gastrointestinal motility disorders |
| UA43347C2 (en) * | 1993-08-19 | 2001-12-17 | Ново Нордіск А/С | METHOD OF TREATMENT OF MENTAL DISEASES |
| US5605908A (en) * | 1994-10-24 | 1997-02-25 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5998404A (en) * | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5672709A (en) * | 1994-10-24 | 1997-09-30 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| US5726193A (en) * | 1994-10-31 | 1998-03-10 | Eli Lilly And Company | Method for treating anxiety |
| US5488056A (en) * | 1994-10-31 | 1996-01-30 | Eli Lilly And Company | Method for treating anxiety |
| US5512574A (en) * | 1994-12-21 | 1996-04-30 | American Home Products Corporation | Quinuclidine and azabicyclo 2.2.1! heptane pyrazinyl ethers as muscarinic agonists |
-
1996
- 1996-12-05 AU AU11282/97A patent/AU1128297A/en not_active Abandoned
- 1996-12-05 US US09/091,143 patent/US5998434A/en not_active Expired - Fee Related
- 1996-12-05 EP EP96942127A patent/EP0874828A4/en not_active Withdrawn
- 1996-12-05 CA CA002239301A patent/CA2239301A1/en not_active Abandoned
- 1996-12-05 WO PCT/US1996/019229 patent/WO1997020819A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0874828A4 (en) | 1999-09-01 |
| AU1128297A (en) | 1997-06-27 |
| WO1997020819A1 (en) | 1997-06-12 |
| US5998434A (en) | 1999-12-07 |
| EP0874828A1 (en) | 1998-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2239301A1 (en) | Composition for treating pain | |
| RU2158262C2 (en) | Derivatives of 1,2,5-thiadiazole, intermediate compounds, methods of synthesis and pharmaceutical composition | |
| US6194416B1 (en) | Heterocyclic compounds and their use | |
| US8796295B2 (en) | Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | |
| US5852037A (en) | Method for treating anxiety | |
| US5763457A (en) | Method for treating anxiety | |
| AU715645B2 (en) | Method for treating pain | |
| US5888999A (en) | Method for treating anxiety with muscarinic cholinergic receptor agonists | |
| WO1997019944A1 (en) | Heterocyclic compounds and their use | |
| JP2000501708A (en) | Pain treatment composition | |
| CA2238815A1 (en) | Composition for treating pain | |
| US8735391B2 (en) | Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods | |
| WO1997019669A2 (en) | Heterocyclic compounds and their use | |
| MXPA06008748A (en) | Diazabicyclic aryl derivatives as cholinergic receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |